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 A brief history of cArdiAc surgery
After a few decades of limited experience in treating congenital heart defects, the intro-
duction of cardiopulmonary bypass in 1954 provided the opportunity to advance cardiac 
surgery into an adult patient population.1, 2 In the 1960s this resulted in the first aortic and 
mitral valve procedures to treat patients with valvular stenosis and/or regurgitation. Evolving 
from ball-caged valves to stentless porcine bioprosthetic valves,3 tens of millions of patients 
have undergone aortic, mitral, or combined valve replacements with excellent short- and 
long-term valve durability and survival, even with the earliest generation of mechanical 
valves.4, 5
Ischemic heart disease was the leading cause of death in the general population (Figure 
1), and the only treatment available at that time -- medical therapy -- fell short to reduce 
early mortality. Despite the pioneering work of Arthur M. Vineberg to induce coronary 
anastomosis of an internal mammary artery graft by burrowing it in the myocardium,6 surgi-
cal revascularization did not take off until in the mid-1960s when coronary artery bypass 
grafting (CABG) through surgical anastomosis was introduced.7,8 Its wide-spread adoption 
caused CABG to rapidly evolve as the standard of care for patients suffering from coronary 
artery disease.9
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figure 1 trends in causes of death in the netherlands through 1960-2010
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A brief history of interventionAl cArdiology
Compared with cardiac surgery, interventional cardiology is a young specialty. Cardiac 
catheterization procedures were introduced in the early 1940s.10 Further developments of 
aortography with contrast finally --by accident-- led to the first coronary catheterization in 
1958.11, 12 After almost two decades, Andreas Grüntzig pioneered percutaneous translumi-
nal coronary angioplasty by reopening the coronary stenosis with a balloon-tipped cath-
eter.13 The subsequent development of bare-metal and drug-eluting stents further improved 
outcomes with percutaneous coronary intervention (PCI).
The introduction of transcatheter heart valves marked a new era. Interventional cardiolo-
gists were no longer only able to treat coronary artery disease, but indications expanded to 
valvular disease as well. Transcatheter aortic interventions were initially described in 1965 
and the development of balloon aortic valvuloplasty in 1986 was a huge leap forward.14, 
15However, it was not until the first transcatheter aortic valve implantation (TAVI) in 2002 
that there was a definitive catheter-based treatment for aortic stenosis.16
compArAtive effectiveness
The introduction of new treatment strategies --being either an operative technique or the 
launch of innovative technology --should be paralleled by rigorous evaluation compared 
with the standard therapy. Usually this occurs in the setting of a dedicated randomized 
controlled trial (RCT), the highest level of evidence originating from clinical research. Such 
randomized evaluation against standard therapy is needed, as innovation may not always 
be beneficial. A systematic assessment of 205 RCTs identified 72 (35%) trials to have non-
significant results.17 If not evaluated, a significant number of patients would have been 
subject to new but suboptimal therapy.
In case a new therapy seems to be efficient it might be tempting to implement it without 
substantial evidence. This poses the risk of letting such therapies ‘run its course’ without 
proper evaluation. At least observational studies should be performed to assess the safety 
and effectiveness, before a situation is reached where there is no turning back:18
“Accompanying this widespread optimism [regarding CABG], however, is a growing 
uneasiness that by simple common consent, rather than by rational analysis of data, we 
may be adopting for general use a form of treatment that has yet to prove itself. Some fear 
that even though the long-term effectiveness of direct revascularization has not yet been 
demonstrated, we may be propelled into a position in which it will be considered poor 
medical practice to withhold this form of therapy from almost any patient with coronary 
artery disease…” 
Eugene Braunwald, 1976
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 Although data from observational studies may be positive, subsequent data coming 
from RCTs may be necessary to amplify the body of evidence. Results should be weighted 
proportionally, considering the quality of research.19
methodology
Methodological issues are important to consider when interpreting the results of RCTs and 
observational studies. Frequently study results are translated as monochrome outcomes, 
which may result in unsubstantiated treatment recommendations and may jeopardize qual-
ity of care. Important flaws in reporting of trial results have been identified,20, 21 and it might 
therefore be difficult to draw the correct conclusion from trials.17 This results in a need to 
critically evaluate cardiovascular research and methodology to enhance understanding and 
interpretation of study results.
surgery or cAtheter-bAsed interventions?
Since the introduction of catheter-based interventions, cardiac surgeons and interventional 
cardiologists have been treating similar patient populations. Due to significant develop-
ments in percutaneous technology, it has become inevitable that an increasing percentage 
of patients is treated through lesser invasive interventions. However, even though safety and 
efficacy of both surgical and catheter-based interventions has increased, it remains difficult 
to define which patients benefit from a specific treatment strategy.
Risk models can be helpful tools to determine the patient population with optimal 
safety and efficacy of therapies. Many physicians rely on risk models for decision-making 
purposes, and models are often used by policy makers and health care organizations for 
benchmarking and/or benefit-risk analyses. However, risk models are only useful in specific 
patient populations, for certain procedures, and for a particular outcome;22 there remains a 
need for improved risk models.
 16
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 Aim
The goal of this thesis is to appraise the methodological quality of the current evidence, 
provide recommendations to improve methodology, and produce risk-benefit analyses of 
new developments to substantiate evidence-based guidelines.
outline
part 1 of this thesis highlights the current status of patient selection and decision-making. 
Two different aspects are discussed. First, how risk stratification in cardiac surgery can be 
improved. Secondly, how risk stratification can help decision-making in selecting the most 
appropriate surgical or catheter-based intervention for individual patients.
The different strategies for the treatment of aortic stenosis are discussed in part 2. It evaluates 
the outcomes of surgical aortic valve replacement and transcatheter aortic valve implanta-
tion, and provides a comparison between both treatments.
part 3 aims to evaluate the most optimal treatment for complex coronary artery disease. It 
will focus on the comparison between percutaneous and surgical revascularization with 
regard to patients with diabetes, the incidence and outcomes of stroke, and the impact of 
incomplete revascularization. It describes how the outcomes of revascularization can be 
further improved.
A thoughtful evaluation of study methodology is presented in part 4. A specific analysis of 
non-inferiority trial designs is performed, focusing on lessons from recent cardiovascular tri-
als. It furthermore emphasizes the need for a critical appraisal of analyses from randomized 
trials and observational studies.
part 5 addresses harmonization of clinical endpoints, aiming to improve comparability of 
studies evaluating aortic valve interventions.

Part 1
Patient selection and decision-making
London
Chapter 3
The new EuroSCORE II does not improve prediction 
of mortality in high-risk patients undergoing cardiac 
surgery: a collaborative analysis of 2 European 
centers
Head SJ*, Howell NJ*, Freemantle N, van der Meulen TA, 
Senanayake E, Menon S, Kappetein AP, Pagano D
*Shared first-authorship
Eur J Cardiothorac Surg 2013; in press
Part 1 Patient selection and decision-making26
AbstrAct
Objectives
Prediction of operative risk in adult patients undergoing cardiac surgery remains a chal-
lenge, particularly in high-risk patients. In Europe, the EuroSCORE is the most commonly 
used risk prediction model, but is no longer accurately  calibrated to be used in contempo-
rary practice. The new EuroSCORE II was recently published in an attempt to improve risk 
prediction. We sought to assess the improvement in predictive value of EuroSCORE II in 
high-risk patients. 
Methods
Patients who underwent surgery between 01-04-2006 and 31-03-2011 with a preoperative 
logistic EuroSCORE ≥10 were identified from prospective databases. Additional variables 
included in EuroSCORE II but not in the original EuroSCORE were collected through patient 
chart review. The c-statistic to predict in-hospital mortality was calculated for the addi-
tive EuroSCORE, logistic EuroSCORE, and EuroSCORE II models. The Hosmer-Lemeshow 
test was used to assess model calibration by comparing observed and expected mortality 
in a number of risk strata. The fit of the models was compared using Aikike’s Information 
Criterion (AIC). 
Results
A total of 933 patients were identified; the median additive EuroSCORE was 10 (interquar-
tile range 9-11), median logistic EuroSCORE was 15.3 (IQR 12.0-24.1), and the median 
EuroSCORE II was 9.3 (5.8-15.6). There were 90 (9.7%) in-hospital deaths. None of the 
EuroSCORE models performed well with a c-statistic of 0.67 for the additive EuroSCORE and 
EuroSCORE II, and 0.66 for the logistic EuroSCORE. Model fit was poor for the EuroSCORE 
II (chi-square 16.5; p=0.035). Both the additive EuroSCORE and logistic EuroSCORE had 
better model fit, the additive EuroSCORE significantly so (difference in was -5.66; p=0.017). 
Conclusions
The new EuroSCORE II does not improve risk prediction in high-risk patients undergoing 
adult cardiac surgery as compared with original additive and logistic EuroSCOREs. The key 
problem of risk stratification in high-risk patients has not been addressed by this new model. 
Future iterations of the score should explore more advanced statistical methods and focus 
on developing procedure-specific algorithms. In addition, models that predict complica-
tions in addition to mortality may prove of increasing value.
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introduction
Accurate risk stratification is critical for delivering cardiac surgical clinical practice. It has 
helped inform surgeons of the probable risks of surgery allowing them to aid patients in 
making informed choices, particularly when alternative treatments are available it has been 
useful to select those patients that have the most chance of benefiting from surgery.1 Fur-
thermore, it has helped drive improvements in outcome through national audits and it has 
facilitated benchmarking of clinical results between institutions. Recently risk stratification 
has come to clinical prominence in its role of deciding which patients should be offered 
experimental therapeutic interventions, such as trans-catheter aortic valve implantation.2
Within Europe the EuroSCORE and its Logistical variant are the most frequently used 
risk stratification models.3, 4 Developed in 1999 from a relatively small database of 20,000 
patients, its predictive power was good. However, the predictive power of any risk stratifica-
tion algorithms can drift over time due to changes in practice and populations, and in recent 
years a decline in the predictive power of the EuroSCORE has been observed especially 
for procedures such as aortic valve replacement.5, 6 This drift may in part be due to a com-
bination of the change in risk profile observed in cardiac surgery with older patients with 
multiple co-morbidities being considered for more complex procedures,7 and the progress 
seen in improved cardiac surgical outcomes in recent years. The “high-risk” group has been 
shown to be a predictive challenge and the original EuroSCORE fails to provide an accurate 
estimation of risk.5, 6, 8, 9 Outcome prediction in this group of patients is particularly impor-
tant, as often there may be alternative therapeutic strategies available if conventional surgery 
is considered too risky. In light of these developments the EuroSCORE was considered to be 
outdated and due for updating; recently the new EuroSCORE II was published.10 
The aim of this study was to compare the original additive and logistic EuroSCOREs with 
the new EuroSCORE II to assess whether the latter provides improved risk prediction in 
patients at high-risk for mortality following cardiac surgery.
methods
Data from 2 European centers in the Netherlands (Erasmus MC, Rotterdam) and the United 
Kingdom (University Hospital NHS Foundation Trust, Birmingham) were pooled. At both 
centers, prospective collected data were analysed retrospectively to identify patients that 
underwent cardiac surgery from April 2006 – March 2011 and were predicted to be at 
increased risk as defined by a logistic EuroSCORE ≥10.5 Patients were grouped as per 
EuroSCORE II definitions into those that had undergone isolated CABG, isolated valve or a 
combined procedure.11
Part 1 Patient selection and decision-making28
Although this model was proposed as a generic risk stratification tool we excluded 
patients undergoing aortic surgery, those undergoing procedures for adult congenital heart 
disease, thoracic organ transplantation or post-infarction VSD repair to focus specifically 
on patients undergoing conventional high-risk surgery and to avoid the bias that patients 
undergoing these specific procedures may have introduced into the analysis. Patient data 
was initially obtained from the departmental database. The EuroSCORE II model, however, 
also requires a number of variables not previously used. These variables were obtained 
through retrospective patient notes review. The EuroSCORE II was calculated using the 
online calculator available at www.euroscore.com.
statistical analyses
Continuous  variables are expressed as mean (interquartile range (IQR)) and categorical 
data as proportions. Generalised linear models with a logit link and binomial error were 
developed for each version of the EuroSCORE, with patient status at discharge from the 
hospital (in-hospital mortality as end point) as the response variable.  We assessed the 
discriminating ability of the risk models  by using the c-statistic methodology. We  assessed 
model calibration by portioning the cohort into 6 risk strata of similar size and comparing 
the difference between the observed and expected number of events, using calibration plots 
and the Hosmer Lemeshow test, as suggested by Collins and Altman.11 Finally, model fit 
between the EuroSCORE II and the original additive and logistic EuroSCORE was compared 
using the Aikiake Information Criterion (AIC). Analyses were performed using SAS 9.2. 
results
patient characteristics 
A total of 933 patients were identified that fulfilled the study criteria. Median age was 74.3 
years old (IQR 68 - 78.4), and 57.5% were male (Table 1). Isolated CABG was performed 
in 271 patients, and 185 patients underwent isolated single valve procedures. A combined 
procedure was performed in 477 patients (CABG + valve), of which 173 patients underwent 
3 procedures as defined by EuroSCORE II. The high-risk nature of these patients is well 
demonstrated by the high prevalence of previous cardiac surgery (19.4%), urgent surgery 
(50.2%), severe renal impairment or dialysis (41.8%), and patients in NYHA class III/IV 
(70.2%).
prediction of in-hospital mortality 
The observed in-hospital mortality was 9.7% (90 deaths). The m  edian predicted in-hospital 
mortality was 10% (IQR 9-11) by additive EuroSCORE, 15.3% (IQR 12.0-24.1) by logistic 
EuroSCORE, and 9.3% (IQR 5.8-15.6) by EuroSCORE II, The c-statistic was similar for the 3 
EuroSCORE II in high-risk patient 29
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table 1 patient demographics by euroscore ii variable
number of patients (%)
Age, median (IQR) 74.3 (68 - 78.4)
Renal impairment
 Dialysis 21 (2.3)
 Severe 369 (39.5)
 Moderate 439 (47.1)
 Normal 104 (11.1)
Extra cardiac arteriopathy 243 (26)
Poor mobility 67 (7.2)
Previous cardiac surgery 181 (19.4)
Chronic lung disease 260 (27.9)
Active endocarditis 58 (6.2)
Critical pre-operative state 221 (23.7)
Diabetic on insulin 84 (9)
NYHA III 333 (35.7)
NYHA IV 322 (34.5)
CCS IV 255 (27.3)
LV function
 Good 390 (41.8)
 Moderate 412 (44.2)
 Poor 104 (11.1)
 Very poor 27 (2.9)
Recent MI 313 (33.5)
Pulmonary hypertension
 Severe 183 (19.6)
 Moderate 151 (16.2)
 Normal 599 (64.2)
Urgency
 Elective 376 (40.3)
 Urgent 468 (50.2)
 Emergency 86 (9.2)
 Salvage 3 (0.3)
Weight of the intervention
 Isolated CABG 271 (29)
 Single non-CABG 185 (19.8)
 2 procedures 304 (32.6)
 3 procedures 173 (18.5)
Additive EuroSCORE, median (IQR) 10 (9 - 11)
Logistic EuroSCORE, median (IQR) 15.26 (12.0 - 24.1)
EuroSCORE II, median (IQR) 9.15 (5.7 - 15.5)
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models (0.67 for both the additive EuroSCORE and EuroSCORE II, and 0.66 for the logistic 
EuroSCORE).
The observed versus expected deaths for all three models are described in Figure 1. 
The Hosmer-Lemeshow statistic was compared to a Chi-squared distribution and the p 
value calculated. Model prediction was poor across risk strata for the EuroSCORE II; for the 
Expected
Expected
Expected
A. Additive EuroSCORE
B. Logistic EuroSCORE
C. EuroSCORE II
Observed
Observed
Observed
0.4
0.3
0.2
0.1
0.0
      0.0                        0.1                         0.2                         0.3                        0.4
0.4
0.3
0.2
0.1
0.0
      0.0                        0.1                         0.2                         0.3                        0.4
0.4
0.3
0.2
0.1
0.0
      0.0                        0.1                         0.2                         0.3                        0.4
Chi-square 2.4; P = 0.66
Chi-square 7.8; P = 0.45
Chi-square 16.5; P = 0.35
 figure 1 
observed versus expected risk of mortality (± 95% ci) for risk strata of the additive 
euroscore (A), the logistic euroscore (b), and the euroscore ii (c)
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additive EuroSCORE χ2 was 2.40 (p=0.66), for the logistic EuroSCORE χ2 was 7.81 (p=0.45), 
and for EuroSCORE II χ2 was16.55 (p=0.040). Model fit was significantly worse for the 
Comparing the EuroSCORE II compared with the additive EuroSCORE - difference in AIC of 
-5.66 (p=0.017). Between the logistic EuroSCORE and EuroSCORE II there was no evidence 
of a real difference in model fit - AIC = -1.00 (p=0.32).
discussion
The main finding of this study is that EuroSCORE risk stratification models have poor predict-
ability in high-risk patients and the EuroSCORE II did not improve risk stratification when 
compared to the additive and logistic EuroSCORE. Furthermore, the EuroSCORE II exhibited 
worse calibration than the additive EuroSCORE in our data set. 
We chose to assess the prediction models in a population of patients with multiple co-
morbidities and or advanced age, as these are known to be at higher risk for conventional 
cardiac surgery. It is in this group that it is important to have a reliable tool to predict 
outcome, as often in these patients there are also alternative therapeutic strategies. Patients 
considered for high-risk procedures will be discussed in a multi-disciplinary setting. For 
these patients it is important to consider surgical and percutaneous options available for 
both aortic valve disease 2 and coronary artery disease 12 and it is therefore important to 
have an accurate assessment of operative risk so that recommendations can be justified,13 
and patients fully informed. The accurate assessment of risk is now also important for the 
benchmarking of results as part of the current quality improvement agenda. 
 The risk prediction of all EuroSCORE systems is based on early operative mortality. The 
operative mortality of routine cardiac surgery has been significantly reduced over the last 
decades, which may complicate the longevity of risk models because they no longer rep-
resent contemporary practice. Such reductions could furthermore produce a paradigm shift 
in which mortality may no longer be the key outcome to evaluate. In the United Kingdom 
the in-hospital mortality for non emergency isolated first time CABG is now <1%, and in 
these patients it is equally important to develop tools to predict significant complications 
and or long-term survival. The EuroSCORE II adopted a pragmatic approach to encompass a 
wide spectrum of surgical procedures and risk, and overall its predictability appears to have 
improved over previous iterations of the model. However, when a new risk stratification 
scoring system is introduced, there is also the potential disadvantage that a wealth of data 
from previous systems is no longer useful particularly for contemporaneous benchmark-
ing and quality control. This needs to be offset by a significant improvement in the new 
prediction model, particularly in the areas where the previous EuroSCOREs have shown to 
have a problem. The original EuroSCORE could have been re-calibrated. This approach was 
initially used in the United Kingdom when mortality for first time CABG was benchmarked 
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against the logistic EuroSCORE and divided by a correction factor calculated from the drift 
of predictability with time. This has the advantages of allowing benchmarking against previ-
ously collected data and allows the use of current data capture systems for future work. 
Another option is to design contemporary bespoke models for procedure-specific predic-
tion; the approach adopted by the Society of Thoracic Surgeons (STS). The STS approach 
has the advantage of utilising procedure-specific risk data, but to do so an entirely new 
dataset needs to be constructed in a prospective manner, and it then becomes impossible 
to benchmark results against existing datasets. The EuroSCORE investigators have taken a 
‘half-way house’ approach. They have retained the majority of the pre-specified variables, 
but have added further fields such as estimated glomerular filtration, which has previously 
been shown to be an independent predictor of risk in addition to the EuroSCORE.14
In this study we have tested the EuroSCORE II, in a selected high risk group of patients and 
it is not surprising that a model designed for a range of procedures and risk would not neces-
sarily perform well in such a subset. There might be several reasons for this phenomenon.15
The EuroSCORE II dataset has been based upon data from a multitude of centres through-
out Europe in whom there are differences in outcomes. This phenomenon is demonstrated 
by the fact that while EuroSCORE II seems to be accurate for high risk CABG patients in 
Finland,16 in the UK national database it has shown to have a 30% calibration drift by 
over-estimating predicted mortality.17 The original EuroSCORE model was based on data 
from 128 surgical centres in 8 European countries.18 Patients from these countries showed 
major differences in risk profile and model discrimination ranged from 0.74 in Spain to 
0.87 in Finland.19 For EuroSCORE II a total of 154 centres from 43 European (n=27) and 
non-European (n=16, such as Argentina, India, Saudi Arabia, South Africa, Sudan, Taiwan) 
participated, which is an even more heterogenic patient cohort and represents very different 
practices. 
The new model is quite simple and did not for example explore the value of using 
interaction terms between variables, which is important especially in high-risk patients 
with multiple co-morbidities. The cumulative risk of these factors may cause significant 
over-estimation of the risk of mortality if no interaction terms are used. The STS model 
does take into account interactions (e.g., age x reoperation),20, 21 which allows for a more 
continuous increase of risk that correspond better with observed mortality rates in high-risk 
patients (Figure 2).5, 6 In our cohort of 933 patients, a large number of patients were high-risk 
because they had multiple co-morbidities and/or underwent ≥2 procedures and/or required 
urgent intervention. Their risk would probably have been more accurate if interaction terms 
were used.
Similar to interactions between risk factors, procedure-specific models can be developed 
based on interaction terms between risk factors and the type of procedure.20, 21 The use of 
procedure-specific models, or at least procedure-related coefficients with interaction terms, 
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is clearly one solution to more accurate risk estimation if designing tools with a specific aim 
towards high risk groups. 
While the EuroSCORE II model did include several variables that were not in the original 
EuroSCORE (e.g., NYHA classification), there are still some predictive variables that were 
not included. Studies have shown that frailty is an important predictor in patients under-
going cardiac surgery, particularly in patients with advanced age,22 and a recent report 
showed that the addition of frailty to existing STS and EuroSCORE models increased model 
discrimination.23
Finally, the trade-off between number of variables to include in any model and its result-
ing accuracy, remains unclear. Some simple, user-friendly models with limited number of 
variables (e.g. ACEF score) have shown to be very predictive,24 while inclusion of a great 
number of variables may cause inaccuracies by differently interpreting definitions or calcu-
lation errors.15, 25
limitations
The addition of the new variables in EuroSCORE II has meant that we had to retrospectively 
collect a number of variables. Some patients may therefore be misclassified as having a risk 
factor and the EuroSCORE II might be slightly different. Nevertheless, all included patients 
were already labelled as high-risk by the logistic EuroSCORE.
The current dataset was too small to perform procedure-specific analyses, which would 
have provided additional insights with regard to the development of procedure-specific 
models. Future, larger studies should focus on whether the EuroSCORE II performs equally 
well in CABG, valve, or combined surgery. The additive EuroSCORE was not intended for 
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figure 2
the effect of risk factors on the euroscore ii and sts score in a patient undergoing Avr 
+ cAbg for aortic stenosis and three-vessel disease
DM = diabetes mellitus; LVEF = left ventricular ejection fraction; NYHA = New York Heart Association 
classification
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cohort studies, nevertheless it has been used widely in clinical practice ,and for this reason 
we included it in study design. Our analysis allows relative comparison of EuroSCORE 2 
with the additive and its logistic iteration.
conclusions
The new EuroSCORE II does not improve risk prediction in high-risk patients undergoing 
adult cardiac surgery as compared with the original additive or logistic EuroSCORE. Future 
iterations of the score should explore more advanced statistical methods and focus on devel-
oping procedure-specific algorithms. In addition, the possibility of predicting procedure-
related complications (e.g., stroke) would add significant value to the Euro SCORE model.
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comment: 
Physicians need to make predictions on the prognosis of a treatment that helps them in the 
choice of therapy. Medicine used to be much more subjective than in the current evidence-
based era. Shared decision-making, where physicians and patients both participate in 
deciding on choices for therapy, is also more common.1 Clinical prediction models like 
EuroSCORE may provide the evidence-based input for shared decision-making by providing 
an estimate of the operative risk of patients undergoing cardiac surgery. An ideal clinical 
model would be something simple dividing the patients into ‘good’ and ‘bad’ without 
further specification of the survival chances. The original EuroSCORE was a compromise 
between the ‘statistical ideal’ and the ‘clinical ideal’. It was developed from a large multi-
national European population and was a model predicting mortality based on 17 variables, 
either from a logistic regression equation or from an additive model. Numerous institutions 
throughout the world have tested and validated EuroSCORE.
Loss of calibration with the additive and logistic EuroSCORE has been observed by many 
investigators and an update of the EuroSCORE was warranted. One possible reason for 
the poor calibration of the original EuroSCORE score is that the score was developed from 
patients undergoing surgery almost 20 years ago. As surgical and perioperative care evolves 
and the impact of clinical variables change, prediction models therefore require revision. 
These factors may also vary between institutions and it is well known that the quality of care 
and comorbidities of patients differs between countries. The original EuroSCORE already 
identified major differences in the risk profile of national samples.2 This is therefore one of the 
major concerns with EuroSCORE II: 154 hospitals from 43 countries participated, of which 
many were outside Europe.3 One may, therefore, question whether the term EuroSCORE 
is still valid or another name should be used that reflects the fact that so many countries 
outside Europe participated. With this in mind, it becomes even more important that, as 
indicated by the authors, units and surgeons calculate their own risk-adjusted mortality 
ratio. The model is probably more reliable in the prediction of death over a wide range of 
risk groups rather than the prediction of the vital status of an individual patient.
Another reason for the poor calibration in the original EuroSCORE might be that a large 
number of risk factors in the model are highly correlated. It is important to recognize cor-
relation between predicting variables, as the additional risk contribution of certain variables 
can in some part be explained by the effect of other variables. Some predicting variables 
may also be more important for some types of operations then for others. The large num-
ber of risk factors with potential interaction may overestimate risk in certain categories of 
patients (e.g. intermediate risk or extreme risk). It is therefore a pity that the authors have 
not explored possible interaction terms in the new EuroSCORE II, something the Society of 
Thoracic Surgeons score has taken into account.
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For the analysis, the authors chose to drop cases with missing data. Besides inefficient use 
of available data, bias may arise due to systematic differences between subjects with com-
plete data and subjects with missing data. An estimated regression coefficient for a predictor 
might be influenced if the missing data are associated in some way with the outcome.4 They 
could have chosen to use some form of imputation to preserve those cases. In general, the 
quality of those centres with missing data or those unable to provide specific outcome data 
may be questioned.
One of the major concerns with EuroSCORE II is that the primary outcome was mortality 
at the base hospital. In current practice, however, it is common that patients are transferred 
to referring hospitals at different points in time after the operation. There is significant geo-
graphic and hospital variance with regard to the day of transfer. For example, the length of 
stay in coronary bypass patients in the SYNTAX trial ranged from a mean of 5–20 days. A 
fixed point in time in a mortality prediction model has advantages over the current model, 
as it provides the ability to compare centres. Current guidelines and clinical trial practices 
mandate mortality assessment at 30, 60 or 90 days.5, 6The number of centres that provided 
30- or 90-day mortality was disappointing.
The authors are to be admired for the amount of work they have put into the new model 
and for their energy in starting already on a EuroSCORE III project. We have to be careful, 
however, not to add prognostic factors all the time. Models with only a few parameters 
are quite stable and estimating a few calibration parameters might be enough.7 ‘Garbage 
in, garbage out’ is a well-known problem inherent to risk models, causing inaccurate risk 
prediction. The inclusion of a greater number of variables increases the risk of errors that 
can be caused by differences in the interpretation of definitions, typing errors or conflicting 
chart information.8
It took many years to learn the advantages and shortcomings of EuroSCORE I. Many 
institutions have adopted the EuroSCORE in their quality control programmes. Implement-
ing EuroSCORE II and learning the benefits will also take some time. There is currently more 
need for models that not only focus on mortality but also on postoperative complications 
and the development of procedure-specific models. As clinicians are confronted with more 
elderly patients, it might also be useful to focus on specific subsets of patients. A prognostic 
model is only useful if its predictions are at least as accurate as those of the doctors who 
would use it. We have to be thankful to the initiators of the EuroSCORE project for their great 
contribution to our profession.
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AbstrAct
Transcatheter aortic valve implantation (TAVI) is a less invasive alternative to surgical aortic 
valve replacement (SAVR) for patients with symptomatic severe aortic stenosis (AS) and a 
high operative risk. Risk stratification plays a decisive role in the optimal selection of thera-
peutic strategies for AS patients. The accuracy of contemporary surgical risk algorithms for 
AS patients has spurred considerable debate especially in the higher risk patient population. 
Future trials will explore TAVI in patients at intermediate operative risk. During the design 
of the SURgical replacement and Transcatheter Aortic Valve Implantation (SURTAVI) trial, 
a novel concept of risk stratification was proposed based upon age in combination with a 
fixed number of predefined risk factors, which are relatively prevalent, easy to capture and 
with a reasonable impact on operative mortality. Retrospective application of this algorithm 
to a contemporary academic practice dealing with clinically significant AS patients allocates 
about one-fourth of these patients as being at intermediate operative risk. Further testing is 
required for validation of this new paradigm in risk stratification. Finally, the Heart Team, 
consisting of at least an interventional cardiologist and cardiothoracic surgeon, should have 
the decisive role in determining whether a patient could be treated with TAVI or SAVR.
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introduction
Transcatheter aortic valve implantation (TAVI) is rapidly emerging as a viable and less 
invasive alternative to surgical aortic valve replacement (SAVR) for high-risk patients with 
symptomatic severe aortic valve stenosis (AS).1-4 In spite of the ever improving outcome 
with SAVR, especially in higher risk cohorts, the EURO Heart survey suggested that a 
considerable number of AS patients are denied surgery for various reasons including age, 
left ventricular (LV) dysfunction and comorbidities.5 By precluding sternotomy and car-
diopulmonary bypass, TAVI provides the potential for off-pump and beating heart valve 
implantation, which may translate into faster recovery, shorter hospitalisation and more 
rapid improvement in quality of life. Risk stratification plays a decisive role in the optimal 
selection of therapeutic strategies among AS patients.
Various national and multicentre TAVI registries, and single centre experiences have 
reported favourable short- and mid-term clinical outcomes.1-7 Cohort B of the randomised 
Placement of Aortic Transcatheter Valves (PARTNER) trial demonstrated an important 
improvement in 1-year mortality and quality of life with TAVI as compared to optimal medi-
cal therapy and/or isolated balloon aortic valvuloplasty in prohibitive surgical risk patients.8 
The PARTNER Cohort A demonstrated similar 1-year survival rates among high-risk patients 
randomly assigned to either TAVI or SAVR. Vascular complications and neurological events, 
however, were higher in the TAVI cohort, whereas atrial fibrillation and major bleeding were 
more frequent in the SAVR cohort.9 From a European perspective, the PARTNER trial has 
to be critically commented on in regard to the fact that a) patients were selected, thus not 
all-comers were treated and, b) patients were on a waiting list, both of which may lead to 
improved outcomes.
The applicability of contemporary surgical risk algorithms for AS patients has spurred 
considerable debate in both cardiac surgery and cardiology communities.10-14 The STS 
Predicted Risk of Mortality (PROM) and the logistic EuroSCORE have been widely applied to 
determine the operative mortality risk of AS patients undergoing SAVR. Both scoring models, 
however, are fraught with shortcomings, especially in higher-risk patient populations cur-
rently undergoing TAVI. These risk models in isolation may not provide a satisfactory risk 
assessment. Even though the combination of different risk scores may improve their predic-
tive value, combining risk models to determine a predictive value has not been validated 
and raises practical concerns. It is axiomatic that a risk-scoring model should be relatively 
simple, reliable and reproducible.
The SURgical replacement and Transcatheter Aortic Valve Implantation (SURTAVI) trial 
is a multicentre randomised trial to assess the optimal treatment strategy for patients with 
symptomatic, severe AS at intermediate risk by randomising patients to either SAVR or TAVI 
with the Medtronic CoreValve System™ (Medtronic, Minneapolis, MN, USA).
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Our aim was to illustrate the process of conceptualising a randomised trial with TAVI and 
SAVR in patients with symptomatic severe AS at intermediate operative risk with respect to 
the current knowledge of risk stratification. We briefly underscore the inconsistencies and 
shortcomings of the two widely used risk models (STS PROM and Logistic EuroSCORE). In 
accordance with the body of contemporary published literature, we suggest that the concept 
of risk stratification could be based upon age in combination with a fixed number of pre-
defined risk factors. It should be emphasised that, in all scenarios, the Heart Team, consisting 
of at least an interventional cardiologist and cardiothoracic surgeon, has a decisive role in 
determining whether a patient could be treated with TAVI or SAVR.15
inconcistencies in the logistic euroscore And sts prom
Models for predicting surgical outcomes on the basis of preoperative patient characteristics 
are valuable tools for research, quality improvement and clinical practice and may even be 
used for patient counselling about an individual’s operative risk.
The STS PROM and Logistic EuroSCORE are widely used risk models to assess the 
operative risk of AS patients.16-19 However, inaccurate risk estimation for surgical AVR is 
more the rule than the exception, and inconsiderate use of these algorithms for benchmark 
performance testing could lead to inappropriate enthusiasm for technologic innovations like 
TAVI.10, 13 Recent data suggest that a risk model containing only three variables (age, EF and 
creatinine) might have at least as good accuracy and calibration as the more complex risk 
models.20 An Italian multicentre study analysing 29,659 consecutive patients who under-
went cardiac surgery demonstrated that this same simple model led to overestimation of 
short-term operative mortality risk in patients at very-low risk and, conversely, underestima-
tion in patients at very-high risk.21
rAtionAle for the Algorithm of 10 risk fActors
With the established shortcomings of currently used risk models in mind we moved to a 
novel concept of risk stratification, the so-called SURTAVI model. Clearly, according to 
established risk models like the STS PROM and Logistic EuroSCORE, an increasing number 
of risk factors will augment an individual patient’s risk. This begs the question of whether a 
patient’s operative risk will be based on age and the number of risk factors present (Figure 
1). Analysis of the impact of different risk variables and their combination in different age 
cohorts in the STS score and Logistic EuroSCORE suggests risk variables can accommodate 
for age resulting in similaroverall risk profiles. An arbitrarily defined intermediate risk with 
STS score <10 and/or Logistic EuroSCORE <20 is reached by either the combination of an 
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Figure 1. Concept of risk models: impact of age and comorbidities 
on operative risk.
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Figure 2. Intermediate risk in the SURTAVI model (combination of 
age 70-74 years and two or three comorbidities, age 75-79 and one 
or two comorbidities and age ≥80 and one or no comorbidities) and 
resultant STS and Logistic EuroSCORE.
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Figure 4. BERMUDA initiative. Upper Panel: Logistic EuroSCORE 
in different age groups for TAVI and SAVR. Lower Panel: Propensity 
score matched (PSM) analysis: constant Logistic EuroSCORE across 
age groups suggesting more comorbidities in lower age groups.
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Data from the Bern-Munich-Rotterdam (BERMUDA) initiative 
illustrated the concept of age and comorbidities in a pooled dataset 
of 2,884 SAVR and 782 TAVI patients. The estimated logistic 
EuroSCORE increased with age, while each age group of TAVI 
patients had a higher logistic EuroSCORE than SAVR patients 
(Figure 4). Propensity score matching analysis identified a patient 
cohort of 784 patients (392 in each group) and demonstrated 1) both 
TAVI and SAVR cohorts had similar estimated operative risks 
according to the Logistic EuroSCORE and 2) the risk profile was 
similar across all age groups (Figure 4). The latter illustrates that 
younger patients had more comorbidities than their older counter-
parts, which therefore counterbalanced the risk related to age in this 
study. Figure 5 demonstrates that neither the STS score nor Logistic 
EuroSCORE can uniformly discriminate between a patient’s opera-
tive risk. An STS score of 4 for instance did not correlate with 
a logistic EuroSCORE nor with the proposed SURTAVI model. 
Apparently, the established risk models do not uniformly determine 
a patient’s operative risk.
RISK	FACTOR	SELECTION	PROCESS
The risk algorithm should be applicable to potential TAVI candi-
dates. Therefore, particular variables that would preclude TAVI are 
excluded (e.g., infectious endocarditis, concomitant valve surgery, 
emergent procedure, multivessel or left main stem coronary artery 
disease with a SYNTAX score >33, etc… see Appendix). Selected 
risk factors should be relatively prevalent, easy to capture and have 
a reasonable impact on operative mortality.
We reviewed the risk models evaluated in the last 15 years and 
ranked the contained variables according to their corresponding 
figure 1 conc pt of risk models: impact f age and comorbiditi s on operative risk
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age 70-74 years and two or three comorbidities, age 75-79 and one 
or two comorbidities and age ≥80 and one or no comorbidities) and 
resultant STS and Logistic EuroSCORE.
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Figure 4. BERMUDA initiative. Upper Panel: Logistic EuroSCORE 
in different age groups for TAVI and SAVR. Lower Panel: Propensity 
score matched (PSM) analysis: constant Logistic EuroSCORE across 
age groups suggesting more comorbidities in lower age groups.
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Data from the Bern-Munich-Rotterdam (BERMUDA) initiative 
illustrated the concept of age and comorbidities in a pooled dataset 
of 2,884 SAVR and 782 TAVI patients. The estimated logistic 
EuroSCORE increased with age, while each age group of TAVI 
patients had a higher logistic EuroSCORE than SAVR patients 
(Figure 4). Propensity score matching analysis identified a patient 
cohort of 784 patients (392 in each group) and demonstrated 1) both 
TAVI and SAVR cohorts had similar estimated operative risks 
according to the Logistic EuroSCORE and 2) the risk profile was 
similar across all age groups (Figure 4). The latter illustrates that 
younger patients had more comorbidities than their older counter-
parts, which therefore counterbalanced the risk related to age in this 
study. Figure 5 demonstrates that neither the STS score nor Logistic 
EuroSCORE can uniformly discriminate between a patient’s opera-
tive risk. An STS score of 4 for instance did not correlate with 
a logistic EuroSCORE nor with the proposed SURTAVI model. 
Apparently, the established risk models do not uniformly determine 
a patient’s operative risk.
RISK	FACTOR	SELECTION	PROCESS
The risk algorithm should be applicable to potential TAVI candi-
dates. Therefore, particular variables that would preclude TAVI are 
excluded (e.g., infectious endocarditis, concomitant valve surgery, 
emergent procedure, multivessel or left main stem coronary artery 
disease with a SYNTAX score >33, etc… see Appendix). Selected 
risk factors should be relatively prevalent, easy to capture and have 
a reasonable impact on operative mortality.
We reviewed the risk models evaluated in the last 15 years and 
ranked the contained variables according to their corresponding 
figure 2
range of sts score and logistic euroscore in intermediate risk patients according to 
the surtAvi model
The SURTAVI model is a combination of age 70-75 years and 2 or 3 comorbidities, age 75-79 and 1 or 2 
comorbidities and age ≥80 and 0 or 1 comorbidities.
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Figure 2. Intermediate risk in the SURTAVI model (combination of 
age 70-74 years and two or three comorbidities, age 75-79 and one 
or two comorbidities and age ≥80 and one or no comorbidities) and 
resultant STS and Logistic EuroSCORE.
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in different age groups for TAVI and SAVR. Lower Panel: Propensity 
score matched (PSM) analysis: constant Logistic EuroSCORE across 
age groups suggesting more comorbidities in lower age groups.
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Data from the Bern-Munich-Rotterdam (BERMUDA) initiative 
illustrated the concept of age and comorbidities in a pooled dataset 
of 2,884 SAVR and 782 TAVI patients. The estimated logistic 
EuroSCORE increased with age, while each age group of TAVI 
patients had a higher logistic EuroSCORE than SAVR patients 
(Figure 4). Propensity score matching analysis identified a patient 
cohort of 784 patients (392 in each group) and demonstrated 1) both 
TAVI and SAVR cohorts had similar estimated operative risks 
according to the Logistic EuroSCORE and 2) the risk profile was 
similar across all age groups (Figure 4). The latter illustrates that 
younger patients had more comorbidities than their older counter-
parts, which therefore counterbalanced the risk related to age in this 
study. Figure 5 demonstrates that neither the STS score nor Logistic 
EuroSCORE can uniformly discriminate between a patient’s opera-
tive risk. An STS score of 4 for instance did not correlate with 
a logistic EuroSCORE nor with the proposed SURTAVI model. 
Apparently, the established risk models do not uniformly determine 
a patient’s operative risk.
RISK	FACTOR	SELECTION	PROCESS
The risk algorithm should be applicable to potential TAVI candi-
dates. Therefore, particular variables that would preclude TAVI are 
excluded (e.g., infectious endocarditis, concomitant valve surgery, 
emergent procedure, multivessel or left main stem coronary artery 
disease with a SYNTAX score >33, etc… see Appendix). Selected 
risk factors should be relatively prevalent, easy to capture and have 
a reasonable impact on operative mortality.
We reviewed the risk models evaluated in the last 15 years and 
ranked the contained variables according to their corresponding 
figure 3 principles of the surtAvi model
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age 70-74 years and two or three comorbidities, age 75-79 and one 
or two comorbidities and age ≥80 and one or no comorbidities) and 
resultant STS and Logistic EuroSCORE.
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age groups suggesting more comorbidities in lower age groups.
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Data from the Bern-Munich-Rotterdam (BERMUDA) initiative 
illustrated the concept of age and comorbidities in a pooled dataset 
of 2,884 SAVR and 782 TAVI patients. The estimated logistic 
EuroSCORE increased with age, while each age group of TAVI 
patients had a higher logistic EuroSCORE than SAVR patients 
(Figure 4). Propensity score matching analysis identified a patient 
cohort of 784 patients (392 in each group) and demonstrated 1) both 
TAVI and SAVR cohorts had similar estimated operative risks 
according to the Logistic EuroSCORE and 2) the risk profile was 
similar across all age groups (Figure 4). The latter illustrates that 
younger patients had more comorbidities than their older counter-
parts, which therefore counterbalanced the risk related to age in this 
study. Figure 5 demonstrates that neither the STS score nor Logistic 
EuroSCORE can uniformly discriminate between a patient’s opera-
tive risk. An STS score of 4 for instance did not correlate with 
a logistic EuroSCORE nor with the proposed SURTAVI model. 
Apparently, the established risk models do not uniformly determine 
a patient’s operative risk.
RISK	FACTOR	SELECTION	PROCESS
The risk algorithm should be applicable to potential TAVI candi-
dates. Therefore, particular variables that would preclude TAVI are 
excluded (e.g., infectious endocarditis, concomitant valve surgery, 
emergent procedure, multivessel or left main stem coronary artery 
disease with a SYNTAX score >33, etc… see Appendix). Selected 
risk factors should be relatively prevalent, easy to capture and have 
a reasonable impact on operative mortality.
We reviewed t e risk models evaluated in the last 15 years and 
ranked the contained variables according to their corresponding 
figure 4 bermudA initiative
Upper panel: Logistic EuroSCORE in different age groups for TAVI and SAVR. Lower Panel: propensity score 
matched analysis in which the comparable Logistic EuroSCORE across age groups suggests that lower age groups 
have more comorbidities.
The SURTAVI model for risk stratification in AS 51
C
ha
pt
er
 5
age of 70-74 years with two or three comorbidities, or an age of 75-79 with one or two 
comorbidities or an age ≥80 and one or no comorbidities (Figure 2). The SURTAVI model 
1) emphasises the pivotal importance of the independent “age” variable and 2) allows the 
identification of an intermediate risk group across different age cohorts based on the number 
of predefined risk variables. A younger patient with more risk factors may have a similar 
risk profile as that of an older patient who has less risk factors. Accordingly, the SURTAVI 
algorithm defines a low-risk, intermediate and high-risk cohort (Figure 3).
Data from the Bern-Munich-Rotterdam (BERMUDA) initiative illustrated the concept 
of age and comorbidities in a pooled dataset of 2,884 SAVR and 782 TAVI patients. The 
estimated logistic EuroSCORE increased with age, while each age group of TAVI patients 
had a higher logistic EuroSCORE than SAVR patients (Figure 4). Propensity score matching 
analysis identified a patient cohort of 784 patients (392 in each group) and demonstrated 1) 
both TAVI and SAVR cohorts had similar estimated operative risks according to the Logistic 
EuroSCORE and 2) the risk profile was similar across all age groups (Figure 4). The lat-
ter illustrates that younger patients had more comorbidities than their older counterparts, 
which therefore counterbalanced the risk related to age in this study. Figure 5 demonstrates 
that neither the STS score nor Logistic EuroSCORE can uniformly discriminate between 
n
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Table 1. Risk models in the literature.
Database Year (n)	variables (n)	patients Type	of	surgery 30-day	mortality
Providence Health System 2005 12 4,914 3 5
Northern New England 2004 11 5,793 2 6.2
Ambler 2005 14 32,839 3 6.4
Department of Veteran Affairs 2004 14 7,450 2 6.1
NIS 2000 16 46,397 1 6.4
New York State 2007 11 10,702 3 4.41
New York State 2007 12 8,823* 2 8.89
NWQIP 2007 10 4,450 2 4.6
Baden 2006 20 2,198 2 3.8
EuroSCORE 1999 17 13,302 4 4.7
Halifax 2010 10 3,826 4 4.9
STS NCD 2009 23 67,292 1 3.2
STS NCD 2009 23 66,074 2 5.6
Figure 5. The dots represent the STS and EuroSCORE of each 
individual patient in the propensity matched database from the 
BERMUDA initiative (see text). The colour code refers to the risk 
classification according to the SURTAVI model. Green: low risk; 
orange: intermediate risk; red: high risk. The shaded area magnifies 
three patients with an STS score of 4% and a Logistic EuroSCORE 
of 10%. According to the SURTAVI model this combination could 
result in low-, intermediate- or high-risk.
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odds ratio in the respective risk models14,16,17,19,22-31 (Table 1, 
Figure 6). Apart from age, cardiac reoperation, depressed LV func-
tion; chronic obstructive pulmonary disease (COPD), renal insuffi-
ciency, cerebrovascular disease, peripheral arterial disease, 
pulmonary hypertension and diabetes emerged. Particular variables 
not listed in previous models appear relevant in a higher risk popu-
lation eligible for TAVI, and would therefore merit consideration. 
Previous mediastinal radiation, liver failure, chest deformity, porce-
lain aorta and frailty were evaluated32-37. It is especially frailty that 
has emerged as a significant and prevalent risk factor for operative 
mortality. Depending on the definition used, its prevalence in an AS 
population would vary from 4 to 50%36-38.
Eventually, ten risk factors were selected.
Each variable was defined according to contemporary literature 
and those used by professional societies/organisations:
1.	SIGNIFICANT	CONCURRENT	CORONARY	ARTERY	DISEASE	
(CAD)	REQUIRING	REVASCULARISATION
Multivessel CAD and/or left main stem disease with a calculated SYN-
TAX score >33 make catheter bound therapies less favourable, and would 
be considered a relative contraindication for TAVI. Previous CABG or PCI 
is not considered to have considerable impact on short-term outcome.
2.	FRAILTY
In the absence of a generally accepted consensus definition, frailty 
is defined as suggested by Lee and co-workers by the presence of 
any one of the following36: 1. Katz score (independence in “activities 
of daily living”); 2. Ambulation (walking aid/assist?); 3. Diagnosis 
of (pre)dementia.
3.	LEFT	VENTRICULAR	DYSFUNCTION
Defined as an EF <35%, with respect to the pivotal position of this 
particular threshold in the heart failure population39.
4.	NEUROLOGICAL	DYSFUNCTION
Neurologic disease severely affecting ambulation or day-to-day 
functioning excluding TIA and carotid artery disease, adapted from 
the Logistic EuroSCORE19.
5.	PULMONARY	DISEASE
COPD Gold Stage II: moderate COPD with worsening airflow 
limitation (FEV1/FVC <70%; 50% ≥FEV1 <80% predicted), with 
shortness of breath typically developing on exertion40.
figure 5
the sts and euroscore of each individual patient in the propensity matched database 
from the bermudA initiative
The colour code refers to the risk classification according to the SURTAVI mode; gre n  =  low risk, orange  =  
intermediate risk, red  =  high risk. The shaded are magnifies three patients with an STS score of 4% and a Logistic 
EuroSCORE of 10%. According to the SURTAVI model this combination could result in low, intermediate or high 
risk.
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a patient’s operative risk. An STS score of 4 for instance did not correlate with a logistic 
EuroSCORE nor with the proposed SURTAVI model. Apparently, the established risk models 
do not uniformly determine a patient’s operative risk.
risk fActor selection process
The risk algorithm should be applicable to potential TAVI candidates. Therefore, particular 
variables that would preclude TAVI are excluded (e.g., infectious endocarditis, concomitant 
valve surgery, emergent procedure, multivessel or left main stem coronary artery disease 
with a SYNTAX score >33). Selected risk factors should be relatively prevalent, easy to 
capture and have a reasonable impact on operative mortality.
We reviewed the risk models evaluated in the last 15 years and ranked the contained 
variables according to their corresponding odds ratio in the respective risk models (Table 
1, Figure 6).14, 16, 17, 19, 22-31 Apart from age, cardiac reoperation, depressed LV function; 
chronic obstructive pulmonary disease (COPD), renal insufficiency, cerebrovascular dis-
ease, peripheral arterial disease, pulmonary hypertension and diabetes emerged. Particular 
variables not listed in previous models appear relevant in a higher risk population eligible 
for TAVI, and would therefore merit consideration. Previous mediastinal radiation, liver 
failure, chest deformity, porcelain aorta and frailty were evaluated.32-37It is especially frailty 
table 1 preoperative risk models
database year variables (n) patients (n) 30-day mortality
Providence Health System 2005 12 4,914 5%
Northern New England 2004 11 5,793 6.2%
Ambler 2005 14 32,839 6.4%
Department of Veterans Affairs 2004 14 7,450 6.1%
NIS 2000 16 46,397 6.4%
New York State* 2007 11 10,702 4.4%
New York State* 2007 12 8,823 8.9%
NWQIP 2007 10 4,450 4.6%
Baden 2006 20 2,198 3.8%
EuroSCORE 1999 17 13,302 4.7%
Halifax 2010 10 3,826 4.9%
STS NCD† 2009 23 67,292 3.2%
STS NCD† 2009 23 66,074 5.6%
*† These models have been developed for different patient populations, including patients undergoing coronary 
artery bypass grafting and aortic valve replacement.
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that has emerged as a significant and prevalent risk factor for operative mortality. Depending 
on the definition used, its prevalence in an AS population would vary from 4 to 50%.36-38
Eventually, ten risk factors were selected. Each variable was defined according to con-
temporary literature and those used by professional societies/organisations:
1. SIGNIFICANT CONCURRENT CORONARY ARTERY DISEASE (CAD) REQUIRING 
REVASCULARISATION
Multivessel CAD and/or left main stem disease with a calculated SYNTAX score >33 make 
catheter bound therapies less favourable, and would be considered a relative contraindica-
tion for TAVI. Previous CABG or PCI is not considered to have considerable impact on 
short-term outcome.
2. FRAILTY
In the absence of a generally accepted consensus definition, frailty is defined as suggested 
by Lee and co-workers by the presence of any one of the following:36 1. Katz score (inde-
pendence in “activities of daily living”); 2. Ambulation (walking aid/assist?); 3. Diagnosis of 
(pre)dementia.
3. LEFT VENTRICULAR DYSFUNCTION
Defined as an EF <35%, with respect to the pivotal position of this particular threshold in 
the heart failure population.39
4. NEUROLOGICAL DYSFUNCTION
Neurologic disease severely affecting ambulation or day-to-day functioning excluding TIA 
and carotid artery disease, adapted from the Logistic EuroSCORE.19
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6.	PERIPHERAL	VASCULAR	DISEASE
Adapted from the STS risk model: claudication, either with exertion 
or at rest; amputation for arterial vascular insufficiency; vascular 
reconstruction, bypass surgery, or percutaneous intervention to the 
extremities; documented aortic aneurysm with or without repair; 
positive noninvasive test (e.g., ankle brachial index ≤0.9, ultrasound, 
magnetic resonance or computed tomography imaging of >50% 
diameter stenosis in any peripheral artery, i.e., renal, subclavian, fem-
oral, iliac); noninvasive carotid test with >60% diameter occlusion or 
prior carotid surgery or symptomatic carotid stenosis >50%16,41-43.
7.	RENAL	DISEASE
At least moderate chronic kidney disease with GFR <60 mL/min 
according to the National Kidney Foundation kidney disease out-
come quality initiative advisory board44.
8.	REDO	CARDIAC	SURGERY
9.	PULMONARY	HYPERTENSION
>60 mmHg at most recent measurement.
10.	DIABETES	MELLITUS
On oral or insulin therapy.
An expert panel of interventional cardiologists and cardiac sur-
geons assessed and confirmed the selected variables and introduced 
the feature of the “open box” in order to capture those risk variables 
that would appear less prevalent, but nevertheless would merit con-
sideration for the risk stratification of the individual AS patient. 
Typical entities in the “open box’ will be (among others) porcelain 
aorta, complex chest deformity, previous extensive mediastinal 
radiation and advanced liver failure (Child-Pugh class C).
APPLICATION	OF	THE	SURTAVI	MODEL	IN	PRACTICE
As proof of concept, we applied the SURTAVI risk algorithm to all 
AS patients undergoing SAVR or TAVI over a 5-year period in the 
Figure 6. Odds ratio of variables in different surgical risk models.
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Figure 7. Rotterdam database on AS patient undergoing SAVR or 
TAVI and categorisation into three risk groups according to the 
SURTAVI model.
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Thoraxcenter, Rotterdam, The Netherlands. Data collection was 
complete for the TAVI cohort, whereas frailty was not reliably mon-
itored in the SAVR cohort. Figure 7 illustrates the subdivision of 
patients into three risk groups according to the SURTAVI algo-
rithm. Over 60% of cases would be deemed low risk, whereas 26% 
would be adjudicated at intermediate risk. This implies that the 
anticipated SURTAVI trial entails grossly one fourth of contempo-
rary AS practice.
The incomplete data on frailty and the “open box” items (porce-
lain aorta, liver failure, mediastinal radiation…) suggest that 
patients could shift to a higher risk cohort based on the presence of 
additional risk variables not captured in the predefined “list of 10 
comorbidities” or frailty. With these limitations in mind, the 30-day 
mortality was 98.2, 95.0 and 89.2% (p <0.001) and the 1-year mor-
tality was 95.5, 88.4 and 78.4% (p <0.001) in the low, intermediate 
and high-risk groups respectively (Figure 8 and Figure 9). As for 
the intermediate risk group in particular, we could not detect any 
difference in outcome between the three age cohorts underscoring 
the SURTAVI concept of risk stratification (Figure 10).
figure 6 odds ratio of variables in different surgical risk models
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5. PULMONARY DISEASE
COPD Gold Stage II: moderate COPD with worsening airflow limitation (FEV1/FVC <70%; 
50% ≥FEV1 <80% predicted), with shortness of breath typically developing on exertion.40
6. PERIPHERAL VASCULAR DISEASE
Adapted from the STS risk model: claudication, either with exertion or at rest; amputation 
for arterial vascular insufficiency; vascular reconstruction, bypass surgery, or percutaneous 
intervention to the extremities; documented aortic aneurysm with or without repair; positive 
noninvasive test (e.g., ankle brachial index ≤0.9, ultrasound, magnetic resonance or com-
puted tomography imaging of >50% diameter stenosis in any peripheral artery, i.e., renal, 
subclavian, femoral, iliac); noninvasive carotid test with >60% diameter occlusion or prior 
carotid surgery or symptomatic carotid stenosis >50%.16, 41-43
7. RENAL DISEASE
At least moderate chronic kidney disease with GFR <60 mL/min according to the National 
Kidney Foundation kidney disease outcome quality initiative advisory board.44
8. REDO CARDIAC SURGERY
9. PULMONARY HYPERTENSION
>60 mmHg at most recent measurement.
10. DIABETES MELLITUS
On oral or insulin therapy.
An expert panel of interventional cardiologists and cardiac surgeons assessed and confirmed 
the selected variables and introduced the feature of the “open box” in order to capture those 
risk variables that would appear less prevalent, but nevertheless would merit consideration 
for the risk stratification of the individual AS patient. Typical entities in the “open box’ will 
be (among others) porcelain aorta, complex chest deformity, previous extensive mediastinal 
radiation and advanced liver failure (Child-Pugh class C).
ApplicAtion of the surtAvi model in prActice
As proof of concept, we applied the SURTAVI risk algorithm to all AS patients undergoing 
SAVR or TAVI over a 5-year period in the Thoraxcenter, Rotterdam, The Netherlands. Data 
collection was complete for the TAVI cohort, whereas frailty was not reliably monitored 
in the SAVR cohort. Figure 7 illustrates the subdivision of patients into three risk groups 
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according to the SURTAVI algorithm. Over 60% of cases would be deemed low risk, 
whereas 26% would be adjudicated at intermediate risk. This implies that the anticipated 
SURTAVI trial entails grossly one fourth of contemporary AS practice. The incomplete data 
on frailty and the “open box” items (porcelain aorta, liver failure, mediastinal radiation…) 
suggest that patients could shift to a higher risk cohort based on the presence of additional 
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6.	PERIPHERAL	VASCULAR	DISEASE
Adapted from the STS risk model: claudication, either with exertion 
or at rest; amputation for arterial vascular insufficiency; vascular 
reconstruction, bypass surgery, or percutaneous intervention to the 
extremities; documented aortic aneurysm with or without repair; 
positive noninvasive test (e.g., ankle brachial index ≤0.9, ultrasound, 
magnetic resonance or computed tomography imaging of >50% 
diameter stenosis in any peripheral artery, i.e., renal, subclavian, fem-
oral, iliac); noninvasive carotid test with >60% diameter occlusion or 
prior carotid surgery or symptomatic carotid stenosis >50%16,41-43.
7.	RENAL	DISEASE
At least moderate chronic kidney disease with GFR <60 mL/min 
according to the National Kidney Foundation kidney disease out-
come quality initiative advisory board44.
8.	REDO	CARDIAC	SURGERY
9.	PULMONARY	HYPERTENSION
>60 mmHg at most recent measurement.
10.	DIABETES	MELLITUS
On oral or insulin therapy.
An expert panel of interventional cardiologists and cardiac sur-
geons assessed and confirmed the selected variables and introduced 
the feature of the “open box” in order to capture those risk variables 
that would appear less prevalent, but nevertheless would merit con-
sideration for the risk stratification of the individual AS patient. 
Typical entities in the “open box’ will be (among others) porcelain 
aorta, complex chest deformity, previous extensive mediastinal 
radiation and advanced liver failure (Child-Pugh class C).
APPLICATION	OF	THE	SURTAVI	MODEL	IN	PRACTICE
As proof of concept, we applied the SURTAVI risk algorithm to all 
AS patients undergoing SAVR or TAVI over a 5-year period in the 
Figure 6. Odds ratio of variables in different surgical risk models.
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Figure 7. Rotterdam database on AS patient undergoing SAVR or 
TAVI and categorisation into three risk groups according to the 
SURTAVI model.
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Thoraxcenter, Rotterdam, The Netherlands. Data collection was 
complete for the TAVI cohort, whereas frailty was not reliably mon-
itored in the SAVR cohort. Figure 7 illustrates the subdivision of 
patients into three risk groups according to the SURTAVI algo-
rithm. Over 60% of cases would be deemed low risk, whereas 26% 
would be adjudicated at intermediate risk. This implies that the 
anticipated SURTAVI trial entails grossly one fourth of contempo-
rary AS practice.
The incomplete data on frailty and the “open box” items (porce-
lain aorta, liver failure, mediastinal radiation…) suggest that 
patients could shift to a higher risk cohort based on the presence of 
additional risk variables not captured in the predefined “list of 10 
comorbidities” or frailty. With these limitations in mind, the 30-day 
mortality was 98.2, 95.0 and 89.2% (p <0.001) and the 1-year mor-
tality was 95.5, 88.4 and 78.4% (p <0.001) in the low, intermediate 
and high-risk groups respectively (Figure 8 and Figure 9). As for 
the intermediate risk group in particular, we could not detect any 
difference in outcome between the three age cohorts underscoring 
the SURTAVI concept of risk stratification (Figure 10).
figure 7
patients with aortic stenosis treated with tAvi or sAvr in rotterdam, categorized into 3 
risk groups according to the surtAvi model
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Figure 8. Rotterdam database on AS patient undergoing SAVR or 
TAVI: 30-day mortality in low-, intermediate- and high-risk cohorts.
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Figure 9. Rotterdam database on AS patient undergoing SAVR or 
TAVI: 1-year mortality in low-, intermediate- and high-risk cohorts.
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Figure 10. Rotterdam database on AS patient undergoing SAVR or 
TAVI: 30-day and 1-year mortality in the intermediate risk cohort 
according to different age groups.
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representing minimal risk. Finally, the FDA also stated that less 
prevalent risk factors to be captured in the “open box” (like por-
celain aorta, immunosuppressive disorders, mediastinal radia-
tion…) would place a patient immediately in the high-risk 
category. Although the protocol has been revised according to the 
FDA suggestions, we still believe the above-stipulated SURTAVI 
risk paradigm is valid, and indeed may prove to be an accurate 
and yet user-friendlier tool, in identifying the “intermediate risk” 
patient.
Conclusion
The forthcoming SURTAVI trial introduces a new concept of risk strat-
ifying patients with severe AS undergoing surgical or catheter based 
therapy. Risk stratification is based on the combination of age and a 
fixed number of predefined risk variables. Retrospective application of 
this algorithm to a contemporary academic practice dealing with clini-
cally significant severe AS patients allocates about one fourth of 
patients as being at intermediate operative risk, which will constitute 
the target patient population for the SURTAVI trial. Further testing is 
required for validation of this new paradigm in risk stratification.
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Appendix
–  Exclusion criteria for SURTAVI model
–  Blood dyscrasias as defined: leukopenia (WBC <1000 mm3), 
thrombocytopenia (platelet count <50,000 cells/mm3), history of 
bleeding diathesis or coagulopathy, or hypercoagulable states
–  Ongoing sepsis, including active endocarditis
–  Cardiogenic shock manifested by low cardiac output, vasopressor 
dependence, or mechanical haemodynamic support
–  Recent (within six months of randomisation) cerebrovascular 
accident (CVA) or transient ischaemic attack (TIA)
–  Gastrointestinal (GI) bleeding within the past three months
–  Severe dementia (resulting in either inability to provide informed 
consent for the trial/procedure, prevents independent lifestyle outside 
of a chronic care facility, or will fundamentally complicate rehabilita-
tion from the procedure or compliance with follow-up visits)
–  Multivessel coronary artery disease with a SYNTAX score >33
–  Estimated life expectancy of less than 12 months due to associ-
ated non-cardiac comorbid conditions
–  Evidence of an acute myocardial infarction ≤30 days before the 
index procedure
–  Need for emergency surgery for any reason
–  End stage renal disease requiring chronic dialysis or creatinine 
clearance <20 cc/min
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FDA	PERSPECTIVE
Initially started as an investigator driven trial, SURTAVI evolved 
into a so-called industry sponsored (i.e., Medtronic Inc.) trial 
seeking Investigational Device Exemption (IDE) approval by the 
Federal Drug Administration (FDA). Since TAVI heralds the use 
of a “significant risk device”, FDA approval is essential to qualify 
for future regulatory purposes and product labelling in the USA. 
Therefore, a complete pre-IDE application was submitted to the 
FDA for critical review. According to the FDA, the STS Risk Cal-
culator should be used for mortality prediction with outliers 
allowed by qualitative surgical assessment for patients with risk 
factors not captured by the STS score. A calculated risk between 4 
and 8% would define intermediate risk. The FDA argued against 
the introduction of arbitrary age-range groups. Furthermore, the 
FDA suggested many of the comorbidities could be interpreted as 
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Figure 8. Rotterdam database on AS patient undergoing SAVR or 
TAVI: 30-day mortality in low-, intermediate- and high-risk cohorts.
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Figure 9. Rotterdam database on AS patient undergoing SAVR or 
TAVI: 1-year mortality in low-, intermediate- and high-risk cohorts.
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Figure 10. Rotterdam database on AS patient undergoing SAVR or 
TAVI: 30-day and 1-year mortality in the intermediate risk cohort 
according to different age groups.
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representing minimal risk. Finally, the FDA also stated that less 
prevalent risk factors to be captured in the “open box” (like por-
celain aorta, immunosuppressive disorders, mediastinal radia-
tion…) would place a patient immediately in the high-risk 
category. Although the protocol has been revised accor ing to the
FDA sugge tions, we still believe the above-stipulated SURTAVI 
risk paradigm is valid, and inde d may prove to be a  accurate 
and yet user-friendli r tool, in identifying the “interm diate risk”
p ient.
Conclusion
The for hcoming SURTAVI trial introduces a new concept of risk strat-
ifying patients with severe AS undergoing surgical or catheter based 
therapy. Risk stratification is based on the combination of age and a 
fixed number of predefined risk variables. Retrospective application of 
this algorith  to a contempo ary academic practice dealing w th clini
cally significant severe AS patients allocates about one fourth of
patients as being at intermediate operativ risk, which will constitute
the target patient population for the SURTAVI trial. Further tes ng is
required for valid ti  of this new p radigm in risk str t fication.
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bleeding diathesis or coagulopathy, or hypercoagulable states
Ongoing sepsis, including active en ocarditis
Cardiogenic shock mani ested by low cardiac output, vasopressor
dependence, or mechanical haemodynamic support
–  R cent (within six m nths of randomisation) cerebrovascular 
accide t (CVA) or transient ischa mic attack (TIA)
G str intestinal (GI) bleeding within the past three months
–  S v re dementia (resulting in ither i bility to provide informed 
conse t for the trial/procedure, preve ts independent lif style outside
of a chronic care facility, or will fundamen ally complicate rehabilita-
tion fr m the procedure or compliance with follow-up visits)
Multivessel coronary artery disease with a SYNTAX score >33
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ated non-cardiac comorbid conditions
–  Evidence of an acute myocardial infarction ≤30 days before the 
index procedure
Need for emergency surgery for any reason
–  En stage ren l disease requiring chronic dialysis or creatinine 
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short-te m 30-day (A) an  1-year (b) outcomes of patients with aortic stenosis treated 
with tAvi or sAvr in rotterdam, stratified according to the surtAvi risk model
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risk variables not captured in the predefined “list of 10 comorbidities” or frailty. With these 
limitations in mind, the 30-day mortality was 98.2, 95.0 and 89.2% (p <0.001) and the 
1-year mortality was 95.5, 88.4 and 78.4% (p <0.001) in the low, intermediate and high-risk 
groups respectively (Figure 8). As for the intermediate risk group in particular, we could not 
detect any difference in outcome between the three age cohorts underscoring the SURTAVI 
concept of risk stratification (Figure 9).
fdA perspective
Initially started as an investigator driven trial, SURTAVI evolved into a so-called industry 
sponsored (i.e., Medtronic Inc.) trial seeking Investigational Device Exemption (IDE) approval 
by the Federal Drug Administration (FDA). Since TAVI heralds the use of a “significant risk 
device”, FDA approval is essential to qualify for future regulatory purposes and product 
labelling in the USA. Therefore, a complete pre-IDE application was submitted to the FDA 
for critical review. 
According to the FDA, the STS Risk Calculator should be used for mortality prediction 
with outliers allowed by qualitative surgical assessment for patients with risk factors not 
captured by the STS score. A calculated risk between 4 and 8% would define intermediate 
risk. The FDA argued against the introduction of arbitrary age-range groups. Furthermore, 
the FDA suggested many of the comorbidities could be interpreted as representing minimal 
risk. Finally, the FDA also stated that less prevalent risk factors to be captured in the “open 
box” (like porcelain aorta, immunosuppressive disorders, mediastinal radiation…) would 
place a patient immediately in the high-risk category. Although the protocol has been 
revised according to the FDA suggestions, we still believe the above-stipulated SURTAVI 
n
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Figure 8. Rotterdam database on AS patient undergoing SAVR or 
TAVI: 30-day mortality in low-, intermediate- and high-risk cohorts.
0 1 2 3 4 ≥5
<60
60-64
65-69
70-74
75-79
≥80
A
ge
 (
ye
ar
s)
Comorbidities (n)
98.2%
95.0% 89.2%
p<0.001
Figure 9. Rotterdam database on AS patient undergoing SAVR or 
TAVI: 1-year mortality in low-, intermediate- and high-risk cohorts.
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Figure 10. Rotterdam database on AS patient undergoing SAVR or 
TAVI: 30-day and 1-year mortality in the intermediate risk cohort 
according to different age groups.
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representing minimal risk. Finally, the FDA also stated that less 
prevalent risk factors to be captured in the “open box” (like por-
celain aorta, immunosuppressive disorders, mediastinal radia-
tion…) would place a patient immediately in the high-risk 
category. Although the protocol has been revised according to the 
FDA suggestions, we still believe the above-stipulated SURTAVI 
risk paradigm is valid, and indeed may prove to be an accurate 
and yet user-friendlier tool, in identifying the “intermediate risk” 
patient.
Conclusion
The forthcoming SURTAVI trial introduces a new concept of risk strat-
ifying patients with severe AS undergoing surgical or catheter based 
therapy. Risk stratification is based on the combination of age and a 
fixed number of predefined risk variables. Retrospective application of 
this algorithm to a contemporary academic practice dealing with clini-
cally significant severe AS patients allocates about one fourth of 
patients as being at intermediate operative risk, which will constitute 
the target patient population for the SURTAVI trial. Further testing is 
required for validation of this new paradigm in risk stratification.
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–  Blood dyscrasias as defined: leukopenia (WBC <1000 mm3), 
thrombocytopenia (platelet count <50,000 cells/mm3), history of 
bleeding diathesis or coagulopathy, or hypercoagulable states
–  Ongoing sepsis, including active endocarditis
–  Cardiogenic shock manifested by low cardiac output, vasopressor 
dependence, or mechanical haemodynamic support
–  Recent (within six months of randomisation) cerebrovascular 
accident (CVA) or transient ischaemic attack (TIA)
–  Gastrointestinal (GI) bleeding within the past three months
–  Severe dementia (resulting in either inability to provide informed 
consent for the trial/procedure, prevents independent lifestyle outside 
of a chronic care facility, or will fundamentally complicate rehabilita-
tion from the procedure or compliance with follow-up visits)
–  Multivessel coronary artery disease with a SYNTAX score >33
–  Estimated life expectancy of less than 12 months due to associ-
ated non-cardiac comorbid conditions
–  Evidence of an acute myocardial infarction ≤30 days before the 
index procedure
–  Need for emergency surgery for any reason
–  End stage renal disease requiring chronic dialysis or creatinine 
clearance <20 cc/min
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Initially started as an investigator driven trial, SURTAVI evolved 
into a so-called industry sponsored (i.e., Medtronic Inc.) trial 
seeking Investigational Device Exemption (IDE) approval by the 
Federal Drug Administration (FDA). Since TAVI heralds the use 
of a “significant risk device”, FDA approval is essential to qualify 
for future regulatory purposes and product labelling in the USA. 
Therefore, a complete pre-IDE application was submitted to the 
FDA for critical review. According to the FDA, the STS Risk Cal-
culator should be used for mortality predicti n with outliers 
allowed by qualitative surgical assessment for patients with risk 
factors not captured by the STS score. A calculated risk between 4 
and 8% would define intermediate risk. The FDA argued against 
the introduction of arbitrary age-range groups. Furthermore, the 
FDA suggested many of the comorbidities could be interpreted as 
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evaluation of internal consistency for 30-day and 1-year outcomes in intermediate-risk 
patients with aortic stenosis treated with tAvi or sAvr in rotterdam
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risk paradigm is valid, and indeed may prove to be an accurate and yet user-friendlier tool, 
in identifying the “intermediate risk” patient.
conclusions
The forthcoming SURTAVI trial introduces a new concept of risk stratifying patients with 
severe AS undergoing surgical or catheter based therapy. Risk stratification is based on the 
combination of age and a fixed number of predefined risk variables. Retrospective applica-
tion of this algorithm to a contemporary academic practice dealing with clinically significant 
severe AS patients allocates about one fourth of patients as being at intermediate operative 
risk, which will constitute the target patient population for the SURTAVI trial. Further testing 
is required for validation of this new paradigm in risk stratification.
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AbstrAct
Objective
Risk prediction in adult patients undergoing cardiac surgery remains inaccurate and should 
be further improved. Therefore we aimed to identify risk factors that are predictive of mortal-
ity, stroke, renal failure, and/or length of stay after adult cardiac surgery in contemporary 
practice.
Methods
We searched the Medline database for English-language original contributions from January 
2000 through December 2011 to identify preoperative independent risk factors of one of 
the following outcomes after adult cardiac surgery: death, stroke, renal failure, and/or length 
of stay. Two investigators independently screened the studies. Inclusion criteria were: (i) the 
study described an adult cardiac patient population; (ii) the study was an original contribu-
tion; (iii) multivariable analyses were performed to identify independent predictors; (iv) ≥1 
of the predefined outcomes was analyzed; (v) at least one variable was an independent 
predictor, or a variable was included in a risk model that was developed.
Results
The search yielded 5,768 studies. After the initial title screening a second screening of the 
full texts of 1,234 studies was performed. Ultimately, 844 studies were included in the 
systematic review. In these studies, we identified a large number of independent predictors 
of mortality, stroke, renal failure, and length of stay, which could be categorized in variables 
related to: disease pathology, planned surgical procedure, patient demographics, patient 
history, patient co-morbidities, patient status, blood values, urine values, medication use, 
and gene mutations. Many of these variables are frequently not considered as predictive of 
outcomes.
Conclusions
Risk estimates of mortality, stroke, renal failure, and length of stay may be improved by 
inclusion of additional (non-traditional) innovative risk factors. Current and future databases 
should consider collecting these variables.
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introduction
Predicting procedural mortality in adult cardiac surgery is critical for decision-making 
purposes particularly when there are different treatments options available, as well as for 
benchmarking and outcome evaluation both at institutional and surgeon level. Several 
prediction models have been developed with the main goal of estimating the risk of opera-
tive mortality for patients undergoing coronary artery bypass grafting (CABG), aortic valve 
replacement (AVR), or cardiac surgery in general.1-4 Despite their usefulness, it remains 
challenging to develop a risk model that performs accurately across the spectrum of low-, 
intermediate-, and high-risk patients evaluated for cardiac surgery. Although the recently 
developed EuroSCORE II may be associated with improvements when compared to the 
original additive and logistic EuroSCOREs,5 risk prediction remains a challenge in Euro-
pean patients.6-8 The Society of Thoracic Surgeons (STS) score has shown to outperform the 
EuroSCORE,9-11 but still a number of studies has demonstrated poor model performance in 
certain patient subgroups.12-14 Especially in high-risk patients, risk models have been shown 
to be poorly calibrated and overpredict mortality.
The reasons for suboptimal model performance are multifactorial. While conventional 
cardiovascular risk factors (e.g. renal failure, diabetes) are considered for inclusion in a 
model, less obvious factors may be valuable as well. Many risk models are developed through 
standard statistical approaches not taking into account risk factor interactions or procedure-
specific weightings.15 A mismatch is frequently present between the model development 
patient cohort and the patient cohort that it is used for in practice; some patient subgroups 
are continuously underrepresented. Considering these arguments, it is important to i) clarify 
the purpose of a model, ii) develop a model that is useful, and iii) define the limits of that 
usefulness. Any model should be based on the available literature and clinical intuition to 
define the appropriate dataset for model development.
The EACTS is establishing a quality improvement programme for adult cardiac surgery 
with an international database as an important component, aiming to bring forward an 
EACTS risk model. We performed a systematic review of the literature to identify which 
variables may need to be collected to be able to develop a better risk prediction model.
methods
search strategy
We systematically searched the Medline database for English-language original contribu-
tions from January 2000 through December 2011 to identify preoperative independent risk 
factors of one of the following outcomes after adult cardiac surgery: death, stroke, renal 
failure, and/or length of stay. Our search entry consisted of outcome keywords: ‘mortality’ 
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OR ‘death’ OR ‘stroke’ OR ‘cerebrovascular event’ OR ‘renal failure’ OR ‘length of stay’ OR 
‘LOS’; subject keywords: ‘cardiac surgery’ OR ‘heart surgery’ OR ‘heart valve surgery’ OR 
‘valve replacement’ OR ’AVR’ OR ‘MVR’ OR ‘valve repair’ OR ‘MVP’ OR ‘coronary artery 
bypass grafting’ OR ‘CABG’; and analysis keywords: ‘risk model’ OR ‘risk score’ OR ‘risk 
factor’ OR ‘independent’ OR ‘multivariate’ OR ‘multivariable’ OR ‘c-index’ OR ‘c-statistic’ 
OR ‘area under the curve’ OR ‘AUC’.
study inclusion
Two investigators (S.J.H. and R.L.J.O) independently screened the studies identified by the 
search. During the first round of screening all titles were judged for their relevance. Stud-
ies evaluating non-cardiac surgery, percutaneous or transcatheter therapies, or diagnostic 
modalities were excluded. Many risk models have been developed for coronary artery 
bypass surgery and/or valvular surgery, therefore to be homogeneous but also comprehen-
sive, we excluded studies that focused on pediatrics, congenital cases, aortic arch or root 
surgery, or heart transplants. Studies that were inconclusive with respect to the performed 
procedures and reported outcomes of a non-defined group, for example “patients that 
underwent cardiac surgery”, were included.
After identifying potentially relevant studies, the full-length articles were screened using 
the following criteria: (i) the study indeed described an adult cardiac patient population; (ii) 
the study was an original contribution; (iii) multivariable analyses were performed to identify 
independent predictors; (iv) the outcome of mortality, stroke, renal failure, and/or length of 
stay was assessed; and (v) at least one variable was an independent predictor, or a variable 
was included in a risk model that was developed.
data extraction
For each endpoint, independent predictors were extracted from the included studies.
The terminology of predictors differed significantly among studies. For example, “aortic 
calcification” was also reported as “extend of atherosclerotic ascending aorta disease”, 
“thoracic aorta total plaque-burden”, or “severe atheromatous aortic disease”. Risk factors 
were measured and reported according to different indexes; for example, renal function 
was indicated with serum creatinine, creatinine clearance, or estimated glomerular filtration 
rate. Such variations were merged into a single variable to avoid repetition.
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results
The search yielded 5,768 results (Figure 1). After excluding non-relevant studies from an 
initial title screening a second screening of the full texts of 1,234 studies was performed. 
Another 351 studies were found to be irrelevant because the patient population did not meet 
the criteria, the endpoint used was not death, stroke, renal failure, or length of stay, or no 
independent predictors were identified. The full texts of 78 studies could not be retrieved 
so the abstracts were screened for their relevance. Ultimately, 844 studies were included in 
the systematic review.
	   Potentially	  relevant	  studies	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figure 1 flow diagram: systematic inclusion of studies
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The diagnosed disease pathology and planned surgical procedure are essential elements 
in a risk model and always need to be documented (Table 1). The independent predictors of 
death, stroke, renal failure, and length of stay are listed in Tables 2-5. The predictors were 
categorized as patient demographics, patient history, patient co-morbidities, patient status, 
blood values, urine values, medication use, and gene mutations.
discussion
In this systematic review we screened 5,768 studies and included 844 studies in which we 
identified relevant independent predictors of death, stroke, renal failure, and length of stay 
after adult cardiac surgical procedures. This study was the first to identify systematically all 
predictors of adverse events after coronary artery bypass grafting and/or valvular surgery 
in adults. Many risk factors with a significant impact are frequently not considered when 
evaluating patients for major invasive procedures. Decision-making may be improved by 
taking into account these neglected yet predictive risk factors. Beside demographics (e.g. 
age, gender), disease complexity (e.g. coronary and/or valve lesions), and co-morbidities 
(e.g. renal failure), other factors such as medication intake and the patient’s psychiatric, 
mental, and social-economic status have also been shown to have a predictive power.16-17
Over the last decade(s) there has been a growing interest in risk prediction models both 
for monitoring innovations and benchmarking outcomes as well as for clinical use to mul-
tidisciplinary shared-decision making. The latter is especially true in an era of expanding 
multi-modality therapy for coronary artery and aortic valve disease when risk prediction 
plays an important role to determine which patients would benefit most from surgery or 
interventional therapy.18
The inaccuracy of risk models  may in part be due to the selection of variables.18 As 
table 1 patient’s disease pathology and planned surgical procedure
disease pathology planned surgical procedure
Number of coronary vessel disease Coronary artery bypass grafting
Significant left main stenosis Aortic valve replacement
Coronary artery disease complexity (e.g. SYNTAX score) Aortic valve repair
Aortic valve stenosis Aortic root surgery
Aortic valve regurgitation Mitral valve replacement
Mitral valve stenosis Mitral valve repair
Mitral valve regurgitation Tricuspid valve replacement
Tricuspid valve regurgitation Tricuspid valve repair
Persistent atrial fibrillation Aortic surgery
Ascending aorta aneurysm MAZE
Aortic arch aneurysm
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shown by previous studies, risk models are inconsistent in including variables and are miss-
ing several different yet important risk factors,19-20 although until now it has been unclear 
which factors need to be considered. Furthermore, different definitions are used for some of 
the risk factors, resulting in a different weighting of that factor between models. Collection 
table 2 independent predictors of death
demographics Age; Gender; Race; Weight; Height; Body surface area; Geographic region 
(city, rural); Social economic status; Employment status (unemployed); Type 
of personality; Family history; Primary payer; Current smoker; Alcohol abuse; 
Depression; Anxiety; Psychosis
history Pack-years smoking; Previous hospitalization for heart failure; Timing and number of 
previous PCI(s); Timing of congestive heart failure; Timing and location of previous 
MI*; Timing of dialysis; Timing of previous TIA/CVA; Timing or previous angina; 
History of hematological disorder/coagulopathy; Previous surgery for thrombosis; 
History of thyroid disease; Immune deficiency; Connective tissue disease; 
Pathological weight-loss; Pacemaker implantation; Number and type of reoperations
co-morbidities Diabetes; Metabolic syndrome; Cerebrovascular disease; Neurological disorder; 
Carotid artery disease; Peripheral vascular disease; (Severity of) Atherosclerotic 
aortic disease; Atrial fibrillation; Type of arrhythmia; Hypertension; Pulmonary 
function/disease (e.g. COPD); Pulmonary hypertension; Renal function/failure; Liver 
function/disease; Malignancy; Peptic ulcer disease
status Frailty; Energy level; Problems with self-care; Non-ambulatory state; Mental 
component score (SF-36); Physical component score (SF-36); Health status (EQ-5D); 
CCS classification; NYHA classification; LVEF; LV end-systolic diameter/volume; LV 
hypertrophy; LV end-diastolic pressure/diameter; Restrictive LV filling; LV posterior 
wall thickness; LV mass index; Lack of contractile reserve; Left atrial diameter; Small 
annulus; RV end-diastolic pressure; Cardiothoracic ratio; Heart rate; Conduction 
defect; Corrected QT interval; Amount of ST-segment depression; Preoperative 
ICU stay; On intubation/ventilation; Sepsis; Active endocarditis; Vegetation 
size (endocarditis); Prosthetic valve endocarditis; Staphylococcus endocarditis 
infection; Pulmonary edema; Ventilator-associated pneumonia; Multi-organ failure; 
Ventricular assist device; Resuscitation; Posterior septal rupture; Unstable/shock; 
Intra-aortic balloon pump; Urgency of surgery; ASA score; Pulse pressure
blood values Hemoglobin; Hematrocrit; Homocysteine; Creatinine; HbA1c; Glucose; CRP; BNP; 
NT-proBNP; IL-6; Endotoxin core antibody; Sodium; Magnesium; Protein; Albumin; 
Bilirubin; ASAT; uric acid level; CK-MB; High-sensitive Troponin T; Troponin 
T; Troponin I; Lactate dehydrogenase; INR group; PTT; Antithrobin 3; HPF4 
antibodies; Thrombocytes; Lymfocytes; Neutrophils; Total cholesterol; Non-HDL 
cholesterol; Cholesterol esters; Triglycerides
urine values Proteinuria
medication Aspirin; Warfarin or coumadin; Other anticoagulant; Thrombolysis; Nitroglycerine; 
Statin; Beta-blocker; Catecholamine; Digoxin; Digitalis; Antidepressant (SSRI); 
Inotropic support; Immunosuppressive therapy
gene mutations C677T mutation in MTHFR gene; VEGF +405 GG; rs10116277 (2 allele) -- 
Chromosome 9p21; rs1042579 recessive
*Inferior/anterior myocardial infarction. ACE = angiotensin-converting enzyme; ASA = American Society of 
Anaesthesiologists; BNP = brain natriuretic peptide; CCS = Canadian Cardiovascular Society; CK-MB = creatine 
kinase myocardial band; COPD = chronic obstructive pulmonary disease; CRP = c-reactive protein; CVA = 
cerebrovascular accident; HDL = high density lipoprotein; HPF4 = heparin-platelet factor 4; INR = international 
normalized ratio; MI = myocardial infarction; NT-proBNP = N-terminal-pro-brain natriuretic peptide; NYHA = 
New York Heart Association; PTT = partial thromboplastin time; SSRI = selective serotonin reuptake inhibitor; TIA = 
transient ischemic attack
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of the variables identified in this study may help to improve future risk models, and standard-
ize risk factor definitions best suitable for inclusion.
A number of studies has identified genetic variations or mutations that carry an increased 
risk of adverse events after cardiac surgery. Indeed, collection of these variables in a large 
database could potentially provide insights into the understanding of the patient’s risk, but 
it might be too optimistic to apply genetic profiling to a large international database. Costs 
of sequencing technologies are decreasing, but genetic profiling is still not widely used. It 
will be interesting to see whether genetic phenotyping might be more suitable to identify 
patients at higher risk of adverse events,21 although little evidence is available at this time 
to use this technique for risk stratification in cardiac surgery. Some of the laboratory values 
or echocardiographic measures that have shown to be independent predictors may be too 
costly to collect. Quality of life assessments are time-consuming activities that will need to 
table 3 independent predictors of stroke.
Demographics Status
Age Left ventricular ejection fraction
Gender Active infection
Race Active endocarditis
Body surface area Intra-aortic balloon pump
Current smoker Unstable/Shock
History Urgency of surgery
Timing of smoking Pulse pressure
Timing of previous TIA/CVA Blood
Timing of previous MI Hemoglobin
Previous deep vein thrombosis Creatinine
Number of reoperations INR group
Dialysis Medications
Co-morbidities Aspirin
Diabetes Statin
Cerebrovascular disease ACE inhibitor
Neurologic status (e.g. deficit, dementia) Beta-blocker
Carotid artery disease Inotropic support
Peripheral vascular disease Gene mutations
(Severity of) Atherosclerotic aortic disease Interleukine 6 (-174G/C)
Atrial fibrillation CRP 3’UTR1846C/T
Hypertension
Hypercholesterolemia/lipidemia
Renal function/failure
Pulmonary hypertension
Left ventricular hypertrophy
ACE=angiotensin-converting enzyme; CVA=cerebrovascular accident; INR=international normalized ratio; 
MI=myocardial infarction; TIA=transient ischemic attack
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be performed by educated research nurses. Therefore, a model will always be lacking some 
variables that could potentially increase its performance.
The balance between the number of variables and model performance should be care-
fully considered when developing a risk model. Although many variables may be predictive 
(Tables 2-5), they cannot all be included because this will decrease the user-friendliness of 
table 4 independent predictors of renal failure
demographics Age; Gender; Race; Weight; Height; Body surface area
history Timing of previous MI; Timing of recent cardiac catheterization; Timing of previous 
PCI; Dialysis; Congestive heart failure; Number of reoperations
co-morbidities Diabetes; Metabolic syndrome; Cerebrovascular disease; Peripheral vascular disease; 
Atrial fibrillation; Hypertension; Renal function/failure; Pulmonary disease (e.g. 
COPD); Pulmonary hypertension; Charlson comorbidity index
status CCS classification; NYHA classification; Left ventricular ejection fraction; Sepsis; 
Active endocarditis; Intra-aortic balloon pump; Unstable/shock; Urgency of surgery; 
ASA physical status
blood values Hemoglobin; Hematocrit; Creatinine; Platelet count; HbA1c; Hyperuricemia; urea 
nitrogen; Bicardbonate; Sodium; Albumin; Bilirubin
urine values Albumin to creatinine ration; Proteinuria
medication Statin; Calcium channel blocker; ACE inhibitor; Renin-angiotensin system inhibitor; 
Diuretic; Immunosuppressive therapy
gene mutations Catechol-O-methyltransferase LL
ACE =  angiotensin-converting enzyme; ASA = American Society of Anaesthesiologists; CCS = Canadian 
Cardiovascular Society; COPD = chronic obstructive pulmonary disease; MI = myocardial infarction; NYHA = New 
York Heart Association; PCI = percutaneous coronary intervention
table 5 independent predictors of length of stay
demographics Age; Gender; Race; Weight; Height; Body surface area; Geographic region (e.g. rural); 
Social status; Post-traumatic stress disorder; Depression
history Previous TIA/CVA; Previous embolism; Timing or previous MI; Timing of previous 
PCI; (Duration of preceding) Hypertension; Previous arrhythmia treatment; Dialysis; 
Previous endocarditis; Congestive heart failure; Number of reoperations
co-morbidities Diabetes; Cerebrovascular disease; Peripheral vascular disease; Atherosclerotic aortic 
disease; Atrial fibrillation; Arrhythmia; Hypertension; Pulmonary function/disease 
(e.g. COPD); Pulmonary hypertension; Renal function/failure; Liver function/failure; 
Malignancy; Dyslipidemia/hypercholesterolemia; Hyperglycemia
status SF-36 quality of life; CCS classification; NYHA classification; Left ventricular ejection 
fraction; Diastolic dysfunction; Right ventricular end-systolic diameter; Cardiothoracic 
ratio; Frailty; Immunosuppressive therapy; Rheumatic fever; Active infection; Active 
endocarditis; Large endocarditis vegetation (15 mm); Unstable/shock; Intra-aortic 
balloon pump; Urgency of surgery
blood values Hemoglobin; NT-proBNP; BNP; Creatinine
medication Beta-blocker; Nonaspirin platelet inhibitor; Inotropic support
gene mutations Il-8-251AA; Catechol-O-methyltrasferase LL
BNP = brain natriuretic peptide; CCS = Canadian Cardiovascular Society; COPD = chronic obstructive pulmonary 
disease; CVA = cerebrovascular accident; MI = myocardial infarction; NT-proBNP = N-terminal-pro-brain natriuretic 
peptide; NYHA =  New York Heart Association; PCI = percutaneous coronary intervention; TIA = transient ischemic 
attack
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the model.22 Furthermore, a great number of variables will likely result in missing data that 
will have a negative impact on the accuracy of a newly developed risk model. On the other 
hand, ignoring some of these variables may produce a model with modest performance at 
best. It is recommended to exclude only variables with little impact on the predictive value 
of the model. Factors must be relatively present in the population, and enough adverse 
events must occur in a frequent manner to be able to have enough power for each risk 
factor to weight it in a multivariate model. Factors that are only present in a very small 
minority (<1%) of patients may not be relevant to collect, although their relative weight 
may be high. Ideally, the impact of the identified risk factors would be used to select which 
factors are more important to collect than others. However, to obtain an accurate estimate 
of the impact on the model, a broad range of risk factors need to be collected -- including 
(non-)conventional factors -- in a large database. Only then can unnecessary risk factors be 
excluded. Collection of these factors will furthermore identify specific factors with interna-
tional variation in prevalence or dynamic effect weights, which might result in different or a 
changing impact of factors on short- and/or long-term risk.23
It is unrealistic to collect for each patient the hundreds of variables that were identified 
in this study. It might be appropriate to start data collection with a small selection of centers 
as a feasibility project. This helps to determine the relative impact of certain variables and 
whether it is necessary and possible to collect these on a larger scale. Nevertheless, even 
in a feasibility design there are variables that may need to be prioritized over others. This 
study provides a framework for future model development, from which certain variables 
can be chosen depending on the prevalence of a risk factor, its relative impact, the patient 
population, the type of model (e.g. short-or long-term), the endpoints for which the model 
is developed, and the cost and resources available.
Risk models that have been developed on a cohort of patients undergoing a specific 
procedures may have limited value when applied to other population groups, as the impact 
of any one variable can have a very different weighting when applied to a cohort of patients 
undergoing another procedure. This may also be one of the reasons why risk models fail to 
predict accurately outcomes of low- to high-risk patient cohorts. This is clearly evident when 
examining the predictive power of the original EuroSCORE. It was developed on relatively 
low-risk patients undergoing CABG 24 but subsequently has been widely used with limited 
value for high-risk AVR, probably because such patients were hardly represented in the 
EuroSCORE database. 
The EuroSCORE II was developed with 22381 patients of which 46.7% and 46.3% 
underwent isolated CABG and valve procedures, respectively.5 However, recent evidence 
suggests that this more balanced inclusion of procedures was at the expense of decreased 
model performance in isolated CABG procedures.8 Although generic risk models are useful 
in describing the risk profile of large patient populations included in randomised clinical 
trials or registries, procedure-specific models for CABG, AVR, and mitral valve surgery are 
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advocated to increase risk prediction for individual patients. Clearly some of the risk factors 
we identified will more likely be included in a CABG risk model while others are more 
specific for an AVR model, such as the SYNTAX score or prosthetic valve endocarditis, 
respectively. The predictive power of some factors remains unclear when evaluating a cohort 
of patients undergoing a specific procedure, which is why there is a need to collect these 
factors in a generic database. This will furthermore provide the opportunity to examine 
whether useful generic models with procedure-related interaction terms can be constructed 
or whether only procedure-specific models are required for accurate risk prediction.
One major limitation of the widely used European risk scores remains that they have been 
developed to predict operative mortality although this is not the only outcome of interest 
to either patients, health care systems or policy makers. Many variables predictive of death 
will also be significant for other outcomes including renal failure, stroke, and length of stay. 
However, the associated odds ratios might be different for specific outcomes. For example, in 
the STS model for isolated valve surgery the OR of active infectious endocarditis for mortality 
is 1.95 (95% CI 1.68-2.27) but 2.79 (95% CI 2.51-3.09) for prolonged length of stay.4 One 
of the goals of the forthcoming EACTS risk model will be to develop a model able to predict 
accurately multiple outcomes using outcome-specific ORs, similar to the STS risk model. 
Although risk models can be improved, random events will always occur and a predic-
tion model can therefore never be perfect. Thus, clinical guidelines recommend that clinical 
decision-making related to interventional and surgical interventions should be performed 
by a multidisciplinary Heart Team that consists of at least an interventional cardiologist and 
cardiovascular surgeon to interpret and weight risk models and additional information to 
come up with the most appropriate treatment recommendation for the individual patient.25
limitations
The focus of this study was adult patients undergoing coronary artery bypass grafting and/or 
valve surgery, because the available surgical risk models have predominantly been devel-
oped for these populations. Although there may indeed be significant overlap, the identified 
independent risk factors may not be applicable to other surgeries such as on the aortic root 
or aorta, congenital cases, or heart transplantations.
conclusions
This systematic review identified a significant number of independent predictors of adverse 
outcomes after adult coronary and valvular procedures, many of which are frequently not 
considered. These variables will be collected in a dedicated European database, and used 
for the development of the forthcoming EACTS risk model. However, the clinical value of 
these risk factors needs to be weight against the cost and effort of collecting them.
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Chapter 7
The SYNTAX Score and its clinical implications
Head SJ, Farooq V, Serruys PW, Kappetein AP
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AbstrAct
Percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) are 
both treatment options for coronary revascularisation in selected patients with stable coro-
nary artery disease and ischemia. In 2006 the anatomical SYNTAX Score was introduced to 
quantify the complexity of coronary artery disease. The SYNTAX Score was found to be a 
good predictor of major adverse cardiac or cerebrovascular events after PCI but not CABG. 
Currently available studies have shown that the SYNTAX Score is a useful tool to determine 
the optimal revascularisation strategy in patients with left main and/or three-vessel disease. 
Both European and US revascularisation guidelines recommend treatment selection based 
on the SYNTAX Score. Both guidelines do however state that decision-making between 
CABG and PCI should be performed by a dedicated coronary Heart Team that includes 
a non-interventional/clinical cardiologist, interventional cardiologist, and cardiovascular 
surgeon (Class I indication).
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introduction
Percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) are 
both treatment options for coronary revascularization in selected patients with stable coro-
nary artery disease and ischemia. Current European and US revascularization guidelines 
indicate that the treatment selection depends on patient preferences, co-morbidity, and 
complexity of coronary artery disease.1, 2 Less complex single- or double-vessel coronary 
artery disease is preferably treated with PCI, where the level of acceptance is higher for PCI 
compared to CABG, whereas complex three-vessel disease is best treated with CABG, where 
the level of acceptance is higher for CABG compared to CABG.1, 2
Not only the number of diseased coronary vessels is a marker for the extensiveness of 
coronary artery disease. The location of the lesions and their impact on blood flow,w1 the 
degree of vessel stenosis, lesion classifications, and the diameter and calcification of the 
vessel are also important factors that affects the technical feasibility by PCI, and prognosis. 
Considering these factors, there are different degrees of multi-vessel disease and the pre-
ferred revascularization strategy may be different for specific lesion complexities. To assess 
this hypothesis the angiographic SYNTAX Score was introduced.3
figure 1
components of the complexity of coronary artery disease that are used to calculate a 
patient’s syntAX score
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the syntAX score
The SYNTAX Score was developed through expert consultation, and integrated previous 
angiographic scores that assessed lesion complexity: the AHA classification modified for 
the ARTS study,w2, w3 the Leaman score,w4 the ACC/AHA lesions classification system,w5the 
total occlusion classification system,w6 and the Duke and ICPS classification systems for 
bifurcation lesions.w7  Subsequently the Medina classification of bifurcation lesions was 
introduced.w8
The SYNTAX Score was designed to quantify the complexity of left main or three-vessel 
disease. Using the open accessible web-based score calculator (www.syntaxscore.com) 
one is able to calculate each patient’s SYNTAX Score by answering a series of questions. 
The SYNTAX Score corresponds to the lesion complexity measured by the coronary tree 
characteristics and the lesion locations and specifics (Figure 1). One of the most crucial 
features of the SYNTAX Score is that it is a lesion-based score, which integrates all lesions to 
determine the degree of myocardium that is at risk and the technical success rate of treating 
the each lesion. Three general questions are asked, and for every lesion, 8 questions need 
to be answered to determine the lesion’s individual score, which accumulates to form the 
overall SYNTAX Score of the patient.
case examples
Figure 2 illustrates the SYNTAX Scores of two patients. The first patient has three lesions in 
three arteries: two >50% lesions in the mid portions of the right coronary artery (RCA) and 
left circumflex artery (LCX), and a left main (LM) bifurcation lesion. The second patient also 
has three-vessel disease, but the complexity of disease is greater. Patient 2 has a trifurcation 
involving the LM artery (segment 5), the proximal left anterior descending (LAD) artery 
(segment 6), the proximal LCX (segment 11), and the intermediate/anterolateral artery 
(lesions 12). In addition, the angiogram shows a totally occluded first diagonal with a severe 
angulated (>70˚) bifurcation, a >50% stenosis in the intermediate/anterolateral artery, and 
diffusely diseased and narrowed vessels in the distal LCX.
Comparing these two patients, it is clear that one can easily distinguish less complex and 
complex disease; this is translated in SYNTAX Scores of 18 and 42 in these patients, respec-
tively. When evaluating these patients for coronary revascularisation through either PCI or 
CABG, the technical feasibility of percutaneous revascularisation may be questioned in the 
second patient, while the targets in patient #1 can be easily stented. Therefore, the SYNTAX 
Score may be helpful to discriminate which patients can safely undergo revascularisation by 
PCI or should preferably undergo CABG.
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Patient 2
Lesion #1
Segment 1:      1x2       2
Lesion 1 score:         2
Lesion #2
Segment 5:   2x5     10
+ Bifurcation (Medina 1,0,0)    1
Lesion 2 score:       11
Lesion #3
Segment 11:   1.5x2       3
+ Severe tortuosity        2
Lesion 3 score:         5
SYNTAX Score  18
Lesion #1
Segment 5:   5x2     10
Segment 6:   3.5x2       7
Segment 11:   1.5x2       3
Segment 12:   1x2       2
+ Trifurcation 4 segments     6
Lesion 1 score:       28
Lesion #2
Segment 9:   1x5       5
+ Total occlusion: age unknown   1  
 - Blunt stump             1
 - Both >1.5mm and <1.5mm 
   sidebranches            1
+ Bifurcation (Medina 0,0,1)    2
 - Angulation 70˚         1
Lesion 2 score:       11
Lesion #3
Segment 12:  1x2       2
Lesion 3 score:         2
*Diffuse disease/small vessels 
Segment 13          1
SYNTAX Score  42
*
RCA >50%
LCX >50%
LCX >50%
1st diagonal
      100%     
LM >50%
Patient 1
figure 2 case examples of two patients with three-vessel disease
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the syntAX score As A prediction tool
Initial validation of the SYNTAX Score was accomplished by retrospective application to 
1,292 lesions in 306 patients who had undergone PCI for three-vessel disease in the Arterial 
Revascularisation Therapies Study part II (ARTS-II).4 Thirty-day results showed a stepwise 
increase in major adverse cardiac or cerebrovascular events (MACCE) for patients with an 
increasing SYNTAX Score from low (≤18) to intermediate (19-26) to high (≥26): 3% vs. 5% 
vs. 12%, p=0.03. This was mainly driven by peri-procedural myocardial infarction (p=0.04) 
and target vessel revascularisation (p=0.02). After a median follow-up of 370 days, patients 
with SYNTAX Scores ≥26 had significantly higher MACCE rates. Multivariate analyses 
showed that the raw SYNTAX Score was an independent predictor of MACCE (HR=1.07, 
95% CI 1.03-1.11). A number of studies have since evaluated the predictive power of the 
SYNTAX score in patients undergoing PCI. The SYNTAX Score has repeatedly been identi-
fied as a strong independent predictor of death and MACCE during long-term follow-up.w9, 
w10, w11, w12
The data regarding the predictive ability of the SYNTAX Score in patients undergoing 
CABG has been conflicting. Although some reports have shown that the SYNTAX Score is 
related to adverse events during follow-up after CABG,w13, w14, w15 the majority of studies 
have shown that the SYNTAX Score is less valuable as a predictor in patients undergoing 
CABG (Table 1).w16, w17, w18 Therefore, the general agreement is that the SYNTAX Score is of 
less significance in patients undergoing CABG, particularly since the randomised SYNTAX 
trial did not associate any prognostic value of the SYNTAX Score at 5 years.5 The rationale is 
that for a coronary bypass it does not matter how complex the proximal lesions in the vessel 
are. These are always bypassed without any additional procedural complexity or surgical 
risk, provided there are suitable distal graftable targets. The SYNTAX Score may be regarded 
as a marker of coronary anatomical disease complexity, and therefore is an indirect marker 
of plaque burden. Greater plaque burden, as evident by higher SYNTAX Scores, may be 
one of the reasons higher SYNTAX Score patients confer more benefit from CABG, second-
ary to the graft ‘protecting’ the vessel, whereas a  stent would treat the individual lesion. 
Nevertheless, the SYNTAX Score will likely be related to outcomes in some degree; it is 
perceptible that a patient with a SYNTAX Score of 80 will have an increased risk of adverse 
events as compared to a patient with a SYNTAX Score of 20,6 since the SYNTAX Score may 
be regarded as a marker for systemic atherosclerosis.7
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compArAtive effectiveness: pci versus cAbg
The most compelling data about the difference in outcome between CABG and PCI accord-
ing to the SYNTAX Score comes from the SYNTAX trial itself.8, 9 The SYNYAX Scores were 
assessed by all participating centres in the SYNTAX Trial (18 countries, 85 centres), as a tool 
to force the surgeon and interventional cardiologist to examine the coronary angiogram 
in detail, and agree that equivalent anatomical revascularization could be achieved. The 
SYNTAX Score performed by the study sites was corroborated by an independent core labo-
ratory, blinded to the treatment assignment and all clinical events. Since the distribution of 
SYNTAX Score was normal (Gaussian) in the SYNTAX Trial, patients were stratified by the 
complexity of coronary disease (tertiles), to allow meaningful comparisons with enough 
statistical power in each group. The division into tertiles of the randomised cohort of 1,800 
patients produced the following cohorts: patients with low lesion complexity had SYNTAX 
Scores ≤22, intermediate lesion complexity was defined as a SYNTAX Score 23-32, and high 
lesion complexity as a SYNTAX Score ≥33. 
At one-year follow-up, there was a significant treatment-by-SYNTAX Score interaction 
(p=0.01) in the hypothesis-generating subgroup analysis according to lesion complexity. 
Although the general trial conclusion was that PCI with drug-eluting stents was not non-
inferior to CABG, no differences between CABG and PCI in MACCE in patients with a 
SYNTAX Score ≤22 were reported (respectively 13.6% versus 14.7%, p=0.71). There was 
clear superiority of CABG over PCI in patients with SYNTAX Scores ≥33 (respectively 10.9% 
versus 23.4%, p<0.001). With follow-up extending to 3 and 5 years,9 the Kaplan-Meier 
curve of MACCE after PCI or CABG in patients with low SYNTAX Scores (≤22) remained 
superimposed (Figure 3A). In patients with intermediate SYNTAX Scores 23-32 there was no 
significant difference at one year (CABG: 12.0% versus PCI: 16.7%, p=0.10), but the diverg-
ing curves during follow-up suggest that CABG may be of greater benefit in these patients 
(Figure 3B). For patients with SYNTAX Scores ≥33, the difference between CABG and PCI 
further increased during follow-up, demonstrating the superiority of CABG compared to 
PCI in this subgroup (Figure 3C). Detailed separate analyses of patients with left main and 
three-vessel disease demonstrated similar findings, except for patients with an intermediate 
SYNTAX Scores of 23-32, where outcomes between CABG and PCI were comparable. Here 
the difference between CABG and PCI seems negligible in patients with LM disease (Figure 
3H), while in those with three-vessel disease the rate of MACCE after CABG is significantly 
lower than after PCI (Figure 3E).
Two recent large randomized trials have since compared CABG with PCI: the PRECOM-
BAT and FREEDOM trials.10,11 The PRECOMBAT trial was performed in the setting of left 
main coronary disease and enrolled 300 patients in each treatment arm; 180 patients with 
SYNTAX Scores ≤19, 198 patients with SYNTAX Scores >19-≤29, and 180 patients with 
SYNTAX Scores >29.10 After two years of follow-up, there was no interaction between 
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figure 3
long-term follow-up of the syntAX trial comparing cAbg with pci with paclitaxel-
eluting (taxus) stents
In patients with low lesion complexity (SYNTAX Score ≤22) there was no difference in the rate of MACCE. 
In patients with SYNTAX Scores 23-32 there was a significant benefit of CABG over PCI, and this was even 
more profound in patients with high lesion complexity of SYNTAX Scores ≥32. Copied with permission from 
the SYNTAX Investigators.7 CABG = coronary artery bypass grafting; MACCE = major adverse cardiac or 
cerebrovascular events; PC I= percutaneous coronary intervention
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treatment and SYNTAX Score for the primary composite endpoint of MACCE (p=0.80). From 
low to intermediate to high SYNTAX Scores, the hazard ratio non significantly changed from 
1.38 (95% CI 0.40-4.21) to 2.32 (95% CI 0.82-6.57) to 1.60 (95% CI 0.73-3.54). Remark-
ably, a subgroup analysis according to left main + additional vessel disease --a proxy for 
SYNTAX Score-- showed a stepwise increase from isolated left main to left main +1, +2, and 
+3 vessel disease. The hazard ratio in favour of CABG increased from 0.39 to 0.70 to 1.04 
to 3.05. Thus, although the SYNTAX Score subgroup analysis found no interaction, the trial 
was underpowered to detect a difference, possibly secondary to an unexpectedly low event 
rate, and recruitment of patients with less complex coronary artery disease (mean SYNTAX 
score 25 versus 30 for left main patients in the SYNTAX trial) and a low clinical risk profile 
(mean additive EuroSCORE 2.7 versus 3.8 for left main patients in the SYNTAX trial). The 
non-inferiority margin of the study was wide making the results of the study none clinically 
directive.12
The FREEDOM trial was performed in 1900 diabetic patients with multivessel disease, of 
which 669, 844, and 374 patients had SYNTAX Scores ≤22, 23-32, and ≥33, respectively.11 
There was no interaction between SYNTAX Score and treatment (p=0.58). In both treat-
ment arms the 5-year event rate of the primary composite endpoint for death, myocardial 
infarction, or stroke increased with higher lesion complexity (PCI: 23 versus 27 versus 31%; 
CABG: 17 versus 18 versus 23%). This result is inconsistent with the 5-year follow-up in 
diabetic patients enrolled in the SYNTAX trial.13 Although the interaction was not significant 
in that study either, there was a stepwise increase in death, MI, or stroke in patients that 
underwent PCI (19.4% versus 22.2% versus 31.0%) but not in those treated with CABG 
(20.1% versus 21.5% versus 16.0%). The lack of a treatment-by-SYNTAX Score interaction 
in the FREEDOM trial may be the result of low power. Only 678/1900 patients reached 
5-year follow-up (197 deaths and 481 remained at risk). Furthermore, it may have been 
better to use their own Gaussian distribution instead of the SYNTAX Score tertiles to include 
more patients in the high SYNTAX Score group and allow an even comparison with more 
statistical power.  
Apart from randomized trials, several registries performed comparative effectiveness 
analyses. Two studies (n=556, n=932) were able to confirm the findings of the left main 
subgroup analysis from the SYNTAX trial,w19, w20 by showing similar event rates of death, 
myocardial infarction, or stroke between CABG and PCI in patients with SYNTAX Scores 
≤32. The effect that SYNTAX Score tertiles have on outcome differences between CABG and 
PCI have also been denied in an analysis from the MAIN-COMPARE registry that included 
1,580 patients with left main disease.w21 However, the authors correctly stated that unavoid-
able selection biases may be present in studies retrospectively assessing the SYNTAX Score, 
in particular when comparing outcomes between PCI and CABG without being blinded for 
treatment and outcome. These results should therefore be interpreted as hypothesis generat-
ing, subject to outcomes from ongoing randomised trials.
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the syntAX score in prActice
Based on the data showing the usefulness of the SYNTAX Score in PCI patients, the most 
recent European guidelines recommended that the SYNTAX Score be calculated for risk 
stratification in candidates for PCI (level of evidence IIa B).1 Since the SYNTAX Score lacks 
a prognostic value in patients undergoing CABG, the guidelines consider the SYNTAX Score 
not to be effective/useful in candidates for CABG (level of evidence III B). This recommenda-
tion is however somewhat monochrome, since the SYNTAX Score is useful for selecting 
PCI patients, a fact that allows the SYNTAX Score to be useful for decision making between 
CABG and PCI. The SYNTAX Score is helpful to identify which patients would benefit most 
from either revascularization strategy and thus in clinical practice it is useful to calculate in 
CABG patients as well. In this regard, the American guidelines do take this into consideration 
and recommend calculation of the SYNTAX Score in patients considered for both CABG and 
PCI equally with a level of evidence IIa B.2
The guidelines are consistent in their optimal treatment recommendations for three-vessel 
disease as determined by the SYNTAX Score. It is reasonable to perform PCI in patients with 
less complex three-vessel disease (SYNTAX Score ≤22), while CABG is clearly preferable in 
patients with more complex three-vessel disease (SYNTAX Score >22).1, 2 In patients with 
left main disease the guidelines are more progressive. In Europe the indication to perform 
PCI in left main disease is a SYNTAX Score ≤32 1 while the American guidelines use a 
SYNTAX Score ≤22 as the cutoff.3 However, a SYNTAX Score cutoff of ≤32 can be used if 
there is a low or intermediate risk of procedural PCI complications.
The current treatment recommendations have been interpreted by many as a broadening 
indication to perform PCI. The introduction of the SYNTAX Score has mainly reduced the 
uncertainty in selecting which patients should undergo either CABG or PCI,w22 although 
the patient distribution to CABG and PCI has remained relatively stable. Data from the 
SYNTAX run-in phase showed that 74% and 26% of patients with de novo three-vessel or 
left main disease underwent CABG and PCI, respectively (Figure 4A).14 If the current revas-
cularization guidelines are adhered to in clinical practice, the ‘new’ distribution of patients 
recommended to undergo CABG and PCI might be considered to be approximately 75% 
and 25%, respectively (Figure 4B). There remains an area of investigation regarding patients 
with left main disease and a SYNTAX Score of 23-32 (approximately 6% of population). The 
ongoing EXCEL trial will provide the necessary insights into the safety and efficacy of PCI 
in this cohort.15 With a stronger recommendation to perform PCI in patients with left main 
disease and intermediate coronary complexity (SYNTAX Score 23-32), 40% of the total left 
main patient cohort can be referred to PCI. Using the SYNTAX trial and registries (Figure 4), 
the estimated CABG/PCI distribution of patients with left main or three-vessel disease will 
then be 69%/31%, respectively.
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limitAtions of the syntAX score
SYNTAX Score assessments have shown variability among investigators (inter-observer 
agreement) and even within different assessments of the same investigator (intra-observer 
agreement).16-17 This variability may be problematic because the optimal treatment rec-
ommendation could depend on the SYNTAX Score. Introduction of observer bias may 
therefore result in inappropriate treatment decisions, especially when the SYNTAX Score 
value is close to accredited cutoff values 23 or 32. Genereux and colleagues showed that 
appropriate physician training substantially reduced this issue.16 Non invasive assessment 
of the SYNTAX Score with computed tomography and non invasive functional assessment 
of lesions are being developed,w23-w25 will simplify the calculation of the SYNTAX Score in 
the near future. 
To prevent inappropriate treatment recommendations, the SYNTAX Score value should 
not be a blind indication for treatment. Although from the SYNTAX trial it is clear that 
patients with severe complex three-vessel disease (SYNTAX Score ≥33) have superior out-
comes with CABG, even patients with a SYNTAX Score ≥33 may still undergo PCI if there 
are co-morbidities that exclude the patient from undergoing CABG. In the SYNTAX PCI 
nested registry, 43% (82/189 patients) had a score ≥33.6 The SYNTAX Score should therefore 
merely be one of the factors that is weighted by a multidisciplinary Heart Team consisting 
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figure 4
the distribution of patients undergoing cAbg or pci before (A) and after (b) the 
syntAX trial and the introduction of the syntAX score
Current American and European guidelines recommend the use of the SYNTAX Score in the decision-making 
process to determine the optimal revascularisation strategy. Applying these recommendations, approximately 75% 
and 25% of patients with left main or three-vessel disease are referred to CABG and PCI, respectively. However, 
this distribution will likely change in the near future due to new data from randomized controlled trials. Adapted 
with permission from the SYNTAX Investigators.7, 14
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of a non-interventional/clinical cardiologist, interventional cardiologist, and cardiovascular 
surgeon.18
The SYNTAX Score is limited by the assessment of coronary disease complexity while 
there are other clinical patient factors that are prognostically important and should be 
weighted by the Heart Team; for example age, pulmonary disease, and renal function. 
In an attempt to combine these factors, a number of new prediction models have been 
established.19-20 Initial alidation of such models has been encouraging and further studies 
are forthcoming.w24
globAl use of the syntAX score
Evidently the inclusion of the SYNTAX Score in practice guidelines and the growing evi-
dence supporting the anatomical SYNTAX Score have led to an increase in its use. As of 
31 December 2012, the SYNTAX Score website (www.syntaxscore.com) has been visited 
277,039 times, and the online SYNTAX Score calculator has been used 197,201 times. A 
peak in site visits was seen after the main publication of the SYNTAX trial in 2009.6 Never-
theless, the monthly visits have been continuously increasing (Figure 5 and Table 2) despite 
missing returning visitors who have downloaded the application (n>90,000 downloads). The 
number of pages per visit and the average visit duration are continuously declining (Table 2), 
likely because returning visitors have become familiarized with the website.
The SYNTAX Score is currently being used as inclusion criteria in randomized trials 
evaluating optimal treatment strategies for coronary artery disease, such as the EXCEL 
trial.w26 Moreover, new clinical trials evaluating transcatheter aortic valve implantation in 
patients at intermediate surgical risk are using the SYNTAX as an exclusion criteria: PART-
NER 2 (NCT01314313) and SURTAVI (NCT01586910). Therefore, it is expected that not 
only coronary Heart Teams but also valvular Heart Teams will integrate the SYNTAX Score 
in their decision-making.
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figure 5
the number of page-views that www.syntaxscore.com has received since its 
introduction
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conclusions
The anatomical SYNTAX Score has emerged as a valuable tool to grade the complexity of 
patients with left main or three-vessel coronary artery disease. Although there is inter-and 
intraobserver variability in calculating the SYNTAX Score, this appears to be no longer a 
clinically relevant issue after appropriate training. The SYNTAX Score is now advocated 
in clinical guidelines and its use has been increasingly used around the world in everyday 
clinical practice. Integrating the SYNTAX Score in multidisciplinary coronary and valvular 
Heart Team decision-making appears inevitable, as current trials and clinical guidelines 
continue to expand the use of the anatomical SYNTAX Score.
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A crucial factor in shared decision-making: the team 
approach
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to the editor:
As discussed in your Editorial on shared decision making (March 5, p 784),1 treatment deci-
sions are unfortunately often dominated by physician-related factors.2 The current efforts to 
include patients in a shared decision-making process concerning treatment are encouraged. 
Even in a shared setup, however, patients rely on the pros and cons conveyed by the treating 
physician. Certain details of alternative treatments can intentionally or unintentionally be 
omitted, resulting in a failure to allow the patient to make a well-informed decision.
To move away completely from this physician-centric model, physicians should group 
themselves around the patient as a multidisciplinary team which can better disclose both 
the pros and cons of available therapies, thereby making the individual patient’s choice 
objective and optimal. As an example, the SYNTAX study3 pioneered the multidisciplinary 
“heart team approach” in a randomised trial to establish a discussion between different 
specialties leading to sufficiently deliberated patient advice. This approach has since gained 
popularity in an attempt to eliminate “competition” between percutaneous and surgical 
treatment. Several randomised trials now include patients only after a team discussion, and 
in the recently published guidelines on myocardial revascularisation, the heart team has 
been introduced as a class I recommendation for decision making.4 
We propose that a guidelines-driven team approach that formally includes patients’ 
preferences be implemented throughout all specialties to achieve optimal evidence-based 
and well-informed decisions in medicine.
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Chapter 9
The rationale for Heart Team decision-making 
in patients with stable, complex coronary artery 
disease
Head SJ, Kaul S, Mack MJ, Serruys PW, Taggart DP,  
Holmes Jr DR, Leon MB, Marco J, Bogers AJ, Kappetein AP
Eur Heart J 2013;34:2510-2518
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AbstrAct
Stable complex coronary artery disease can be treated with coronary artery bypass graft-
ing (CABG), percutaneous coronary intervention (PCI), or medical therapy. To select the 
most optimal treatment strategy for individual patients with stable complex coronary artery 
disease, multidisciplinary decision-making has gained more emphasis over the recent 
years. However, the so called “Heart Team” concept has not been widely implemented. Yet, 
decision-making has shown to remain suboptimal; there is large variability in PCI-to-CABG 
ratios, which may predominantly be the consequence of physician-related factors that have 
raised concerns regarding overuse, underuse, and inappropriate selection of revasculariza-
tion. In this review we summarize these and additional data to support the statement that 
a multidisciplinary Heart Team consisting of at least a clinical/non-invasive cardiologist, 
interventional cardiologist, and cardiovascular surgeon, can together better analyze and 
interpret the available diagnostic evidence, put into context the clinical condition of the 
patient as well as consider individual preference and local expertise, and through shared 
decision-making with the patient can arrive at a most optimal joint treatment strategy rec-
ommendation for patients with stable complex coronary artery disease.
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introduction
There is precedence in the field of medicine that the level of care can be improved and 
made more consistent with the use of multidisciplinary teams to recommend the most opti-
mal treatment. An example of this is the introduction of the tumor board in the 1960s, which 
has shown to significantly improve the quality of care.1-3 A pre-treatment multidisciplinary 
discussion was associated with improved survival as well as reduced hospital-variations in 
survival rates 1 and has been identified as an independent predictor of treatment recom-
mendations’ conformity to clinical practice guidelines.3
The area of cardiovascular diseases has seen the development of Heart Teams early on 
for treatment of heart failure, pediatric and adult cases of congenital heart disease, and 
more recently for aortic and mitral valve interventions. In the context of coronary revascu-
larization, multidisciplinary Heart Teams have been introduced through randomized trials. 
While decision-making for patients with acute indications or less complex coronary disease 
may be straightforward, for patients with stable complex (e.g. left main and/or multivessel) 
coronary artery disease (CAD), a Heart Team consisting of a clinical/non-invasive cardiolo-
gist, interventional cardiologist, and cardiac surgeon is considered optimal to best assess 
the advantages and disadvantages of the various treatment strategies. The Heart Team has 
recently become a class 1C recommendation in European and American guidelines on 
coronary revascularization.4-5 However, while in oncology 63% of centers in the western 
countries have embraced multidisciplinary teams6, this approach has not yet been widely 
implemented for cardiovascular indications for a myriad of reasons including the novelty of 
the concept, lack of experience, lack of proven benefit, logistical issues, as well as turf pro-
tection.7-8 Yet, there is clearly a need for improved decision-making. A recent study suggests 
that noncompliance to guidelines can result in inappropriate or underuse of revasculariza-
tion.9 In patients with an indication for coronary artery bypass grafting (CABG), only 53% 
received such treatment, 34% underwent percutaneous coronary intervention (PCI), 12% 
received medical management, and 1% did not receive any treatment.
The purpose of the current manuscript is to explorethe rationale behind Heart Team 
evaluation and to advocate for wider, regular use of Heart Teams in an orderly fashion, 
thereby enhancing the value of care for patients with stable complex CAD.
revAsculArizAtion: WhAt the heArt teAm could improve
Since CABG was demonstrated in the 1980s to be superior to medical therapy in patients 
with three-vessel or left main (LM) disease, many patients have been revascularized by this 
approach. The introduction of PCI with balloon angioplasty and subsequently stents resulted 
in a consideration of both therapies as treatment options. The different treatment strategies 
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should ideally be considered complementary. However, evidence suggests that the current 
decision-making process and treatment selection is questionable, thereby potentially result-
ing in suboptimal care and increased health care expenditures.
variability
Due to technical and therapeutic advancements and reduced invasiveness, PCI has been 
utilized increasingly since its introduction over 3 decades ago. Evidence from Europe, the 
United States, and Canada suggests that the PCI-to-CABG ratio has shifted significantly 
towards more PCI procedures.10-12This is in some degree caused by expanding indications 
for PCI. However, the Organization of Economic Cooperation and Development (OECD) 
reported a mean PCI-to-CABG ratio of 3.29 in 2007 in those countries affiliated with the 
organization, ranging from a low of 0.67 in Mexico to a high of 8.63 in Spain (Figure 1).13 
Even within the same health care system, a large difference in PCI-to-CABG ratios has been 
reported across different regions (Figure 2).13 This wide variability in the type of revascular-
ization utilization might be driven by economic and reimbursement considerations14, but 
other factors may also be contributory. Consistency and generality of recommendations 
might be best approached by Heart Team based care.
Differences in baseline patient characteristics might explain part of the variance in the PCI-
to-CABG ratio. However, physician-related factors dominate treatment decisions. Surgeons 
and cardiologists significantly differ in the information they provide the patient regarding the 
figure 1 revascularization procedures performed in countries throughout the Western world
Data from the Organisation for Economic Cooperation and Development (OECD) shows a great variety in the 
number of revascularization procedures per 100,000 inhabitant.13 CABG = coronary artery bypass grafting; PCI = 
percutaneous coronary intervention
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figure 2 rates of pci and cAbg in hospital referral regions within the united states
The mean rate of CABG was 5.2 per 1000 Medicare enrollees and 11.3 for PCI. Rates are adjusted for age, sex, 
and race. Copied from the Dartmouth Atlas of Health Care.84 Abbreviations as previous
table 1
overt and subconscious factors that influence whether comprehensive and well-balanced 
information of revascularization strategies is provided by physicians
‘Building an empire’ leading to (inter)national recognition 
Conflict of interest with industry
Knowledge of patient’s preferences
No appreciation of personal therapeutic limits 
Not being up-to-date regarding PCI and/or CABG (technology, outcomes, indications, etc)
Opportunity to include a patient in an enrolling randomized trial
Personal conflict between interventional cardiologist and/or surgeon
Physician-patient bonding
Preservation of patient-referral pathways 
The physician’s center is a center of excellence in PCI or CABG
‘Turf protection’ (protection of patient access and salary)
CABG = coronary artery bypass grafting; PCI = percutaneous coronary intervention
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choice between PCI and CABG, thereby creating a bias towards a specific treatment.15 Stud-
ies have shown that in 68% of patients who underwent PCI and 59% who underwent CABG, 
the alternative revascularization strategy was not discussed with the patient.16 Several overt 
and subconscious physician-related factors may influence these treatment recommenda-
tions (Table 1). To overcome these issues, the Heart Team may increase agreement among 
surgeons and cardiologists regarding the choice of the preferred treatment.17
decision-making
Typically, and according to the guidelines, revascularization is indicated if there is signifi-
cant angiographic diameter stenosis (≥50-70%) with documented ischaemia or fractional 
flow reserve <0.80.4
Factors that should be taken into account prior to decision-making are patient co-
morbidities, the patient’s history, coronary lesion complexity, and operative risk, but also 
the anticipated goals of therapy and the life-expectancy or expected quality of life improve-
ment. Several risk models have been developed to estimate the operative risk and long-term 
outcome,18-22 which can provide guidance for the Heart Team regarding safe and efficient 
treatment recommendations. However, these risk models should inform, not replace, clini-
cal judgment and local operator expertise in estimating the overall benefit-risk balance of 
treatment interventions.
The STS score 18 and logistic EuroSCORE 19 are the most commonly used models to 
assess the patients’ operative mortality risk.Both models include patient characteristics, 
co-morbidities, previous events, and operative factors to calculate a risk of mortality. The 
EuroSCORE has a satisfactory inter-observer variance (κ=0.71), but still the calculation is 
subject to many errors, ranging from simple encoding errors to re-calculation errors (e.g. 
creatinine plasmatic level to creatinine clearance).23 It can be expected that errors are more 
likely to occur in complex models with more variables, such as the STS score or the new 
EuroSCORE II.24 As a joint group the Heart Team enables an extra check with regard to the 
accuracy of the scores but cannot overcome the modest prognostic utility of scores. Simpler 
risk models with a limited number of variables, such as the ACEF score that includes only 
three factors,25 may also provide satisfactory risk stratification and are likely to have fewer 
errors.26
The SYNTAX score, established in 2005, was developed to grade complexity of CAD.27 
Validated in the SYNTAX trial, the score was found to be a good predictor of adverse events 
in the PCI population, however, not in CABG patients.28 Although it is vital to acknowledge 
the hypothesis-generating nature of the SYNTAX trial subgroup data, the score is a promis-
ing tool to stratify which patients can be revascularized with PCI or CABG and numerous 
publications support the prognostic capacity of the score in various patient populations.29-33 
Therefore, the SYNTAX score is increasingly used to guide treatment decisions and the 
new revascularization guidelines recommend the use of the SYNTAX score for treatment 
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selection.4-5 Despite the encouraging use of established SYNTAX Score threshold values 
(≤22 and ≥33), the SYNTAX Score needs to be weighted in the context of the overall evalua-
tion by the Heart Team which might overrule these threshold-based decisions.34 A limitation 
of the SYNTAX Score is its notable intra-observer and inter-observer variability, which can 
cause inappropriate revascularization strategies (Table 2).35-39
The inconsistency in the SYNTAX score is in part due to interpretations of coronary 
angiogram. The inaccuracy of grading vessel stenosis on angiograms has been addressed in 
a number of different studies in which a high inter-observer and intra-observer variability 
of angiogram analysis was demonstrated.40-41 However, the correlation between angiogram 
interpretations and the “normal” phantom study reference values increased when taking 
the mean of three (r=0.88) and five (r=0.89) physicians instead of the value of individual 
physicians (r=0.79).41 Another study showed that by replacing individual readings by panel 
readings, the appropriateness of the indication for CABG and PCI changed from necessary 
or appropriate to uncertain or inappropriate in 33% and 10% of the cases, respectively.40 
Within the Heart Team the members can interpret the angiograms together and reduce 
errors, so that the SYNTAX score correctly represents the patients’ lesions,36 leading to 
more appropriate revascularization. Nevertheless, Heart Team treatment decisions in which 
the angiographic complexity is weighted with clinical co-morbidity, operator skills, local 
expertise, and patient preference are more likely to yield improved outcomes than those 
based on evaluation of angiographic complexity alone.
table 2 observer variability in assessment of the syntAX score
Author, year patients no. of 
patients
score evaluation intra-observer 
variability (κ)*
inter-observer 
variability (κ)*
Serruys, 200938 LM and/or 
3VD
100 2 corelab technicians 0.59 for raw scores 0.45 for raw 
scores
0.61 for score 
tertiles
0.52 for score 
tertiles
Garg, 201035 LM and/or 
3VD
100 3 interventional 
cardiologists
0.54 for raw scores -
Shiomi, 201139 LM 101 2 interventional 
cardiologists
0.69 for score 
tertiles
0.58 for score 
tertiles
Tanboga, 201137 - 76 2 interventional 
cardiologists
0.69 for score 
tertiles
0.56 for score 
tertiles
Généreux, 
201136
MVD 30 3 interventional 
cardiologists - before 
training
- 0.33 for score 
tertiles
50 3 interventional 
cardiologists - after 
training
0.88, 0.64, 0.66 
for score tertiles
0.76 for score 
tertiles
*The kappa (κ) values represent the strength of agreement and agreement is considered to be fair between 0.21-
0.40, moderate between 0.41-0.60, substantial between 0.61-0.80, and almost perfect between 0.81-1.00.86 
3VD = three-vessel disease; LM = left main; MVD = multivessel disease
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Interactive web-based programs can be used to provide information on different treatment 
strategies with corresponding risks and benefits, which could be helpful for both patients 
and physicians. For patients it is mandatory that the program is user-friendly and easily 
interpretable so that it helps establish patient treatment preferences, and improve patient 
satisfaction.42For physicians, such programs can be used for comprehensive risk assessment 
and simulation of outcomes based on different treatment strategies. New insights into how 
the individual patient can potentially be treated with novel techniques could furthermore be 
provided. An example that is frequently used in oncology is the www.adjuvantonline.com 
table 3 inappropriateness of revascularization procedures
Author, year country inclusion procedures for 
stable angina
rate of
inappropriateness
rate of uncertian 
appropriateness
pci
Hilborne, 199352 USA 1990 519 1% 42%
Bengtson, 199446 Sweden 1990 56 5% 9%
Meijler, 199755 Netherlands 1992 891 33.4% 36.4%
Bernstein, 199947 Sweden 1994-1995 447 36.7% 37.8%
Hemingway, 
199950
UK 1995 ~328 43% 48%
Fitch, 200049 - - 204 15% 44%
Aguilar, 200143 Spain 1997 467 15% 23%
Yim, 200444 Korea 1997 228 8.8% 67.1%
Chan, 201148 USA 2009-2010 144,737 11.6% 38.0%
Hannan, 201258 USA 2009-2010 24,545 14.3% 49.6%
cAbg
Winslow, 198857 USA 1979-1980, 
1982
213 13% -
Gray, 199045 UK and USA 1987-1988 319 16%
Bengtson, 199446 Sweden 1990 307 1% 8%
McGlynn, 199454 Canada and 
USA
1989-1990 ~980 ~15%
Meijler, 199755 Netherlands 1992 1054 4.5% 13.4%
Bernstein, 199947 Sweden 1994-1995 1038 8.5% 13.2%
Hemingway, 
199950
UK 1995 ~323 43% 38%
Fitch, 200049 - - 204 19% 40%
O’Connor, 
200856
USA 2004-2005 806 2.1% 0%
Hannan, 201258 USA 2009-2010 8,168 1.1% 8.6%
CABG = coronary artery bypass grafting; PCI = percutaneous coronary intervention
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website. To the best of our knowledge, no program exists for cardiology and its development 
should be promoted.
inappropriate revascularization
Even though the imbalance in recommendations for therapy has been identified as early 
as the 1980s, recent study showed that inappropriateness rates remain high (Table 3).43-
58 Of 24,545 PCI procedures performed for non-acute indications of stable CAD, 14.3% 
were performed inappropriately and in another 49.6% there was not sufficientinformation 
and either approach could be considered (‘uncertain’).58 Evaluation of CABG procedures 
showed an inappropriateness rate of 1.1% and 8.6% were judged uncertain. However, it 
should be noted that a “zero tolerance” for inappropriate procedures is not expected, due 
to patient preferences and factors not captured in the criteria.48, 59 In addition, the recently 
updated appropriateness criteria have been criticized for several limitations59, including the 
composition of the panel, the role of pre-procedural diagnostic testing, and the fact that it 
does not account for all possible scenarios of clinical care.
Substantial inter-hospital variation of treatment recommendation may explain why the 
rates of inappropriateness vary significantly between studies.48, 57 Cardiologists and surgeons 
frequently favor PCI or CABG, respectively.17, 60-61 Appropriateness ratings can therefore 
depend on specific individual choices that have been shown to vary across geographic 
regions, which in turn could be a surrogate for cultural differences.62 However, it could also 
be evidence of particular excellence in PCI or CABG in certain centers. Thus, evaluation 
of an accurate rate of inappropriate revascularization will require adjustment for all these 
factors.
underuse of revascularization
An important limitation of the appropriateness criteria is that it can only be applied to 
patients that underwent revascularization. Preferably, it should be applied to all patients 
after a diagnostic angiogram or stress test, so that these criteria can also be used to identify 
patients in whom revascularization is underused (Table 4).51, 63-66 Based on existing studies, 
in 18-34% of patients in whom PCI was rated necessary or appropriate, no revascular-
ization took place. For CABG patients this number is approximately 25%. The incidence 
can vary for several patient groups; men are more likely to undergo revascularization than 
women, and whites more than blacks.63 The study by Leape and colleagues also found 
a large in-hospital variance in performance of necessary revascularization, ranging from 
21 to 87% (p<0.001).66 The clinical relevance of these findings was demonstrated by sig-
nificantly higher rates of angina at 1-year (odds ratio = 1.97 [1.29-3.00]) in patients that 
received medical therapy while PCI would have been appropriate.51 In a CABG patient 
group this effect was even more pronounced, with an odds ratio of 3.03 [2.08-4.42] for 
angina. Furthermore, CABG patients appeared to have significantly lower rates of death or 
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MI compared to patients that should have had revascularization (HR=0.25 [0.17-0.35]). 
In contrast, there was no evidence of a difference in death or MI rates between PCI and 
patients that received medical therapy (HR=1.30 [0.80-2.08]).51 A recent study by Hannan 
and colleagues contradicted this finding.67 They showed that patients who should have had 
PCI were more likely to experience death (14.5 vs. 10.2%, HR=1.46 [1.08-1.97]) or the 
composite of death or MI (21.2 vs. 16.5%, HR=1.49 [1.16-1.93]) at 4 years when compared 
to those patients that did undergo PCI. Furthermore, Filardo and colleagues showed that 
underuse of any revascularization was associated with significantly increased mortality dur-
ing follow-up (multivariate HR=3.23 [2.00-5.26]).64
table 4 underuse of revascularization procedures
Author, year country inclusion number of 
patients
revascularization 
not given (%)
outcome
pci necessary/appropriate
Kravitz, 199565 USA 1990-
1991
107 34% no PCI 3.7 versus 5.6%
25% no 
revascularization
-
Leape, 199966 USA 1995 57 18% no 
revascularization
-
Hemingway, 200151 UK 1996-
1997
908 34% no 
revascularization
Death or nonfatal MI: 
HR=1.30 [0.80-2.08]
cAbg necessary/appropriate
Kravitz, 199565 USA 1990-
1991
424 41% no CABG 16.7 versus 9.7%
25% no 
revascularization
-
Leape, 199966 USA 1995 442 25% no 
revascularization
-
Hemingway, 200151 UK 1996-
1997
1353 26% no 
revascularization
Death or nonfatal MI: 
HR=0.25 [0.17-0.35]
revascularization necessary/appropriate
Kravitz, 199565 USA 1990-
1991
671 25% 23.3% (none) versus 
9.3% (CABG) or 
8.9% (PCI)
Leape, 199966 USA 1992 631 26% -
Filardo, 200164 Italy 1995 1213 29% Survival: 
HR=0.31 [0.19-0.51]
Epstein, 200363 USA 1991-
1992
1526* and 
2049†
23.9%* and 24.6%† -
*According to RAND method. †According to ACC/AHA method. HR=hazard ratio; MI=myocardial infarction; 
other abbreviations as previous.
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history of the coronAry heArt teAm
Initiated in early randomized trials comparing CABG with medical therapy for stable 
CAD,68-69 a Heart Team was used to select patients eligible for randomization. Partly due 
to the introduction of PCI, interventional cardiologists and cardiac surgeons were increas-
ingly targeting the same patient population. Randomized trials comparing CABG and PCI 
followed,70-71 in which specialties worked in close proximity to ensure accurate patient 
selection and assume clinical equipoise between treatments. This provided new insights 
into decision-making as performed by a Heart Team. The EAST 72 and BARI 73trials included 
nested registries along with the randomized cohorts, to demonstrate if physician or patient 
treatment preferences yielded different results than patients in whom equipoise was 
assumed. Remarkably, three-year survival of the EAST registry patients was slightly better 
than randomized patients (96.4% versus 93.4%, p=0.044), which suggests that the selection 
of treatment after discussion with a cardiologist, cardiac surgeon, and the patient provides 
better outcomes in comparison to randomization. Similar results were confirmed by the 
BARI trial, showing improved survival of registry patients over randomized patients at seven-
year follow-up. The SYNTAX trial also included nested registries but differed from previous 
trials such as EAST and BARI registries in that inclusion was not due to patient preferences, 
figure 3 syntAX trial recruitment
CTO = chronic total occlusion; LM = left main; other abbreviations as previous.
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but specifically focused on inclusion of patients with assumed superiority of either PCI or 
CABG.28 The SYNTAX Heart Team demonstrated the contemporary PCI/CABG distribution 
of patients with left main and/or three-vessel disease (Figure 3); in 58.5% of patients both 
PCI and CABG was suitable, while 6.4% and 35.0% could only undergo PCI and CABG, 
respectively, due to co-morbid and lesion specific factors according to the Heart Team.34
Further evidence supporting Heart Team decision-making originated from the MASS-II 
trial in which patients were randomized to PCI, CABG, or medical therapy.74 Before ran-
domization, experienced clinical/non-interventional cardiologists recorded their personal 
choice of treatment. Survival comparison between the chosen and randomized treatment 
showed excellent outcomes and good clinical judgment with respect to CABG and medical 
therapy (Figure 4). However, survival was significantly worse in patients randomized to PCI 
in whom CABG or medical therapy would have been preferred. This speaks to the value of 
additional expertise that could have improved patient selection.
At present time, both European (2010) and American (2011) guidelines on coronary 
revascularization were a joint effort of cardiology and surgical associations.4-5 This concept 
recapitulates the Heart Team, where specialists work together to optimize treatment recom-
mendations based on an exchange of knowledge and experience with specific therapies.
figure 4
probability of survival according to the treatment selection per randomization or 
clinical judgment
Before randomization in the MASS II trial took place, two experienced cardiologists had to state their preference 
of therapy. This table shows the survival of patients as they were treated by the randomized therapy, set out against 
the survival that would have been the case if the preferred treatment had been given. Copied with permission from 
Pereira and colleagues.74 Abbreviations as previous.
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heArt teAm orgAnizAtion And involvement
organization and logistics
It has been shown that in cancer teams up to 15% of treatment recommendations are not 
implemented.75This is most often the case when co-morbid conditions are not discussed at 
the meeting, if patient preferences are unknown, or if further diagnostics became available 
after the meeting. As emphasized by the ‘uncertain’ classification in the appropriateness 
criteria, treatment decisions are frequently not substantiated because there is insufficient 
diagnostic data or inadequate documentation for an evidence-based decision. Therefore, it 
is crucial that all necessary patient information is available during the Heart Team meeting. 
The appointment of a non-clinical coordinator would be particularly helpful for gathering 
patient information or making sure this is accessible electronically, ensuring the necessary 
attendance and documentation of specialties that are present, and recording treatment 
recommendations.
Leadership is of the utmost importance for a team to be efficient as objectives need to be 
made clear, it can stimulate participation, encourage commitment to excellence, and drive 
innovation.76 Active participation of all team members is a prerequisite, and the discussion 
should take place in a non-autocratic setting. To achieve a positive dynamic it is essential to 
have mutual respect where all input is acknowledged with transparent positive and negative 
feedback.
The frequency and length of Heart Team meetings depends strongly on the case-load and 
complexity of patients. Ideally, the Heart Team should convene on a regular basis so that the 
length of the meetings can be kept to a minimum and each case can be discussed in 5-10 
minutes. A lower number of meetings results in a higher number of cases to be discussed 
and physicians can become less motivated to actively attend lengthy meetings. For centers 
that do not have an on-site surgical department, Heart Team meetings can be organized 
through teleconference with the potential for integrated WebEx screen-sharing. For complex 
cases, surgical consultation may be obtained through weekly meetings. Tumor boards often 
convene through teleconference to discuss patients to obtain multiple experts’ opinions 
about treatment strategies and discuss whether referral to centers of excellence is warranted.
Logistics are of course the major barrier to convening the Heart Team. In some institutions, 
at least initially, ad hoc meetings between interventional cardiologist and cardiac surgeon 
may be the best approach to initiate collaboration. What works well in one institution may 
not be the optimal approach in another. Successful realization of regular multidisciplinary 
team evaluation is based on participation of all the necessary physicians.
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involvement
Clinical/non-invasive cardiologists, interventional cardiologists, and cardiac surgeons 
should always be present to evaluate whether optimal medical therapy, PCI, or CABG is the 
preferred treatment. However, other physicians with specific expertise can be added if nec-
essary. An anesthesiologist can assess surgical risk in potential CABG patients by providing 
input about the ability of the patient to safely undergo general anesthesia. Residents and/or 
schooled research nurses should have gathered the necessary data to interpret, and share the 
prepared score assessments on a plenary screen so that definition, typing, or re-calculation 
errors can be avoided through feedback by the rest of the team.
The concept of shared decision-making with physicians and patients has received more 
emphasis, and patients should be integrated in the process of decision-making (Figure 5). 
Involvement of patients’ families and friends in the Heart Team can increase patient satisfac-
tion.77 A prospective cohort study of 3,045 CABG patients treated at 16 hospitals showed 
that a “supportive group culture” in hospitals was significantly correlated with higher patient 
physical and mental health scores as determined by SF-36 questionnaires 6 months post-
CABG.78
Decision-making should be based on three key points: i) knowledge transfer, in which it 
is equally important that the physician provides information to the patient and the patient 
to the physician, ii) discussion, and iii) reaching an agreement on which revascularization 
The patient
with CAD
Clinical cardiologist
(non interventional)
Interventional
cardiologist
Ca
rd
iac
su
rg
eo
n
figure 5
the basis for a heart team is involvement of necessary specialties and the patient to 
facilitate shared decision-making
Copied with permission from Wijns and colleagues.85 CAD = coronary artery disease
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strategy will be performed in which patient preferences should be prioritized. It is crucial 
that during the exchange of information at least a team of one clinical/non-invasive cardiolo-
gist, an interventional cardiologist, and a cardiac surgeon is present to ensure that sufficient 
information on pros and cons of all therapies is provided to the patient.
AdditionAl AdvAntAges
Physicians can be held accountable for inappropriate decision-making and can ultimately 
face medico-legal consequences. In general, team physicians “share the burden” and this 
approach might potentially minimize medical malpractice exposure, because there is a 
shared responsibility of recommending the most optimal therapy to the patient. Neverthe-
less, all members of the team can be held accountable for decisions within their expertise.79
In a group discussion it is gratifying and self-assuring to be acknowledged for an opinion 
that is shared with peers, and multidisciplinary approaches have been linked to improved 
wellbeing of physicians.80
Another benefit of the Heart Team approach is creating a more robust clinical research 
program with enhanced quality of care monitoring. Studies suggest that the use of multi-
disciplinary teams can increase trial recruitment.81 Information regarding existing and new 
therapies is more complete, and patients can interpret the advantages and disadvantages 
of these treatments to decide whether they are willing to be enrolled in a randomized trial.
vAlidAtion of the heArt teAm
Although we have summarized the rationale in support of a Heart Team approach, it is 
difficult to upgrade the class 1C recommendation in the current guidelines.4-5 Because of 
the lack of randomized data, it is crucial to perform observational studies to produce data on 
the pros and cons of the Heart Team. Currently only a single study has been reported, which 
showed that decisions made by the Heart Team are reproducible.82 Several hypothetical 
designs are listed in Table 5. Although there are limitations to such designs, these studies will 
provide the necessary insights into adoption of the Heart Team and determine whether joint 
decision-making and treatment recommendations can increase uniformity of care, adher-
ence to practice guidelines, and decrease the number of patients receiving inappropriate 
care.
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limitAtions of the heArt teAm
The Heart Team approach can cause delays in decision-making and treatment, inefficiency 
in care and increased expense by foregoing “ad hoc” decisions. Heart Team meetings fur-
thermore require an investment in time of surgeons, cardiologists and ancillary personal, 
thereby increasing direct costs. One might therefore suggest that the Heart Team should only 
convene specifically for those cases in which there is a legitimate question regarding which 
revascularization strategy should be recommended, and whether treatment decisions can 
be made without a formal Heart Team meeting. Surgeons and (interventional) cardiologists 
can specify in a local protocol which patients can be left out from a Heart Team meeting, for 
example, patients with single vessel disease or a SYNTAX score ≤22; according to the 2010 
ESC/EACTS revascularization guidelines, patients with low lesion complexity (e.g., single or 
double-vessel disease) may undergo ad-hoc stenting to avoid two separate catheterizations.4 
It is recommended to schedule an informal ‘time-out’ to allow surgical consultation in the 
catheterization laboratory; this concept could therefore accelerate the decision-making 
process in relatively simple cases and in patients with acute coronary syndromes. However, 
ischaemia, fractional-flow reserve, or SYNTAX score should be recorded to allow the oppor-
tunity for active decision-making as well as the reasons for preclusion of a formal Heart 
Team discussion so that treatment decisions can retrospectively be acknowledged. 
Still, the increased short-term costs associated with multidisciplinary meetings may be 
of concern. However, in the Netherlands for example, health care providers reimburse the 
Heart Team as it is likely to reduce inappropriate revascularization and improve outcomes on 
the long-term, which will compensate for these investments. In some fragmented health care 
systems, some payers might be concerned with increased short-term cost without acknowl-
edging benefit from reduced long-term costs, and the different parties should attempt to 
come to an agreement so that the Heart Team approach is beneficial for all those involved. 
In the early phase of PCI introduction, surgeons had the ability to influence hospital deci-
sions postponing large-scale PCI use; in several institutions with highly influential cardiac 
table 5 possible study designs to validate and evaluate the heart team concept
Exploring the reproducibility of the Heart Team by presenting treatment decision of specific cases to 
different Heart Teams. For example, this can be done for teams in different regions or teams with different 
inclusion/consistencies of physicians
Assessing the change in treatment recommendation by comparing an initial individual physicians’ 
evaluation to a re-evaluation by the Heart Team
Cluster randomized trial in which centers evaluate patients either in a Heart Team or according to the 
original referral patterns by the surgeon or cardiologist
Before-and-after study to compare treatment decisions and outcomes before and after implementation of 
a Heart Team
Comparison of treatment decisions and outcomes of different centers with and without Heart Team 
evaluation
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surgeons the adoption rate of PCI was lower than in other institutions where they were less 
influential.83 There have been concerns that multidisciplinary decision-making can be based 
on autocratic individuals that consider themselves highest on the hierarchical tree.80 This 
could result in revascularization strategies that are chosen by the highest rank without a real 
team discussion. Adherence to current clinical guidelines can then become questionable. 
Nevertheless, oncology studies have shown that the use of multidisciplinary teams resulted 
in treatment that is more congruent with evidence-based recommendations and guide-
lines.3, 77 Although it has been implied that improved concordance with revascularization 
guidelines can be achieved by multidisciplinary input9, this requires further investigation.
There is evidence suggesting that the longer a team has worked together, the more pleas-
ant, interactive and successful it becomes. The initial experiences of a Heart Team might 
therefore not always be positive, but it is crucial to maintain the initiative as it could eventu-
ally lead to better treatment recommendations and personal well-being.
conclusions 
Underutilization, overutilization, and inappropriate use of coronary revascularization are 
common, and rates differ significantly between geographic regions and hospitals. Clinical 
and anatomical risk scores that are used for decision-making have high inter- and intra-
observer variability and this can therefore lead to inaccurate recommended revasculariza-
tion strategies. A balanced multidisciplinary Heart Team, consisting of at least a clinical/
non-invasive cardiologist, interventional cardiologist, and cardiac surgeon, has the potential 
to i) better interpret the available diagnostics, ii) implement guideline directed therapy, iii) 
consider local expertise, and iv) through shared-decision making take into account patient 
preferences, to provide a more objective and uniform decision-making process. Even though 
definitive data from trials demonstrating a direct patient benefit to the Heart Team approach 
is lacking, indirect evidence from both cardiac disease and oncology fields strongly recom-
mends the implementation of the Heart Team.
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AbstrAct
Aims
Numerous studies have linked prosthesis–patient mismatch (PPM) after aortic valve replace-
ment (AVR) to adverse outcomes. Its correlation with long-term survival has been described 
but with contradicting results. This systematic review and meta-analysis of observational 
studies aims to determine the hazard of PPM after AVR.
Methods and results
The Medline and EMBase databases were searched for English-language original publica-
tions. Two researchers independently screened studies and extracted data. Pooled estimates 
were obtained by random effects model. Subgroup analyses were performed to detect 
sources of heterogeneity. The search yielded 348 potentially relevant studies; 34 were 
included comprising 27 186 patients and 133 141 patient-years. Defined by the universally 
accredited indexed effective orifice area <0.85 cm2/m2, 44.2% of patients were categorized 
as having PPM. In 34.2 and 9.8% of patients moderate (0.65–0.85 cm2/m2) and severe 
(<0.65 cm2/m2) PPM was present, respectively. Prosthesis–patient mismatch was associated 
with a statistically significant increase in all-cause mortality (HR = 1.34, 95% CI: 1.18–1.51), 
but only a trend to an increase in cardiac-related mortality (HR = 1.51, 95% CI: 0.88–2.60) 
was recognized. Analysis by severity of PPM demonstrated that both moderate and severe 
PPM increased all-cause mortality (HR = 1.19, 95% CI: 1.07–1.33 and HR = 1.84, 95% 
CI: 1.38–2.45) and cardiac-related mortality (HR = 1.32, 95% CI: 1.02–1.71 and HR = 
6.46, 95% CI: 2.79–14.97). Further analyses showed a consistent effect over separate time 
intervals during follow-up.
Conclusions
Prosthesis–patient mismatch is associated with an increase in all-cause and cardiac-related 
mortality over long-term follow-up. We recommend that current efforts to prevent PPM 
should receive more emphasis and a widespread acceptance to improve long-term survival 
after AVR.
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IntroductIon
The problem of prosthesis–patient mismatch (PPM) after valvular surgery has been a topic 
of discussion ever since it was first described in 1978.1 Prosthesis–patient mismatch occurs 
when the effective orifice area (EOA) of the prosthesis is physiologically too small in relation 
to the patient’s body size, thus resulting in abnormally high post-operative gradients. Hence, 
the parameter that has been used to characterize PPM is the indexed EOA (iEOA), i.e. the 
EOA of the prosthesis divided by the patient’s body surface area.2–4
Results from clinical studies demonstrated the negative effect of PPM following aortic 
valve replacement (AVR) on left ventricular (LV) mass regression, recovery of LV systolic 
function, New York Heart Association functional class, quality of life, and bioprosthetic 
valve durability.5,6 Furthermore, aortic PPM has been associated with increased incidence 
of operative mortality and late cardiac events.7–11
Although, patients with PPM have been shown to have worse haemodynamic and func-
tional outcomes following AVR, survival analyses have not yet uniformly demonstrated that 
PPM is a predictor of increased mortality.12,13 In an attempt to further explore the association 
of PPM and long-term survival after AVR in adults, a systematic review and meta-analysis 
was performed of both retro- and prospective cohort studies that stratify survival by the 
presence of PPM.
Methods
The reporting of this systematic review and meta-analysis is according to the Meta-analysis 
of Observational Studies in Epidemiology (MOOSE) guidelines.14
search strategy
In January 2011 the Medline and EMBase databases were systematically searched to identify 
published full-length English studies reporting the long-term survival of patients after AVR, 
stratified by the presence of PPM. No year of publication exclusion was implied. Studies 
were identified by a search using the following key words in all fields: ‘mismatch OR PPM’ 
AND ‘AVR OR aortic valve replacement’. To ensure that no potentially valid studies were 
missed, the reference lists from reviews and included studies were checked.
study inclusion
The title and abstract of studies identified by the search were independently screened by 
two investigators (S.J.H. and M.M.M) using the following criteria: (i) the publication was 
an original full-article contribution in a peer-reviewed journal; (ii) patients were adults; 
(iii) patients had undergone AVR with a bioprosthetic or mechanical valve; (iv) PPM was 
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assessed; and (v) long-term survival a minimum of 5 years of follow-up was available and 
stratified for PPM. Studies reporting only a specific patient group (e.g. patients with renal 
failure) were excluded. For studies that met these criteria, or in case of uncertainty, the 
full-texts were further evaluated.
Finally, the study site(s), inclusion period, patient demographics (e.g. age), and diagnosis 
of potential studies were compared to ensure minimal patient overlap in different publica-
tions. If extensive overlap existed, only the publication with the largest or diagnostically 
most complete cohort (e.g. all patients instead of only patients with aortic stenosis) was 
included.
data extraction
From each study, we collected the design, number of patients, patient baseline characteris-
tics, type of implanted valve, presence of PPM according to the corresponding iEOA cut-off 
threshold, follow-up, and patient-years of follow-up. If the number of patient-years was not 
mentioned, it was calculated by multiplying the number of patients with the mean follow-
up. If data were unclear or unavailable, the authors were contacted by e-mail.
Studies that reported results of a PPM (iEOA <0.85, <0.80, or <0.75 cm2/m2) vs. no PPM 
group were included in the ‘any PPM’ analysis. Studies that reported results for moderate 
PPM (iEOA 0.65/0.60–0.90/0.85 cm2/m2) or severe PPM (iEOA <0.65 or <0.60 cm2/m2) 
separately were included in ‘moderate PPM’ and ‘severe PPM’ pooled analyses.
All-cause mortality and cardiac-related mortality were evaluated. Mortality was extracted 
as an HR. For studies that did not report an HR with corresponding variance, this was 
extracted per 6-month period from the Kaplan–Meier survival curve by two independent 
investigators (S.J.H. and R.L.J.O). Survival was obtained up to a representative number of 
patients at risk.15,16 The method described by Williamson et al.17 was used to estimate a 
logarithmic HR with corresponding variance when the number of patients at risk was given 
at each time frame. If these data were not provided, the method by Parmar et al. was used.18 
For each study, we used a spreadsheet programmed to estimate the overall HR with 95% 
confidence intervals (CI) using an inverse variance-weighted average.19,20
statistical analysis
Statistical analyses were performed using Review Manager version 5.0 for Windows (The 
Cochrane Collaboration, 2008). A random-effects model was used to obtain pooled esti-
mates. Weighting of studies was based on the standard error (SE) of the logarithmic HR, in 
which studies with a large SE are weighted less than studies with a small SE. Heterogeneity 
was examined with the I2 statistic; whether this was statistically significant in subgroup 
analyses was explored with the Q test. Sources of heterogeneity were explored by subgroup 
analyses of study characteristics (study design, study location, year of publication, mean 
follow-up), patient characteristics (age, type of valve implanted), and the method used to 
The impact of PPM on survival after AVR 133
C
ha
pt
er
 1
0
define PPM. Sensitivity analyses were performed for the year of patient inclusion to study the 
effect of characteristics that may have changed over time.
A separate analysis was performed with obtained HRs and corresponding SEs per 1-year 
period, calculated with the extraction spreadsheet. An overall pooled HR estimate per sepa-
rate time period was obtained with a random effects model. Subsequently, the pooled year 
estimates were again combined to assess whether the HRs were different between intervals.
Funnel plots were produced for visualization of possible publication bias.21
results
The database search yielded 348 potentially relevant studies (Figure 1). After the title and 
abstract were screened, 176 studies were excluded because they did not focus on AVR with 
bioprosthesis or mechanical valve and the association of PPM with survival. Another 73 
studies were excluded because they were not original full-length contributions.
Ninety-nine full-text original articles were reviewed in more detail. Studies were further 
excluded for various reasons (Figure 1), and a remainder of 34 studies were included in the 
 
Potentially relevant studies screened for 
retrieval on basis of title and abstract (n=348) 
Studies excluded: 
- Not clinically relevant (n=176) 
- No original contribution (n=73) 
Potentially studies retrieved for more 
detailed evaluation (n=99) 
Studies excluded: 
- No long-term follow-up, or not stratified 
by prosthesis-patient mismatch (n=49) 
- Article not in English (n=3) 
Potentially appropriate studies to be included 
(n=47) 
Relevant studies from reference lists or 
previous reviews (n=0) 
Studies excluded because of overlap with 
other included studies or insufficient data 
(n=13) 
Studies included and analysed in the  
meta-analysis (n=34) 
Figure 1 Flow diagram: systematic inclusion of studies for meta-analysis
Part 2 Surgical or transcatheter therapy for aortic stenosis134
Ta
bl
e 
1
st
ud
y 
ch
ar
ac
te
ri
st
ic
s 
Fi
rs
t 
au
th
or
Ye
ar
 o
f 
pu
bl
ic
at
io
n
st
ud
y 
lo
ca
ti
on
In
cl
us
io
n
st
ud
y 
de
si
gn
n
o.
 o
f 
pa
ti
en
ts
M
al
e
ge
nd
er
 (
%
)
M
ea
n 
ag
e 
(Y
ea
rs
)
ty
pe
 o
f v
al
ve
ie
o
A
 c
ut
-o
ff
 
(c
m
2/
m
2)
PP
M
 
(%
)
M
ea
n 
fo
llo
w
-u
p 
(y
ea
rs
)
M
or
ta
lit
y 
an
al
ys
is
Sa
ka
m
ot
o 
20
10
Ja
pa
n
19
96
-2
00
8
re
tr
os
pe
ct
iv
e
34
2
61
.7
69
.7
bi
op
ro
st
he
tic
<
0.
85
28
3.
2
ov
er
al
l
Ja
m
ie
so
n 
20
10
C
an
ad
a
19
82
-2
00
3
re
tr
os
pe
ct
iv
e
33
43
65
.7
68
.1
m
ix
≤0
.8
5
54
6.
2
ov
er
al
l
Fl
am
en
g 
20
10
B
el
gi
um
19
91
-2
00
3
re
tr
os
pe
ct
iv
e
56
4
51
73
.6
bi
op
ro
st
he
tic
<
0.
85
51
6.
1*
ov
er
al
l
B
le
iz
iff
er
20
10
G
er
m
an
y
20
00
-2
00
7
re
tr
os
pe
ct
iv
e
64
5
56
.4
72
.3
bi
op
ro
st
he
tic
<
0.
85
40
2.
7
ca
rd
ia
c
U
rs
o 
20
09
Sp
ai
n
20
00
-2
00
7
re
tr
os
pe
ct
iv
e
16
3
49
.7
78
.0
m
ix
≤0
.8
5
43
3.
1
ov
er
al
l
M
ro
w
cz
yn
ks
i 
20
09
G
er
m
an
y
19
95
-2
00
4
re
tr
os
pe
ct
iv
e
30
9
63
.6
71
.6
m
ix
<
0.
85
66
2.
8*
ov
er
al
l
M
oo
n 
20
09
U
SA
19
92
-2
00
7
re
tr
os
pe
ct
iv
e
13
99
58
.5
71
.1
bi
op
ro
st
he
tic
<
0.
85
62
3.
8
ov
er
al
l
M
oh
ty
 
20
09
C
an
ad
a
19
92
-2
00
5
re
tr
os
pe
ct
iv
e
25
76
61
68
.5
m
ix
≤0
.8
5
32
4.
8
bo
th
M
an
na
ci
o 
20
09
Ita
ly
19
97
-2
00
2
re
tr
os
pe
ct
iv
e
15
7
67
.4
66
.7
m
ix
≤0
.7
5
61
7.
0
ov
er
al
l
V
ic
ch
io
 
20
08
Ita
ly
19
88
-2
00
6
re
tr
os
pe
ct
iv
e
34
5
33
.0
74
.5
m
ec
ha
ni
ca
l
<
0.
85
60
4.
2
ov
er
al
l
Ts
ut
su
m
i 
20
08
Ja
pa
n
19
90
-2
00
9
re
tr
os
pe
ct
iv
e
12
4
50
.8
59
.3
m
ec
ha
ni
ca
l
<
0.
85
20
9.
1
ca
rd
ia
c
R
yo
m
ot
o 
20
08
Ja
pa
n
19
90
-2
00
7
re
tr
os
pe
ct
iv
e
10
1
45
.5
72
.4
m
ix
≤0
.8
5
34
3.
1
ov
er
al
l
M
as
ch
er
ba
ue
r 
20
08
A
us
tr
ia
19
98
-2
00
5
pr
os
pe
ct
iv
e
36
1
47
.4
69
.5
m
ix
≤0
.8
0
54
4.
2
ov
er
al
l
Ko
hs
ak
a 
20
08
U
SA
19
93
-1
99
8
pr
os
pe
ct
iv
e
46
9
66
.7
56
.1
m
ec
ha
ni
ca
l
≤0
.8
5
43
7.
9*
ov
er
al
l
K
at
o 
20
08
Ja
pa
n
19
86
-2
00
6
re
tr
os
pe
ct
iv
e
84
50
68
.5
m
ix
≤0
.8
5
25
4.
5
bo
th
Fl
or
at
h 
20
08
G
er
m
an
y
19
96
-2
00
5
re
tr
os
pe
ct
iv
e
53
3
54
.2
71
.1
m
ix
≤0
.8
5
80
4.
7
ov
er
al
l
Ta
o 
20
07
Ja
pa
n
20
00
-2
00
5
re
tr
os
pe
ct
iv
e
15
0
45
.3
68
.7
m
ec
ha
ni
ca
l
≤0
.8
5
23
2.
5
bo
th
N
oz
oh
oo
r 
20
07
Sw
ed
en
19
96
-2
00
6
re
tr
os
pe
ct
iv
e
17
97
…
…
m
ix
≤0
.8
5
53
4.
3
ov
er
al
l
M
on
in
 
20
07
Fr
an
ce
19
94
-2
00
5
pr
os
pe
ct
iv
e
13
9
74
.1
72
m
ix
≤0
.8
5
57
3.
7*
ov
er
al
l
K
at
o 
20
07
Ja
pa
n
19
90
-2
00
5
re
tr
os
pe
ct
iv
e
14
6
56
.8
68
.2
m
ix
≤0
.8
5
45
4.
5
bo
th
G
ar
ci
a 
Fu
st
er
 
20
07
Sp
ai
n
19
94
-2
00
5
re
tr
os
pe
ct
iv
e
33
9
55
.8
66
.5
m
ix
≤0
.8
5
38
6.
9
ca
rd
ia
c
W
al
th
er
 
20
06
G
er
m
an
y
19
96
-2
00
4
pr
os
pe
ct
iv
e
41
31
62
.8
58
.9
m
ix
<
0.
85
29
5.
2
ov
er
al
l
Ta
sc
a
20
06
Ita
ly
19
97
-2
00
3
pr
os
pe
ct
iv
e
31
5
49
.8
70
.8
m
ix
≤0
.8
0
47
3.
7
ov
er
al
l
The impact of PPM on survival after AVR 135
C
ha
pt
er
 1
0
ta
bl
e 
1
C
on
ti
nu
ed
Fi
rs
t 
au
th
or
Ye
ar
 o
f 
pu
bl
ic
at
io
n
st
ud
y 
lo
ca
ti
on
In
cl
us
io
n
st
ud
y 
de
si
gn
n
o.
 o
f 
pa
ti
en
ts
M
al
e
ge
nd
er
 (
%
)
M
ea
n 
ag
e 
(Y
ea
rs
)
ty
pe
 o
f v
al
ve
ie
o
A
 c
ut
-o
ff
 
(c
m
2/
m
2)
PP
M
 
(%
)
M
ea
n 
fo
llo
w
-u
p 
(y
ea
rs
)
M
or
ta
lit
y 
an
al
ys
is
M
oo
n 
20
06
U
SA
19
92
-2
00
4
re
tr
os
pe
ct
iv
e
14
00
57
.2
66
.8
m
ix
<
0.
75
38
3.
8
ov
er
al
l
M
oh
ty
 
20
06
U
SA
19
85
-2
00
0
re
tr
os
pe
ct
iv
e
38
8
31
.4
62
.3
m
ec
ha
ni
ca
l
≤0
.8
5
43
5.
3
ov
er
al
l
H
ow
el
l 
20
06
U
K
19
97
-2
00
5
pr
os
pe
ct
iv
e
14
18
61
.6
65
.5
m
ix
<
0.
85
56
3*
ov
er
al
l
Fl
am
en
g 
20
06
B
el
gi
um
19
85
-2
00
3
re
tr
os
pe
ct
iv
e
50
6
50
73
.3
bi
op
ro
st
he
tic
<
0.
85
20
6.
1
ov
er
al
l
Pe
nt
a 
de
 P
ep
po
 
20
05
Ita
ly
19
91
-2
00
2
pr
os
pe
ct
iv
e
83
71
.1
46
.5
m
ec
ha
ni
ca
l
<
0.
85
28
6.
7
ca
rd
ia
c
R
ue
l 
20
04
C
an
ad
a
19
76
-2
00
1
pr
os
pe
ct
iv
e
12
26
58
.6
63
.8
m
ix
≤0
.8
5
77
4.
3
ca
rd
ia
c
M
ila
no
 
20
02
Ita
ly
19
81
-1
99
5
re
tr
os
pe
ct
iv
e
22
9
20
.1
63
.7
m
ec
ha
ni
ca
l
≤0
.9
0
73
10
bo
th
H
an
ay
am
a
20
02
C
an
ad
a
19
90
-2
00
0
pr
os
pe
ct
iv
e
76
8
66
.0
64
.7
m
ix
<
0.
60
10
3.
5
ov
er
al
l
Fr
ap
ie
r 
20
00
Fr
an
ce
19
86
-1
99
0
re
tr
os
pe
ct
iv
e
90
62
.2
72
.6
bi
op
ro
st
he
tic
≤0
.8
5
71
7.
3*
bo
th
R
ao
 
20
00
C
an
ad
a
19
76
-1
99
6
pr
os
pe
ct
iv
e
21
54
60
.1
66
.1
bi
op
ro
st
he
tic
≤0
.7
5
11
6.
2
bo
th
Pi
ba
ro
t 
19
98
C
an
ad
a
19
86
-1
99
5
pr
os
pe
ct
iv
e
39
2
71
.7
68
.4
bi
op
ro
st
he
tic
≤0
.8
5
45
…
ov
er
al
l
*m
ed
ia
n 
fo
llo
w
-u
p.
 iE
O
A
 =
 in
de
xe
d 
ef
fe
ct
iv
e 
or
ifi
ce
 a
re
a;
 P
PM
 =
 p
ro
st
he
si
s-
pa
tie
nt
 m
is
m
at
ch
Part 2 Surgical or transcatheter therapy for aortic stenosis136
Figure 2 Pooled estimate for all-cause mortality
Ratios demonstrate the additional hazard with prosthesis-patient mismatch in relation to a no prosthesis-patient 
mismatch reference group. Studies that stratified results according to the severity of prosthesis-patient mismatch 
are analysed individually. HR  =  hazard ratio; CI  =  confidence interval; PPM  =  prosthesis-patient mismatch
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present systematic review (Table 1).4,5,8,10,11,22–50 They comprised a total of 27 186 patients 
and 133 141 patient-years. In 27 studies with 21 802 patients, the iEOA threshold of 0.85 
cm2/m2 was used, and 44.2% of patients were diagnosed with PPM. Seven studies found 
that 34.2% of patients had moderate PPM (>0.65 to >0.85 cm2/m2), and 9.8% had severe 
PPM (<0.65 cm2/m2).
long-term outcomes
Prosthesis–patient mismatch was associated with decreased long-term survival (HR = 1.34, 
95% CI: 1.18–1.51) when compared with patients without PPM (Figure 2). In studies that 
stratified outcomes by the severity of PPM, both moderate (HR = 1.19, 95% CI: 1.07–1.33) 
and severe (HR = 1.84, 95% CI: 1.38–2.45) PPM showed a statistically significant increase 
in all-cause mortality.
Prosthesis–patient mismatch was associated with a 1.51-fold (95% CI: 0.88–2.60) non-
significant increase in cardiac-related mortality (Figure 3). Differentiation by moderate and 
severe PPM demonstrated HRs of 1.32 (95% CI: 1.02–1.71) and 6.46 (95% CI: 2.79–14.97), 
respectively.
There was a constant hazard over time for all-cause mortality (P = 0.93) (Figure 4). The 
cardiac-related analysis showed more variation in HRs over time.
Sensitivity analysis with studies that included patients operated after 1990 and after 1995 
demonstrated that the effect was slightly higher with later inclusion, but this difference was 
not statistically significant (Table 2). No analyses were performed for the moderate and severe 
PPM group for cardiac-related mortality, due to the low number of studies included (n = 3).
sources of heterogeneity
The subgroup analyses detected statistical heterogeneity between bioprosthetic and 
mechanical valves (Figure 5). There was also a statistically significant heterogeneity in the 
all-cause mortality analysis by determining the EOA, but this is likely due to the low number 
of studies that used echocardiographic measurement because this heterogeneity was not 
significant in other analyses. Again, no analyses were performed for the moderate and 
severe PPM group for cardiac-related mortality.
Publication bias
There was no evidence of publication bias in funnel plots of all-cause and cardiac-related 
mortality survival assessments.
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dIscussIon
Prosthesis–patient mismatch has been associated with reduced LV mass regression, impaired 
physical recovery, and higher incidence of adverse cardiac events after AVR; however, no 
consistent association between PPM and long-term survival has been established.13 The 
current unprecedented meta-analysis shows a significant reduction in overall and cardiac-
related long-term survival for patients with PPM after AVR. Moreover, this association 
increases with PPM severity and appears constant over time. These results have important 
clinical implications given that PPM is a potentially modifiable risk factor.
The marked statistical significant heterogeneity in the explorative subgroup analyses 
is mainly related to the type of prosthesis, whether this was a bioprosthetic or mechani-
cal valve. The type of prosthesis could be a confounding factor, as mechanical valves are 
Figure 3 Pooled estimate for cardiac-related mortality
Ratios demonstrate the additional hazard with prosthesis-patient mismatch in relation to a no prosthesis-patient 
mismatch reference group. Studies that stratified results according to the severity of prosthesis-patient mismatch 
are analysed individually. HR  =  hazard ratio; CI  =  confidence interval; PPM  =  prosthesis-patient mismatch
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Figure 4 hazard of mortality in separate time intervals
Pooled estimates of studies to detect variance in all-cause (A) and cardiac-related (B) hazard over separate 
intervals during follow-up. Within the first year of follow-up, studies were excluded if analyses were performed 
without hospital mortality. The number of studies with corresponding lengths of follow-up is indicated between 
brackets. HR  =  hazard ratio; CI  =  confidence interval
table 2 sensitivity analysis with patient inclusion after 1990 and 1995
hr (95% cI) P for heterogeneity
All-cause Mortality
Any PPM 0.71
All studies (n=18) 1.34 (1.18-1.51)
Patient inclusion >1990 (n=13) 1.43 (1.27-1.61)
Patient inclusion >1995 (n=7) 1.42 (1.13-1.77)
Moderate PPM 0.87
All studies (n=10) 1.19 (1.07-1.33)
Patient inclusion >1990 (n=6) 1.24 (1.03-1.49)
Patient inclusion >1995 (n=3) 1.27 (0.96-1.69)
Severe PPM 0.94
All studies (n=12) 1.84 (1.38-2.45)
Patient inclusion >1990 (n=8) 1.86 (1.26-2.73)
Patient inclusion >1995 (n=4) 2.06 (1.33-2.39)
cardiac-related Mortality
Any PPM 0.67
All studies (n=9) 1.51 (0.88-2.60)
Patient inclusion >1990 (n=6) 1.97 (1.04-3.74)
Patient inclusion >1995 (n=2) 2.18 (1.13-4.19)
Moderate PPM …*
Severe PPM …*
*Not assessed due to low number of studies. PPM = prosthesis-patient mismatch
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implanted more often in younger patients. These patients generally have a more active life 
style and higher metabolic rate, thereby increasing the flow and thus the gradient across the 
valve in case of PPM.13 In this regard, some studies have suggested that the impact of PPM 
on post-operative survival is more pronounced in younger patients than in older ones.31,45 In 
this study, individual patient data were unavailable and the results from subgroup analyses 
should be regarded as hypothesis-generating. Future PPM studies should report the inci-
dence and outcomes of patients with a mechanical and bioprosthetic valve separately, so 
that evidence is more substantiated.
Figure 5 subgroup analyses to explore the source of heterogeneity
All-cause and cardiac-related results were analyses according to baseline- and study-related factors (A). Moderate 
and severe analyses (B) were also performed for all-cause mortality, but not for cardiac-related mortality due to the 
low number of studies included (n = 3). HR  =  hazard ratio; CI  =  confidence interval; PPM  =  prosthesis-patient 
mismatch. *Analysis excluded one study because of missing data.
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Several factors may explain the association between PPM and reduced survival after 
AVR. The persistent LV afterload imposed by PPM may impair the post-operative recovery 
of the coronary flow reserve 51 and hinder the regression of LV hypertrophy and dysfunc-
tion.8,27,52 Other negative outcomes previously reported in association with aortic PPM 
may have contributed to increase post-operative mortality, including: abnormalities of the 
Von Willebrand factor and associated bleeding complications,53,54 higher occurrence of 
exercise-induced arrhythmias,44 and higher incidence of late congestive heart failure.8 
Unger et al. also observed that, in patients with severe aortic stenosis and concomitant 
mild mitral regurgitation, PPM is associated with more important residual regurgitation after 
operation. 55 A recent study showed that PPM is an important risk factor for early structural 
valve deterioration of aortic bioprostheses.5 Finally, PPM may also be a surrogate marker for 
other co-morbidities (e.g. small calcified aortic root).
Prevention of prosthesis–patient mismatch
The observed increased mortality hazard should encourage surgeons to prevent PPM. 
As opposed to most other risk factors for post-operative mortality, PPM may be avoided 
or its severity may be reduced by the application of a preventive strategy at the time of 
operation.6,56,57 The first step in this strategy is to calculate the minimal prosthetic valve EOA 
required to avoid PPM by multiplying patient’s body surface area by 0.85.6 The second step 
is to select a prosthetic valve model and size that fits into the patient’s aortic annulus/root 
and that meets the minimum EOA calculated in the first step. It is important to emphasize 
that the currently available prosthetic valve models are not equivalent in terms of sizing 
and haemodynamic performance.6,58 For example, the implantation of a 21-mm valve can 
produce an EOA ranging between 1.2 ± 0.1 and 2.0 ± 0.7 cm2, depending on the type 
of prosthesis.13,58 Given the significant improvements in prostheses design, contemporary 
prevention of PPM can largely be accomplished by the implantation of prosthetic valve 
models providing better haemodynamic performance. In cases where severe PPM cannot 
be avoided with the use of currently available prosthetic valves, aortic root enlargement 
may be contemplated if the risk–benefit ratio is considered acceptable. Root enlargement is 
a surgical technique to accommodate a valve with a larger EOA and thereby avoiding PPM. 
This procedure has shown to be effective in reducing rates of PPM, although none of these 
studies have shown that annulus enlargement results in improved long-term survival.59,60
Two recent studies have reported that valve haemodynamics are superior with trans-
catheter aortic valve implantation (TAVI) than with surgical AVR, especially in the subset of 
patients with small aortic root.61,62 In these studies, PPM was less frequently present in TAVI 
patients (11 and 17.8%) than those who underwent AVR (27 and 30.5%, respectively).61,63 
Transcatheter aortic valve implantation may thus provide another potential alternative to 
avoid PPM in high-risk patients and yet provide a less invasive procedure. Although initial 
results with TAVI are promising, studies to date have only included a small number of 
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patients. These results should thus be interpreted with caution and further studies in larger 
series of patients are needed to corroborate the usefulness of this procedure for the preven-
tion of PPM.
Prevention of PPM needs to be stressed especially in younger patients. These patients 
often receive a mechanical valve, and PPM may have a higher impact on survival. Other 
studies have also emphasized the importance of avoiding PPM in patients with depressed LV 
systolic function given that they are most vulnerable to the residual LV afterload associated 
with PPM.7,64,65
haemodynamics and effective orifice area
There is a strong inverse relationship between pressure gradients and iEOA, which has led 
to a widely accepted iEOA cut-off for defining PPM at 0.85 cm2/m2 for moderate and 0.65 
cm2/m2 for severe PPM. Significant valve gradients at rest or during exercise can be avoided 
with an iEOA >0.85 cm2/m2.13 It has been shown that patients without PPM have stable hae-
modynamics, while an increase in gradient has been demonstrated in patients with an iEOA 
≤0.85 cm2/m2, which is even worse in patients with severe PPM (≤0.65 cm2/m2).4 Hence, 
table 3 literature derived effective orifice areas of popular valves
Valve size (mm)
19 21 23 25 27 29
stented bioprostheses
Mosaic 1.1 ± 0.2 1.2 ± 0.3 1.4 ± 0.3 1.7 ± 0.4 1.8 ± 0.4 2.0 ± 0.4
Hancock II … 1.2 ± 0.1 1.3 ± 0.2 1.5 ± 0.3 1.6 ± 0.2 1.6 ± 0.2
CE Perimount 1.1 ± 0.3 1.3 ± 0.4 1.5 ± 0.4 1.8 ± 0.4 2.1 ± 0.4 2.2 ± 0.4
CR Magna* 1.3 ± 0.3 1.7 ± 0.3 2.1 ± 0.4 2.3 ± 0.5 … …
Biocor (Epic)* … 1.3 ± 0.3 1.6 ± 0.3 1.8 ± 0.4 … …
Mitroflow* 1.1 ± 0.1 1.3 ± 0.1 1.5 ± 0.2 1.8 ± 0.2 … …
stentless bioprostheses
Medtronic Freestyle 1.2 ± 0.2 1,4 ± 0.2 1.5 ± 0.3 2.0 ± 0.4 2.3 ± 0.5 …
SJM Toronto SPV … 1.3 ± 0.3 1.5 ± 0.5 1.7 ± 0.8 2.1 ± 0.7 2.7 ± 1.0
Mechanical prostheses
Medtronic Hall 1.2 ± 0.2 1.3 ± 0.2 … … … …
Medtronic Advantage* … 1.7 ± 0.2 2.2 ± 0.3 2.8 ± 0.6 3.3 ± 0.7 3.9 ± 0.7
SJM Standard 1.0 ± 0.2 1.4 ± 0.2 1.5 ± 0.5 2.1 ± 0.4 2.7 ± 0.6 3.2 ± 0.3
SJM Regent 1.6 ± 0.4 2.0 ± 0.7 2.2 ± 0.9 2.5 ± 0.9 3.6 ± .13 4.4 ± 0.6
On-X 1.5 ± 0.2 1.7 ± 0.4 2.0 ± 0.6 2.4 ± 0.8 3.2 ± 0.6 3.2 ± 0.6
CarboMedics 1.0 ± 0.4 1.5 ± 0.3 1.7 ± 0.3 2.0 ± 0.4 2.5 ± 0.4 2.6 ± 0.4
CE = Carpentier-Edwards, SJM = St Jude Medical
*Results are based on a limited number of patients.
Reproduced with permission of Pibarot et al.67
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the difference in gradient that is observed at rest between patients with PPM vs. those with 
no PPM increases dramatically with exercise and is associated with an increase in the flow 
rate. It should, however, be emphasized that some patients may exhibit a relatively low 
gradient despite the presence of a small iEOA. This ‘pseudo-normalization’ of gradient is 
related to the presence of a low-flow state, similar to what occurs in patients with low-flow, 
low-gradient aortic stenosis. Patients with PPM and a low gradient are likely at higher risk 
for adverse events.
Over time valve companies have developed prosthetic valves with better haemodynamic 
performance and thus with larger EOAs. The older generation of prostheses tends to have 
smaller EOAs for a given prosthesis size (Table 3). This meta-analysis includes studies with a 
long-time period of patient inclusion. Many centres, however, are still using certain popular 
valves (e.g. St Jude Medical Standard mechanical valve, CarboMedics mechanical valve, 
Perimount bioprosthesis, etc). The use of a newer generation of valve prostheses may influ-
ence the prevalence of PPM, but, as shown in this analysis, the effect of PPM on mortality 
will not change.
Company-provided iEAO charts should be interpreted with caution. There are no stan-
dards for creating these charts and it has been shown that the most optimistic EOA values are 
often chosen to be reported.56,66,67 A more reliable and manufacturer-independent source 
of reference EOA data has been published by Pibarot et al. and is displayed in Table 3.58 
This table can be used to predict the average post-operative EOA for each given model and 
size of prosthesis. This information is particularly useful to anticipate the risk of PPM at the 
time of operation. If, after calculating the predicted iEOA from Table 3 (with information of 
valve model and sizing) and patient’s body surface area, the surgeon concludes that there is 
risk of PPM, and especially of severe PPM, an alternative prosthesis model and/or surgical 
technique could be used to avoid PPM or, at least, reduce its severity. A comparison of the 
different models of prostheses based on the label size in Table 3 may be misleading given 
that the dimensions of the sizers and the correspondence with the label prosthesis size may 
vary from one manufacturer to the other. The establishment of universal sizers and a sizing 
process that would be the same for all prosthetic valves of all manufacturers would certainly 
help to implement operative strategies for the prevention of PPM.
study limitations
To reduce the limitations inherent to meta-analysis, we included multiple databases in the 
literature search, and used minimal exclusion criteria. As a result, a wide time horizon of 
patient inclusion is present, which some consider problematic due to changes in cardiac 
surgery and echocardiography. However, sensitivity analysis by years of patient inclusion 
could not demonstrate a difference in HRs when only studies with inclusion of patients 
operated after 1990 and 1995 were used.
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First of all, many of the studies were retrospective by design and, therefore, follow-up 
was incomplete. The method by Williamson et al.17 to estimate HRs from Kaplan–Meier is a 
widely accepted method recommended in the PRISMA guidelines,19 but the corresponding 
HR is not as accurate as to when reported in the original paper. Nonetheless, a subgroup 
analysis by study design was unable to detect a difference in effect between retro-and pro-
spective studies. The quality of studies was generally high because completion of follow-up 
was often >95%.
Secondly, only 8 of the 34 studies used EOAs determined by echocardiographic measure-
ment. Although direct measurement is considered a more appropriate method, the other 
studies used previously reported reference values of the EOA to calculate the iEOA, due to a 
lack of post-operative echocardiographic data.5,13 It is possible that some patients may thus 
have been mis-classified with the use of this ‘projected’ iEOA. However, the utilization of 
the iEOA measured by Doppler echocardiography early after operation also has limitations. 
Its accuracy may be altered by LV outflow or chronotropic conditions and by technical pit-
falls or measurement errors. Furthermore, data are not available on patients who died in the 
operative or early post-operative periods. Nevertheless, the subgroup analysis demonstrated 
no difference in outcomes in studies using measured or reference values, and long-term 
survival is significantly impaired in both categories of studies (Figure 5).
Thirdly, despite significant efforts to instruct authors to report results according to guide-
lines,68 outcome reporting in the included studies differed considerably. In some studies 
hospital or procedure-related mortality was in-or excluded. In several instances, the in-or 
exclusion was not even specified. Both authors and editors of journals should be encour-
aged to use uniform definitions and reporting of outcomes. Meta-analysis is an important 
method in clinical research. With standardized methods and reporting, a larger number of 
studies can be included in meta-analyses and evidence can be more accurately and less 
spuriously defined.69
conclusIons
Although the adverse effect of PPM on long-term survival has been denied in some studies, 
this meta-analysis of 34 studies with 27 186 patients demonstrates a significant increase in 
all-cause and cardiac-related mortality over long-term follow-up after AVR. Current efforts 
to prevent PPM should therefore receive more emphasis and widespread acceptance to 
improve long-term survival.
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AbstrAct
Background
Degenerative aortic valve stenosis (AS) is associated with conduction abnormalities. Pace-
maker implantation is encountered after surgical aortic valve replacement (SAVR). Not much 
is known about the pacemaker implantation rate during midterm follow-up after SAVR. Our 
objectives were to determine the incidence of permanent pacemaker implantation (PPI) in 
the midterm after SAVR in a tertiary care facility.
Methods
We reviewed procedural data of 734 consecutive patients (56% men; mean age, 68.9 ± 
9.5 years) with degenerative severe AS who underwent SAVR between January 1, 2003, 
and December 31, 2008. Perioperative electrocardiograms were assessed for occurrence of 
conduction abnormalities, and we sought to determine the incidence and indication for PPI 
with a median follow-up of 3.76 years (interquartile range, 2.44 to 5.59 years). Univariate 
and multivariate logistic regression models were applied to identify predictors for early (≤ 
30 days) and late (> 30 days) PPI.
Results
Isolated SAVR was performed in 56%, SAVR with coronary artery bypass grafting in 35%, 
and SAVR with any other valve therapy in 5.8%. Complete bundle branch block (BBB) was 
present in 7% and first-degree atrioventricular block in 11%. New BBBs were detected in 
63 patients (8.6%). Fifteen patients (2.0%) required a PPI within 30 days after SAVR, and 
28 (4.0%) underwent PPI more than 30 days after SAVR. The linearized rate of PPI after 
SAVR was 1.01% ± 0.37% per patient-year. Patients with BBB at baseline had a higher PPI 
incidence after SAVR than patients without BBB, both within 30 days (8% vs 1.5%, p = 
0.001) and after 30 days (10% vs 2.9%, p = 0.006). PPI incidence after 30 days was also 
significantly higher in patients with a new BBB after SAVR (7.8% vs 2.9%, p = 0.038). By 
multivariate logistic regression analysis, BBB and the combination of AS and regurgitation 
predicted PPI within 30 days after SAVR (hazard ratio [HR], 470; 95% confidence interval 
[CI], 1.55 to 14.27; and HR, 1.33; 95% CI, 0.03 to 1.73, respectively). BBB (HR, 3.26; 95% 
CI, 1.41 to 7.54), previous cardiac operation (HR, 3.40; 95% CI, 1.16 to 9.94), and severe 
left ventricular dysfunction (HR, 9.82; 95% CI, 2.90 to 33.26) were predictors for PPI after 
30 days post-SAVR.
Conclusions
Patients with severe AS who underwent SAVR have a persistent 1% annual risk for PPI. 
Postoperative presence of BBB predicted the need for PPI both within 30 days and after 30 
days after SAVR.
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IntroductIon
Surgical aortic valve replacement (SAVR) is the standard of care for patients with symptom-
atic severe aortic valve stenosis (AS). Since the pioneering work by Ross, Starr and Harken 
in the early 1960s, continued procedural refinements have turned SAVR into a reliable and 
life-prolonging procedure at a reasonable operative risk in most patients.1-4 Despite the 
shift to an older and higher-risk patient population undergoing SAVR, overall mortality rates 
have dropped to approximately 3%, with a postoperative permanent stroke risk of less than 
2%.5, 6
Degenerative AS is associated with electrical conduction abnormalities because calci-
fication in and around the aortic valve can progress and extend to involve the electrical 
conduction system of the heart.7 SAVR can impair the atrioventricular (AV) conduction 
bundles by operative trauma during valve excision and debridement of the aortic annulus 
and placement of the sutures.8-18 The reported 30-day permanent pacemaker implantation 
(PPI) incidence after SAVR varies between 3.0% and 8.5%.9-11, 13-16, 18 Little is known about 
pacemaker requirement during midterm follow-up (up to 5 years). Nevertheless, continuous 
degenerative changes at the level of the sino-AV conduction system may lead to clinically 
significant conduction disturbances mandating PPI or, in the worst-case scenario, evoke 
sudden cardiac death.
Better insight into pacemaker requirement during follow-up after SAVR is clinically 
relevant because it may underscore the importance of clinical and electrocardiographic 
follow-up and improve patient counseling. The aim of this study was to report the midterm 
(up to 5 years) incidence of postoperative conduction disturbances and PPI and to identify 
relevant predictive risk variables.
MAterIAl And Methods
From January 2003 to December 2008, 919 consecutive patients with severe AS, with or 
without concomitant aortic regurgitation (AR), underwent SAVR in the Thoraxcenter, Eras-
mus Medical Center, Rotterdam. The study excluded patients with congenital AS and active 
infectious endocarditis and those undergoing coronary artery bypass grafting (CABG) with 
concomitant moderate AS or periprocedural death. No aortic root replacement procedures 
were included. Fifteen patients were excluded because of a permanent pacemaker at base-
line.
Similar SAVR techniques were applied throughout the study period in all patients, 
including a midline sternotomy, antegrade cardioplegia with cold St. Thomas solution, and 
implantation of mechanical or stented bioprostheses with interrupted sutures after prior 
aortic root decalcification.
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Baseline patient characteristics undergoing valve operations in our department are pro-
spectively collected in a dedicated database in accordance with Institutional Review Board 
approval. The Institutional Review Board formally approved the study and waived the need 
for additional patient consent. Two experienced cardiologists analyzed the standard resting 
12-lead electrocardiograms at baseline and during the postoperative period.
For the purpose of the present study, specifically, heart rhythm and conduction abnormali-
ties were collected. The presence of first-, second-, or third-degree AV block, complete left 
or right bundle branch block (BBB), and QRS duration exceeding 150 ms was documented 
and entered in a separate database. Data on PPI were gathered by reviewing the patient 
records, contacting the treating physicians (treating cardiologist and general practitioner), 
and finally, by sending questionnaires to the patients. Postoperative in-hospital PPI was 
based on persistent high-grade AV block or symptomatic bradycardia up to 14 days after the 
operation. The indication for PPI after the index hospital discharge was at the discretion of 
the treating cardiologist in accordance with the American College of Cardiology/American 
Heart Association guidelines.19
Data related to mortality rates and cause of death were obtained from the hospital 
records and the Dutch Civil Registry. Follow-up data on death and PPI up to October 2010 
was 100% and 92% complete, respectively, with a mean follow-up duration of 3.76 years 
(interquartile range, 2.44 and 5.59 years).
statistical analysis
Continuous variables are presented as mean ± standard deviation or as median (interquartile 
range [IQR]). Categorical variables are presented as absolute numbers and percentages 
and compared with the χ2 test or Fisher exact test, when appropriate. Cumulative survival 
probability was calculated by means of Kaplan-Meier estimator curves. Hazard ratios (HR), 
with their 95% confidence intervals (CI), were generated using a Cox regression analysis. A 
hazard plot was used to evaluate the yearly pacemaker risk after SAVR.
Age, sex, previous cardiac operation, recent myocardial infarction, systolic left ventricular 
function, atrial fibrillation (AF) at baseline, any AF, concomitant CABG, and combined AS 
and AR were the variables selected to assess as potential predictors for (1) PPI within 30 days 
after SAVR, (2) PPI more than 30 days after SAVR, and (3) any PPI after SAVR. Baseline and 
new-onset BBB was also evaluated as a predictor for early and late PPI after SAVR. Variables 
with a value of p of less than 0.10 in the univariate analysis were entered in the multivariate 
logistic regression model. A two-sided α = 0.05 was considered statistically significant. All 
analyses were performed with SPSS 17.0 software (SPSS Inc, Chicago, IL).
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results
baseline characteristics
A total of 734 patients (56% men) underwent SAVR for a primary diagnosis of symptomatic 
degenerative severe AS. Median follow-up was 3.76 years (IQR, 2.44 to 5.59 years). Base-
line characteristics and procedural details are reported in Table 1. Patients were a mean age 
table 1 baseline and procedural characteristics
Patients (n=734)
Age (mean ±SD) 68.9 ± 9.5
Male 409 (56%)
Diabetes 131 (18%)
PVD 52 (7%)
COPD 89 (12%)
Renal Failure (Creat > 200μmol) 13 (2%)
Previous stroke 35 (5%)
Previous Cardiac Surgery 38 (5%)
Recent MI 17 (2%)
Atrial fibrillation 92 (13%)
LV Function
Normal 546 (74%)
Moderate 69 (9%)
Mild 103 (14%)
Poor 15 (2%)
Unstale Angina 10 (1%)
Logistic EuroSCORE 6.7 ± 5.8
Bicuspid Aortic Valve 48 (7%)
Combined AS and AR 91 (13%)
Baseline ECG
LBBB 22 (3%)
RBBB 28 (4%)
Long QRS (>150 msec) 22 (3%)
1st Degree AV-Block 79 (11%)
Procedures
Isolated AVR 416 (57%)
AVR + CABG 257 (35%)
AVR + other Valve Repair/Replacement 43 (6%)
AVR + CABG + Valve Repair/Replacement 18 (2%)
AR = aortic regurgitation; AS = aortic stenosis; CABG = coronary artery bbypass grafting; COPD = chronic 
obstructive pulmonary disease; ECG = electrocardiography; EF = ejection fraction; QRS = ventricular complex on 
ECG; SD = standard deviation
Part 2 Surgical or transcatheter therapy for aortic stenosis156
of 68.9 ± 9.5 years. Isolated SAVR was performed in 56%, SAVR with CABG in 35%, and 
SAVR with any other valve therapy in 5.8%. AS with concomitant AR was present in 13% 
of patients. From an electrocardiographic perspective at baseline, permanent AF, complete 
BBB, and first-degree AV block were present in 12.5%, 7%, and 11%, respectively (patients 
who had undergone PPI at baseline were excluded from the analysis).
Postoperative outcome
The 30-day mortality was 1.9%. Survival was 95.2% at 1 year and 84.0% at 5 years (Figure 
1). During follow-up, there were 113 deaths. Cause of death was unknown in 10% and 
cardiac in 38%. Total AV block was documented as cause of death in 2 patients with out-
of-hospital cardiac arrest.
AF (transient or permanent) in the postoperative phase was noted in 42% of patients. 
New-onset AF requiring inter-vention (medication or electrical cardioversion) occurred in 
66 patients (9%). BBB was documented in 92 patients (12.5%) after SAVR. New BBB was 
detected in 63 patients (8.6%), left BBB (LBBB) in 47 (6.4%) and right BBB (RBBB) in 16 
(2.2%; Table 2). PPI was required in 15 patients (2.0%), who were a mean age of 71.5 ± 8.4 
years, within 30 days after SAVR; the indication was equally divided in high-grade AV block 
and sick sinus syndrome (and unknown in 1 patient). Thereafter, another 28 patients (4.0%), 
who were a mean age of 67.0 ± 10.0 years, underwent a PPI at a median of 580 days after 
SAVR (IQR, 34 to 2,159 days [6 years]) for high-grade AV block in 75%. 
The linearized rate of PPI after SAVR was 1.01% ± 0.37% per patient-year (Figure 2). 
Patients with a BBB at baseline had a higher PPI incidence after SAVR than patients without 
BBB before 30 days (8% vs 1.5%, p = 0.001) and also after 30 days (10% vs 2.9%, p = 
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Figure 1 Kaplan-Meier curve shows survival after surgical aortic valve replacement
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0.006; Figure 3). Patients with newly acquired BBB after SAVR had a higher incidence of 
PPI after 30 days after SAVR (7.8% vs 2.9%, p = 0.038). Postoperative LBBB and RBBB 
correlated with any PPI after SAVR, only RBBB was associated with significantly more PPI 
within 30 days or after 30 days after SAVR separately (Figure 3).
table 2
univariate predictors for permanent pacemaker implantation after surgical aortic valve 
replacement
 univariate or (95% cI) P value
PPI ≤30 days  
  Combined AS/AR 1.33 (1.03-1.72) 0.031
  Any pre-or postop BBB 4.70 (1.55-14.27) 0.006
PPI >30 days  
  Male gender 2.55 (1.08-5.99) 0.032
  Previous cardiac surgery 3.18 (1.10-9.19) 0.032
  Severe LV dysfunction 13.16 (4.56-38.00) <0.001
  Logistic EuroSCORE 1.07 (1.03-1.11) <0.001
  Any pre-or postop BBB 3.67 (1.67-8.09) 0.001
Any PPI  
  Male gender 2.42 (1.22-4.80) 0.012
  Severe LV dysfunction 8.91 (3.50-22.69) <0.001
  Logistic EuroSCORE 1.06 (1.02-1.09) 0.001
  Any pre-or postop BBB 3.80 (2.02-7.15) <0.001
AR = aortic regurgitation; AS = aortic stenosis; BBB = bundle branch block; CI = confidence interval; HR = hazard 
ratio; LV = left ventricle; PPI = permanent pacemaker implantation
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Figure 2
Annual hazard is shown for permanent pacemaker implantation after surgical aortic 
valve replacement (with 95% confidence intervals)
SAVR  =  surgical aortic valve replacement.
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Predictors for PPI within and after 30 days
Univariate predictors of PPI are listed in Table 2. Multivariate logistic regression analysis 
showed that BBB and the combination of AS and AR predicted PPI within 30 days after SAVR 
(odds ratio, 4.70 [95% CI, 1.55 to 14.27] and 1.33 [95% CI, 1.03 to 1.73], respectively; 
Figure 4). BBB (HR, 3.26; 95% CI, 1.41 to 7.54), previous cardiac operation (HR, 3.40; 95% 
CI, 1.16 to 9.94), and severe left ventricular dysfunction (HR, 9.82; 95% CI, 2.90 to 33.26) 
were predictors for PPI after 30 days post-SAVR. BBB (HR, 3.69; 95% CI, 1.95 to 6.99), male 
sex (HR, 2.12; 95% CI, 1.05 to 4.27), and severe left ventricular dysfunction (HR, 5.31; 95% 
CI, 1.85 to 15.28) were predictors for any PPI after SAVR.
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Figure 3 bundle branch block (bbb) and incidence of permanent pacemaker implantation
(A) No BBB (red bars) versus baseline BBB (green bars) versus newly acquired BBB (blue bars). (B) No BBB (red 
bars) versus left BBB (green bars) versus right BBB (blue bars).
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dIscussIon
In our series of patients with severe degenerative AS who underwent SAVR, the incidence 
of PPI was 2.0% within 30 days and 4.0% thereafter at a median follow-up of 3.76 years. 
This study demonstrates a persistent 1% annual risk for PPI after SAVR in the first years after 
SAVR. Baseline and newly acquired BBB after SAVR was the only consistent predictor for 
both early (≤ 30 days) and late (> 30 days) PPI after SAVR.
Cardiac operations are associated with a postoperative need for PPI in approximately 
1.5% of patients; however, this rate appears higher after SAVR.20The 30-day PPI rate in our 
series compares favorably with rates that have previously been reported. Several groups 
have presented 30-day PPI rates after SAVR, yet considerable heterogeneity among these 
reports exists. Bagur and colleagues 10 found a 30-day PPI incidence of 3.2% in 780 patients 
undergoing isolated SAVR (concomitant CABG was excluded) for severe degenerative AS. 
In mixed cohorts consisting of AS and AR patients, the incidence of PPI varied between 
3.2% and 8.5%.9, 12, 14, 20, 21. SAVR for severe AR is associated with a higher PPI frequency 
compared with SAVR for AS.11
In our study population with a median follow-up of 3.8 years, the post-SAVR PPI rate 
was 4.1% after 30 days, with a persistent 1% annual risk for PPI. Data on late PPI rates after 
SAVR are scarce. In a mixed cohort of 102 patients with severe AS or AR and at a median 
follow-up of 4.2 years, Keefe and colleagues 9 noted a PPI rate of 3.2% late after SAVR. 
In 342 patients with AS or AR and a median follow-up of 114 ± 192 days, Dawkins and 
Multivariate HR (95% CI)
0.1                   1                     10
Any vaseline or new-onset BBB     4.70 (1.55-14.27)
Previous cardiac surgery                      3.40 (1.16-9.94)
Severe LV dysfunction                          9.82 (2.90-33.26)
Any baseline or new-onset BBB           3.69 (1.95-6.99)
Male gender          2.12 (1.05-4.27)
Severe LV dysfunction                          5.31 (1.85-15.28)
Any time
Follow-up
Within 30 days
Combined AI and AS        1.33 (1.03-1.73)
Any baseline or new-onset BBB           3.26 (1.41-7.54)
Figure 4
Multivariate predictors of permanent pacemaker implantation after surgical aortic valve 
replacement
AI = aortic insufficiency; AS = aortic stenosis; BBB = bundle branch block; CI = confidence interval; LV = left 
ventricle
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colleagues 14 reported a global PPI rate of 8.5%; of these, 90% of PPIs occurred during the 
index hospitalization, with the latest PPI at 57 days after SAVR.
The anatomy of the aortic valvular complex and its intimate relationship with the cardiac 
conduction system has been described previously.22, 23 With advancing age, progressive 
conduction fiber degeneration, fibrosis, and calcification of the cardiac skeleton may cause 
compression and sometimes disruption of the conduction fibers.24 A small study with 
histopathologic analysis of the conduction system from deceased patients with electrocar-
diographically confirmed LBBB disclosed total or subtotal destruction of the connection 
between the left main bundle and the bundle of His.25 Studies demonstrating structural 
His bundle and bundle branch lesions in almost all patients with AS suggest accelerated 
conduction fiber degeneration. Spontaneous conduction disturbances seem related to the 
extent of calcium deposits in the aortic valve and adjacent structures.9 Electro-physiologic 
assessment in AS patients has also shown AV conduction disturbances below the His bundle 
characterized by longer HV intervals.7
Mechanical and ischemic pathophysiologic mechanisms have been suggested for newly 
acquired conduction abnormalities, including complete AV block after SAVR. Decalcifica-
tion and debridement of annular tissue before AVR may decrease the interface between the 
AV node/bundle of His and the aortic cusps.
A pathology study in 57 patients who died within 30 days after SAVR demonstrated 
that the sutures used to anchor the prosthesis were the most common cause of conduction 
system injury, followed by compression from residual calcific material or directly from the 
prosthesis on the conduction bundles.26 Interestingly, a continuous suture technique to 
secure the aortic prosthesis was associated with a higher incidence of PPI compared with 
an interrupted suture technique.27 Hypoxia and focal hemorrhage also may damage the 
conduction bundles.26
In our study, BBBs increased the incidence of both early and late PPI approximately 
fourfold. The prevalence of BBB at baseline was 7%. Newly acquired BBB after SAVR was 
found in 8.6%. In patients with baseline BBB, the incidence of both early and late PPI 
after SAVR was significantly higher compared with patients without BBB. Newly acquired 
BBB postoperatively only increased PPI requirement after 30 days post-SAVR. This find-
ing suggests a newly acquired BBB after SAVR may expedite the process of conduction 
degeneration and identify additional patients at risk for future conduction abnormalities. 
Previous reports have consistently indicated BBB as an independent predictor of 30-day PPI 
after SAVR.10, 12, 13 The coexistence of AR at baseline (present in 13% of the patients) also 
predicted PPI within 30 days after SAVR and corroborates the findings by others.11, 14 AR 
causes left ventricular and aortic annular enlargement with consequently increased wall 
tension (by Laplace’s Law) and thus excessive mechanical stretch on the nearby AV node 
and His bundle, which catalyzes fibrous endocardial thickening. Female sex, hypertension, 
prior myocardial infarction, severe mitral insufficiency, and smaller annulus size have been 
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suggested as predictors of PPI.11, 12, 18, 28, 29 Unsurprisingly, concomitant complex cardiac 
operations (concomitant CABG, reoperation, multivalve operations, sub-AS resection) were 
previously found to be associated with early PPI.12, 15, 18, 29
The annual risk for PPI after SAVR in an AS patient cohort with a mean age of 68.9 ± 9.5 
years was 1% per year and is higher than what can be expected in a general population. 
A retrospective cohort study based on the adult population of Olmsted County, Minnesota, 
covering the interval between 2000 and 2004, noted a PPI rate of 99.1/100,000 person-
years.30 Incidence rates for PPI per 100,000 person years-were 21.5 for age quartiles 18 to 
69, 364.1 for 70 to 79, 901.6 for 80 to 84, and 1,026.8 for 85 to 110. The amplified and 
continuous process of conduction fiber degeneration, fibrosis, and calcification in patients 
with AS may hypothetically explain the steady annual rate of PPI after SAVR. This hypothesis 
is indirectly supported by data suggesting that new pacemaker dependency developed in 
23% of patients who initially required a PPI after their cardiac operation vs 4% of patients 
who required a PPI without a prior cardiac operation.31, 32 Another study indicated 17% 
of patients who developed a new BBB after SAVR had experienced complete AV block, 
syncope, or sudden death at a mean follow-up of 54 months.8
Our findings may create awareness among surgeons treating patients with AS about the 
continuous PPI rate in the years after AVR and also underscore the effect of conduction 
abnormalities. The need for regular office visits and rhythm follow-up assessment is evident 
and may lead to better midterm and longer-term outcome. Cardiac surgeons should inform 
their patients about these issues before proceeding with AVR. Better information may then 
stimulate patients to comply with these essential follow-up visits.
limitations
This retrospective study is subjected to the well-known limitations related to all retrospective 
analyses. Information on perioperative rate-controlling therapies was not available. The tim-
ing of postoperative electrocardiogram analysis was not standardized, and transient conduc-
tion abnormalities may have been missed. The indication for PPI after hospital discharge was 
left to the treating physician’s discretion, which introduces inherent bias. Specific periopera-
tive variables, such as cardiopulmonary bypass time, were not systematically collected and 
therefore not evaluated. Cause of death was cardiac in 43 patients and unexplained in 11. 
Although speculative, these patients may have suffered from life-threatening conduction 
abnormalities, which would only reinforce our findings that patients who underwent SAVR 
for degenerative AS are at persistent risk for such conduction abnormalities after SAVR. 
Finally, the event rate was too small to make any firm statement regarding the relative effect 
of LBBB and RBBB separately.
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conclusIons
Degenerative AS is associated with conduction abnormalities. SAVR has a 2.0% PPI rate 
within 30 days after the operation and a persistent 1% per-year risk for PPI thereafter. These 
findings suggest patients with a BBB after SAVR should be monitored closely for progressive 
conduction disturbances with fixed office visits, including electrocardiogram and Holter 
monitoring, to avoid major adverse events, including syncope, complete AV block, and 
sudden death.
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AbstrAct
Background
Recently, the published Valve Academic Research Consortium (VARC) definitions have 
helped to add uniformity for reporting outcomes after Transcatheter Aortic Valve Replace-
ment (TAVR). 
Objectives
We sought to perform a weighted meta-analysis to determine rates of major outcomes after 
TAVR using VARC definitions and to evaluate their current use in the literature.
Methods
A comprehensive search of multiple electronic databases from January 1st 2011 through 
October 12th 2011 was conducted using predefined criteria. We included studies reporting 
at least one outcome using VARC definitions. 
Results
A total of 16 studies including 3,519 patients met inclusion criteria and were included in 
the analysis. The pooled estimate rate of outcomes were determined according to VARC’s 
definitions: device success: 92.1%, 95%CI [88.7,95.5]; all cause 30-day mortality: 7.8%, 
95%CI [5.5,11.1]; myocardial infarction: 1.1%, 95% CI [0.2,2.0]; acute kidney injury stage 
II-III: 7.5%, 95%CI [5.1,11.4]; life threatening bleeding: 15.6%, 95% CI [11.7,20.7]; major 
vascular complication: 11.9%, 95% CI [8.6,16.4]; major stroke 3.2%, 95%CI [2.1,4.8]; and 
new permanent pace maker (PPM) implantation: 13.9%, 95% CI [10.6,18.9]. Medtronic 
CorevalveTM prosthesis use was associated with a significant higher rate of PPM implanta-
tion compared to the Edwards’s prosthesis (28.9%, 95% CI [23.0,36.0] vs. 4.9%, 95% CI 
[3.9,6.2], p value < 0.0001). The 30-day safety composite endpoint rate was 32.7%, 95%CI 
[27.5,38.8] and the 1-year total mortality was 22.1%, 95% CI [17.9,26.9].
Conclusions
VARC definitions have already been used by the TAVR clinical research community, 
establishing a new standard for reporting clinical outcomes. Future revisions of the VARC 
definitions are needed based upon evolving TAVR clinical experiences.
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IntroductIon
Since the first transcatheter aortic valve replacement (TAVR) case in 2002,1 >35,000 transcath-
eter aortic valve procedures have been performed worldwide. This has resulted in a substantial 
number of published case series, registries, and, lately, randomized controlled trials.2-13 Diver-
sity in technique and study devices as well as disparity in the learning curve may potentially 
explain some of the discrepancies in outcomes that have been reported. However, the absence 
of standardized definitions may be the most significant factor to explain inconsistencies in the 
early literature. The recent publication of the Valve Academic Research Consortium (VARC) 
definitions has provided uniformity in outcome reporting after TAVR, which should ensure a 
more balanced interpretation of clinical results.14 Currently, there is a growing body of litera-
ture applying these new VARC definitions. Therefore, we sought to perform a meta-analysis of 
all published studies reporting outcomes using VARC definitions after TAVR to evaluate current 
acceptance and use patterns and to determine whether future revisions are warranted.
Methods
studies and endpoint definitions
All studies reporting outcomes using at least 1 VARC definition from January 1, 2011, to 
October 12, 2011, were selected and included in the current analysis. Only outcomes prop-
erly reported conforming to VARC definitions (clear mention in the paper) were included in 
the pooled analysis. Intrahospital 30-day and 1-year outcomes are reported conforming to 
the VARC definitions previously described.14
data source and study selection
Relevant studies were identified through PubMed, Cochrane, and EMBASE database 
searches, using the key words trans-catheter aortic valve implantation, trans-catheter aortic 
valve replacement, percutaneous aortic valve implantation, percutaneous aortic valve 
replacement, transfemoral aortic valve implantation, transapical aortic valve implantation, 
transarterial aortic valve implantation, direct aortic valve implantation,aortic stenosis, and 
valve academic research consortium. Two investigators (P.G., S.J.H.) independently reviewed 
the titles, abstracts, and studies to determine whether they met the inclusion criteria. Con-
flicts between reviewers were resolved by consensus.
statistical analysis
Outcome rates were first presented as the minimum and maximum rates reported among 
selected articles. Cumulative rates for each VARC outcome were then obtained from a 
pooled analysis among selected studies. Given the high heterogeneity among reported 
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rates, summary rate estimates and 95% confidence intervals (CIs) were obtained using a 
random-effects model, as described by DerSimonian and Laird.15 The random-effects model 
was chosen for its conservative summary estimate and incorporating both between and 
within study variance. To assess heterogeneity across trials, we used the Cochrane Q statistic 
(a p value ≤0.1 was considered significant). The I2 statistic was also used to measure the 
consistency among studies with values of 25%, 50%, and 75% showing, respectively, low, 
moderate, and high heterogeneity.
Data collection, study selection, processing of the data, and reporting of the results 
were performed according to accepted principles related to systematic review and meta-
analysis.16-19 The Mann-Whitney test was used to compare proportions, with a significance 
level of p < 0.05. Statistical analyses were performed using SAS software version 9.3 (SAS 
Institute, Cary, North Carolina).
results
Of 482 potentially relevant articles initially screened, 16 unique studies with 3,519 patients 
met the inclusion criteria and were included in the final pooled analysis (Figure 1). 10, 20-34 
 
 
 
 
482 identified articles 
Removing duplicates (n=52) 
 
396 hand-searched articles 
Exclusion of articles without VARC citation or VARC 
mentioning in the text (n=340) 
52 articles with VARC citation 
4 articles with VARC mentioning in the text 
No outcomes reported according to VARC (n=23) 
23 potential articles 
Exclusion of articles duplicating outcomes (n=5) 
Exclusion of articles strictly on valve-in-valve (n=1) 
17 articles included in the pooled analysis 
430 potentially valid articles 
 Inaccessible document (n=29) 
Author named “Tavi” (n=5) 
Figure 1 Flow diagram of the study
Among the 482 potentially relevant articles, 16 were included in the final pooled analysis. VARC = Valve 
Academic Research Consortium
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A total of 1,903 Edwards Lifesciences (Irvine, California) prosthesis (54.1%) and 1,186 
Medtronic CoreValve (Minneapolis, Minnesota) prosthesis (33.7%) implantations were 
identified. The type of implanted device was not clearly reported by authors in 430 patients 
(12.2%). Basic study characteristics are shown in Table 1. The 30-day Society of Thoracic 
table 2 Proportion of studies reporting outcomes using appropriately VArc definitions
outcomes n (%)
Device success 10/17 (58.8)
30-day mortality 16/17 (94.1)
30-day cardiovascular mortality 15/17 (88.2)
1-year mortality 7/17 (41.2)
1-Year cardiovascular mortality 4/17 (23.5)
Myocardial infarction ≤ 72h 14/17 (82.4)
Acute kidney injury 9/17 (52.9)
Bleeding 7/17 (41.2)
Transfusions 7/17 (41.2)
Vascular complications 16/17 (94.1)
Stroke 30-day 14/17 (82.4)
PPM 14/17 (82.4)
30-day composite endpoint safety 6/17 (35.3)
1-year composite endpoint efficacy 2/17 (11.8)
Failure to delivery or implantation of the valve in the correct position 10/17 (58.8)
Multiple valve implanted 9/17 (52.9)
Aortic valve area ≤ 1.2 cm2 2/17 (11.8)
Mean gradient ≥ 20 mm Hg 4/17 (23.5)
Aortic regurgitation ≥ moderate 11/17 (64.7)
Valve embolization 10/17 (58.8)
Valve in valve 8/17 (47.1)
Conversion to open surgery 10/17 (58.8)
Repeat procedure for valve dysfunction 8/17 (47.1)
Unplanned cardiopulmonary bypass use 3/17 (17.6)
Coronary obstruction 7/17 (41.2)
Left ventricular perforation 3/17 (17.6)
Tamponade 6/17 (35.3)
Annulus rupture 3/17 (17.6)
Aortic dissection 2/17 (11.8)
Aortic rupture 2/17 (11.8)
Endocarditis 3/17 (17.6)
Valve thrombosis 2/17 (5.9)
Left ventricular outflow tract rupture 1/17 (5.9)
Ventricular septal defect 1/17 (5.9)
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Surgeons score and logistic EuroSCORE were 8.7% (95% CI: 7.0% to 10.3%) and 22.8% 
(95% CI: 20.3% to 25.3%), respectively. Table 2 shows the proportion of articles that appro-
priately used and reported outcomes according to VARC definitions.
table 3 30-day and 1-year VArc outcomes after tAVr
outcomes reported rate
min - max
(%)
cumulative 
rate
I2 (%) P value for 
heterogeneity
Pooled 
estimate 
rate (%)
95% cI
Device success 80.0 - 100.0 1748/1899 93.2 <0.0001 92.1 88.7 , 95.5
30-day mortality 1.7 - 14.3 258/3465 74.1 <0.0001 7.8 5.5 , 11.1
30-day cardiovascular mortality 1.7 - 11.5 142/2645 72.5 <0.0001 5.6 3.7 , 8.3
1-year mortality 15.3 - 30.7 336/1530 78.3 0.0001 22.1 17.9 , 26.9
1-year cardiovascular mortality 14.3 - 19.6 113/800 85.2 0.0002 14.4 10.6 , 19.5
Myocardial infarction ≤ 72h 0.0 - 5.6 34/3018 88.9 <0.0001 1.1 0.2 , 2.0
Acute kidney injury
I 3.2 - 24.6 149/1150 91.1 <0.0001 13.3 9.8 , 18.0
II 0.8 - 5.3 29/1150 64.9 0.02 2.7 1.5 , 5.3
III 1.0 - 10.2 98/1929 73.0 0.0005 5.3 3.5 , 8.2
II-III 3.0 - 15.0 93/1275 80.9 <0.0001 7.5 5.1 , 11.4
I I-II-III 6.5 - 34.1 232/1150 94.8 <0.0001 20.4 16.2 , 25.8
Bleeding
Life-threatening 7.0 - 25.9 207/1350 86.1 <0.0001 15.6 11.7 , 20.7
Major 2.9 - 47.0 298/1363 96.6 <0.0001 22.3 17.8 , 28.3
Minor 3.0 - 16.0 95/987 81.9 0.0002 9.9 6.9 , 14.3
All 26.8 - 77.0 408/987 98.4 <0.0001 41.4 35.5 , 47.6
Transfusion ≥1 unit 6.3 - 80.0 386/906 85.3 <0.0001 42.6 19.8 , 62.4
Vascular Complications
Major 5.0 - 23.3 282/2417 81.3 <0.0001 11.9 8.6 , 16.4
Minor 5.6 - 28.3 203/2142 88.8 <0.0001 9.7 6.7 , 14.0
All 9.5 - 51.6 511/2740 92.6 <0.0001 18.8 14.5 , 24.3
Stroke 30-day
Major 0.8 - 9.0 84/2730 70.7 <0.0001 3.2 2.1 , 4.8
Minor 0.0 - 1.7 12/1450 54.6 0.03 1.0 0.5 , 1.9
TIA 0.0 - 12.0 18/1826 83.4 <0.0001 1.2 0.0 , 2.3
Major + minor 1.0 - 6.8 68/1,706 67.4 0.005 4.0 2.4 , 6.3
All 1.3 - 21.0 103/1892 72.8 0.0003 5.7 3.7 , 8.9
Permanent pacemaker 3.4 - 50.0 396/2914 95.9 <0.0001 13.9 10.6 , 18.9
Composite endpoint Safety 30-day 17.0 - 61.8 420/1286 96.6 <0.0001 32.7 27.5 , 38.8
Composite endpoint efficacy 1-year 70.2 - 72.2 209/294 0 0.58 71.1 65.6 , 76.0
CI = confidence interval
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In-hospital and 30-day follow-up outcomes
Overall device success reported in the literature ranged from 80% to 100%, with a pooled 
estimate rate of 92.1% (95% CI: 88.7% to 95.5%) (Table 3). The most frequent modes of 
failure were moderate to severe aortic regurgitation (7.4%; 95% CI: 4.6% to 10.2%), aortic 
valve area (AVA) <1.2 cm2 (4.8%; 95% CI: 3.0% to 6.6%), and failure of delivery or implan-
tation of the valve in the correct position (3.5%; 95% CI: 2.2% to 5.6%) (Table 4).
All-cause 30-day mortality rates were reported between 1.7% and 14.3%, with a pooled 
estimate of 7.8% (95% CI: 5.5% to 11.1%). Cardiovascular death accounted for most of the 
30-day mortality after TAVR, with a pooled estimate rate of 5.6% (95% CI: 3.7% to 8.3%) 
(Table 3 and Figure 2).
Myocardial infarction (MI) was repor-ted as a complication of TAVR in 0% to 5.6% of 
studies, with a pooled estimate rate 1.1% (95% CI: 0.2% to 2.0%). Acute kidney injury (AKI) 
at all stages was a frequent complication, with a pooled estimate rate of 20.4% (95% CI: 
16.2% to 25.8%). However, most of the AKI was at stage I (13.3%; 95% CI: 9.8% to 18.0%), 
table 4 Prosthesis-related complications according to VArc
outcomes reported 
rate
min - max
(%)
cumulative 
rate
I2 
(%)
P value for 
heterogeneity
Pooled 
estimate 
rate (%)
95% cI
Failure to delivery or implantation of the 
valve in the correct position
0.8 - 5.6 79/2,383 53.8 0.02 3.5 2.2 , 5.6
Multiple valves implanted 0.6 - 4.1 38/2,208 62.1 00.69 1.8 1.1 , 3.1
Aortic valve area ≤ 1.2 cm2 0.0 - 9.7 30/814 98.2 <0.0001 4.8 3.0 , 6.6
Mean gradient ≥ 20 mm Hg 0.0 - 2.9 11/1,064 85.2 0.0002 1.0 0.0 , 2.1
Aortic regurgitation ≥ moderate 0.0 - 30.0 167/2,601 95.3 <0.0001 7.4 4.6 , 10.2
Valve embolization 0.0 - 5.6 45/2,329 85.9 <0.0001 1.7 0.2 , 3.3
Valve in valve 0.0 - 9.0 43/2,014 80.9 <0.0001 2.3 1.3 , 4.5
Conversion to open surgery 0.0 - 5.6 23/2,189 84.1 <0.0001 1.3 0.0 , 2.6
Repeat procedure for valve dysfunction 0.0 - 4.1 31/1,920 51.7 0.04 1.8 1.0 , 3.7
Unplanned cardiopulmonary bypass use 0.0 - 1.9 15/1,081 78.0 0.01 1.3 0.3 , 2.2
Coronary obstruction 0.0 - 3.0 13/1,984 54.1 0.04 0.7 0.4 , 1.1
Left Ventricle perforation 0.2 - 0.8 3/702 0 0.43 0.4 0.1 , 1.5
Tamponade 0.6 - 4.6 29/1,097 74.4 0.0015 2.7 1.7 , 4.2
Annulus rupture 0.3 - 0.8 3/560 0 0.77 0.5 0.2 , 1.7
Aortic rupture 0.8 - 1.0 5/539 0 0.82 0.9 0.4 , 2.2
Aortic dissection 0.9 - 1.7 5/468 0 0.40 1.1 0.4 , 2.5
Endocarditis 0.3 - 1.1 5/832 0 0.39 0.6 0.2 , 1.4
Valve thrombosis 0.0 - 2.7 2/380 93.5 <0.0001 1.2 0.3 , 2.2
Left ventricular outflow tract rupture 0.6 1/165 - - 0.6 0.1 , 4.3
Ventricular septal defect 0.6 1/165 - - 0.6 0.1 , 4.3
CI = confidence interval
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whereas the AKI at stages II/III (significant AKI according to VARC criteria) was less frequent 
(7.5%; 95% CI: 5.1% to 11.4%).
Life-threatening bleeding and major vascular complications occurred at a pooled estimate 
rate of 15.6% (95% CI: 11.7% to 20.7%) and 11.9% (95% CI: 8.6% to 16.4%). All neurologic 
events (all strokes and transient ischemic attacks) were reported from 1.3% to 21.0% and 
occurred at a pooled estimate rate of 5.7% (95% CI: 3.7% to 8.9%), and all strokes (major 
and minor) were reported from 1.0% to 6.8%, with a pooled estimate rate of 4.0% (95% CI: 
2.4% to 6.3%). The reported rates for a new permanent pacemaker implantation after TAVR 
range from 3.4% to 50%, with a pooled estimate rate of 13.9% (95% CI: 10.6% to 18.9%). 
Medtronic CoreValve prosthesis use was associated with a significantly higher rate of new 
permanent pacemaker implantation compared with the Edwards prosthesis (28.9% [95% CI: 
23.0% to 36.0%] vs. 4.9% [95% CI: 3.9% to 6.2%], p < 0.0001). Device-related outcomes 
and other complications are shown in Table 4.
composite endpoint and 1-year follow-up outcomes
The 30-day safety composite endpoint was correctly reported in 6 studies (37.5%) (Table 2), 
with a pooled estimate rate of 32.7% (95% CI: 27.5% to 38.8%). The 1-year safety composite 
endpoint was reported in only 2 studies (12.5%), with a pooled estimate rate of 71.1% (95% 
CI: 65.6% to 76.0%). One-year all-cause mortality and cardiovascular mortality rates were 
reported in 7 studies (43.8%) and 4 studies (25.0%), respectively, with an associated pooled 
estimate rate of 22.1% (95% CI: 17.9% to 26.9%) and 14.4% (95% CI: 10.6% to 19.5%).
7,8% 
5,6% 
1,1% 
7,5% 
15,6% 
22,3% 
42,6% 
11,9% 
3,2% 4,0% 
5,7% 
13,9% 
32,7% 
0%
5%
10%
15%
20%
25%
30%
35%
40%
45%
Figure 2 thirty-day event rates of major VArc-related outcomes
AKI = acute kidney injury; CV = cardiovascular, LT = life-threatening; MI = myocardial infarction ≤72h after 
procedure; PPM = permanent pacemaker; VARC = Valve Academic Research Consortium
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dIscussIon
The current report, which includes 3,519 patients from 16 unique studies, is the first pooled 
analysis reporting outcomes after TAVR according to the recently proposed VARC defini-
tions. The main results of the current study are as follows: 1) VARC definitions have already 
been widely used by the TAVR community since their introduction earlier this year; 2) VARC 
definitions have established an important uniformity for outcomes after TAVR; 3) the pooled 
estimate outcomes after TAVR reported in this meta-analysis represent a new standard of 
quality for TAVR clinical research; 4) specific issues in the first version of the VARC defini-
tions were identified; and 5) refinement and modifications of the current VARC definitions 
may be needed and are in progress.
Since January 2011,14 VARC definitions have been rapidly incorporated into clinical 
and research practice (Figure 3). Although most of the VARC-related endpoints have been 
reported in high proportion among selected studies, the 30-day and 1-year composite end-
points and the 1-year mortality rates have been reported by only a few authors (Table 2). 
The relative complexity of the 2 hierarchical composite endpoints, the absence of all data 
fields required to compute the endpoints, and inadequate follow-up may explain the low 
reporting rates.
Not surprisingly, device-related outcomes, such as coronary obstruction, ventricular sep-
tal defect, annulus rupture, aortic rupture, aortic dissection, and left ventricle perforation, 
occurring less frequently after TAVR, were not systematically reported by authors (Table 4). 
However, considering that this technique is in its infancy, systematic reports of such compli-
0
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12
14
Figure 3 VArc-related publications since original publication in January 2011
Early after its publication in January 2011, VARC definitions were already in use and incorporated into clinical 
practice, showing acceptance by the TAVR community. TAVR = transcatheter aortic valve replacement; VARC = 
Valve Academic Research Consortium
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cations (present or not) are strongly recommended to provide a complete understanding of 
the risks associated with TAVR procedures.
In-hospital, 30-day, and 1-year follow-up outcomes
The device success rate of the current pooled analysis appears to be lower than previously 
reported. This difference is mostly explained by the fact that VARC uses stricter definitions, 
with echocardiography-derived criteria not used before, such as AVA <1.2 cm2 and residual 
moderate to severe prosthetic valve aortic regurgitation. Indeed, Gurvitch et al. 22 reported a 
relatively low success rate of 80% using VARC definitions and explained that the main reasons 
for“device failure”were a calculated AVA of <1.2 cm2, a criterion that may not be reasonable 
for either a small annulus or low body weight patients. Despite this low success rate, clinical 
and symptomatic improvement in these patients was dramatic, with 97% of patients with 
procedural AVA <1.2 cm2 improving to New York Heart Association functional class I or II. 
Ikeda et al. 35 also reported some concerns with the 1.2 cm2 criterion for device success, 
especially in small body size populations, such as Asian patients, in whom an indexed valve 
area may be more appropriate. Until now, no evidence has been shown that patients with an 
AVA <1.2 cm2 after TAVR have a worse outcome. Conversely, Ewe et al. 36 recently showed 
that patients with prosthesis–patient mismatch after TAVR, defined as an indexed effective 
orifice area ≤0.85 cm2/m2, had a slower and smaller reduction in mean transaortic gradient, 
limited left ventricular mass regression, and a higher proportion of patients not improving 
in New York Heart Association functional class compared with patients without mismatch. 
Moreover, no standardized method for echocardiographic measurement of the left ventricu-
lar outflow tract diameter after TAVR has been validated. Therefore, AVA may vary consider-
ably, depending on where the left ventricular outflow tract measurement is performed after 
TAVR.37 These issues will be addressed in future versions of VARC definitions.
The 30-day mortality rate in the current report is similar to the mortality rate reported in 
the early registries,4, 5, 7, 8 reflecting the use of first-generation devices, early experience of 
operators, and a population of patients at high or prohibitive risk of surgery. Interestingly, the 
30-day mortality rate pooled estimate of our report (7.8%; 95% CI: 5.5% to 11.1%) is similar 
to the 30-day predicted mortality rate by the Society of Thoracic Surgeons score (8.7%; 95% 
CI: 7.0% to 10.3%). Considering that the population of the current report represents a mix 
of several approaches (transapical, transfemoral [TF], subclavian) and different devices, this 
finding underlines the high-risk profile of the patients included in this meta-analysis.
The cardiovascular mortality rate, both at 30 days and 1 year, represents >65% of the 
total mortality in the present study. Although such results might be expected in a population 
of high-risk patients who underwent a major cardiac procedure, some authors have chal-
lenged the clinical relevance to systematically attribute unknown death to cardiovascular 
death and, consequently, its relationship to the device and underlying aortic pathology.38 
In fact, according to the current VARC definitions, unknown deaths should be considered 
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as cardiovascular in origin. Although VARC suggests the use of all-cause mortality as the 
primary endpoint of choice and cardiovascular mortality as a secondary endpoint, ascer-
tainment and adjudication of cardiovascular death remain a challenge.
Periprocedural MI (≤72 h after TAVR) occurred at a rate of 1.1% (95% CI: 0.2% to 2.0%) 
after TAVR in the current analysis. Although coronary obstruction is a potential cause, other 
factors such as global ischemia due to hypotension, rapid pacing, microembolism induced 
by device delivery or implantation, myocardial tissue compression by the device expansion, 
and direct trauma of the apex during transapical access must also be considered. VARC 
proposed the use of a relatively conservative definition for MI, for which the recommended 
biomarker is the creatine kinase-myocardial band isoenzyme, and not troponin and clinical 
signs of infarction. This may explain the low rate of MI reported after TAVR. Conversely, 
Rodes-Cabau et al. 39 were the first to report the incidence and implication of troponin 
increase after TAVR, in which 97% of TF patients and 100% of the transapical patients 
showed some degree of troponin increase. After multivariate analysis, a greater magnitude 
of troponin T increase (15 times the upper normal range) was shown to be an independent 
predictor of mortality at a mean follow-up of 9 months as well as a factor correlated with 
lesser degrees of improvement in left ventricular ejection fraction. However, the inclusion 
of troponin as a criterion for MI after TAVR is still a matter of debate, and more data and 
validation are needed.
AKI was reported according to the VARC definition in 9 studies (56.3%). However, less 
than one-third of the authors appropriately reported AKI stage II or III, which is the proposed 
stage to be reported according to VARC definitions. Most of the AKIs were stage I, and the 
frequency of stage II/III was 7.5%. Noticeably, the rate of AKI stage I reported in the literature 
was as high as 24.6% in 1 study (Table 3). This may be explained by the low threshold 
chosen by the first VARC committee, in which any increase of >0.3 mg/dl is considered AKI 
stage I.
Life-threatening and major bleeding after TAVR occurred in 15.6% (95% CI: 11.7% to 
20.7%) and 22.3% (95% CI: 17.8% to 28.3%), respectively (Table 3). These rates appear 
higher compared with previous reports. However, bleeding complications have been incon-
sistently reported and likely even underreported in the early literature.5, 11, 40, 41 Among 
the 16 studies in our analysis, transfusion rates were reported by 7 authors (43.8%), with a 
pooled estimate rate of needing 1 or more transfusions after TAVR of 42.6% (95% CI: 19.8% 
to 62.4%). VARC strongly recommended reporting the rate of transfusions after TAVR. How-
ever, Gurvitch et al. 22 previously reported that a significant proportion of patients received 
blood transfusions without an obvious source of bleeding, in whom anemia was pre-existent 
or the cause of the hemoglobin decrease was unclear. Généreux et al. 42 also reported that 
among the 25% of patients who needed red blood cells after TAVR, 57% of the transfusions 
given were not directly related to the procedure (gastrointestinal bleeding, genitourinary 
bleeding, or no obvious source). Such findings may warrant a possible separate category 
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in future revised VARC criteria so that a clear distinction can be made between procedure-
related blood loss and nonprocedural bleeding.
Major vascular complications occurred in 11.9% (95% CI: 8.6% to 16.4) of patients 
in the current study. Before VARC definitions, vascular complications were inconsistently 
reported, and when they were, it was mostly reported by site and according to the investiga-
tor definitions. Moreover, classification of severity was rarely done. Piazza et al. 5 reported 
their early data using the TF approach with the Medtronic CoreValve device with a low rate 
(1.9%) of vascular complications, whereas Eltchaninoff et al. 11 reported a much higher rate 
(7.5%) using the same device and the same access route. Similarly, early studies using the 
Edwards device via the TF route reported 30-day vascular complication rates ranging from 
6.3% to 22.9%.8, 11 The TA approach has been associated with a lower rate of vascular 
complications than the TF route.8, 40, 43
Moreover, further clarification of the current VARC criteria may be needed because the 
TF approach is moving toward a full-percutaneous procedure. Also, inclusion of “new” 
alternative access sites, such as the subclavian-axillary artery 41, 44, 45 and direct transaortic 
access,46 should be considered in the elaboration of new definitions.
Stroke has emerged as one of the major foci of attention after TAVR. The major stroke rate 
reported in our study is 3.2% (95% CI: 2.1% to 4.8%). Interestingly, minor strokes and tran-
sient ischemic attacks were less frequently reported, underlying the difficulty to adequately 
identify such post-procedural events, especially in a population of elderly sick patients.
Before VARC definitions, the 30-day stroke rates had been variably reported, ranging 
from 1.5% (40) to 4.2% 11 for the Edwards device and 0% (11 and 47) to 10% 4 for the 
Medtronic device. These were mostly self- or site-reported results and nonadjudicated 
events. VARC emphasizes the necessity to confirm the diagnosis by neuroimaging technique 
(computed tomography and/or magnetic resonance imaging) and to classify the severity of 
stroke using conventional neurological assessment tools. VARC recommended the modified 
Rankin Scale score at 30 and 90 days for the stroke assessment. However, Ikeda et al. 35 
suggested that the National Institutes of Health Stroke Scale should also be used, and the 
time point of the evaluations should also cover event onset (acute phase). Given the different 
level of invasiveness and pattern of recovery after surgical aortic valve replacement and 
TAVR, assessment and comparison of stroke rates between these 2 approaches has become 
challenging. Early recognition of events, use of an appropriate scoring system (National 
Institutes of Health Stroke Scale and the modified Rankin Scale), neuroimaging tools, and 
adjudication by a neurology specialist will provide a more accurate comparison of stroke 
frequency between different therapies.
The permanent pacemaker insertion rate in the current analysis is 13.9% (95% CI: 
10.6% to 18.9%), resulting from the pooling of data including both devices (Medtronic 
CoreValve system and Edwards Lifesciences device). It is generally accepted that the self-
expandable CoreValve, because of its higher and longer lasting radial force as well as the 
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deeper implantation site in the left ventricular outflow tract, has a higher rate of pacemaker 
requirement than the Edwards valve. Current evidence shows that 20% to 30% of patients 
after CoreValve implantation and 3% to 5% of patients after Edwards valve placement will 
require a new permanent pacemaker. An additional analysis was performed, pooling data 
from centers where TAVR were done with 1 type of device, showing similar results (Edwards 
valve, 4.9% [95% CI: 3.9% to 6.2%] vs. CoreValve, 28.9% [95% CI: 23.0% to 36.0%], p < 
0.0001). However, differences between operator and institution relating to the threshold for 
permanent pacemaker insertion must also be considered.
Another important focus has been the higher incidence of paravalvular leak after 
TAVR compared with surgical aortic valve replacement. The pooled estimate for residual 
moderate or severe aortic regurgitation after TAVR was 7.4% (95% CI: 4.6% to 10.2%) in 
this report. Currently, however, there are no standardized methods to grade paravalvular 
regurgitation after TAVR. Whereas the current VARC definition suggests criteria such as jet 
density, jet width, and jet deceleration time for central aortic regurgitation, paravalvular 
leak assessment is based on the percentage of the circumferential extent of paraprosthetic 
aortic regurgitation, which has not been validated in a TAVR population. Uniformity and a 
standardized echocardiographic definition for paravalvular leak after TAVR is mandatory for 
the next version of VARC definitions.
As mentioned earlier, many authors have not reported composite endpoints. However, 
among those reporting the 30-day composite endpoint, disparity seems to exist, with rates 
ranging from 17.8% to 68%. Although differences in population risk profiles may explain a 
portion of this discrepancy, correct interpretation of the hierarchical order and use of proper 
echocardiographic findings are mandatory with this composite endpoint.
The 1-year safety endpoint rate was reported by 2 studies and occurred in ~70% of 
patients. The high rate of this endpoint is explained by the inclusion of recurrent heart 
failure requiring admission as a component of this outcome. Although important, this com-
ponent can introduce“background noise,”reflecting more on the presence of suboptimal 
heart failure management, multiple comorbidities, or different severities of left ventricular 
depression, despite a perfectly functioning valve. In a recent comment, Ikeda et al. 35 also 
underlined the possible bias by each country’s medical care setting, where thresholds for 
hospitalization would vary from country to country, according to local culture.
study limitations
Several important limitations of the present analysis warrant discussion. This report repre-
sents a study-level pooled analysis of 16 TAVR articles. A patient-level analysis would have 
been preferable. We pooled data that were clearly reported in each article. Authors may not 
have reported outcomes simply because they did not occur, which may have led to some 
overestimation of events in our analysis. Reported outcomes from the 16 studies were mainly 
self- or site reported, with only 2 studies adequately reporting adjudicated events.33, 34 
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This is likely to have contributed significantly to the high heterogeneity that is observed 
in this report. Different devices and approaches were used in the selected studies, and no 
systematic comparison of the devices or approaches has been attempted thus far. Although 
unlikely, a publication bias is always possible. The aim of this meta-analysis was to evaluate 
the performance and the use of the VARC definitions among the most recent TAVR literature. 
A patient-level pooled analysis comparing the different devices and access approaches was 
beyond the scope of this paper.
conclusIons
VARC definitions have already been used successfully in the literature and are being rap-
idly adopted by the TAVR community. However, slight modifications are needed and may 
improve their application in the future. Although VARC definitions have brought uniformity 
and standardization in reporting outcomes after TAVR, appropriate recognition and ascer-
taining, reporting and adjudication of outcomes should be reinforced and will ensure that 
TAVR study results are a valid reflection of ”real-world” clinical events.
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AbstrAct
Paravalvular leak (PVL) is a frequent complication of transcatheter aortic valve replacement 
(TAVR) and is seen at a much higher rate after TAVR than after conventional surgical aortic 
valve replacement. Recent reports indicating that PVL may be correlated with increased late 
mortality have raised concerns. However, the heterogeneity of methods for assessing and 
quantifying PVL, and lack of consistency in the timing of such assessments, is a hindrance 
to understanding its true prevalence, severity, and effect. This literature review is an effort to 
consolidate current knowledge in this area to better understand the prevalence, progression, 
and impact of post-TAVR PVL and to help direct future efforts regarding the assessment, 
prevention, and treatment of this troublesome complication.
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IntroductIon
Transcatheter aortic valve replacement (TAVR) has become the treatment of choice for 
inoperable patients with severe aortic stenosis and is comparable to surgical aortic valve 
replacement (SAVR) for patients at high risk. 1, 2 However, paravalvular leak (PVL) is more 
frequently seen after TAVR than after SAVR, and its potential association with mortality 
has raised concerns.3-6 Moreover, recent reports have suggested that PVL could negatively 
impact mid- and long-term prognosis following TAVR.7, 8 Although concerning, the lack of 
standardized quantitative and qualitative methods to assess and categorize PVL and the 
heterogeneity in the timing of post-procedural assessment of PVL warrant caution in inter-
pretation of these data. Therefore, we sought to perform a systematic review of the current 
literature to better define the rate, progression over time, predictors, and consequences of 
PVL after TAVR. Furthermore, recommendations for measuring PVL are provided to improve 
consistency throughout the literature.
rAte oF PArAVAlVulAr leAK
Multiple studies have reported the frequency and severity of PVL after TAVR.9 There is, how-
ever, significant heterogeneity that is caused by differences in: 1) imaging modalities (trans-
thoracic echocardiography, transesophageal echocardiography, angiography); 2) timing of 
assessment (immediately after implantation, before discharge, at 30 days); 3) transcatheter 
heart valve (THV) system; 4) grading scale; and 5) adjudication of events. When PVL was 
evaluated before hospital discharge and without central core laboratory analysis, its absence 
was reported in 6% to 59% of patients, whereas moderate or severe PVL was seen in 0% to 
24% (Table 1).1-5, 10-16
Thus far, only the PARTNER (Placement of Aortic Transcatheter Valve) trial has used a 
central echocardiography core laboratory to evaluate PVL.1, 2 PVL was graded in accor-
dance with the American Society of Echocardiography recommendations for native valves 
17 because there were no recommendations for prosthetic valve assessment at the start of 
the trial. In addition, because of the inevitable eccentric nature of the jet and the frequent 
“spray” of the jet contour in the outflow tract, the color Doppler in the available parasternal 
short-axis view(s) was weighted in a subjective fashion more heavily than other signals 
in providing an integrated assessment. The following definition was applied: no PVL (no 
regurgitant color flow), trace (pinpoint jet in atrioventricular [AV] short-axis view), mild (jet 
arc length <10% of the AV annulus short-axis view circumference), moderate (jet arc length 
10% to 30% of the AV annulus short-axis view circumference), and severe (jet arc length 
>30% of the AV annulus short-axis view circumference). In the PARTNER trial, trace/mild 
PVL was found in 66% of patients and moderate/severe in 12%.1, 2
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No prospective direct comparison of the rate of PVL after TAVR has been published 
between the 2 most frequently used THV systems (balloon-expandable THV, Edwards 
Lifesciences, Irvine, California; self-expandable CoreValve THV, Medtronic, Minneapolis, 
Minnesota). However, moderate to severe post-procedural PVL seems to be slightly higher 
with the CoreValve (9% to 21%) than the Edwards (6% to 13.9%) device.1-6, 18-22 Recent 
1-year data presented from the FRANCE 2 (French Aortic National CoreValve and Edwards 
2) Registry seemed to confirm this finding—the use of self-expandable prosthesis was identi-
fied as one of the major determinants of significant PVL after TAVR. At patient discharge, 
self-expandable prosthesis was associated with a moderate to severe PVL rate of 19.8%, 
compared with 12.2% for balloon-expandable prosthesis (p value not available).23
ProgressIon oVer tIMe
One of the initial concerns about PVL was potential worsening during extended follow-up. 
Because a large percentage of patients are discharged with trace or mild PVL, worsening of 
PVL could have important consequences on the volume load imposed on the left ventricle 
(LV), ultimately resulting in significant heart failure. In addition, if many cases progress to 
clinically significant leakage, hemolysis requiring repeated transfusions or reoperation may 
further complicate the course of patients.
Despite the lack of “common language” among previous reports in assessment of PVL 
severity, several studies have reported comparable findings with respect to time trends of 
PVL severity. Webb et al. 24 reported the evolution of PVL over time in a cohort of 168 
patients and found that PVL was generally mild and remained stable between 30-day and 
1-year follow-ups, a result that has been confirmed by other studies (Table 2). A recent report 
by Ussia et al. 16 showed that rates of mild (53%) and moderate (15%) post-procedural PVL 
had been reduced to 47% and 10%, respectively, at a follow-up of 3 years. Some attrition of 
the “sickest” patients might have been due to patients with worsening PVL dying, but there 
were no cases of worsening from mild to moderate/severe regurgitation in individual patient 
progression of PVL.
Data from the PARTNER trial suggested, however, that PVL at 2 years had increased by ≥1 
grade in 22.4% of patients, whereas it remained unchanged in 46.2% and improved by ≥1 
grade in 31.5% of patients (Fig. 1).8 So far, no studies have explored the mechanisms behind 
improvement or worsening of PVL in individual patients, and measurement methods may 
explain, at least in part, these changes.
Part 2 Surgical or transcatheter therapy for aortic stenosis194
ta
bl
e 
2
Pr
og
re
ss
io
n 
of
 a
or
ti
c 
an
d/
or
 p
ar
av
al
vu
la
r 
re
gu
rg
it
at
io
n 
ov
er
 t
im
e
A
ut
ho
r, 
ye
ar
n
o.
 o
f 
pa
ti
en
ts
si
gn
ifi
ca
nt
po
st
-p
ro
ce
du
ra
l
si
gn
ifi
ca
nt
 a
t
6 
m
on
th
s
si
gn
ifi
ca
nt
 a
t
1 
ye
ar
si
gn
ifi
ca
nt
 a
t
2 
ye
ar
s
si
gn
ifi
ca
nt
 a
t
3 
ye
ar
s
Pa
ra
va
lv
ul
ar
 le
ak
ag
e
W
eb
b,
20
09
, 
16
8
30
 d
ay
s
2+
 =
 3
7%
3+
 =
 5
%
…
“S
ta
bl
e”
…
…
M
uñ
oz
-G
ar
ci
a,
 
20
11
 
14
4
72
 h
ou
rs
m
ild
 =
 4
0%
m
od
er
at
e 
=
 2
3%
m
ild
 =
 4
7%
m
od
er
at
e 
=
 1
9%
…
…
…
U
ss
ia
, 
20
12
 
18
1
Po
st
-p
ro
ce
du
re
m
ild
 =
 5
3%
m
od
er
at
e 
=
 1
5%
…
m
ild
 =
 4
8%
m
od
er
at
e 
=
 1
8%
m
ild
 =
 5
0%
m
od
er
at
e 
=
 1
7%
m
ild
 =
 4
7%
m
od
er
at
e 
=
 1
0%
Ye
, 
20
10
 
71
30
 d
ay
s
m
ild
 =
 2
6%
m
od
er
at
e 
=
 5
%
…
…
…
“R
em
ai
ne
d 
un
ch
an
ge
d 
an
d 
cl
in
ic
al
ly
 
in
si
gn
ifi
ca
nt
 d
ur
in
g 
fo
llo
w
-u
p”
Ta
ka
gi
, 
20
11
79
30
 d
ay
s
1+
 =
 5
1%
2+
 =
 2
0%
3+
 =
 3
%
1+
 =
 4
9%
2+
 =
 2
7%
3+
 =
 0
%
…
…
…
Ew
e,
 
20
11
 
10
7
Po
st
-p
ro
ce
du
re
1+
 =
 5
8%
2+
 =
 1
6%
3+
 =
 5
%
≥6
 m
on
th
s
1+
 =
 5
1%
2+
 =
 3
1%
3+
 =
 0
%
…
…
G
od
in
o,
 
20
10
 
13
7
Po
st
-p
ro
ce
du
re
1+
 ≈
 6
0%
2+
 ≈
 1
2%
3+
 =
 4
%
4+
 =
 2
%
1+
 ≈
 6
5%
2+
 ≈
 9
%
3+
 ≈
 5
%
4+
 =
 0
%
…
…
…
Paravalvular leak after TAVR 195
C
ha
pt
er
 1
3
ta
bl
e 
2
C
on
ti
nu
ed
A
ut
ho
r, 
ye
ar
n
o.
 o
f 
pa
ti
en
ts
si
gn
ifi
ca
nt
po
st
-p
ro
ce
du
ra
l
si
gn
ifi
ca
nt
 a
t
6 
m
on
th
s
si
gn
ifi
ca
nt
 a
t
1 
ye
ar
si
gn
ifi
ca
nt
 a
t
2 
ye
ar
s
si
gn
ifi
ca
nt
 a
t
3 
ye
ar
s
A
or
ti
c 
re
gu
rg
it
at
io
n
B
au
er
, 
20
10
 
88
2+
 =
 2
9%
3+
 =
 7
%
…
2+
 =
 2
4%
3+
 =
 0
%
2+
 =
 2
3%
3+
 =
 0
%
…
R
aj
an
i, 
20
10
, 
46
W
ith
in
 5
 d
ay
s
m
ild
 =
 3
3%
m
od
er
at
e 
=
 1
9%
m
od
er
at
e-
se
ve
re
 =
 5
%
…
m
ild
 =
 3
1%
m
od
er
at
e 
=
 8
%
m
od
er
at
e-
se
ve
re
 =
 1
5%
…
…
C
la
ve
l,
20
09
,
50
D
is
ch
ar
ge
tr
iv
ia
l =
 3
8%
m
ild
 =
 4
2%
m
od
er
at
e 
=
 8
%
se
ve
re
 =
 0
%
6 
to
 1
2 
m
on
th
s
tr
iv
ia
l =
 2
6%
m
ild
 =
 4
6%
m
od
er
at
e 
=
 6
%
se
ve
re
 =
 0
%
…
…
Le
fe
vr
e,
 
20
11
 
13
0
D
is
ch
ar
ge
2+
 =
 4
2%
3+
 =
 5
%
…
2+
 =
 2
5%
3+
 =
 0
%
…
…
B
ue
lle
sf
el
d,
 
20
11
12
6
30
 d
ay
s
1+
 =
 3
2%
2+
 =
 9
%
3+
 =
 0
%
1+
 =
 3
9%
2+
 =
 6
%
3+
 =
 0
%
1+
 =
 3
4%
2+
 =
 3
%
3+
 =
 0
%
1+
 =
 3
7%
2+
 =
 0
%
3+
 =
 0
%
…
B
le
iz
iff
er
, 
20
12
 
22
7
D
is
ch
ar
ge
m
ild
 =
 3
1%
m
ild
-m
od
er
at
e 
=
 1
3%
m
od
er
at
e 
=
 8
%
m
od
er
at
e-
se
ve
re
 =
 3
%
m
ild
 =
 4
5%
m
ild
-m
od
er
at
e 
=
 1
1%
m
od
er
at
e 
=
 6
%
m
od
er
at
e-
se
ve
re
 =
 0
%
se
ve
re
 =
 0
%
m
ild
 =
 4
0%
m
ild
-m
od
er
at
e 
=
 1
6%
m
od
er
at
e 
=
 6
%
m
od
er
at
e-
se
ve
re
 =
 0
.5
%
se
ve
re
 =
 0
.5
%
m
ild
 =
 4
1%
m
ild
-m
od
er
at
e 
=
 1
5%
m
od
er
at
e 
=
 5
%
m
od
er
at
e-
se
ve
re
 =
 1
%
se
ve
re
 =
 1
%
…
Ko
os
,
20
11
, 
57
A
fte
r 
im
pl
an
t
1+
 =
 7
7%
2+
 =
 9
%
3+
 =
 5
%
M
ea
n 
83
±8
0 
da
ys
1+
 =
 8
2%
2+
 =
 5
%
3+
 =
 0
%
…
…
…
Part 2 Surgical or transcatheter therapy for aortic stenosis196
ta
bl
e 
2
C
on
ti
nu
ed
A
ut
ho
r, 
ye
ar
n
o.
 o
f 
pa
ti
en
ts
si
gn
ifi
ca
nt
po
st
-p
ro
ce
du
ra
l
si
gn
ifi
ca
nt
 a
t
6 
m
on
th
s
si
gn
ifi
ca
nt
 a
t
1 
ye
ar
si
gn
ifi
ca
nt
 a
t
2 
ye
ar
s
si
gn
ifi
ca
nt
 a
t
3 
ye
ar
s
D
’O
no
fr
io
,
20
11
 
50
4
D
is
ch
ar
ge
1+
 =
 3
0%
2+
 =
 9
%
…
M
ea
n 
9.
2±
6.
5 
m
on
th
s
“n
o 
ch
an
ge
s 
in
 th
e 
de
gr
ee
 o
f 
A
R
 w
er
e 
fo
un
d.
”
…
…
G
ur
vi
tc
h,
20
10
 
70
Po
st
-p
ro
ce
du
re
tr
iv
ia
l =
 4
0%
m
ild
 =
 4
4%
m
od
 =
 6
%
…
…
…
tr
iv
ia
l =
 6
0%
m
ild
 =
 3
3%
m
od
 =
 3
%
W
al
th
er
, 
20
11
 
16
8
…
3-
6 
m
on
th
s
1+
 =
 5
1%
2+
 =
 1
%
3+
 =
 0
%
1+
 =
 4
6%
2+
 =
 5
%
3+
 =
 0
%
…
…
Paravalvular leak after TAVR 197
C
ha
pt
er
 1
3
IMPAct on clInIcAl outcoMes
After SAVR, moderate to severe residual aortic regurgitation (AR) occurs infrequently in 
approximately 4% of patients.25 A recent study showed that AR after SAVR was an inde-
pendent predictor of long-term mortality with a hazard ratio of 1.7 (95% CI: 1.2 to 2.3). 
The TAVR community has focused extensively on the effect of AR on survival because its 
prevalence is much higher after TAVR than after SAVR.8 A number of studies have identified 
AR ≥2+ to be an independent predictor of short- and long-term mortality (Table 3).3 Fur-
thermore, patients with AR ≥2+ were 10 times more likely to be nonresponders to therapy 
at 6 months’ follow-up; nonresponsiveness was defined as either death or New York Heart 
Association classification ≥2.
Few studies have devoted analyses specifically to PVL. This is not surprising because the 
low post-operative rate of PVL in surgical series makes statistical analysis not meaningful. 
However, even in TAVR after which post-procedural AR is largely paravalvular, there have 
been only a few large registries and randomized trials focused on PVL. Data on 663 patients 
from the Italian registry found that PVL grade ≥2+ was not associated with early 30-day 
mortality, but multivariate analysis did find a hazard ratio of 3.79 for patients with PVL ≥2+ 
for late mortality beyond 30 days.6 More disturbingly, although it was generally believed 
that only moderate or severe regurgitation would impact long-term outcomes,26 the recently 
published 2-year results from the PARTNER trial showed that even mild PVL was associated 
with significant mortality (Fig. 2).8 Multivariable analyses did not identify AR or PVL as 
independent predictors of mortality in this trial, but, interestingly, there is a trend toward 
improved survival in patients undergoing TAVR compared with SAVR if PVL was negligible 
(70% vs. 65%).
Importantly, based on the current literature, the direct causal relationship between 
PVL and mortality (vs. PVL being a marker for other factors) still needs to be determined. 
Careful analyses of baseline patient characteristics, the repercussion of all degrees of PVL 
on LV geometry and remodeling, and the determination of the precise cause of death 
2	  Years	  
Post-­‐
procedure	  
None	   Trace	   Mild	   Moderate	   Severe	  
None	   17	   8	   6	   1	   0	  
Trace	   24	   12	   11	   1	   0	  
Mild	   3	   10	   34	   5	   0	  
Moderate	   2	   1	   5	   3	   0	  
Severe	   0	   0	   0	   0	   0	  
Figure 1 change in paravalvular leak severity over 2-year follow-up
Adapted with permission from Kodali and colleagues.8
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table 3 outcomes associated with aortic and/or paravalvular regurgitation
Author, year no. of 
patients
Variable outcome univariate analysis Multivariate analysis
Abdel-
Wahab, 2011
690 AR ≥2 In-hospital 
mortality
OR = 2.50 [1.37-4.55] OR = 2.43 [1.22-4.85]
Gotzmann, 
2011
122 AR ≥2 6-month 
mortality
No clinical 
improvement
…
…
OR = 4.26 [1.59-11.45]
OR = 10.1 [3.20-31.94]
Takagi, 2011 41 AR ≥2 6-month 
mortality
12.2% vs. 25.0%, 
p=0.25
…
Hayashida, 
2012 
260 AR ≥2 median 217 days 
[IQR 54-401]
HR = 1.97 [1.19-3.28] …
Leber, 2011 69 AR >2 1-year mortality 9% vs. 37.5%, p=0.07 …
Moat, 2011 870 AR ≥2 1-year mortality HR = 1.49 [1.00-2.21] HR = 1.66 [1.10-2.51]
Sinning, 2012 152 PVL ≥2 1-year mortality HR = 4.0 [2.1-7.5] HR = 4.9 [2.5-9.6]
Tamburino, 
2011 
663 PVL ≥2 Late mortality … HR = 3.79 [1.57-9.10]
Sinning, 2012 146 Moderate/
severe PVL
1-year survival HR = 3.9 [2.0-7.5] HR = 2.4 [1.0-5.4]
Unbehaun, 
2012
358 None vs. 
trace vs. 
mild AR
2-year survival 66% vs. 72% vs. 67%, 
p=0.77
…
Kodali, 2012 158 Mild to 
severe AR
2-year survival HR = 1.75 [1.17-2.61] Not significant
Mild to 
severe PVL
2-year survival HR = 2.11 [1.43-3.10] Not significant
AR = aortic regurgitation; HR = hazard ratio; IQR = interquartile range; OR = odds ratio; PVL = paravalvular leak
Log-rank p=0.0001
Hazard ratio = 2.11, 95% CI 1.43-3.10
None - trace
Mild - severe
Months post-procedure
A
ll-
ca
us
e 
m
or
ta
lit
y 
(%
) 60
40
20
  0
0       6     12            18             24            30            36
None-trace 158   142             134              121              84                39              15
Mild-severe  160         134              112              101              64                26              12
Figure 2 Impact of paravalvular leak on 2-year all-cause mortality
Reprinted with permission from Kodali and colleagues.8 HR = hazard ratio
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(cardiovascular vs. noncardiovascular) are needed to confirm the strength and the nature of 
this relationship. At this point, any previous observations linking PVL (especially mild) with 
mortality should be considered hypothesis generating.
PredIctors oF PArAVAlVulAr leAK
Significant PVL most commonly results from: 1) incomplete prosthesis apposition to the 
native annulus due to patterns or extent of calcification 11, 27-30 or annular eccentricity;26 2) 
undersizing of the device;10, 31, 32 and/or 3) malpositioning of the valve.33 These observations 
seem to be true for both balloon-expandable and self-expandable THVs.
Valve sizing has been shown to be one of the strongest predictors of PVL. A low cover 
index reflecting a lower degree of oversizing of the prosthesis based on transthoracic 
echocardiography annulus measurement predicts significant PVL.10 More recently, studies 
have evaluated the use of multidetector computed tomography (MDCT) for THV sizing, and 
MDCT showed good predictability and reduced rates of significant PVL.34-37 Furthermore, 
larger and eccentric annuli were identified as predictors of PVL in multiple studies and most 
likely reflect inadequate sizing of the THV.3, 15, 26 A smaller aortic valve area was found to 
predict PVL in one study, but this was likely because the smaller area indicates a greater 
degree of calcification.3 The extent of calcification and asymmetrical distribution, as well 
as the location of calcium on the aortic wall, valve commissure, or THV landing zone, as a 
predictor for PVL has been confirmed in several studies.11, 26, 29, 37, 38
In studies specifically evaluating the CoreValve (Medtronic), a lower depth of implanta-
tion and a greater angle between the aorta and LV outflow tract were found to predict PVL 
(14 and 15).
AssessMent oF PArAVAlVulAr regurgItAtIon
Angiographic and hemodynamic assessment
Aortic root angiography is an established tool for qualitative and semiquantitative assessment 
of AR.39 It is readily available during the TAVR procedure and can be quickly and safely 
executed to provide essential information and initiate adjunctive maneuvers if needed in 
case of significant (para) valvular AR. Typically, Sellers criteria are applied to grade AR:40 1) 
grade 1 or mild AR corresponds to a small amount of contrast entering the LV during diastole 
without filling the entire cavity and clearing with each cardiac cycle; 2) grade 2 or moderate 
AR corresponds to contrast filling of the entire LV in diastole but with less density compared 
with contrast opacification of the ascending aorta; 3) grade 3 or moderate to severe AR 
corresponds to contrast filling of the entire LV in diastole equal in density to the contrast 
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opacification of the ascending aorta; and 4) grade 4 or severe AR corresponds to contrast 
filling of the entire LV in diastole on the first beat with greater density compared with the 
contrast opacification of the ascending aorta. During the contrast injection, no material may 
cross the aortic valve leaflets (e.g., guidewires, catheters) because incomplete valve closure 
may artificially be generated, thus resulting in AR. Particularly with self-expanding systems, 
it is important to wait some time (empirically 10 min) after deployment of the bioprosthesis 
to allow the system to expand to its maximum. The downside of qualitative aortography AR 
assessment is that it relies on subjective interpretation of unidimensional images; therefore, 
interobserver and intraobserver variability can be an issue and additional contrast volume 
required. Moreover, it is difficult to determine the contribution of PVL and central AR.
Classic findings of acute AR (acute drop in the aortic diastolic pressure with or without 
elevated LV end-diastolic pressure [LVEDP]) may be seen after TAVR and may be suggestive 
of moderate to severe AR. However, these findings must be interpreted with caution because 
the concomitant use of sedatives, vasopressors, inotropes, and intravenous fluids all impact 
hemodynamics, and the presence of material through the aortic valve (e.g., wire) may inter-
fere temporarily with the THV function. Recently, the AR index, the ratio of the end-diastolic 
gradient across the aortic valve bioprosthesis to systolic blood pressure ([ADP − LVEDP]/
ASP; ADP-aortic diastolic pressure, ASP-aortic systolic pressure), was described.41 An AR 
index <25 was associated with 1-year mortality. Although this association is interesting, 
more data and validation are needed to establish the role of this new index in the therapeu-
tic decision process after TAVR.
echocardiographic assessment
Although the native valve regurgitation quantitative grading scheme has been advocated for 
the evaluation of prosthetic valve regurgitation,42 there are limited data to support the use of 
these parameters following TAVR. The majority of semiquantitative parameters for assessing 
AR apply to central regurgitant jets, which are more uniform, making semiquantitative grad-
ing schemes more reliable.
Unlike central jets, paravalvular regurgitant jets are commonly eccentric with crescentic, 
irregular orifices. Because these jets occur between the annulus and sewing ring, jet areas 
and lengths may not represent the same severity of regurgitation compared with central 
jets and these parameters cannot be used to reliably assess regurgitant severity. Although 
guidelines suggest using the circumferential extent of the regurgitant jet as a semiquantita-
tive measure of severity,42 this parameter has not been validated against any quantitative 
parameters of regurgitation. Even if we accept the limited validation of this scheme for 
surgical prostheses, the anatomy and physiology of THVs are different than that of surgi-
cal valves. In the balloon-expandable valve, paravalvular regurgitation should be assessed 
just below the skirt; for central jets, the regurgitation should be assessed at the coaptation 
point of the leaflets. In addition, there is no scheme that specifically addresses the unusual 
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regurgitation that accompanies the THV. The intact calcified cusps and annulus significantly 
influence the location and shape of paravalvular jets; typically, these jets appear smaller and 
more irregular at the level of the intact/calcified cusps and larger just apical to the THV stent.
Quantitative assessment of total AR, or advanced imaging techniques for assessing 
paravalvular regurgitant orifices, may be a more accurate way of assessing severity and 
thus a more accurate assessment of risk. Quantitative Doppler uses comparative flow mea-
surements across a regurgitant valve and a nonregurgitant valve to calculate regurgitant 
volume or fraction.17 The effective regurgitant orifice area is then calculated by dividing the 
regurgitant volume by the velocity time integral of the regurgitant jet continuous wave spec-
tral profile. Alternatively, the LV stroke volume calculated by 2-dimensional (2D) biplane 
Simpson method of discs 43 can be used in place of total (regurgitant plus forward) stroke 
volume; however, systematic underestimation of ventricular volumes has been reported 
for this method. Although this quantitative assessment has been largely validated in the 
literature,44-51 has shown reproducibility, and is endorsed by scientific authorities,17, 52 it 
should be acknowledged that this assessment is based on 4 parameters, any one of which 
may be determined with significant inaccuracy.
Three-dimensional (3D) echocardiography can overcome the limitations of 2D and 
standard Doppler measurements for quantifying regurgitation.43 Pitfalls of 2D LV imaging, 
including foreshortening, malrotation, and angulation, can be overcome by 3D imaging. 
However, limitations of 3D imaging (lower line density and low volume rates) may reduce 
the utility of this method for assessing total stroke volume. Color Doppler 3D volumes can 
be useful for the identification and localization of regurgitation jets, as well as planimetry of 
the vena contracta area.53, 54 This imaging modality may be particularly useful for post-TAVR 
assessment of PVL.55, 56
table 4
VArc II recommendations for the evaluation of aortic and/or paravalvular regurgitation 
after tAVr
Mild Moderate severe
semi-quantitative Parameters
Diastolic flow reversal in the 
descending aorta—PW 
Absent or brief 
early diastolic
Intermediate Prominent, holodiastolic
Circumferential extent of 
prosthetic valve paravalvular 
regurgitation (%)*
<10 10-29 ≥30
quantitative Parameters‡
Regurgitant volume (ml/beat) <30 30-59 ≥60
Regurgitant fraction (%) <30 30-49 ≥50
EROA (cm2) 0.10 0.10-0.29 ≥0.30
*Not well-validated and may overestimate severity compared to quantitative Doppler. ‡For LVOT >2.5 cm, 
significant stenosis criteria is <0.20. Adopted with permission from Kappetein and colleagues.31
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With the increased use of multimodality imaging capable of 3D reconstruction of the 
aortic root,36, 57-62 there has been intense interest in the shape of the annulus and appropri-
ate sizing of the transcatheter heart valve to reduce PVL. The oval shape of the annulus has 
been well documented,36, 60, 61, 63-65 and a single sagittal plane measurement is significantly 
smaller than the coronary plane measurement. Algorithms using 3D imaging tools have 
been suggested to improve annular sizing and reduce PVL.34, 35
Recently, the Valve Academic Research Consortium (VARC) published the VARC II defini-
tions and suggested the use of TAVR-specific criteria for the assessment of AR and/or PVL 
after TAVR (Table 4).66 Figure 2 and Figure 3 illustrate echocardiographic assessment of PVL 
after TAVR. Figure 4 illustrates a case using 3D echocardiography assessment of PVL.
A                        B
C                        D RVOT VTI =
15 cm
LVOT VTI =
18 cm
RVOT Diam = 1.9 cm
LVOT Diam = 2.0 cm
Figure 3
Quantitative doppler echocardiography can be used to calculate the regurgitant orifice 
and volume
(A) Post-transcatheter heart valve (THV) left ventricular outflow (LVOT) diameter (just apical to the THV stent). 
(B) Right ventricular outflow tract (RVOT) diameter. (C) LVOT Doppler with sample volume located just apical to 
the THV stent aligned in the short-axis view of the LVOT pulse Doppler signal just below the THV stent. Stroke 
volume (SV) across the THV = LVOT area X LVOT velocity time intergral (VTI) = 56 ml. (D) RVOT VTI yields an SV 
across the RVOT of 43 ml. The regurgitation volume = LVOT SV – RVOT SV = 13 ml. AR = aortic regurgitation; PG 
= pressure gradient
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treAtMent For sIgnIFIcAnt PArAVAlVulAr leAK
Improved positioning of the TAVR could require advanced imaging techniques for angio-
graphic planning; having the best coplanar view will ensure accurate fluoroscopic local-
ization of the valve before implantation. In addition, simultaneous “real-time” imaging, 
such as echocardiogram (both 2D and 3D), 3D angiographic reconstruction via rotational 
aortic root angiogram,67 and the use of novel imaging systems,68, 69 may assist in choos-
ing intraprocedurally the optimal projection for THV positioning and deployment, leading 
potentially to less frequent PVL.
Intraprocedurally, several interventional alternatives to reduce regurgitation are avail-
able.70 Severe calcification of the native valve might prevent the implanted valve from 
expanding completely against the annulus, leaving residual orifices through which PVL 
may occur. Post-implantation balloon dilation of the valve might be effective in reducing 
PVL and may be considered the initial option for patients with PVL.71 A slightly oversized 
balloon is recommended to fully expand the valve. Studies have shown that post-dilation 
can be safely performed, with a reduction of the regurgitation in a majority of patients.38 
Calcification of the valve significantly influences the success of this intervention. However, 
in some patients, post-dilation has no effect in reducing AR;15 in addition, post-dilation has 
been shown to be associated with a higher incidence of cerebrovascular events.38 The effect 
of post-dilation on survival has yet to be determined.
AR VTI =
190 msec
A                           BArea 1 = 4 mm2
Area 2 = 1 mm2
Figure 4
three-dimensional echocardiography can be used to quantitate the regurgitant orifice 
and volume
(A) Multiplanar reconstruction of a 3-dimensional color Doppler volume set, aligned in the short-axis view of the 
LVOT just below the THV stent. The planimetered regurgitant orifices are 4 mm2 and 1 mm2, consistent with a 
total effective regurgitant orifice area (EROA) of 5 mm2. (B) Aortic regurgitant continuous wave spectral Doppler 
with AR VTI of 190 ms. The regurgitant volume = EROA X AR VTI = 10 ml (same patient as in Figure 3). AR = 
aortic regurgitation; PG = pressure gradient
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Especially with the CoreValve, implantation of the valve that is too low is associated with 
PVL. Repositioning to a higher implantation depth could therefore reduce PVL. However, 
no retrievable valve is currently available on the market. Therefore, a snaring maneuver has 
been described, in which the valve is pulled up by attaching a snare to one of the frame 
loops.72, 73 Although successful cases have been reported,74 the valve may also move to 
the original (too low) position as soon as tension is released.70 An extra word of caution is 
warranted when the snaring technique is considered in patients with extensively calcified 
valves because chunks of calcium may detach as a result of friction. Furthermore, there is a 
risk of damaging the ascending aorta during the snaring maneuver.
A valve-in-valve procedure may be necessary in some cases in which post-dilation or 
other techniques do not improve the degree of PVL. This is specifically indicated for patients 
in whom the valve was suboptimally positioned (i.e., too shallow or too deep). In the Italian 
registry, a valve-in-valve procedure was used in 3.6% of 663 patients.75 Compared with 
patients who were implanted with a single valve, those who underwent valve-in-valve had 
similar safety and efficacy over a 1-year follow-up. Encouraging results have been reported 
from other series as well.76
As a final option for patients with continued severe PVL in whom interventional therapy 
does not suffice, conversion to conventional SAVR may be needed.77 SAVR may be undesir-
able because these patients are generally at high or extreme risk, but the procedure may be 
unavoidable in some cases.
eMergIng tAVr technologIes
Currently, there is no proven or generally accepted treatment for PVL. However, there are 
emerging THV systems and technologies that are promising in minimizing PVL after TAVR 
(Fig. 5). These devices may reduce PVL by better supra-, infra-, or intra-annular sealing (cuff) 
or by allowing controlled deployment, repositioning, or removal of the THV. Preimplanta-
tion calcification debulking (surgically or not) also remains one of the most interesting areas 
of development to ensure adequate THV expansion and annulus sealing.
lIMItAtIons oF the current lIterAture
Many limitations of the current literature should be acknowledged. Although some stud-
ies have used echocardiography, others have used angiography to assess PVL immediately 
after THV implantation, making comparison between studies difficult. Most of the studies 
have used site self-reported PVL severity and lack independent adjudication of clinical 
events. Although the PARTNER trial had the advantage of a central echocardiography core 
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laboratory and adjudication of clinical events, we are still waiting for in-depth analysis of 
the outcomes associated with PVL. Baseline characteristics of patients with no/trace PVL 
may be different than those with mild to severe PVL and may explain the difference in mor-
tality and the absence of PVL as a predictor for mortality in several reported multivariable 
analyses. Finally, better criteria to establish PVL severity are needed to ensure appropriate 
classification and uniformity among studies.
conclusIons
The association of PVL after TAVR with mortality has made it the new “in vogue” Achilles’ 
heel of TAVR. Although post-procedural moderate to severe PVL can understandably be a 
predictor of a worse outcome, the association with mild PVL may be debatable. Given the 
limitations of the current literature, the nature and strength of the relationship between PVL 
and mortality are still to be determined. Future studies should standardize the evaluation of 
PVL and ensure an appropriate classification of its severity. Upcoming THV systems should 
be designed to minimize PVL, and emerging technology, such as noninvasive calcification 
debulking of the aortic valvular complex, brings promises of lower PVL rates after TAVR, 
potentially as low as those after SAVR.
A          B              C            D
E          F             G             H
Figure 5
emerging tAVr devices involving improved technologies, potentially minimizing 
paravalvular leak after tAVr
(A) SAPIEN 3 (Edwards Lifesciences, Irvine, California). (B) CENTERA (Edwards Lifesciences). (C) Direct Flow 
Medical (Direct Flow Medical, Santa Rosa, California). (D) Portico (St. Jude Medical, St. Paul, Minnesota). (E) 
Engager (Medtronic, Minneapolis, Minnesota). (F) Heart Leaflet Technologies (Heart Leaflet Technologies, Maple 
Grove, Minnesota). (G) JenaValve (JenaValve Technology, Munich, Germany). (H) Sadra Lotus Medical (Boston 
Scientific SciMed Inc., Maple Grove, Minnesota).
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AbstrAct
Surgical aortic valve replacement (SAVR) is currently the standard of care to treat patients 
with severe symptomatic aortic stenosis (AS) and is generally accepted to alleviate symp-
toms and prolong survival. Based on the results of randomized trials, transcatheter aortic 
valve implantation (TAVI) is the new standard of care for patients with symptomatic AS who 
are deemed ‘inoperable’. Debatably, TAVI is also an alternative to SAVR in selected patients 
who are at high risk but operable. As we approach 10 years of clinical experience with 
TAVI, with over 50 000 implantations in 40 countries, a review of the current literature and 
clinical outcomes with this rapidly evolving technology is appropriate.
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IntroductIon
Symptomatic severe aortic stenosis (AS) has a poor prognosis when treated medically and 
inevitably leads to functional deterioration, heart failure, and death.1 Surgical aortic valve 
replacement (SAVR) is currently the standard of care and is generally accepted to alleviate 
symptoms and prolong survival, but ~30% do not undergo SAVR.2 However, since Dr Alain 
Cribier pioneered the first transcatheter aortic valve implantation (TAVI) procedure in 2002,3 
this relatively new technique has been used extensively in over 40 countries accumulat-
ing to >50 000 implantations.4-19 With results from the randomized Placement of AoRTic 
TraNscathetER Valves (PARTNER) trial,20 TAVI is now the standard of care for extremely 
high risk or ‘inoperable’ patients and is a valid alternative to surgery for selected high-risk 
but ‘operable’ patients with symptomatic AS.21 Currently, two different TAVI devices are 
widely used: the balloon-expandable Edwards SAPIEN Transcatheter Heart Valve (Edwards 
Lifesciences, Irvine, CA, USA) and the self-expanding Medtronic CoreValve™ (Medtronic, 
Minneapolis, MN, USA) (Figure 1). Both devices received CE Mark approval for European 
commercial sale in 2007, and the Edwards SAPIEN valve received FDA pre-market approval 
in the USA in November 2011. As we approach 10 years of clinical experience with TAVI, a 
review of the current literature and clinical outcomes is appropriate.
InItIAl exPerIence
First-in-man, initial reports, and feasibility studies
Cribier and co-workers 3 performed the first TAVI in an inoperable patient in 2002 using a 
transeptal antegrade approach and a balloon-expandable aortic valve prosthesis, demon-
strating the feasibility of percutaneous valve implantation. The antegrade approach was fur-
ther explored,22 coinciding with the first-in-man retrograde experience of a self-expanding 
prosthesis (CoreValve™).23 Larger series quickly followed, with early experiences of small 
initiatives using both the balloon-expandable Cribier valve (Edwards Lifesciences Inc.) and 
the self-expandable CoreValve™ system.9, 19 The devices showed a procedural success rate 
of ~80%.
After these single-centre experiences, several larger multicentre feasibility studies were 
initiated first in Europe and later in the USA.6, 24–26 These studies showed that transapical 
(TA) and transfemoral (TF) TAVI in high-risk patients was feasible and could be performed 
with a high procedural success rate and a 30-day mortality of ~10–15% (Table 1).
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regIstrIes
Several large European and Canadian registries have been published, showing excellent 
short- and mid-term results after TAVI using both the TF and TA devices.12,15 The largest reg-
istry reported to date is the SOURCE (SAPIEN Aortic Bioprosthesis European Outcome) reg-
istry.17, 18 Overall, 1038 patients were enrolled at 32 European centres and were treated with 
either a TF (n = 463) or TA approach (n = 575). Patients treated by TA had more co-morbidities 
D
C
   Valve size (mm)            26    29    31
A     Inflow part diameter (mm)        26    29    31
B    Constrained part diameter (mm)  22   24    24   
C    Outflow part diameter (mm)    40    43    43
D    Height (mm)              55    53    53
A
B
C
B
A
Nitenol stent in diamond configuration
Porcine pericardium leaflets
  29 mm           26 mm     23 mm    20 mm
19.1 mm
17.2 mm 14.3 mm
14 mm
14.3 mm 16.1 mm
23 mm 26 mm
Bovine pericardial tissue
Balloon-expendable cobalt
chromium frame
Bovine pericaridal tissue
Balloono-expendable 
stainless steel frame
Polyethylene Terephthalate (PET) skirt
Figure 1
(A) edwards-sAPIen transcatheter heart valve (edwards lifesciences)
(B) edwards-sAPIen xt transcatheter heart valve (edwards lifesciences) 
(C) Medtronic coreValve (Medtronic)
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at baseline than TF patients, resulting in a significantly higher EuroSCORE (European System 
for Cardiac Operative Risk Evaluation) (29.1 vs. 25.7%; P < 0.001). Procedural success was 
95.2 and 92.7% and 30-day mortality was 6.3 and 10.3% in the TF and TA populations, 
respectively. The major limitations of this registry were that >70% of the enrolling centres 
had no prior experience with TAVI and all adverse events were site-reported without core 
lab analysis. In early 2011, 1-year results were published, demonstrating a 1-year survival 
of 76.1% overall, 72.1% for TA and 81.1% for TF patients. Among the surviving patients, 
73.5% were New York Class Association (NYHA) class I or II.17
A number of large dedicated CoreValve registries have been reported; generally, these 
have been somewhat larger than Edwards registries.14, 16 Promising 3-year results were 
recently reported by Ussia et al. 27 and although not yet published, the results of the 
ADVANCE CoreValve™ registry were presented recently.28 ADVANCE represents a 100% 
monitored ‘real-world’ experience, with a core laboratory and an independent clinical 
events committee adjudicating events. The registry included 1015 patients from 44 experi-
enced (>40 prior procedures) centres between March 2010 and July 2011. The mean logistic 
EuroSCORE was 19.2%. At 30 days and 6 months, the rate of all-cause mortality was 4.5 
and 12.8%, respectively, with cardiac mortality of 3.4 and 8.4%, respectively. ADVANCE 
provides insights into contemporary TAVI data of experienced operators, and is a benchmark 
for comparing outcomes.
In 2011, results from four mixed CoreValve™ and Edwards European national registries 
have been reported, mostly using the TF and TA routes (Table 2).4, 8, 29, 30 Overall, patients 
included in these registries were at high-risk according to surgical risk models; mean 
EuroSCORE 18–30%. These registries showed 1-year survival rates ranging between 71.9 
and 81.6%. The UK registry reported the longest follow-up; survival was 73.7% at 2 years.30 
Several of these national initiatives performed access-route comparisons and reported 
that survival was generally higher in patients treated through the TF route.4, 30 However, it 
should be noted that a transfemoral-first approach is often advocated, which may introduce 
selection bias and an unfair comparison between the two access routes.31 Recently, the 
largest registry to date was reported by the FRANCE 2 (FRench Aortic National CoreValve 
table 1 Multicenter feasibility studies
study enrollment number
of patients
Approach device Procedural
success
30-day
mortality
I-REVIVE/RECAST 2003-2005 26 Transseptal Edwards SAPIEN 85% (22/26) 16.7% (6/36)
7 TF Edwards SAPIEN 57% (4/7)
Grube et al. 2005-2007 86 TF CoreValve 74% (64/86) 11.6% (10/86)
TRAVERCE 2006-2008 168 TA Edwards SAPIEN 95.8% (161/168) 14.9% (25/168)
REVIVAL 2006-2008 40 TA Edwards SAPIEN 100% (40/40) 12.5% (7/40)
2005-2006 55 TF Edwards SAPIEN 87% (48/55) 7.3% (4/55)
TA = transapical; TF = transfemoral
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and Edwards) investigators.32 They included 3195 patients treated between January 2010 
and December 2011 at 34 centres. The registry reflects contemporary real-life use of avail-
able TAVI devices in patients at high surgical risk; the Edwards SAPIEN and the Medtronic 
CoreValve devices were used in, respectively, 66.9 and 33.1%. The transfemoral approach 
was most popular (74.6%), followed by transapical (17.8%) and subclavian (5.8%), while 
1.8% underwent some other approach. The procedural success rate was 96.9% and 1-year 
survival in patients was 76.0%.
rAndoMIzed trIAls
completed trials
While registry reports are of crucial value to assess ‘real-world’ use of TAVI, more rigorous 
assessments are available from the first multicentre, randomized clinical PARTNER trials 
(Placement of Aortic Transcatheter Valves; ClinicalTrials.gov Identifier: NCT00530894) 
(Figure 2).20, 21
As the first of two parallel trials was completed, the results of PARTNER IB showed that 
TF TAVI was superior to standard therapy in patients not deemed candidates for surgery.20 
The primary endpoint of all-cause mortality was markedly reduced by 46% (P < 0.001). 
Recently reported 2-year outcomes showed continued encouraging results (Figure 3A).33 At 
2 years, the primary endpoint of all-cause mortality was reduced from 67.6% in the standard 
treatment arm to 43.3% in the TAVI arm (P < 0.001). 
 Figure 2 PArtner trial design
Paravalvular leak after TAVR 223
C
ha
pt
er
 1
4
 
 
 
Figure 3 two-year outcomes of the PArtner trial
(A) Two-year with 1-year landmark analysis of all-cause mortality in the PARTNER 1B cohort. Reprinted with 
permission from Leon and colleagues22 and Makkar and colleagues.33 (B) Two-year all-cause mortality in the 
PARTNER 1A cohort. Adapted with permission from Kodali and colleagues.34 (C) Two-year stroke in the PARTNER 
1A cohort. Adapted with permission from Kodali and colleagues.34
A
b
c
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The PARTNER cohort IA compared TAVI with SAVR and met its non-inferiority endpoint: 
the all-cause 1-year mortality in the TAVI group was non-inferior to the SAVR group (24.2 
vs. 26.8%; P = 0.44; P = 0.001 for non-inferiority).21 
Some concerns were raised with regard to neurologic events that were somewhat higher 
with TAVI than SAVR at 30 days (5.5 vs. 2.4%; P = 0.04) and 1 year (8.3 vs. 4.3%; P = 0.04). 
Although the recently published 2-year results showed that stroke rates were similar for TAVI 
and SAVR during 1 and 2 years with a hazard ratio of 1.22 (95% CI 0.67–2.23, P = 0.52), the 
issue of stroke warrants further investigation and should not be underestimated (Figure 3B 
and C).34 The rate of the composite of all-cause death and stroke was encouragingly nearly 
identical after TAVI (37.1%) and SAVR (36.4%) at 2 years (P = 0.85).
ongoing trials
In the USA, a randomized trial is currently ongoing to evaluate the safety and efficacy of the 
Medtronic CoreValve™ in the treatment of severe symptomatic AS in patients at high or extreme 
risk for SAVR (ClinicalTrials.gov Identifier: NCT01240902). The trial consists of two arms. 
Patients in a high-risk arm will be randomized between SAVR and TAVI; the primary endpoint 
consists of all-cause mortality at 1 year. An extreme risk arm will function as an observational 
arm in which a composite of all-cause mortality and major stroke is the primary endpoint.
As a sequel to the PARTNER I trial, a second randomized trial (PARTNER II) is currently 
ongoing. It was designed to investigate the performance and outcomes after TAVI with the 
next-generation Edwards SAPIEN XT valve, model 9300TFX, as well as the new low-profile 
18-Fr NovaFlex™ delivery catheter in patients deemed non-operable (ClinicalTrials.gov 
Identifier:NCT01314313) (Figure 4A). Given the results of the control arm in PARTNER IB, it 
has been judged that a study comparing TAVI against a ‘medical management’ control group 
is no longer ethical.35 Consequently, an ‘old device’ vs. ‘new device’ non-inferiority trial 
was designed. Enrolment began in January 2011 and it is anticipated that primary endpoint 
results will be published mid-2013.
In Denmark, a phase 2 randomized trial evaluating TAVI in patients ≥70 years of age 
started enrolment in December 2009 (ClinicalTrials.goc identifier: NCT01057173). The trial 
will randomize a total of 280 patients to TAVI (n = 140) and SAVR (n = 140). The primary 
endpoint is the composite of all-cause death, myocardial infarction, and stroke at 1 year and 
is scheduled to be completed late 2013.
In an attempt to expand the indication of TAVI to lower-risk patients, the PARTNER 
IIA trial will be randomizing patients between TAVI with the SAPIEN XT valve and SAVR 
in intermediate risk patients (ClinicalTrials.gov Identifier: NCT01314313) (Figure 4A). 
Similarly, the prospective randomized, international SURTAVI trial will randomize 1900 
intermediate risk patients between TAVI with the Medtronic CoreValve™ and SAVR at ~80 
centres throughout the USA, Canada, Europe, and Australia (ClinicalTrials.gov Identifier: 
NCT01586910) (Figure 4B).
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cost-eFFectIVeness
Since TAVI has been shown to be superior to standard medical therapy and non-inferior to 
SAVR and is increasingly being used in current practice, the incremental costs and cost-
effectiveness of this therapy warrant evaluation.
In the PARTNER IB trial, the mean cost for TF TAVI was $42 806 which accumulated to $78 
542 for the initial hospitalization and $106 076 at 1 year.36 Compared with medical therapy, 
Yes No
Yes No
vs vs
Primary endpoint: All-cause death + 
major stroke + repeat hospitalization at 1 year
(non-inferiority)
Primary endpoint: 
All-cause death + major stroke at 2 years
(non-inferiority)
ASSESSMENT by Heart Valve Team
ASSESSMENT:
Transfemoral 
Access
ASSESSMENT:
Transfemoral 
Access
1:1 Randomization 1:1 Randomization 1:1 Randomization Not in study
TF AVR
Sapien XT
TF AVR
Sapien
TF AVR
Sapien XT AVR
TA AVR
Ascendra 2 AVR
Transfemoral (TF)     Transapical (TA)
InoperableIntermediate risk
Symptomatic severe aortic stenosis
2 parallel RCTs:
Individually powered
Heart Team evaluation
Confirm inclusion/exclusion &
intemediate risk classification
Randomization
Stratified by need for
revascularization
SAVR
Medtronic
CoreValve TAVR
STS mortality risk
≥4% and ≤10%
Figure 4
(A) PArtner 2 trial design 
(B) surtAVI trial design (provided by Medtronic on April 26th, 2012)
A
b
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TAVI was ~$52 455 (95% CI, $40 635–$64 275) more expensive at 1 year, but quality of 
life was significantly better in patients who underwent TAVI. This resulted in an incremental 
cost-effectiveness ratio of $50 212 per life-year gained, and $61 889 per quality-adjusted 
life-year (QALY). The authors rightfully concluded that for patients not candidates for surgery 
in the USA, TAVI increases (quality-adjusted) life-years at reasonable costs similar to other 
cardiovascular technologies.
In the PARTNER IA trial, similar costs were found in TF patients as compared with the 
PARTNER IB trial; $71 955 for the index hospitalization and $94 206 at 1 year, which was 
comparable to patients who underwent SAVR ($74 452 and $96 417, respectively). How-
ever, there was only a minor gain in the number of life-years (0.065: 95% CI, 0.011–0.125) 
and QALYs (0.068: 95% CI, 0.017–0.123) in comparison with SAVR. Through bootstrap 
analysis it was concluded that TF TAVI cost was <$50 000 per QALY in 74.7% of times, 
clearly demonstrating cost-effectiveness in the USA. Patients who could not undergo TF due 
to anticipated vascular and/or bleeding complications were randomized between TA TAVI 
(n = 101) and SAVR (n = 91). 
The index hospitalization was more expensive in the TA group, although not signifi-
cantly so ($90 548 vs. $79 540, P = 0.08). At 1-year follow-up, costs accumulated to a 
mean of $107 779 for TA and $98 183 for SAVR, with a small detriment in life-years 
(−0.015: 95% CI, −0.103–0.080) and QALYs (−0.070: 95% CI, −0.151–0.012). Therefore, 
TA TAVI was found to be a less attractive alternative to SAVR, although this conclusion has 
been somewhat criticized because the analysis was not powered and operators were little 
experienced.31
AlternAtIVe Access sItes
Like the TA approach, a subclavian approach allows patients with unfavourable iliofemoral 
anatomy or extensive disease to be treated with TAVI. Petronio et al.13 recently reported a 
series of 54 patients, showing a procedural success rate of 100%, a procedural mortality of 
0, a 30-day mortality of 0%, and 6-month mortality of 9.4%. No specific vascular complica-
tions for subclavian access were reported. The subclavian approach is usually performed 
with the self-expanding CoreValve™ system and can be fully percutaneous.37
Recently, a transaortic approach with direct access to the ascending aorta though an 
anterior minithoracotomy has been advocated. Access is gained through a J-shaped partial 
upper sternotomy or using a small right thoracotomy through the intercostal space. Avoid-
ance of LV apical injury or inadequate healing along with reduction in post-operative pain 
and its associated impairment of respiratory dynamics are potential advantages of this novel 
approach. Encouraging results have been published from small series using both devices.38, 
39 It may be suitable for patients with unfavourable iliofemoral and subclavian anatomy and 
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in whom a TA approach is considered too risky (chest deformity, severe respiratory disease 
or low ejection fraction). Also, TAVI via the carotid artery has been proposed. In such cases, 
it is crucial to evaluate the cerebral arteries, carotid and vertebral arteries, and circle of 
Willis, to assess the risk of ischaemic stroke.40
VAlVe-In-VAlVe For FAIlIng bIoProstheses
Since 2007, when the first TAVI was implanted in a failing surgical aortic bioprosthesis in 
order to avoid redo surgery, interest in this concept has grown and feasibility and safety have 
been established.41, 42 Piazza and colleagues 43 published a series of 20 patients (mostly TA: 
16/20) and reported successful implantation in 18 of 20 patients and in-hospital mortality in 
3 patients. Indeed, transcatheter heart valves have also been implanted in failing mitral pros-
theses or even annuloplasty rings, and failing tricuspid prostheses, expanding the potential 
use of devices originally developed for the aortic position.44, 45
Knowledge of the basic construction, dimensions, and potential failure modes of the 
surgical bioprostheses is of paramount importance for this technique to succeed. Various 
complications such as coronary obstruction and device embolization may be implicated 
with certain surgical bioprostheses but not others.46 Also, small surgical bioprostheses (e.g. 
19 mm) may not respond well to valve-in-valve implantation because of device constraint 
within the rigid bioprosthesis and incomplete stent expansion, frequently leading to pros-
thesis–patient mismatch.47, 48
The presence of a functioning mitral prosthesis may further complicate device delivery, 
although a recent report has shown that optimal valve positioning through a TA approach 
should be technically achievable with modifications of the ‘classic’ procedure.49
eFFIcAcY And long-terM outcoMes
symptom improvement
Improvement in cardiac symptoms and functional class has been reported at short- and 
medium-term after TAVI.14, 18, 20, 21, 50 However, functional assessment of the population 
currently eligible for and treated with TAVI is difficult, mainly because of their multiple 
co-morbidities.51
Three-year follow-up data have been published and are consistent with lasting improve-
ment in cardiac symptoms.52 While 86% of patients were in NYHA class III or IV at base-
line, 93% of surviving patients were in NYHA class I/II at 3-year follow-up. Similarly, the 
PARTNER trial showed that patients treated with TAVI compared with patients treated with 
standard medical therapy have better symptom control at 1 year.20 Indeed, the 1-year rate of 
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NYHA class III or IV was 25.2% for the TAVI group compared with 58.0% for the standard 
medical therapy group (P < 0.001).
Valve durability and haemodynamic performance
TAVI has demonstrated excellent immediate and short-term durability of the prosthesis 
that is comparable to SAVR, sustaining to 3 years.14, 15, 18, 20, 27, 34, 52 Actually, data suggest 
that transcatheter heart valves have greater valve areas and lower gradients than surgical 
bioprostheses (Figure 5),34, 53 which could reduce the prevalence of prosthesis–patient mis-
match.54 For both the Edwards SAPIEN and Medtronic CoreValve™ there was no evidence 
of structural or non-structural valvular deterioration, stent fracture, deformation, or valve 
migration.
Predictors
As emphasized throughout the manuscript, many of the listed complications are predictors 
of short-term and/or long-term mortality. As current randomized trials are moving towards 
evaluating TAVI in a lower-risk patient population (SURTAVI, PARTNER 2) with a longer life 
expectancy, prediction of mid- and long-term outcomes (≥1 year) will become increasingly 
important. Some predictors should be similar to the surgical literature, but the mounting 
TAVI experience has shown that the incidence and ratio may vary significantly between 
the two therapies. For example, paravalvular leakage is more common after TAVI than after 
SAVR and has been identified as a potential significant predictor for long-term mortality.34
Figure 5 two-year time trends in haemodynamics after tAVI versus sAVr 
Adapted with permission from Kodali and colleagues.34
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Table 3 provides a summary of independent predictors of mortality that have been 
identified in previous studies. Due to the relative infancy of TAVI and the lack of large 
databases for SAVR,55 it is likely that additional predictors will come to light over the years. 
Furthermore, accurate hazard ratios of predictors cannot be given at the current time, due to 
the severe heterogeneity between studies.
lessons leArned
Patient selection
One of the critical aspects of TAVI we have learned so far is that patient selection is crucial 
but cumbersome due to inaccuracy of current risk models to predict outcomes in high-risk 
patients.56 Several variables that have shown to be predictive are not included, such as 
frailty, liver disease, and the presence of a porcelain aorta. Decision making should there-
fore not be based exclusively on clinical risk scores. Instead, it is accepted that the heart 
team can better judge patient eligibility for TAVI or SAVR. Such a team is dynamic and can 
include general cardiologists, interventional cardiologists, surgeons, imaging specialists, 
neurologists, anaesthesiologists, geriatricians, and other specialists.57, 58
Besides the decision to treat by means of TAVI or SAVR, one must consider multiple 
access approaches. Frequently, a ‘transfemoral-first’ attitude is advocated and comprehensive 
table 3 Independent predictors of long-term mortality after tAVI
Advanced age 
Smoking 
Logistic EuroSCORE 
STS score 
Calcium score
Baseline renal failure
Baseline anaemia
Pulmonary hypertension
Chronic obstructive pulmonary disease
Liver disease 
Prior stroke
Post-procedural paravalvular leak ≥2+
Myocardial injury
Systematic inflammatory response syndrome
Major vascular complication
Acute kidney injury
Early experience with TAVI
STS = Society of Thoracic Surgeons; TAVI = transcatheter aortic valve implantation
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screening of the peripheral arteries and aorta by angiography or preferably by multislice 
CT-scan (MSCT), is necessary to assess feasibility.59 MSCT also allows for evaluation of 
left ventricular dimensions and function, and other potential diseases (e.g. coronary artery 
disease), which can further help to contemplate feasibility, safety, and efficacy.
sizing
Accurate preoperative annular sizing is one of the main predictors of a successful TAVI 
procedure. Several modalities have been proposed for accurate sizing. At first, trans-thoracic 
and/or trans-oesophageal echocardiography were used to decide which size valve would 
best be implanted to achieve procedural success with limited or no residual para-valvular 
aortic regurgitation. More recently, the use of three-dimensional and even four-dimensional 
MSCT has been shown to be most effective in sizing for TAVI.60,61 In contrast to trans-
esophageal echocardiography, it is non-invasive and has a high reproducibility.62 Recent 
studies have shown that the area-derived diameter and basal ring average diameter of the 
annulus are the most suitable measurements for valve-sizing. Nevertheless, oversizing of 
 First half          Second half
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Figure 6 effect of learning curve on procedural success (A) and 30-day mortality (B) after tAVI 
Data from Gurvitch and colleagues.63
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the transcatheter heart valve in relation to the annulus size remains necessary to obtain 
procedural success with limited aortic regurgitation.
learning curve
Understanding the importance of patient selection, utilizing better anatomical screening 
to clarify both the aortic root and iliofemoral geometry, and the development of new 
devices have led to notable improvements in outcome over time. A report highlighting the 
importance of the learning curve in 270 patients showed that procedural experience was 
an independent predictor of 30-day survival.63 Furthermore, the procedural success rate has 
significantly increased (Figure 6);63, 64 the use of contrast volume use and radiation doses has 
decreased;65 and procedural complications have declined.66
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AbstrAct
Transcatheter aortic valve implantation (TAVI) has been increasingly recognized as a curative 
treatment for severe aortic stenosis (AS). Despite important improvements in current device 
technology and implantation techniques, specific complications still remain and warrant 
consideration. Vascular complications and peri-procedural neurological events were the 
first concerns to emerge with this new technology. Recently, significant post procedural 
para-valvular leak has been shown to be more frequent after TAVI than after surgical aortic 
valve replacement (SAVR), and its potential association with worse long-term prognostic 
has raised concerns. In moving toward treatment of lower risk populations, structural integ-
rity and long-term durability of heat valve prosthesis are becoming of central importance. 
Emerging technologies and newer generations of devices seem promising in dealing with 
these matters.
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IntroductIon
First-generation devices for transcatheter aortic valve implantation (TAVI) were associated 
with specific complications. Although newer technologies, improved devices, and more 
appropriate patient selection and screening, paired with increased operators’ experience 
have shown to reduce the occurrence of such complications, they still deserve special atten-
tion.
coMPlIcAtIons
stroke
Depending on the definition used, reported incidence of stroke in the current literature var-
ies between 1.7 and 8.4%.1-7 Neurological events may occur at different time-points during 
the procedure and may be related to several factors: manipulation of a wire and/or large-
diameter catheter through the aortic arch, positioning of the device, performance of balloon 
aortic valvuloplasty, and inadequate blood flow to the brain during rapid pacing and device 
deployment.8, 9 Moreover, the population currently undergoing TAVI consists of very elderly 
patients in whom the incidence of atrial fibrillation and atherosclerotic disease is high, 
increasing the risk of peri-procedural cerebrovascular events.2, 10, 11 Although stroke clearly 
manifests in clinical symptoms, recent studies have shown ‘silent’ new cerebral ischaemia 
on diffusion-weighted magnetic resonance imaging in up to 70% of patients.12-14 Although 
rarely associated with clinical events, the long-term consequences of these phenomena are 
unknown.
Initially it was anticipated that stroke associated with TAVI occurred during the procedure, 
but in-depth analysis of stroke demonstrated a continuous hazard extending beyond the 
early phase.15 This hazard was thought to be higher after TAVI in comparison with surgical 
aortic valve replacement (SAVR). However, recent data showed that although the difference 
is significant in the first 30 days, the late hazard is similar between TAVI and SAVR.16
Predictors of early neurological events with TAVI included a prior neurological event, 
more severe atherosclerotic burden, and smaller valve area, although other variables predict 
the constant hazard phase over follow-up: more advanced functional disability, previous 
stroke, and transapical access.15 The role of atrial fibrillation as a potential mechanism of 
stroke after TAVI has been emphasized in two recent reports, showing a four times increased 
risk of stroke.17, 18 Further work is needed to determine the clinical significance of these 
findings. Several embolic protection devices are under investigation. Early reports are 
encouraging, and it is hoped that future use of these devices will lead to a decrease in silent 
and clinical neurological events after TAVI.19
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Vascular complications
Vascular complications remain an important limitation of TAVI performed via TF access. 
The use of large-diameter catheters and the high-risk characteristics of the current treated 
population explain the high incidence. Small vessel diameter, severe atherosclerotic disease, 
bulky calcification, and tortuosity are the main determinants of vascular complications. The 
incidence of major vascular complications using the Edwards SAPIEN system (introducer 
sheath of 23 and 26 Fr, outer diameter of 8.38 and 9.14 mm) varies between 8.3 and 23% 2, 
5, 7, 20, 21 and between 1.9 and 14% 3, 4, 21, 22 using the CoreValve™ system (18 Fr introducer 
sheath, outer diameter of 7 mm). However, the use of arbitrary definitions and difficulty in 
identifying and systematically reporting all vascular complications make interpretation of 
the current literature difficult.
Common vascular complications include arterial dissection, closure device failure, arte-
rial closure device-induced stenosis, and haematoma at the puncture site. Artery avulsion 
(‘artery on a stick’), vessel perforation leading to retroperitoneal haematoma, aortic dissec-
tion, annulus rupture, and left ventricular perforation represent more severe complications 
which are fatal if not rapidly recognized and treated. Although urgent surgical interven-
tion may be necessary in the management of major vascular complications, innovative 
percutaneous techniques involving proximal balloon occlusion of the iliac arteries and/or 
endovascular stent deployment have been suggested as useful in preventing and treating 
some of these issues.23-25
An association between the occurrence of major vascular complications and survival 
has been demonstrated by several authors (Figure 1).2, 5, 20, 21, 26 In the light of these data, 
it is crucial to reduce the rate of vascular complications. Improved experience and patient 
selection as well as exploring alternative access routes have shown to be effective.27
bleeding complications
Bleeding rates have been reported without much consistency in the use of definitions. Using 
standardized endpoint definitions, life-threatening bleeding has been reported occurring 
in 15.6%, whereas any minor, major, or life-threatening bleeding occurred in >40% of 
patients.28 At this rate, it is the most frequent complication post-TAVI, with 42.6% of patients 
requiring ≥1 unit of transfused blood. This, however, might be an overestimation of the true 
burden of TAVI; it has been reported that many patients receive blood transfusions although 
no obvious source of bleeding is present,29 which may be the result of the high prevalence 
of baseline anaemia in this elderly cohort of patients.30 In addition, no regulations exist on 
when to transfuse patients, and haemoglobin cut-off values as indication for transfusion may 
be very different between institutions.
Predictors of bleeding complications are similar to those for vascular complications, 
since both complications frequently occur in parallel. A recent study shows that patients 
who received ≥1 unit of blood had a significantly higher rate of in-hospital mortality (14.8 
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vs. 4.3%, P< 0.05) and a longer length of stay (17 ± 2 vs. 7 ± 1 days, P< 0.05). Those patients 
that received ≥3 units of blood had significantly lower 6-month survival, whereas those with 
0–2 units had similar survival to patients without any transfusion.31
The use of newer generations of transcatheter heart valves and smaller delivery systems as 
well as increasing operator experience will likely reduce the rate of bleeding complications. 
The study by Gurvitch et al. 32 showed that, although not statistically significant, the rate of 
patients who received >4 units of packed red blood cells decreased from 11.1% in the first 
half of their experience to 5.9% in their last patients (P= 0.13).
Acute kidney injury
Several reports have focused on acute kidney injury (AKI), and significant injury [risk, injury, 
failure (RIFLE) ≥2] has been reported with an incidence of`~7–8%.28 Many of these studies 
were consistent in identifying blood transfusions as a predictor of AKI, but other factors 
are associated as well: hypertension, chronic obstructive pulmonary disease, baseline renal 
function, previous myocardial infarction, and the logistic EuroSCORE.33, 34
Bagur et al. 34 reported on 213 patients who underwent TAVI. According to their definition 
(a decrease of >25% in eGFR at 48 h following the procedure, or the need of haemodialysis 
during index hospitalization), 11.7% (25 out of 213) of patients had AKI. Those patients 
39.4%
22.8%
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Figure 1 Impact of major vascular complications on 1-year mortality 
Data from a pooled analysis of an as-treated transfemoral transcatheter aortic valve implantation cohort enrolled 
in PARTNER 1A and 1B.26
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had significantly higher in-hospital mortality (28 vs. 7.4%, P= 0.005), and AKI was, even 
in multivariate analysis, a predictor of hospital mortality (OR= 4.14, 95% CI 1.42–12.13).
Long-term survival in patients with AKI has recently been reported by Nuis et al. 33 In 
their cohort of 118 patients, AKI as defined by the RIFLE criteria occurred in 18.6% (n= 
22). At a median of 13 months of follow-up, AKI was the only independent predictor of late 
mortality (HR= 2.79, 95% CI 1.36–5.71).
conduction disturbances
Multiple reports have been published on conduction disturbances post-TAVI.35-37 It is gen-
erally accepted that the self-expandable CoreValve™ system, because of the higher and 
longer-lasting radial forces as well as the deeper implantation site in the left ventricle outflow 
tract, has a higher rate of pacemaker requirement than the Edwards SAPIEN system. A recent 
meta-analysis reported that ~28.9% (23–36%) of patients implanted with the CoreValve™ 
valve and 4.9% (4–6%) of patients implanted with the Edwards SAPIEN valve will require 
a new permanent pacemaker.28 However, the rates reported in the literature have varied 
greatly. Variations in practice and threshold for pacemaker implantation among physicians 
may explain the discrepancy in new pacemaker insertion rates in current published series.
Persistent new left bundle branch block has been shown to be the most prevalent ECG 
finding post-TAVI, being present in up to 55 and 20% at 1 month after implantation of the 
CoreValve™ or Edwards SAPIEN valve, respectively.37, 38 However, the long-term clinical 
significance of this finding is unknown.
Right bundle branch block, low implantation of the prosthesis, small annulus diameter 
compared with implanted valve size, complete atrio-ventricular (AV) block at the time of the 
procedure, and CoreValve™ device have been shown to be potential predictors of complete 
AV block post-TAVI.39, 40 Given the variable timing of occurrence of high-degree AV block, 
continuous post-procedural ECG monitoring should be performed for at least 72 h in all 
patients at increased risk for this complication. Furthermore, recent data suggest that not 
only brady-arrhythmic events are important, but that the occurrence of new tachyarrhyth-
mia, such as new-onset atrial fibrillation, also has a prognostic importance after TAVI.17
Paravalvular regurgitation
Significant transvalvular regurgitation is rare after TAVI. However, paravalvular regurgitation, 
due to incomplete annular sealing, is common. Some degree of paravalvular aortic regurgi-
tation is reported in 80 to 96% of cases. In most cases, the degree of regurgitation is trivial 
or mild. Grade ≥2+ regurgitation is found in 7–24% of patients.2, 41-44 Although no trial has 
directly compared the Edwards SAPIEN and CoreValve™ devices, the rates of regurgitation 
reported in the literature seem to be similar for the two devices.
Data from the PARTNER trial shows that significant paravalvular regurgitation ≥2+ is 
much more prevalent after TAVI than after SAVR (12 vs. 0.9%, P< 0.001).6 During the 
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follow-up, regurgitation is more often reduced rather than worsening after TAVI (Figure 
2A).16, 43, 45 Nevertheless, its clinical importance has been emphasized in several reports 
where grade ≥2+ regurgitation has shown to be an independent predictor of short- and 
long-term mortality (Figure 2B).16, 46-48
Therefore, correction of significant regurgitation post-implantation is needed, especially 
when moving to younger and lower risk patients (e.g. PARTNER II and SURTAVI). Re-dilation 
or implantation of a second, overlapping transcatheter valve can often correct the problem. 
Also, low implantation of the CoreValve™ might be corrected by a snaring manoeuvre in 
which the valve is pulled to the correct position.49
Predictors of ≥1+ paravalvular leakage for the Edwards SAPIEN device have been found 
to be larger annulus size, height, male sex, age, and cover index ≤8% [cover index= 100 
× (prosthesis diameter – TEE annulus size)/prosthesis diameter]. In a study, no aortic regur-
gitation (AR) of at least moderate degree was observed with a cover area >8%.41 For the 
CoreValve™ system, greater angle of the left ventricular outflow tract is associated with 
an increased risk of significant regurgitation, whereas a depth of 10 mm of the device in 
relation to the non-coronary cusp is associated with a decreased likelihood of AR.50
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coronary obstruction and myocardial injury
Non-revascularized coronary artery disease is common in TAVI patients and, when severe, 
can increase procedural risk. In some patients, percutaneous revascularization may be desir-
able; however, clinical experience suggests that the majority of coronary disease in elderly 
patients can be managed conservatively.
Coronary obstruction of the left main or the ostium of the right coronary artery is a rare 
but potentially fatal event.51 It might occur if a calcified native leaflet is displaced over 
a coronary ostium52 or if the valve frame or the sealing cuff is positioned directly over a 
coronary origin. It could happen either at the time of balloon valvuloplasty or during the 
TAVI procedure. Factors that increase the risk of coronary obstruction include an unusually 
bulky native leaflet (adjacent to a coronary ostium), a low origin of the coronary ostium 
(often defined as <12 mm from the basal leaflet insertion as assessed by multidetector com-
puted tomography), a shallow sinus of Valsalva (offering less room for the native leaflet), an 
oversized prosthesis, and high implantation. Anecdotal cases have been reported in which 
acute coronary obstructions were successfully managed by immediate percutaneous angio-
plasty or bypass surgery.51, 53-55 Careful evaluation by echocardiography or multidetector 
computed tomography is crucial to avoid this complication.
Myocardial injury associated with an elevation in cardiac markers following TAVI 
procedures could be explained by some degree of myocardial tissue compression caused 
by the device itself, global ischaemia instigated by short episodes of severe hypotension, 
and, finally, myocardial damage produced by the apical puncture and passage of the 
large catheter through the ventricular apex when the TA route is employed. Interestingly, 
transient ST-elevations, mostly in the anterior and lateral leads, have been described post-
TA-TAVI immediately after the procedure in ~20% of patients and are probably related 
to incision and suturing of the apex.36 In fact, Rodés-Cabau et al. 56 showed that TAVI is 
associated with some degree of cardiac troponin T rise above the upper normal limit in 
97% of TF patients and in 100% of TA patients. Interestingly, after multivariate analysis, 
a greater elevation of cardiac troponin T was an independent predictor of mortality at 9 
months as well as a factor correlated with less improvement in left ventricular ejection 
fraction.
other complications
Other acute complications, less frequent but potentially lethal, have been described after 
TAVI: aortic rupture,57 aortic dissection,58 peri-aortic haematoma,59 ventricular or aortic 
embolization of the valve,60 and tamponade.61 Mitral valve apparatus damage resulting in 
severe acute mitral regurgitation has also been reported, especially with the TA approach.62 
The wire used to deliver the device could have been malpositioned, either under or through 
chordae, resulting in severe distortion or irreversible damage of the mitral valve apparatus. 
Not unexpectedly, endocarditis has been described anecdotally.63, 64 Acute structural valve 
10 years of TAVI: clinical implications 247
C
ha
pt
er
 1
5
failure, including prosthesis rupture or malfunctioning leaflet (‘frozen leaflet’), is a rare but 
possible complication after TAVI.
conclusIons
Currently, SAVR remains the standard of care for most patients with symptomatic severe 
aortic stenosis. However, with the publication of several real-world registries and lately, 
the pivotal PARTNER randomized trials, transcatheter AVR has become the standard of care 
for patients for whom surgical risk is prohibitive and a reasonable alternative for selected 
operable patients in whom the risk of either mortality or morbidity is ‘high’. Although initial 
reports confirmed the feasibility and safety of TAVI, observational registries and completed 
randomized trials have been limited by the use of older generation devices, enrolment of 
small numbers of patients, the initial learning curve of the TAVI operators, self-reported 
outcomes, and the use of non-standardized endpoints. Although bleeding and vascular 
complications are decreasing as TAVI technology improves and continues to miniaturize, 
stroke and residual paravalvular leak remain important challenges. Embolic protection 
devices, improved delivery systems, and restriction of the procedure to high-volume centres 
with a well-trained TAVI heart team offer potential solutions. Improvement of the current 
technology combined with adoption of standardized definitions 65 for important clinical 
endpoints will enable meaningful comparisons and future well-conducted randomized 
trials.
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coMMent:
Recently, the results of the Placement of Aortic Transcatheter Valves (PARTNER) trial were 
published in the New England Journal of Medicine.1 A group of high-risk patients with 
severe aortic stenosis (AS) deemed non-surgical candidates were randomised to either 
transcatheter aortic valve implantation (TAVI) or standard medical therapy including balloon 
aortic valvuloplasty (BAV). The authors need to be congratulated on their excellent results. 
The one-year results showed a reduced rate of death to 30.7% in the TAVI group, compared 
to 50.7% in the standard therapy group. Safety assessment was however less in favour of 
the percutaneous technique, as 6.7% suffered a stroke or TIA 30 days within randomisation, 
compared to only 1.7% in the standard therapy patients (p=0.03). After one year, this differ-
ence was still significant (10.6% vs 4.5%, p=0.04).
Despite this increased incidence of thromboembolic events, the authors conclude that 
TAVI is the new golden standard for patients with severe AS who are too sick for surgery. 
However, in the spring of 2011, the trial will provide the long anticipated answers to whether 
randomisation to TAVI is superior to surgical aortic valve replacement (AVR) in patients 
categorised as surgical candidates.
Since its introduction in 2002,2 TAVI has been used to treat high-risk or inoperable 
patients. In the PARTNER study as well, only high-risk patients were included having in the 
TAVI and standard therapy groups a mean Logistic EuroSCORE (LES) of 26.4% and 30.4%, 
respectively, and the Society of Thoracic Surgery (STS) predicted risk of mortality scores of 
11.2% and 12.1%, respectively. Other published data have also shown these high surgical 
risks in TAVI treated patients.3, 4 Bern and Rotterdam gathered data on 1,122 patients who 
underwent TAVI or AVR. In this cohort, the mean LES of patients treated with TAVI (n=114) 
or AVR (n=1,008) was 20.1%±13.4% and 9.1%±10.2%, respectively. Hence, the scores can 
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expected euroscore distribution of patients with aortic stenosis who undergo treat-
ment (aortic valve replacement or transcatheter aortic valve implantation)
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be displayed in a distribution curve, with, in the far right, the group of patients treated with 
TAVI, similar to those in the PARTNER study (Figure 1).
The identification of this patient group is however, easier said than done. An intermediate 
risk group could include patients between 70-74 years of age with ≥2 but ≤4 comorbid 
factors; 75-79 year-olds with ≥1 but ≤3 factors; and ≥80 years of age with ≤2 factors. If 
we convert these risk factors (Table 1) to corresponding STS score and EuroSCORE, this 
immediately shows the limitations of these scoring systems. The STS score ranges from 
0.9% to 14.1%, while the EuroSCORE predicts mortality ranging from 9.1%-54.5% (Figure 
2). Not only does EuroSCORE calculate scores many times higher than the STS score, the 
discrepancy is not consistent. This is caused by the incomparable magnitude in which 
comorbidities influence the score.
One major shortcoming of both scores is the lack of entry fields. Both scores miss an 
entry for frailty and porcelain aorta. Other risk factors need to be entered in the STS score, 
but are not incorporated in the EuroSCORE, and vice versa. Therefore, a new score including 
table 1 risk factors
Heart failure (Left ventricular dysfunction and NYHA class ≥3)
Poor metabolic state (diabetes, cachexia, albumin ↓, bilirubine ↑)
Peripheral vascular disease (PVD)
Renal disease/dialysis
Coronary artery disease (CAD)
Frailty
Neurological dysfunction
Porcelain aorta
Redo cardiac surgery
Pulmonary disease (COPD)
Pulmonary hypertension
Poor metabolic state (diabetes, cachexia, albumin ↓, bilirubine ↑)
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Figure 2 sts score and euroscore range in a patient with 2 comorbidities
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all factors should be developed to identify which patients will benefit from TAVI or surgical 
AVR. This score should not only include hospital mortality, but also long-term benefit in 
terms of survival and quality of life. Registries and future trials should not only evaluate 
techniques, but also provide data that eventually can lead to the development of a new 
scoring system.
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AbstrAct
Background
Transcatheter aortic valve replacement (TAVR) offers a new treatment option for patients 
with aortic stenosis, but costs may play a decisive role in decision making. Current studies 
are evaluating TAVR in an intermediate-risk population. We assessed the in-hospital and 
1-year follow-up costs of patients undergoing TAVR and surgical aortic valve replacement 
(SAVR) at intermediate operative risk and identified important cost components.
Methods
We prospectively collected clinical data on 141 patients undergoing TAVR and 405 under-
going SAVR. Propensity score matching yielded 42 matched pairs at intermediate risk. 
Costs were assessed using a detailed resource-use approach and compared using bootstrap 
methods.
Results
In-hospital costs were higher in TAVR patients than in SAVR patients (€40802 vs €33354, 
respectively; p = 0.010). The total costs at 1 year were €46217 vs €35511, respectively (p 
= 0.009). The TAVR was less costly with regard to blood products, operating room use, and 
length-of-stay.
Conclusions
For intermediate-risk patients with severe aortic stenosis the costs at 1 year are higher for 
TAVR than for SAVR. The difference was mainly caused by the higher costs of the transcath-
eter valve and was not compensated by the lower costs for blood products and hospital 
stay in TAVR patients. Therefore, SAVR remains a clinically and economically attractive 
treatment option.
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IntroductIon
Surgical aortic valve replacement (SAVR) is the standard treatment for patients with symp-
tomatic aortic stenosis. However, transcatheter aortic valve replacement (TAVR) has rapidly 
emerged as a less invasive treatment option. A TAVR reduces mortality by 20% as compared 
with medical treatment in patients with severe aortic stenosis who are not eligible for sur-
gery due to comorbidities and cardiovascular abnormalities.1 Moreover, TAVR is equivalent 
to SAVR in terms of 1-year survival for patients at high risk.2
Therefore, considerations such as quality-of-life and costs are crucial in the decision-
making process.3 The only randomized controlled trial that reported quality-of-life in high-
risk patients undergoing TAVR demonstrated a small increase in quality-adjusted life years 
at 1 year.4 With equipoise in quality-of-life and survival, costs may play a pivotal role in the 
decision to perform TAVR or SAVR and therefore merit analysis.
Current studies evaluate TAVR in intermediate-risk populations, making the procedure 
more widely available. For these reasons our study assessed the in-hospital and 1-year 
follow-up costs of TAVR and SAVR in intermediate-risk patients with aortic stenosis using a 
detailed resource-use approach. A second objective was to identify important cost compo-
nents.
PAtIents And Methods
study population
Between January 2006 and November 2010 we prospectively collected data on consecutive 
patients with aortic stenosis who underwent self-expanding transfemoral TAVR or SAVR 
at the Erasmus MC, Rotterdam, The Netherlands. All patients were discussed among car-
diologists, interventional cardiologists, and cardiac surgeons during heart team meetings, 
considering risk scores and additional factors such as frailty, porcelain aorta, and patient’s 
preferences.5, 6 Patients underwent either TAVR (n = 141) or SAVR (n = 405). After propensity 
score matching 42 TAVR and 42 SAVR patients remained for the cost analysis (Table 1). 
One-year follow-up data was collected for all 84 propensity-matched patients. The study 
was approved by the Institutional Research Ethics Committee.
resource use and costs
We retrospectively collected in-hospital diagnostic, procedural, and postprocedural resource 
use data from electronic patient records. All patients had at least 1 outpatient clinic visit 
prior to the procedure and several diagnostic and preprocedural tests; laboratory tests, chest 
X-rays, a dental consult, electrocardiography, cardiac ultrasound, coronary angiography, and 
lung function tests. We assumed that all patients had this standard clinical workup and that 
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every TAVR patient underwent computed tomography. Associated costs were retrieved from 
the hospital’s financial unit and subunits in the departments of cardiology, cardiothoracic 
surgery, and radiology.
The self-expanding third generation CoreValve (Medtronic, Minneapolis, MN; €17,590) 
was used for TAVR and SAVR was performed with the bioprosthetic Carpentier-Edwards 
PERIMOUNT Magna Valves (Edwards Lifesciences, Irvine, CA; €2,700). All TAVR valves 
were inserted through a transfemoral approach. Other materials included disposables, 
sutures, needles, anesthesia, sterilized gauzes, and disposables for the heart-lung machine. 
We retrieved these costs from the electronic ordering system and hospital pharmacy. Pro-
cedural and postprocedural blood products comprised packaged cells, fresh frozen plasma, 
and platelets and were priced according to The Dutch Manual for Cost-analysis in Health 
Care.7
Interventional rooms or operating room costs were calculated as costs per minute by 
using a micro-costing approach. A typical surgical team that carried out SAVR consisted 
of 1 cardiothoracic surgeon, 1 anesthesiologist, 1 anesthesia assistant, 1 resident, 2 nurses, 
and 2 technicians. Interventional teams were composed similarly, except that the team also 
comprised 2 interventional cardiologists, while no resident was involved. We assumed the 
table 1 baseline characteristics
characteristic
Parameter
before propensity score matching After propensity score matching
tAVr
(n = 141)
sAVr
(n = 405)
P Value tAVr
(n = 42)
sAVr
(n = 42)
P Value
Age, mean ± SD (years) 81.3 ± 6.7 70.1 ± 9.0 <0.0001 78.8 ± 6.6 79.3 ± 5.5 0.66
Male sex 78 (55%) 240 (59%) 0.41 21 (50%) 22 (52%) >0.99
Logistic EuroSCORE, mean ± SD 16.2 ± 10.9 6.2 ± 5.5 <0.0001 12.9 ± 6.8 12.5 ± 6.4 0.77
Diabetes mellitus 31 (22%) 97 (24%) 0.64 11 (26%) 8 (19%) 0.61
Coronary artery disease 56 (40%) 167 (41%) 0.75 20 (48%) 20 (48%) >0.99
LVEF <0.0001 0.68
>0.50 73 (52%) 371 (92%) 27 (64%) 30 (71%)
0.30–0.50 55 (39%) 29 (7%) 14 (33%) 10 (24%)
<0.30 13 (9%) 5 (1%) 1 (2%) 2 (5%)
Cerebrovascular accident 34 (24%) 18 (4%) <0.0001 2 (5%) 2 (5%) >0.99
Peripheral vascular disease 12 (9%) 31 (8%) 0.75 3 (7%) 4 (10%) >0.99
COPD 36 (26%) 54 (13%) 0.001 10 (24%) 8 (19%) 0.77
Pulmonary hypertension 17 (12%) 16 (4%) 0.001 2 (5%) 3 (7%) >0.99
Serum creatinine, mean ± SD 
(μmol/L)
116.6 ± 94.3 99.7 ± 55.7 0.011 104.7 ± 
92.2
102.8 ± 
64.6
0.92
MI within 90 days before 
procedure
31 (22%) 12 (3%) <0.0001 0 4 (10%) 0.13
COPD = chronic obstructive pulmonary disease; LVEF = left ventricular ejection fraction; MI = myocardial 
infarction; SAVR = surgical aortic valve replacement; TAVR = transcatheter aortic valve replacement
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standby time of the cardiothoracic surgeon during TAVR to be 50% of the total procedure 
time as he was unavailable for other surgeries. Salaries were obtained from the Manual and 
where necessary from collective agreements.7
Postoperative diagnostic tests included electrocardiography, laboratory tests, chest 
X-ray, cardiac ultrasound, coronary angiography, computed tomographic imaging, and 
lung scintigraphy. Additional procedures included chest drain placement, tracheostomy, 
reinterventions for pacemaker implantation, postdilatation of the transcatheter aortic valve, 
paravalvular leakage, sternal wound infection, and bleeding. Associated costs were retrieved 
using a micro-costing approach with data from financial subunits.
Data on length-of-stay (LOS), 1-year follow-up visits, and readmissions to the cardiology 
and neurology departments were collected through our electronic databases or databases 
from readmitting hospitals; where necessary the general practitioner was contacted. While 
TAVR patients were monitored in the academic hospital, SAVR patients were discharged to a 
general hospital to recover from surgery. After that, patients were usually discharged home. 
For TAVR patients, physician visits and tests were scheduled at 1 and 4 months after the ini-
tial procedure. Patients who underwent SAVR were referred to a general hospital for further 
follow-up. Hospital stay (€2,241, €591, and €447 per night for intensive care, academic 
ward stay, and general hospital ward stay, respectively) and follow-up costs were retrieved 
from the Manual.7 These general average costs were based on various micro-costing studies 
and include physician consultations, nursing, nutrition, materials, equipment, overhead, 
and housing.7
For the individual patient costs we combined the Manual with actual costs of tests, 
procedures and materials as described because in The Netherlands individually specified 
charge data are not available. No adjustment with a cost-to-charge ratio was needed as 
all costs were actual costs. Furthermore, administration and overhead, maintenance of the 
building, and equipment were taken into account. The health care perspective was applied 
and consumer price indices were used to convert all costs to the year 2011.8 The total costs 
at 1 year comprise the total in-hospital and follow-up costs.
Propensity score matching and statistical analysis
Comparison of the patient characteristics in the unmatched cohort was done using an 
unpaired t test for continuous variables and using a χ2 test or Fisher exact test for categoric 
variables. In the matched cohort, comparisons were performed using McNemar tests and 
paired sample t tests. Normality of the data was assessed using the Kolmogorov-Smirnov 
test and, if non-normality was proven, the Wilcoxon rank sum test was used. All tests were 
2-sided with anα-level of 0.05.
The propensity score of a patient is defined as the probability to receive the experimental 
treatment conditional on pretreatment covariables.9 After propensity score matching we 
expect TAVR and SAVR cohorts to have comparable baseline characteristics, providing a 
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fair comparison between groups.10 The propensity score for receiving TAVR was estimated 
using a multivariable probit (probability unit) model at a pvalue less than 0.10, including 
gender, age, and other baseline characteristics such as logistic European system for cardiac 
operative risk evaluation (EuroSCORE), diabetes, coronary artery disease, left ventricular 
ejection fraction, creatinine level, pulmonary hypertension, peripheral vascular disease, 
cerebrovascular disease, and chronic obstructive pulmonary disease. Subsequently, we 
performed Mahalanobis 1:1 matching, where a SAVR patient is matched to a randomly 
chosen TAVR patient using a caliper width of 0.05.11 The SAVR patients who were matched 
to a TAVR patient were no longer considered as a possible match. The resulting 42 matched 
pairs were used for the cost analysis.
Missing values were LOS in the intensive care unit (missing in 1 of 84 patients), length of 
ward stay (missing in 3), procedure time (missing in 3), and number of visits (missing in 1). 
The missing values were imputed by assuming they were the mean value of the non-missing 
values for that variable.12
Consistent with intention-to-treat analysis, in-hospital and follow-up costs were calcu-
lated by taking all patients (n = 84) into account, including those who died. To account for 
the skewed distribution of costs, we used bootstrap resampling to construct standard errors 
and confidence intervals of the mean costs for TAVR, SAVR, and the difference between 
treatments.13
Outliers in total costs at 1 year were defined by a Cook distance larger than 4/n, where 
n is the number of data points. We performed sensitivity analysis excluding outliers and 
their matched partners.14We also performed sensitivity analysis in a restricted dataset of 
matched pairs who did not undergo revascularization to deal with the unbalanced number 
of coronary revascularizations in the treatment groups. Analyses were performed by using 
Excel 2007 (Microsoft, Redmond, WA), SPSS for Windows (version 17.0.2; SPSS, Chicago, 
IL), and STATA 11.1 (Stata Corp, College Station, TX).
results
Patients and clinical outcomes
Baseline characteristics of the unmatched and matched cohorts are given in Table 1. The 
logistic EuroSCORE was 12.9 in the TAVR and 12.5 in the SAVR group, which reflects the 
intermediate operative risk. During SAVR, 20 patients underwent a concomitant coronary 
artery bypass grafting (CABG), whereas a concomitant percutaneous coronary intervention 
(PCI) during TAVR or as a staged procedure within the same hospital stay was performed in 
3 patients (Table 2). 
There were no conversions from TAVR to SAVR. Procedure duration and total LOS was 
shorter after TAVR than after SAVR (11.3 vs 18.8 days, respectively; Table 2). This was true 
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for both intensive care unit stay and ward stay, taking into account the stay in our academic 
hospital and in the general hospital to which the patient was discharged for recovery. In 
our propensity matched cohort no patients were discharged to a skilled nursing facility. We 
found no statistically significant difference in complications, mortality at 1 year, follow-up 
duration, readmissions, and outpatient clinic visits (Table 2 and Table 3).
In-hospital costs (table 4)
The in-hospital costs were higher with TAVR than SAVR (€40,802 vs €33,354, respectively). 
The largest difference was found in the procedure costs (€28,785 vs €13,096, respectively) 
and in-hospital stay (€8,481 vs €17,409, respectively). Procedural costs that were signify-
cantly dif-ferent between the treatment groups were operating room use, materials, and 
blood products.
table 2 Initial hospital stay
Parameter tAVr (n = 42) sAVr (n = 42) P Value
Procedure duration, mean ± SD 
(minutes)
229 ± 79 294 ± 76 <0.001
Concomitant PCI/CABG 3 (7%) 20 (48%) <0.001
Length of postoperative stay, mean ± SD
(days)
11.3 ± 8.1 18.8 ± 13.3 <0.001
ICU 1.1 ± 0.48 4.5 ± 8.2 <0.001
Ward staya 10.3 ± 8.2 14.3 ± 7.3 0.008
Ward academic
hospital
10.2 ± 8.0 7.1 ± 4.2 0.004
Ward general hospital 0.14 ± 0.93 7.2 ±6.6 <0.001
In-hospital complicationsb 22 (52%) 14 (33%) 0.08
Major stroke 4 (10%) 1 (2%) 0.38
Myocardial infarction 0 1 (2%) >0.99
Major bleeding 4 (10%) 5 (12%) >0.99
Major vascular 4 (10%) 0 0.13
Reintervention 2 (5%) 5 (12%) 0.45
Infection 7 (17%) 5 (12%) 0.77
Pacemaker 6 (14%) 1 (2%) 0.13
Pneumothorax 0 1 (2%) >0.99
In-hospital mortalityb 2 (5%) 3 (7%) >0.99
aAll patients were operated in the academic center. Patients who underwent TAVR were usually discharged home, 
whereas patients who underwent SAVR were usually discharged to a general hospital for recovery. bIn-hospital 
mortality is defined as death <30 days after procedure or death during initial hospital stay. CABG = coronary artery 
bypass graft; ICU = intensive care unit; MI = myocardial infarction; PCI = percutaneous coronary intervention; PPI 
= permanent pacemaker implantation; SAVR = surgical aortic valve replacement; TAVR = transcatheter aortic valve 
replacement
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Follow-up costs
The costs incurred during follow-up were nonsignificantly higher in the TAVR group than in 
the SAVR group (Δ costs = €3,258; Table 5). In addition, components of the follow-up costs 
were not significantly different. The total costs at 1 year were higher for TAVR than for SAVR 
(€46,217 vs €35,511, respectively; p = 0.009; Figure 1).
table 3 Follow-up
tAVr (n = 42) sAVr (n = 42) P Value
One-year follow-up death 7 (17%) 5 (12%) 0.73
Mean follow-up, mean ± SD (days) 332.1 ± 88 339.8 ± 88 0.51
Outpatient clinic visits, n of patients (%) 33 (79%) 35 (83%) 0.75
Number of outpatient clinic visits per patient, n ± SD 1.8 ± 1.8 2.0 ± 1.6 0.24
Hospital readmission during follow-upa, n of patients 8 (19%) 10 (24%) 0.80
Hospital readmissiona, days ± SD 5.3 ± 19.0 2.4 ± 7.7 0.86
aReasons for readmission included dyspnea, chest pain, endocarditis of the prosthesis, cardiac arrhythmias, 
additional dilatation of the valve, reoperation, transient ischemic attack, and heart failure. SAVR = surgical aortic 
valve replacement; TAVR = transcatheter aortic valve replacement
P = 0.01
p = 0.008
€ 35.511
€ 9.991
€ 13.096
Δ = € 10.706
p = 0.009
€ 46.217
€ 2.458
€ 28.785
1yr follow-up 
Additional procedures
Post-operative blood
Post-operative tests
Ward stay
ICCU stay
Procedure 
Pre-operative
€ 45.000
€ 40.000
€ 35.000
€ 30.000
€ 25.000
€ 20.000
€ 15.000
€ 10.000
  € 5.000
          € 0
  TAVR (n=42)                             SAVR (n=42)
Figure 1 total costs at 1 year; euros for year 2011
Blocks containing numbers represent cost components which differ significantly between treatment groups. ICU = 
intensive care unit; SAVR = surgical aortic valve replacement; TAVR = transcatheter aortic valve replacement
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sensitivity analyses
We identified 3 outliers due to prolonged postprocedural or readmission hospital stay. In 
a sensitivity analysis of the remaining 39 pairs we found similar results as in the original 
analysis for in-hospital costs (€39,945 vs €29,251; p < 0.001), follow-up costs (€3,426 vs 
€2,286; p = 0.37), and total costs at 1 year (€43,370 vs €31,537; p < 0.001) for TAVR and 
SAVR, respectively.
In the sensitivity analysis of 22 matched pairs who did not undergo revascularization we 
found in-hospital costs of €40,154 (standard error of the mean [SE] = 1,504) for TAVR and 
€26,776 (SE = 1,087) for SAVR (Δ costs = €13,378; p < 0.001). The total costs at 1 year were, 
respectively, €48,102 (SE = 4,800) and €29,349 (SE = 1,608) (p < 0.001).
dIscussIon
The results of our study suggest that TAVR is significantly more expensive than SAVR for 
intermediate-risk patients with aortic stenosis. This conclusion refers to both the in-hospital 
costs and the total costs at 1 year. The difference is mainly explained by the costs of materi-
als, which was roughly 4 times higher in TAVR than SAVR. The fact that the patients in the 
TAVR group were less costly with regard to blood products and LOS did not outweigh the 
difference in costs of materials (Figure 1). Furthermore, close monitoring of TAVR patients 
may explain the trend toward higher follow-up costs.
The costs of the procedure were higher for TAVR than for SAVR (Table 4), while procedure 
times with TAVR were shorter (Table 2). This can be explained by the more expensive equip-
ment in intervention rooms than in the operating room (€1.54 vs €4.91 per minute for TAVR 
and SAVR). However, room use is only a fraction of the overall procedural costs (Table 4).
We observed more revascularizations in patients undergoing SAVR because guidelines 
recommend concomitant CABG for patients with moderate to severe coronary artery dis-
ease;15 no such recommendations exist for TAVR. In the sensitivity analysis of matched pairs 
who did not undergo revascularization we found that the difference in costs between TAVR 
and SAVR was larger than in the original analysis. A concomitant procedure such as CABG 
is likely to make SAVR more expensive as the procedure and hospital stay may take longer 
and the complication rate is higher.16 However, PCI in addition to TAVR has shown to be of 
less influence on procedural and midterm outcomes.17 From an economic perspective, an 
additional advantage for SAVR is to be expected if PCI and TAVR are performed as staged 
procedures.
The transcatheter valve is currently priced at €17,590, whereas the surgical aortic bio-
prosthesis costs only €2,700. With more valves being developed, market forces are likely to 
decrease the price of transcatheter valves, similar to the trend previously seen in coronary 
stents.18 Using the mean difference in costs at 1 year and the price of the transcatheter 
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valve, we calculated that the valve would have to be priced at €6,884 to be a cost neutral 
alternative for SAVR.
One other study reported the costs of TAVR, showing quite different estimates compared 
with our results.19 The discordance with our study might be caused by different cost cal-
culation methods, which were briefly described and partly based on a costing study of 
percutaneous pulmonary valves. In studies that used the in-hospital costs for SAVR, the 
table 4 In-hospital costs
tAVr (n = 42) sAVr (n = 42) P Value
Preoperative costs 2,024 ± 0 1,538 ± 0
Procedure costs 28,785 ± 1,014 13,096 ± 315 <0.001
Operating room use 1,124 ± 60 453 ± 18 <0.001
Personnel 2,303 ± 117 2,413 ± 90 0.41
Materials 22,055 ± 869 5,162 ± 0 <0.001
Blood products 176 ± 41 1,869 ± 233 <0.001
Overhead and
housing
3,127 ± 48 3,181 ± 38 0.40
Total stay 8,545 ± 776 17,409 ± 3,116 <0.001
ICU stay 2,458 ± 168 9,991 ± 2,280 0.008
Ward staya 6,087 ± 733 7,418 ± 544 0.087
Academic hospital 6,023 ± 715 4,208 ± 370 0.016
General hospital 64 ± 64 3,210 ± 446 <0.001
Postoperative tests 545 ± 50 674 ± 108 0.31
Postoperative blood products 136 ± 43 63 ± 27 0.17
Additional procedures 768 ± 273 573 ± 209 0.56
Total in-hospital costs 40,802 ± 1,399 33,354 ± 3,357 0.010
All costs are in Euros for the year 2011. aAll procedures were performed in the academic center. TAVR patients 
were usually discharged home, whereas SAVR patients were usually discharged to a general hospital for recovery. 
The subdivision of ward stay reflects this difference. ICU = intensive care unit; SAVR = surgical aortic valve 
replacement; TAVR = transcatheter aortic valve replacement
table 5 one-year follow-up costs
tAVr (n = 42) sAVr (n = 42) P Value
Visit costs 182 ± 28 135 ± 16 0.10
Visit diagnostic tests 582 ± 86 587 ± 69 0.97
Readmission hospital stay 3,336 ± 1,882 1,086 ± 528 0.25
Readmission procedures 1,168 ± 589 245 ± 172 0.13
Readmission diagnostic tests 146 ± 59 104 ± 41 0.58
Total 1-year follow-up 5,414 ± 2,224 2,157 ± 627 0.17
All costs are in Euros for the year 2011. SAVR = surgical aortic valve replacement; TAVR = transcatheter aortic 
valve replacement
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estimates were also quite different from our results.16, 20 However, comparison is difficult as 
none of these studies primarily focused on costs and therefore the methodology for assessing 
costs varied and was not very detailed.
We have found no published report that compared costs in TAVR versus SAVR in 
intermediate-risk patients. In the high-risk patients of the PARTNER (Placement of Aortic 
Transcatheter Valve) trial the total costs at 1-year follow-up were higher than the costs in 
our study.4 Moreover, there was no significant difference in costs between TAVR and SAVR. 
In comparison with our results, the nonprocedural costs were higher, whereas the LOS and 
other resource use were similar. Differences might therefore be attributed to higher costs of 
hospital stay in the United States.21
Using our results we can make some crude statements on the cost effectiveness of TAVR 
versus SAVR. The PARTNER trial showed a quality-of-life gain of 0.068 at 1 year for TAVR 
as compared with SAVR.4 Combining our cost results with this quality-of-life gain yields 
an ICER (incremental cost-effectiveness ratio) of around €150,000 per quality-adjusted life 
year saved, which in general is considered higher than the threshold willingness-to-pay. 
Although ICERs should be calculated using life-time costs, 1-year follow-up costs in our 
study were similar for the 2 treatments and show that periprocedural costs will be the driver 
of cost effectiveness of TAVR. However, more elaborate analyses are needed to confirm 
these results.
limitations
Cost data were not based on a randomized trial but were retrospectively collected from 
a relatively small single-center observational study. However, economic data from well-
performed observational studies are equally valuable to policy makers as such data reflect 
the real-life economic consequences of new treatments.22 Moreover, industry sponsored 
economic evaluations alongside trials are more likely to report favorable results,23 increas-
ing the value of independent economic observational studies.
To overcome the limitation that our study was not randomized, we used propensity 
score matching. This technique corrects for measured confounders but there may have been 
unmeasured confounding in our study. However, we used a very conservative caliper in 
the matching process while other studies have used wider margins.24Thestatistically similar 
clinical outcomes in the matched cohort allow for a valid cost comparison between the 
groups.
Because propensity score matching does not take into account procedural variables, 
it was possible that we found an imbalance in the concomitant revascularization rate. A 
regression model could adjust for this imbalance but makes assumptions on the distribution 
of the outcome variable and would require more revascularizations in the TAVR group. 
Due to the skewed nature of cost variables and the small sample size, the distribution free 
bootstrap method is preferred.13
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Since 2005 our center has performed roughly 250 TAVRs, whereas there is a multitude of 
experience with SAVR. This may result in longer procedures, more personnel being present, 
and longer hospital stay. As experience with TAVR in intermediate-risk patients develops, 
and with the refinement of techniques and protocols, it is likely that costs, LOS, and com-
plication rates will decrease.
The logistic EuroSCORE was used as a matching variable and indicator of operative risk. 
The score fails to include factors such as porcelain aorta, frailty, chest deformities, and 
malnutrition. Therefore we might have underestimated the operative risk of TAVR patients, 
leading to higher costs in this group. It is unlikely that this affected the main conclusion of 
our study as the cost of the transcatheter valve is the main cause of the difference in costs 
between the 2 groups.
In the current study the costs were specific for Dutch centers. However, our results may 
be translated to other countries using regression techniques.25These models can adjust for 
differences in the cost of medical treatments due to demography, epidemiologic factors, and 
differences in medical practice, resource use, and funding of health care.
conclusIons
For intermediate-risk patients with severe aortic stenosis the costs at 1 year are higher for 
TAVR than for SAVR. The difference was mainly caused by the higher costs of the transcath-
eter valve and was not compensated by the lower costs for blood products and hospital 
stay in TAVR patients. Therefore, SAVR remains a clinically and economically attractive 
treatment option.
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AbstrAct
Objectives
The aim of this study was to evaluate the use of percutaneous coronary intervention (PCI) 
and coronary artery bypass grafting (CABG) in “real-world” patients unsuitable for the 
alternative treatment.
Background
No data are available on the risk profile and outcomes of patients that can only undergo 
PCI or CABG.
Methods
In the SYNTAX (Synergy between PCI with TAXUS and Cardiac Surgery) trial, a multi-
disciplinary Heart Team reached a consensus on whether PCI and CABG could result in 
clinical equipoise; if so, the patient was randomized. If not, the patient was enrolled in a 
CABG-ineligible PCI registry or PCI-ineligible CABG registry. A proportion (60%) of patients 
in the CABG registry was randomly assigned to be followed up for 5 years. No statistical 
comparisons were performed between randomized and registry patients. Major adverse 
cardiac or cerebrovascular event (MACCE) rates are presented as observational only.
Results
A total of 3,075 patients were treated in the SYNTAX trial; 198 (6.4%) and 1,077 (35.0%) 
patients were included in PCI and CABG registries, respectively. The main reason for inclu-
sion in the CABG registry was too complex coronary anatomy (70.9%), and the main reason 
for inclusion in the PCI registry was too high-risk for surgery (70.7%). Three-year MACCE 
was 38.0% after PCI and 16.4% after CABG. Stratification by SYNTAX score terciles demon-
strated a step-wise increase of MACCE rates in both PCI and CABG registries.
Conclusions
The SYNTAX Heart Team concluded that PCI and CABG remained the only treatment options 
for 6.4% and 35.0% of patients, respectively. Inoperable patients with major comorbidities 
that underwent PCI had high MACCE rates. In patients not suitable for PCI, surgical results 
were excellent. (SYNTAX Study: NCT00114972)
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IntroductIon
Since the 1980s, coronary artery bypass graft surgery (CABG) is the treatment of choice for 
patients with multivessel and/or left main (LM) coronary artery disease. Numerous trials 
have compared CABG with percutaneous coronary intervention (PCI) but have not been 
able to produce favorable outcomes after PCI due to an excess in repeat revascularization.1
The recent SYNTAX (Synergy between PCI with TAXUS and Cardiac Surgery) trial showed 
that CABG remains superior to PCI, even with the usage of drug-eluting stents (DES).2 It 
has been demonstrated that PCI is as effective as CABG in subgroups of patients with less 
complex coronary artery disease and LM lesions.2-4 Other recent trials have confirmed more 
favorable outcomes with CABG.5, 6
Although CABG is still the gold standard, there are some patients who cannot undergo 
surgery. In addition, a proportion of patients are not eligible for PCI. The SYNTAX study was 
designed as an all-comers trial, but patients could be excluded if the Heart Team concluded 
that either PCI or CABG could not be performed.2, 7 This decision was based on a team 
judgment and not on predefined criteria. Excluded patients were entered in a CABG registry 
to define the population at too high-risk for PCI and in a PCI registry to define the patients 
deemed unsuitable for surgery. Little is known of the characteristics and outcomes of these 
populations. Separate analysis is necessary to fully understand the strengths and limitations 
of PCI and CABG in the “real world”.8 
This study presents characteristics and 3-year outcomes of patients that were deemed 
nonrandomizable and therefore were included in the SYNTAX PCI and CABG nested reg-
istries.
Methods
study design
The SYNTAX trial design has been described previously.2, 9 In brief, patients with 3-vessel or 
LM coronary artery disease were screened for enrollment in the randomized trial. During a 
multidisciplinary Heart Team discussion, including at least 1 surgeon and 1 interventional 
cardiologist, consensus was reached on whether both PCI and CABG would result in clinical 
equipoise.7 If a patient was not eligible for randomization, the patient was enrolled in the 
nested registry for CABG-ineligible patients (PCI registry) or PCI-ineligible patients (CABG 
registry).
Patients in the PCI registry were treated according to local practices with regard to tech-
nique and device preference, either with or without DES.
To compare the risk profile and outcomes of patients in the registries with the randomized 
arms, a randomly selected proportion of patients from the CABG registry and all PCI registry 
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patients were scheduled to undergo clinical follow-up at 1, 6, 12, 36, and 60 months after 
treatment allocation.9
The study protocol was approved by the institutional review board of all 85 enrollment 
sites and is consistent with the International Conference on Harmonisation Guidance of 
Industry E6 Good Clinical Practice, the Declaration of Helsinki, and all local regulations. 
Written consent was obtained from all participating patients. SYNTAX is registered at Clini-
calTrials.gov (NCT00114972).
definitions
The primary outcome of this study was the composite of major adverse cardiac or cerebro-
vascular events (MACCE) at 3 years of follow-up. MACCE included all-cause death, stroke, 
myocardial infarction (MI), and any repeat revascularization. The composite safety endpoint 
consisting of all-cause death, stroke, and MI, was also analyzed as well as individual out-
comes. Adverse events were adjudicated by an independent Clinical Events Committee.
Definitions have been reported elsewhere.4 Briefly, stroke was defined as a focal neuro-
logical deficit of central origin lasting >72 h resulting in permanent brain damage or body 
impairment. Myocardial infarction was defined in relation to intervention status as follows: 
1) after allocation but before treatment: Q-wave MI (new pathological Q waves in ≥2 leads 
lasting ≥0.04 s with creatine kinase-myocardial band [CK-MB] levels elevated above nor-
mal) and non–Q-wave MI [elevation of CK levels >2× the upper limit of normal [ULN] with 
positive CK-MB or elevation of CK levels to >2 × ULN without new Q waves if no baseline 
CK-MB was available); 2) <7 days after intervention: new Q waves and either peak CK-MB/
total CK >10% or plasma level of CK-MB 5 × ULN; and 3) ≥7 days after intervention: new 
Q waves or peak CK-MB/total CK >10% or plasma level of CK-MB 5 × ULN or plasma level 
of CK 5 × ULN (4).
statistical analysis
Analyses were performed with SAS system software, version 8.0 or higher (SAS Institute, 
Cary, North Carolina). Outcomes are presented according to the as-treated-principle. The 
composite MACCE endpoint was analyzed as the time to the first event, whereas individual 
MACCE components are presented as proportions. Patient characteristics are presented as 
proportions (%, count/sample size) or mean ± SD.
We decided that no statistical comparisons between PCI and CABG should be performed, 
because entry into the registries depended on different variables specific for the correspond-
ing registry. Thus, the patient characteristics and outcomes are only representative of patients 
ineligible to undergo PCI or CABG. Results are presented as observational only.
Subgroup analyses of separate SYNTAX score cohorts (low 0 to 22, intermediate 23 to 
32, and high ≥33) were performed.10 The assessment of coronary anatomic complexity by 
SYNTAX score was based on tercile cohorts established in the randomized trial.2 Statistical 
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comparison was performed by overall and pairwise log-rank testing, with a 2-sided p value 
<0.05 considered statistically significant.
results
Inclusion
Between March 2005 and April 2007, a total of 4,337 patients were screened for eligibility 
of enrollment in the trial. After exclusion due to variable reasons (e.g., refusal of informed 
consent or concomitant valvular heart disease, among others), a total of 3,075 patients 
were treated within the SYNTAX trial. In the trial 1,800 patients were randomly assigned to 
undergo PCI (n = 903) and CABG (n = 897). Another 198 (6.4%) and 1,077 (35.0%) patients 
were included in the PCI and CABG registries, respectively (Figure 1). From the 1,077 in the 
CABG registry, 649 were randomly selected to be followed-up for 5 years.
Of the 198 patients in the PCI registry, 192 were treated with PCI, 4 patients were treated 
medically, 1 underwent CABG, and 1 patient withdrew consent. Of the 649 CABG registry 
patients randomly assigned to 5-year follow-up, 644 were treated with CABG, 3 did not 
receive treatment, and 2 were managed medically. Another 9 patients were lost to follow-
up, and 3 patients withdrew consent. Three-year MACCE rates were evaluable in 100% and 
97.2% of the PCI and CABG patients, respectively.
Patients included in the PCI registry were considered too high-risk for CABG (70.7%), 
had no graft material for anastomosis (9.1%), refused CABG (5.6%), had small or poor 
quality of distal vessels (1.5%), or were excluded from randomization because of other 
reasons (13.1%). Reasons for inclusion in the CABG registry included too complex coronary 
anatomy to undergo PCI (70.9%), chronic total occlusion untreatable with PCI (22.0%), 
Randomized	  
PCI	  Registry	  
CABG	  Registry	  
Figure 1 sYntAX patient distribution
CABG = coronary artery bypass grafting; PCI = percutaneous coronary intervention; SYNTAX = synergy between 
PCI with TAXUS and cardiac surgery
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unable to take antiplatelet medication (0.9%), refusal to undergo PCI (0.5%), or other rea-
sons (5.7%).
Patient characteristics
In general, compared with the patients that were randomized in the SYNTAX trial, the 
patients in the PCI registry were older (71.2 ± 10.4 years vs. 65.2 ± 9.7 years) and had a 
high-risk profile because of comorbidities and an eventful cardiovascular and noncardio-
vascular history; this was manifested in a higher Logistic EuroSCORE of 7.7 ± 9.0 (vs. 3.8 
± 4.5 in the randomized PCI group) and Parsonnet score of 14.4 ± 9.5 (vs. 8.5 ± 7.0 in 
the randomized PCI group) (Table 1). In addition, the lesion complexity by SYNTAX score 
was 31.6 ± 12.3 in the PCI registry, which was slightly higher than the 28.4 ± 11.5 in the 
randomized PCI group. A total occlusion was present in 36.5%, whereas this rate was only 
24.2% in the trial.
table 1 baseline patient demographics and lesion characteristics
PcI (n=192) cAbG
With follow-up 
(n=644)
All (n=1072)
Age, years 71.2 ± 10.4 (192) 65.7 ± 9.4 (644) 65.9 ± 9.4 (1072)
Male sex 70.3% (135/192) 80.7% (520/644) 81.1% (869/1072)
Characteristic
Body-Mass Index (kg/m2) 28.0 ± 5.5 (191) 28.0 ± 4.6 (643) 28.0 ± 4.6 (1069)
Medically treated diabetes
Any 35.4% (68/192) 29.7% (191/644) 30.3% (325/1072)
Requiring insulin 15.1% (29/192) 9.2% (59/644) 9.2% (99/1072)
Triglycerides ≥150 mg/dl (1.7 mmol/liter) 33.6% (37/110) 39.6% (114/288) 40.4% (182/451)
Blood pressure ≥130/85 mmHg 69.8% (134/192) 68.5% (441/644) 68.9% (735/1067)
Fasting Glucose ≥110 mg/dl 47.2% (67/142) 49.8% (210/422) 49.7% (338/680)
Increased waist circumference 40.8% (58/142) 46.4% (245/528) 48.1% (414/861)
Hyperlipidemia 67.5% (129/191) 76.4% (480/628) 77.1% (809/1049)
Current smoker 11.2% (21/188) 21.9% (140/639) 19.7% (209/1062)
Previous myocardial infarction 40.4% (76/188) 33.5% (211/629) 32.5% (341/1049)
Previous stroke 7.8% (15/192) 5.5% (35/639) 4.5% (48/1065)
Previous transient ischemic attack 7.9% (15/191) 5.6% (36/638) 6.0% (64/1062)
Previous cardiac surgery 1.6% (3/192) 0.0% (0/644) 0.0% (0/1072)
Congestive heart failure 9.7% (18/186) 5.5% (35/633) 5.1% (54/1057)
Peripheral vascular disease 16.1% (31/192) 13.8% (89/644) 12.5% (134/1072)
Carotid artery disease 10.4% (20/192) 12.3% (79/644) 10.2% (109/1072)
Creatinine >200 micromol/liter 5.7% (11/192) 2.0% (13/644) 2.1% (23/1072)
Chronic obstructive pulmonary disease 19.3% (37/192) 7.9% (51/644) 7.3% (78/1072)
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Patients in the CABG registry had a Logistic EuroSCORE comparable to the CABG patients 
in the randomized trial (4.0 ± 4.4 vs. 3.9 ± 4.4 in the randomized trial) as well as a similar 
mean Parsonnet score (9.0 ± 7.1 vs. 8.4 ± 6.8 in the randomized CABG group) (Table 1). 
However, the lesions were more complex in the registry: the SYNTAX score was 37.8 ± 13.3 
in the registry versus 29.1 ± 11.4 in the randomized trial. A total occlusion was present in 
56.4% versus 22.2% in the randomized trial. More patients had LM and 3-vessel disease in 
the registry (27.6% vs. 13.0% in the trial).
Procedural characteristics
In the PCI registry, a mean of 2.5 ± 1.3 lesions were treated with 3.1 ± 1.8 stents and a mean 
total length of 58.5 ± 41.2 mm. This is much lower than in the randomized trial where 3.6 ± 
1.6 lesions were treated with 4.6 ± 2.3 stents and a mean length of 86.1 ± 47.9 mm. In 76% 
of cases a DES stent (57% TAXUS) was used. Completeness or revascularization was only 
36.5% in the registry compared with 56.7% in the trial.
table 1 Continued
PcI (n=192) cAbG
With follow-up 
(n=644)
All (n=1072)
Angina
Stable 46.4% (89/192) 62.9% (405/644) 63.3% (678/1071)
Unstable 38.0% (73/192) 21.6% (139/644) 22.5% (241/1071)
Ejection fraction <30% 5.7% (11/192) 4.5% (29/644) 3.9% (42/1072)
Logistic EuroSCORE 7.7 ± 9.0 (192) 4.0 ± 4.4 (644) 4.0 ± 4.8 (1072)
Additive EuroSCORE 5.8 ± 3.1 (192) 3.9 ± 2.7 (644) 3.9 ± 2.7 (1072)
Parsonnet score 14.4 ± 9.5 (192) 9.0 ± 7.1 (644) 9.1 ± 7.2 (1072)
Lesion complexity
SYNTAX score 31.6 ± 12.3 (189) 37.8 ± 13.3 (632) Not available
Diffuse disease or small vessels 18.5% (35/189) 13.6% (86/631) Not available
Total occlusion 36.5% (69/189) 56.4% (356/631) Not available
Bifurcation 74.6% (141/189) 80.8% (510/631) Not available
Lesion characteristics
Number of lesions 4.5 ± 1.8 (189) 4.6 ± 1.7 (632) Not available
Left main, any 33.3% (63/189) 40.3% (254/631) Not available
Left main only 2.6% (5/189) 1.6% (10/631) Not available
Left main + 1 vessel 5.8% (11/189) 2.7% (17/631) Not available
Left main + 2 vessel 11.6% (22/189) 8.4% (53/631) Not available
Left main + 3 vessel 13.2% (25/189) 27.6% (174/631) Not available
Three vessel disease only 66.7% (126/189) 59.7% (377/631) Not available
CABG = coronary artery bypass grafting; PCI = percutaneous coronary intervention
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A total of 3.0 ± 0.9 conduits were used per CABG patient (vs. 2.8 ± 0.7 in the random-
ized trial), of which 1.3 ± 0.7 were arterial and 1.7 ± 1.0 venous grafts. Complete arterial 
revascularization was performed in 11.2% compared with 18.9% in the randomized trial. 
table 2 Perioperative medication use
PcI (n=192) cAbG (n=644)
Aspirin
Baseline 83.3% (160/192) 74.7% (481/644)
Discharge 92.7% (178/192) 88.4% (569/644)
Thienopyridine
Baseline 71.9% (138/192) 16.1% (104/644)
Discharge 92.7% (178/192) 16.9% (109/644)
Nonthienopyridine antiplatelet
Baseline 9.9% (19/192) 8.7% (56/644)
Discharge 6.8% (13/192) 6.1% (39/644)
Warfarin derivative
Baseline 4.7% (9/192) 3.9% (25/644)
Discharge 3.6% (7/192) 9.6% (62/644)
Statin
Baseline 64.1% (123/192) 70.0% (451/644)
Discharge 71.9% (138/192) 68.3% (440/644)
Beta-blocker
Baseline 67.7% (130/192) 77.3% (498/644)
Discharge 70.3% (135/192) 79.3% (511/644)
ACE inhibitor
Baseline 43.8% (84/192) 47.2% (304/644)
Discharge 54.2% (104/192) 45.2% (291/644)
Calcium-channel blocker
Baseline 30.2% (58/192) 27.8% (179/644)
Discharge 27.1% (52/192) 21.9% (141/644)
Angiotensin II-receptor antagonist
Baseline 16.1% (31/192) 11.3% (73/644)
Discharge 12.5% (24/192) 5.3% (34/644)
Anti-arrythmic (Amiodarone)
Baseline 1.6% (3/192) 2.5% (16/644)
Discharge 2.6% (5/192) 12.3% (79/644)
H2-recepter blocker
Baseline 4.7% (9/192) 8.9% (57/644)
Discharge 8.9% (17/192) 19.9% (128/644)
ACE = angiotensin-converting enzyme; CABG = coronary artery bypass grafting; PCI = percutaneous coronary 
intervention
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In 96.7% at least 1 arterial graft was used; in the randomized trial this rate was 97.3%. 
Off-pump surgery was performed slightly more often in the registry (18.6% vs. 15.0% in the 
trial). Completeness of revascularization was 74.7% in the registry, compared with 63.2% 
in the trial.
Mean post-procedure hospital stay was 8.2 ± 5.5 days and 4.8 ± 12.0 days in the CABG 
and PCI registries, respectively. Perioperative medication use is displayed in Table 2.
PcI outcomes
Procedural 30-day MACCE occurred in 7.6% of the patients (Table 3). This was mainly 
driven by the 3.1% death rate and 3.6% MI rate. After 3 years of follow-up, the MACCE rate 
was 38.0% (Figure 2 and Table 3), with 18.3% death, 8.4% MI, 1.8% stroke, and 20.0% 
repeat revascularization (repeat PCI 17.8%, and repeat CABG 2.8%).
According to the SYNTAX score terciles, 44 patients had low lesion complexity (mean 
SYNTAX score 16.5 ± 5.1), 63 patients had intermediate complexity (mean SYNTAX score 
27.7 ± 2.8), and 82 patients had high complexity (mean SYNTAX score 42.4 ± 9.2). Subgroup 
analyses revealed a MACCE rate of 29.5% in the cohort with a score ≤22 and increasing 
rates with intermediate (33.3%) and high (46.3%) scores (overall p = 0.09) (Figure 3A). Dif-
ference in MACCE was not statistically significant between the low- and intermediate-score 
groups (p = 0.64) and intermediate- and high-score groups (p = 0.11). There was a trend 
toward a difference between the low- and high-score groups (p = 0.06). Breaking down 
MACCE into separate endpoints (Figure 4A), there was a significant difference between the 
groups in terms of the composite safety endpoint of death, stroke, and MI (13.9% vs. 32.9% 
and 20.6% vs. 32.9%, p = 0.04), which was driven by increased rates of death in the high 
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Figure 2 cumulative incidence of MAcce after PcI or cAbG
CABG = coronary artery bypass grafting; MACCE = major adverse cardiac or cerebrovascular event(s); PCI = 
percutaneous coronary intervention
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SYNTAX score group (24.4% vs. 9.3% in the low SYNTAX score group, p = 0.04). Other 
endpoints were comparable between groups (Figure 4A).
cAbG outcomes
Procedural outcomes after CABG showed low rates of MACCE (3.4%), for the composite 
safety endpoint of death/stroke/MI (3.3%), and the individual components of MACCE: stroke 
(1.2%), MI (1.6%), and repeat revascularization (0.3%) (Table 2). After 3 years, the MACCE 
rate was 16.4% (Figure 2 and Table 3).
Patients were divided into low lesion complexity (n = 68, SYNTAX score 16.8 ± 4.1), 
intermediate complexity (n = 161, SYNTAX score 28.2 ± 2.7), and high complexity (n = 403, 
SYNTAX score 45.2 ± 10.1). Subgroup analysis demonstrates a stepwise increase in MACCE 
with higher SYNTAX score; 9.0% in the low-, 13.8% in the intermediate-, and 18.3% in the 
high-score cohorts (overall p = 0.10) (Figure 3B). Pairwise testing demonstrated no statisti-
cally significant differences (low vs. intermediate, p = 0.32; intermediate vs. high, p = 0.19; 
low vs. high, p = 0.07). Individual MACCE components were not statistically significant 
between groups, except for the endpoint of death where there was a difference between the 
intermediate and high score groups (p = 0.03) (Figure 4B).
table 3 outcomes of patients in the PcI and cAbG registries
PcI (n=192) cAbG (n=644)
 30 
days
6 
Months
1 Year 3 Years 30 
days
6 
Months
1 Year 3 Years
Composite MACCE 7.3% 
(14)
14.1% 
(27)
20.4% 
(39)
38.0% 
(73)
3.4% 
(22)
6.7% 
(43)
8.8% 
(56)
16.4% 
(104)
Composite death/stroke/
MI
6.3% 
(1)
8.4% 
(16)
10.5% 
(20)
24.6% 
(47)
3.3% 
(21)
5.8% 
(37)
6.6% 
(42)
12.6% 
(80)
Death 3.1% 
(6)
5.2% 
(10)
7.3% 
(14)
18.3% 
(35)
0.6% 
(4)
2.2% 
(14)
2.5% 
(16)
6.9% 
(44)
Cardiac death 2.6% 
(5)
3.7% 
(7)
4.7% 
(9)
7.0% 
(13)
0.5% 
(3)
1.4% 
(9)
1.4% 
(9)
2.5% 
(16)
Stroke 0.0% 
(0)
0.0% 
(0)
0.0% 
(0)
1.8% 
(3)
1.2% 
(8)
2.0% 
(13)
2.2% 
(14)
3.8% 
(24)
Myocardial infarction 3.6% 
(7)
3.7% 
(7)
4.2% 
(8)
8.4% 
(15)
1.6% 
(10)
2.2% 
(14)
2.5% 
(16)
3.7% 
(23)
Repeat revascularization, 
any
1.6% 
(3)
7.3% 
(14)
12.0% 
(23)
20.0% 
(36)
0.3% 
(2)
1.4% 
(9)
3.0% 
(19)
5.7% 
(35)
PCI 1.0% 
(2)
6.8% 
(13)
11.0% 
(21)
17.8% 
(32)
0.2% 
(1)
1.3% 
(8)
2.8% 
(18)
5.5% 
(34)
CABG 0.5% 
(1)
0.5% 
(1)
1.0% 
(2)
2.8% 
(5)
0.2% 
(1)
0.2% 
(1)
0.2% 
(1)
0.2% 
(1)
CABG = coronary artery bypass grafting; MACCE = major adverse cardiac or cerebrovascular events; MI = 
myocardial infarction; PCI = percutaneous coronary intervention
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dIscussIon
The SYNTAX nested registries presented in this study are important to complete the knowl-
edge of the current use of PCI and CABG for 3-vessel or LM coronary artery disease in 
the real world. The SYNTAX randomized trial, among other trials, included only selective 
patients in whom both PCI and CABG could be performed with satisfactory results. Those 
patients not suitable for randomization are crucial to fully understand the indications, 
strengths, and limitations of PCI and CABG, with the corresponding outcomes. In this study 
we showed that the Heart Team decided that 35.0% of patients were not suitable for PCI and 
therefore underwent CABG. Patients were deemed inoperable and received PCI treatment 
in 6.4% of the cases.
other studies
Patients in these registries were selected on the basis of clinical judgment of a multidis-
ciplinary team of physicians.7 Results from other studies cannot be compared with the 
SYNTAX registry results, because this study presents patients in whom only 1 treatment 
option was considered appropriate. Therefore these patients represent not the total PCI or 
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Figure 3 MAcce after PcI or cAbG stratified by sYntAX score
Kaplan-Meier incidence of MACCE in the PCI registry (A) and CABG registry (B). CABG = coronary artery bypass 
grafting; MACCE = major adverse cardiac or cerebrovascular event(s); PCI = percutaneous coronary intervention
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CABG cohort but only a selected group with different baseline risk and lesion complexity. 
Many patients receiving either PCI or CABG in other studies would probably have been 
randomized in the SYNTAX trial.2
PcI registry
Patients in the SYNTAX PCI registry present a completely different patient population as the 
patients described in other registries or trials.1, 2, 11-13 First, the mean age was 71.2 ± 10.4, 
and nearly 75% of patients were ≥65 years of age; thus patients were significantly older. 
Second, patients more often presented with an eventful cardiac and noncardiac history. The 
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Figure 4 outcomes within the PcI and cAbG registries stratified by sYntAX score
Event rates in the PCI registry (A) and CABG registry (B). *p < 0.05 for low versus high SYNTAX Score group 
comparison. †p < 0.05 for intermediate versus high SYNTAX Score group comparison. CABG = coronary artery 
bypass grafting; Composite = composite of death/stroke/myocardial infarction; MACCE = major adverse cardiac or 
cerebrovascular event(s); MI = myocardial infarction; PCI = percutaneous coronary intervention
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mean Logistic EuroSCORE was higher in the registry (7.7 ± 9.0) than in the randomized arm 
(3.8 ± 4.5) as well as the Parsonnet score (14.4 ± 9.5 compared with 8.5 ± 7.0, respectively).
Indeed, the 3-year 38.0% MACCE rate in the PCI registry was much higher than the 
28.0% in the randomized trial. However, this is not unexpected, due to the advanced age 
and severe comorbidities. Both the EuroSCORE and Parsonnet score have been associated 
with increased rates of adverse events during follow-up.13-15 In addition, some of the patients 
were included in the PCI registry because they had cancer or other severe diseases. This 
could be one of the reasons that the death rate is very high.
The high-risk profile of these PCI patients was influential in choosing the treatment strategy. 
Fewer lesions were stented and the number of stents that were used was much lower. It might 
be the case that only the culprit lesion was stented, whereas other lesions remained untreated, 
resulting in a 63.5% rate of incomplete revascularization in the registry. Also, 24% of patients 
received a bare-metal stent; this might have had an influence on the results as well.16
cAbG registry
Patients included in the CABG registry represent a population completely different from 
the patients in the PCI registry. Where in the PCI registry patients were high-risk but had 
similar lesion complexity, in the CABG registry it was the exact opposite. Patients had a 
similar mean EuroSCORE (4.0 ± 4.4 vs. 3.9 ± 4.4) and Parsonnet score (9.0 ± 7.1 vs. 8.4 ± 
6.8) as the randomized patients. However, they were most often denied PCI because of too 
complex coronary anatomy, demonstrated in a higher SYNTAX score (37.8 ± 13.3 vs. 29.1 
± 11.4), more patients with a total occlusion (56.4% vs. 22.2%), and a slightly higher rate 
of bifurcation (80.8% vs. 73.3%).
The 3-year MACCE rate in the CABG registry (16.4%) is actually lower than in the ran-
domized patients (20.2%), which was caused by lower rates of repeat revascularization.4, 17 
Interestingly, however, the actual difference in MACCE rates between the registry and trial 
do not increase over follow-up. At 1 year the difference was 3.2%, and at 3 years this was 
still only 3.8%. Therefore, it seems that the registry patients did significantly better especially 
during short-term follow-up. This was confirmed by a trend in lower rates of hospital and 
30-day MACCE rates in the registry patients.17 This lower incidence of MACCE cannot be 
described by a difference in risk profile, because patients had similar risk. A previous study 
showed that it was likely related to procedural characteristics.17 In the registry, patients had 
a 74.7% rate of complete revascularization, whereas this was only 63.2% in the randomized 
trial. Furthermore, the number of grafts and distal anastomoses per patient was higher, which 
was identified to be independently associated with reduced rates of MACCE.17
sYntAX score
Since 2009, a large number of studies have tested the accuracy of the SYNTAX score as a 
risk algorithm in predicting adverse outcomes. A recent review summarized these data and 
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concluded that, especially in LM patients treated with PCI, the score is a useful prognostic 
tool.18 Although Birim et al. 19 reported a stepwise increase in MACCE rates with higher 
SYNTAX scores, in patients treated with CABG generally less discriminative power could be 
attributed to the SYNTAX score. Remarkably, this study shows that in both PCI and CABG 
patients a stepwise increase of MACCE rates can be seen with higher SYNTAX scores, 
although this was not statistically significant in the CABG registry.
There was, however, a significant difference in death between the intermediate- and 
high-score groups. A hypothesis behind this finding is that in the high SYNTAX score group 
more patients with extreme high scores were present. Although the predictive power of the 
SYNTAX score is limited in CABG patients, with extreme scores it is likely that ultimately the 
score will identify those patients at higher risk. The fact that death did not increase stepwise 
from low- to high-score groups demonstrates that the increased death in cohort with scores 
≥33 might be caused by these extreme cases. Furthermore, these intragroup comparisons 
are post hoc subgroup analyses with relatively low statistical power, thus a change finding 
cannot be ruled out.
study limitations
It is important to recognize that an emphasis should lay on long-term results after PCI and 
CABG. From this study, follow-up is only available up to 3 years. Ongoing prospective data 
collection will provide 5-year results.
The PCI registry contains a relatively small number of patients. Therefore some of the 
results should be interpreted with caution. Furthermore, explorative subgroup analyses by 
lesion subsets could not performed, due to the low patient number in separate groups.
conclusIons
In the SYNTAX trial the Heart Team concluded that, for 6.4% and 35.0% of patients, the 
only treatment option was PCI or CABG, respectively. Patients with complex coronary 
anatomy often underwent CABG, whereas inoperable high-risk patients were included in 
the PCI registry. Patients deemed inoperable for CABG had a high-risk profile, resulting in 
a suboptimal outcome after PCI. In patients who are not candidates for PCI, bypass surgery 
produces excellent results. To identify those patients at high risk for MACCE, the SYNTAX 
score discriminates well.
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Chapter 19
Incidence, predictors, and outcomes of incomplete 
revascularization after percutaneous coronary 
intervention and coronary artery bypass grafting: 
a subgroup analysis of 3-year SYNTAX data
Head SJ, Mack MJ, Holmes DR Jr, Mohr FW, Morice MC,  
Serruys PW, Kappetein AP
Eur J Cardiothorac Surg 2012;41:535-541
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AbstrAct
Objective
To assess whether incomplete revascularization by percutaneous coronary intervention (PCI) 
or coronary artery bypass grafting (CABG) has an effect on long-term outcomes.
Methods
During a heart team discussion to evaluate whether patients were eligible for randomization 
in the SYNTAX trial, both the cardiologist and surgeon agreed on which vessels needed 
revascularization. This statement was compared with the actual revascularization after treat-
ment. Incomplete revascularization was defined as when a preoperatively identified vessel 
with a lesion was not revascularized. Outcomes were major adverse cardiac or cerebrovas-
cular events (MACCE), the composite safety endpoint of death/stroke/myocardial infarction 
(MI), and individual MACCE components death, MI and repeat revascularization at 3 years. 
Predictors of incomplete revascularization were explored.
Results
Incomplete revascularization was found in 43.3% (388/896) PCI and 36.8% (320/870) 
CABG patients. Patients with complete revascularization by PCI had lower rates of MACCE 
(66.5 versus 76.2%,P < 0.001), the composite safety endpoint (83.4 versus 87.9%, P = 
0.05) and repeat revascularization (75.5 versus 83.9%, P < 0.001), but not death and MI. In 
the CABG group, no difference in outcomes was seen between incomplete and complete 
revascularization groups. Incomplete revascularization was identified as independent pre-
dictor of MACCE in PCI (HR = 1.55, 95% CI 1.15–2.08, P = 0.004) but not CABG patients. 
Independent predictors of incomplete revascularization by PCI were hyperlipidaemia (OR = 
1.59, 95% CI 1.04–2.42, P = 0.031), a total occlusion (OR = 2.46, 95% CI 1.66–3.64, P < 
0.001) and the number of vessels (OR = 1.58, 95% CI 1.41–1.77, P < 0.001). Independent 
predictors of incomplete revascularization by CABG were unstable angina (OR = 1.42, 95% 
CI 1.02–1.98, P = 0.038), diffuse disease or narrowed ( < 2 mm) segment distal to the lesion 
(OR = 1.87, 95% CI 1.31–2.69, P = 0.001) and the number of vessels (OR = 1.70, 95% CI 
1.53–1.89, P < 0.001).
Conclusions
Despite the hypothesis-generating nature of this data, this study demonstrates that incom-
plete revascularization is associated with adverse events during follow-up after PCI but not 
CABG.
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IntroductIon
Percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) are 
both options for the treatment of coronary disease. Whether PCI or CABG is preferred for a 
particular patient often depends on the number of diseased vessels, lesion complexity and 
co-morbidities. Complete revascularization cannot always be achieved due to procedural 
difficulties.1, 2
Previous studies have tried to address whether incomplete revascularization is associated 
with reduced survival and increased revascularization.3-6 However, these have been meth-
odologically restricted by a retrospective design and most often relied on post-procedural 
classification of completeness of revascularization by the treating physician. The Synergy 
between PCI with TAXUS and Cardiac Surgery (SYNTAX) trial7 had a more accurate method 
to determine the completeness of revascularization. Preoperatively, both the interventional 
cardiologist and surgeon had to agree which vessels needed revascularization on a basis 
of any lesion with more than 50% diameter stenosis in coronary vessels ≥1.5 mm. Patients 
were categorized as incompletely revascularized when the number of diseased segments 
that were treated did not match the Heart Team decision. The objective of this study was to 
assess whether incomplete revascularization according to the SYNTAX definition had an 
effect on the 3-year outcome of the SYNTAX trial.
Methods
study design
The SYNTAX trial design and methods have been described previously.7, 8 It was a prospec-
tive, multicentre randomized trial in which patients with de novo left main and/or three-
vessel disease were randomly assigned to undergo PCI with the TAXUS drug-eluting stent 
or CABG. 
The institutional review board of each of the 85 participating cites approved the 
protocol. The trial is registered on the National Institute of Health website with identifier 
NCT00114972.
definitions
During the Heart Team meeting when patients were assessed for randomization,9 both the 
interventional cardiologist and surgeon documented which vessels with a ≥1.5 mm diameter 
and a 50% stenosis needed revascularization. Incomplete revascularization was assessed by 
correlating this preoperative statement to the actual revascularization.
The composite endpoint of major adverse cardiac or cerebrovascular events (MACCE) 
included all-cause death, myocardial infarction (MI), cerebrovascular accident (CVA) or 
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repeat revascularization (subsequent PCI or CABG).10 Cerebrovascular events, or stroke, 
were defined as focal neurological deficits of central origin lasting >72 h, resulting in perma-
nent brain damage or body impairment. MI was defined in relation to intervention status as 
follows: (i) after allocation but before treatment: Q-wave [new pathological Q-waves in ≥2 
leads lasting ≥0.04 s with creatine kinase-MB (CK-MB) levels elevated above normal] and 
non-Q-wave MI [elevation of CK levels >2× the upper limit of normal (ULN) with positive 
CK-MB or elevation of CK levels to >2× ULN without new Q-waves if no baseline CK-MB 
was available]; (ii) <7 days after intervention: new Q-waves and either peak CK-MB/total CK 
>10% or plasma level of CK-MB 5× ULN; and (iii) ≥7 days after intervention: new Q-waves 
or peak CK-MB/total CK >10% or plasma level of CK-MB 5× ULN or plasma level of CK 5× 
ULN. The CK/CK-MB enzyme levels were obtained and measured by a core laboratory for 
all randomized patients. All events were adjudicated by a Clinical Event Committee.
statistical analysis
Baseline data were presented as proportions or mean ± standard deviation. Continues 
variables were compared using Student’s t-tests. Discrete variables were compared with 
the Chi-square test. Uni- and multivariate logistic regression analyses were performed to 
identify predictors of incomplete revascularization in PCI and CABG patients. Variables 
tested in the univariate analysis were: age, gender, any medically treated diabetes, diabetes 
requiring insulin, triglycerides ≥150 mg/dl (1.7 mmnol/l), fasting glucose ≥110 mg/dl, 
hyperlipidaemia, current smoker, previous MI, previous stroke, previous TIA, congestive 
heart failure, peripheral vascular disease, carotid artery disease, renal failure (creatinine 
>200 micromol/l), unstable angina, low left ventricular ejection fraction (<35%), logistic 
EuroSCORE, Parsonnet score, SYNTAX score tercile, total occlusion, bifurcation lesion, dif-
fuse disease or narrowed (<2 mm) segment distal to the lesion and the number of lesions. If 
a variable had a trend towards an association with incomplete revascularization (P < 0.20), 
it was entered in the multivariate forward Wald model. Univariate cox-regression was used 
to determine the effect of incomplete revascularization on outcomes. Variables with a trend 
towards an association (P < 0.20) were included in a final forward Wald multivariate model.
For all analyses, a P-value <0.05 was considered to be statistically significant. Analyses 
were performed using SPSS version 17.0 statistical software (SPSS Inc., Chicago, IL, USA).
results
Patient characteristics
In the SYNTAX trial, 1800 patients were randomized to PCI (n = 903) or CABG (n = 897). 
Revascularization was not performed or informed consent was withdrawn in 34 patients. A 
total of 1766 patients were analysed. In the PCI cohort, 43.3% (388/896) had incomplete 
Incomplete revascularization with PCI and CABG 303
C
ha
pt
er
 1
9
revascularization, compared with 36.8% (320/870) in the CABG cohort. Table 1 shows the 
baseline characteristics of complete and incomplete revascularized patients. 
Incomplete revascularization was especially present in patients with three-vessel disease 
(Figure 1). Within SYNTAX score terciles, an increasing score is associated with an increased 
rate of incomplete revascularization (Figure 2).
In the PCI group, patients with incomplete revascularization had a higher prevalence of 
diabetes and hyperlipidaemia. Patients with complete and incomplete revascularization had 
a comparable logistic EuroSCORE (3.7 ± 5.0 versus 3.9 ± 3.8, respectively, in the complete 
and incomplete revascularization groups) and Parsonnet score (8.2 ± 6.8 versus 9.0 ± 7.1, 
respectively). The coronary disease complexity, however, was significantly worse in patient 
with incomplete revascularization. The SYNTAX score was 31.4 ± 11.8 compared with 26.2 
± 10.6 in the complete revascularization group. More often, a total occlusion (33.4 versus 
16.9%, P < 0.001) or bifurcation (67.3 versus 58.9%, P = 0.010) lesion was present. Patients 
with incomplete revascularization had more frequently diffuse disease or narrowed (<2 mm) 
segments distal to the lesion (26.5 versus 19.1%, P = 0.008). A higher mean number of lesions 
were seen in incompletely revascularized patients (4.6 ± 1.5 versus 3.5 ± 1.6, P < 0.001).
In the CABG cohort, patients with incomplete revascularization had a higher logistic 
EuroSCORE (4.3 ± 4.9 compared with 3.6 ± 4.0 in the complete revascularization group, P = 
0.014) (Table 1). Similar to the PCI cohort, CABG patients with incomplete revascularization 
had more complex coronary disease according to the SYNTAX score (31.3 ± 11.4 versus 
27.9 ± 11.1), and higher incidences of diffuse disease or narrowed vessels (29.1 versus 
16.4%, P < 0.001), a total occlusion (27.4 versus 19.3%, P = 0.006) and a bifurcation (69.3 
N=   40    47                   67     70                  111   106                 134   119                 544   527
0
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56.7
47.9 48.3
42.7
60%
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LM Only         LM + 1VD       LM + 2VD        LM + 3VD        3VD Only
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CABG
Figure 1 rates of incomplete revascularization within patient lesion subsets
CABG = coronary artery bypass grafting; LM = left main; PCI = percutaneous coronary intervention; 
VD = vessel disease
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table 1 baseline characteristics
characteristics PcI 
(n=896)
cAbG 
(n=870)
complete 
(n=508, 
56.7%)
Incomplete 
(n=388, 
43.3%)
P 
value
complete 
(n=550, 
63.2%)
Incomplete 
(n=320, 
36.8%)
P value
Age, years 65.1 ±9.4 65.6 ± 10.0 0.392 64.7 ± 9.9 65.3 ± 9.8 0.339
Male sex 74.2% 
(377/508)*
79.6% 
(309/388)
0.057 79.4% 
(439/550)*
78.8% 
(252/320)
0.707
Comorbid risk factors
Body-Mass Index (kg/m2) 28.2 ± 4.9 28.0 ± 4.7 0.408 28.0 ± 4.5 27.8 ± 4.3 0.540
Medically treated diabetes
Any 22.2% 
(113/508)
30.2% 
(117/388)
0.007 22.7% 
(125/550)
25.3% 
(81/320)
0.387
Requiring insulin 7.5% 
(38/508)
13.1% 
(51/388)
0.005 8.9% 
(49/550)
12.2% 
(39/320)
0.122
Triglycerides ≥150 mg/dl (1.7 
mmol/liter)
32.4% 
(158/488)*
32.1% 
(116/361)
0.940 38.5% 
(191/496)*
39.1% 
(111/284)
0.874
Blood pressure ≥130/85 mmHg 68.7% 
(349/508)
69.6% 
(270/388)
0.776 64.2% 
(353/550)
63.1% 
(202/320)
0.754
Fasting Glucose ≥110 mg/dl 41.8% 
(151/361)
49.8% 
(139/279)†
0.044 39.5% 
(149/377)
39.3% 
(95/242)†
0.947
Increased waist circumference    48.6% 
(221/455)
45.9% 
(158/344)
0.459 46.7% 
(221/473)
44.9% 
(129/287)
0.634
Hyperlipidemia 75.7% 
(383/506)
82.2% 
(315/383)
0.018 77.5% 
(424/547)
76.8% 
(242/315)
0.816
Cardiovascular history
Current smoker 19.1% 
(97/508)
17.8% 
(69/388)
0.617 23.8% 
(130/547)
19.2% 
(61/318)
0.117
Previous myocardial infarction 32.1% 
(160/499)
32.0% 
(124/387)
0.994 31.0% 
(168/542)
37.1% 
(118/318)
0.066
Previous stroke 3.9% 
(20/507)
3.9% 
(15/385)
0.970 4.9% 
(27/546)
5.0% 
(16/319)
0.963
Previous transient ischemic 
attack
3.3% 
(17/508)
5.7% 
(22/386)
0.088 4.2% 
(23/544)
6.3% 
(20/318)
0.180
Previous cardiac surgery 0.2% 
(1/508)
0% (0/388) 0.382 0.2% 
(1/550)
0.3% 
(1/320)
0.698
Congestive heart failure 4.2% 
(21/505)
3.9% 
(15/386)
0.838 5.0% 
(27/539)
5.4% 
(17/314)
0.797
Peripheral vascular disease 7.9% 
(40/508)
10.8% 
(42/388)
0.129 8.7% 
(48/550)
13.4% 
(43/320)
0.029
Carotid artery disease 8.3% 
(42/508)
8.0% 
(31/388)
0.880 7.5% 
(41/550)
9.7% 
(31/320)
0.249
Creatinine >200 micromol/liter 1.2% 
(6/508)
1.0% 
(4/388)
0.832 1.3% 
(7/550)
1.9% 
(6/320)
0.480
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table 1 Continued
characteristics PcI 
(n=896)
cAbG 
(n=870)
complete 
(n=508, 
56.7%)
Incomplete 
(n=388, 
43.3%)
P 
value
complete 
(n=550, 
63.2%)
Incomplete 
(n=320, 
36.8%)
P value
Chronic obstructive pulmonary 
disease
7.5% 
(38/508)
8.5% 
(33/388)
0.574 10.0% 
(55/550)
7.8% 
(25/320)
0.282
Angina
Stable 57.9% 
(294/508)
56.2% 
(218/388)
0.613 60.7% 
(334/550)
52.2% 
(167/320)
0.014
Unstable 27.6% 
(140/508)
30.4% 
(118/388)
0.350 26.0% 
(143/550)
32.5% 
(104/320)
0.040
Ejection fraction <35% 1.4% 
(7/508)
1.3% 
(5/388)
0.908 2.4% 
(13/550)
2.2% 
(7/320)
0.867
Logistic EuroSCORE 3.7 ± 5.0 3.9 ± 3.8 0.614 3.6 ± 4.0 4.3 ± 4.9 0.014
Parsonnet score 8.2 ± 6.8 9.0 ± 7.1 0.117 8.1 ± 6.7 8.9 ± 7.2 0.079
Lesion complexity
SYNTAX score 26.2 ± 
10.6*
31.4 ± 11.8 <0.001 27.9 ± 
11.1*
31.3 ± 
11.4
<0.001
Diffuse disease or small vessels 19.1% 
(97/508)
26.5% 
(103/388)
0.008 16.4% 
(90/550)
29.1% 
(93/320)
<0.001
Total occlusion 16.9% 
(85/504)
33.4% 
(129/386)
<0.001 19.3% 
(106/548)
27.4% 
(87/317)
0.006
Bifurcation 58.9% 
(299/508)
67.3% 
(261/388)
0.010 62.0% 
(341/550)
69.3% 
(221/319)
0.030
Number of lesions 3.5 ± 1.6 4.6 ± 1.5 <0.001 3.5 ± 1.5 4.8 ± 1.6 <0.001
Lesion † <0.001 † <0.001
Left main, any 44.7% 
(227/508)
32.2% 
(125/388)
45.1% 
(248/550)
29.5% 
(94/319)
Left main only 7.9% 
(40/508)
0% (0/320) 8.0% 
(44/550)
0.9% 
(3/320)
Left main + 1 vessel 11.8% 
(60/508)
1.8% 
(7/388)
10.9% 
(60/550)
3.1% 
(10/320)
Left main + 2 vessel 13.6% 
(69/508)
10.8% 
(42/388)
14.9% 
(82/550)
7.5% 
(24/320)
Left main + 3 vessel 11.4% 
(58/508)
19.6% 
(76/388)
11.3% 
(62/550)
17.8% 
(578/320)
Three vessel disease only 52.4% 
(266/508)
67.3% 
(261/388)
53.5% 
(294/550)
67.5% 
(216/320)
* P<0.05 for comparison PCI complete revascularization versus CABG complete revascularization
†P<0.05 for comparison PCI incomplete revascularization versus CABG incomplete revascularization
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versus 62.0%,P = 0.030). The number of lesions was significantly higher in the incomplete 
revascularization group (4.8 ± 1.6 versus 3.5 ± 1.5 in the complete revascularization group, 
P < 0.001).
In the PCI cohort, incomplete and complete revascularization groups had similar number 
of stents implanted (respectively, 4.6 ± 2.0 versus 4.7 ± 2.4, P = 0.55) and a comparable 
total stent length in mm (respectively, 83.6 ± 42.3 versus 88.0 ± 51.7, P = 0.18). CABG 
patients in the incomplete revascularization group had similar procedure time as those with 
complete revascularization (respectively, 3.4 ± 1.0 versus 3.5 ± 1.5, P = 0.13).
Predictors of incomplete revascularization
Predictors of incomplete revascularization are displayed in Table 2. For stent patients, 
hyperlipidaemia (OR = 1.59, 95% CI 1.04–2.42), a total occlusion (OR = 2.46, 95% CI 
1.66–3.64) and the number of lesions (OR = 1.58, 95% CI 1.41–1.77) were independent 
predictors of incomplete revascularization in the multivariate model (Table 2).
In CABG patients, multivariate analysis identified only unstable angina (OR = 1.42, 95% 
CI 1.02–1.98), the diffuse disease or small vessels (OR = 1.87, 95% CI 1.31–2.69) and the 
number of lesions (OR = 1.70, 95% CI 1.53–1.89) as independent predictors.
outcomes
Incomplete revascularization was associated with a higher MACCE rate at 3 years follow-up 
in patients who underwent PCI (33.5 versus 23.8% in patients with complete revasculariza-
tion, P < 0.001) (Figure 3) but not in patients that underwent CABG (21.9 versus 18.9% in 
patients with complete revascularization, P = 0.29).
N=          295           267                                      309           291                                      288          307
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Figure 2 rates of incomplete revascularization within sYntAX score terciles
CABG = coronary artery bypass grafting; ; PCI = percutaneous coronary intervention
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The composite safety endpoint (16.6 versus 12.1%, P = 0.05) was higher with incomplete 
revascularization in the PCI cohort, but within the CABG cohort there was no difference 
(12.5 versus 11.4%, respectively, in incomplete and complete revascularization groups, P 
= 0.62).
Mortality was not significantly different between incomplete and complete revasculariza-
tion groups in patients that underwent PCI (respectively, 10.1 versus 7.4%, P = 0.13) or 
CABG (respectively, 7.1 versus 6.2%, P = 0.60). Rates of MI were also not significantly 
different in PCI (8.2 versus 6.2% in incomplete and complete revascularization, P = 0.25) 
and CABG (respectively, 4.5 versus 2.9%, P = 0.26). However, in the incomplete revascular-
ization group, there was a significantly higher rate of repeat revascularization in PCI (24.5 
versus 16.1%, P < 0.001), but not CABG (13.0 versus 9.4%, P = 0.11).
Predictors of MAcce
Univariate Cox regression analysis identified incomplete revascularization as one of the pre-
dictors of MACCE, among others (Table 3). In the PCI arm, significant multivariate predictors 
table 2
univariate and multivariate predictors of incomplete revascularization within PcI and 
cAbG cohorts
univariate 
or (95% cI)
P value Multivariate 
or (95% cI)
P value
PcI
Any medically treated diabetes 1.51 (1.12-2.04) 0.007
Insulin requiring diabetes 1.87 (1.20-2.91) 0.006
Fasting glucose ≥110 mg/dl 1.38 (1.01-1.89) 0.044
Hyperlipidemia 1.49 (1.07-2.07) 0.019 1.59 (1.04-2.42) 0.031
SXS tercile 1.70 (1.43-2.01) <0.001
Diffuse disease or small vessels 1.53 (1.12-2.10) 0.008
Total occlusion 2.45 (1.81-3.39) <0.001 2.46 (1.66-3.64) <0.001
Bifurcation 1.44 (1.09-1.89) 0.010
Number of lesions 1.60 (1.46-1.77) <0.001 1.58 (1.41-1.77) <0.001
cAbG
Peripheral vascular disease 1.62 (1.05-2.51) 0.030
Unstable angina 1.37 (1.01-1.85) 0.041 1.42 (1.02-1.98) 0.038
Logistic EuroSCORE 1.04 (1.01-1.07) 0.017
SXS tercile 1.44 (1.21-1.71) <0.001
Diffuse disease or small vessels 2.10 (1.51-2.93) <0.001 1.87 (1.31-2.69) 0.001
Total occlusion 1.58 (1.14-2.18) 0.006
Bifurcation 1.38 (1.03-1.85) 0.031
Number of lesions 1.71 (1.55-1.90) <0.001 1.70 (1.53-1.89) <0.001
CABG = coronary artery bypass grafting; CI = confidence interval; PCI = percutaneous coronary intervention; OR 
= odds ratio; SXS = SYNTAX score
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for increased MACCE at 3 years were incomplete revascularization (HR = 1.55, 95% CI 
1.15–2.08, P = 0.004), insulin requiring diabetes (HR = 1.94, 95% CI 1.33–2.84,P = 0.001), 
previous MI (HR = 1.42, 95% CI 1.04–1.92, P = 0.026) and carotid artery disease (HR = 
1.96, 95% CI 1.24–3.11, P = 0.004). In the CABG cohort, only PVD (HR = 1.82, 95% CI 
Figure 3 three-year outcomes of incomplete revascularization versus complete revascularization
Kaplan-Meier estimates of total MACCE (A), the composite endpoint of death/stroke/myocardial infarction (B), 
all-cause mortality (C), myocardial infarction (D), and repeat revascularization (E) in PCI (left) and CABG (right) 
cohorts.
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1.21–2.74, P = 0.004) and the Parsonnet score (HR = 1.03, 95% CI 1.01–1.05, P = 0.006) 
remained associated with MACCE in the multivariate model.
dIscussIon
This study shows that in the SYNTAX population of patients with left main and/or multi-vessel 
coronary disease, PCI with complete revascularization is associated with improved outcome 
compared with incomplete revascularization. In CABG patients, there was no additional risk 
of adverse events with incomplete revascularization.
The increased rate of MACCE in incomplete revascularized PCI patients is mainly attrib-
uted to a higher rate of repeat revascularization. The composite endpoint of death, MI and 
stroke was also higher with incomplete PCI, but for the individual components of MACCE 
no significant difference between complete and incomplete revascularization could be 
demonstrated.
table 3 univariate and multivariate predictors of MAcce within PcI and cAbG cohorts
univariate 
hr (95% cI)
P value Multivariate 
hr (95% cI)
P value
PcI
Incomplete revascularization 1.54 (1.20-1.97) 0.001 1.55 (1.15-2.08) 0.004
Age 1.02 (1.01-1.03) 0.008
Any medicaly treated diabetes 1.62 (1.25-2.11) <0.001
Insulin requiring diabetes 1.94 (1.38-2.74) <0.001 1.94 (1.33-2.84) 0.001
Previous myocardial infarction 1.33 (1.03-1.72) 0.030 1.42 (1.04-1.92) 0.026
Peripheral vascular disease 1.68 (1.16-2.42) 0.006
Carotid artery disease 1.58 (1.06-2.36) 0.024 1.96 (1.24-3.11) 0.004
Unstable angina 1.39 (1.07-1.81) 0.013
Logistic EuroSCORE 1.02 (1.01-1.04) 0.002
Parsonnet score 1.02 (1.00-1.04) 0.029
Number of lesions 1.09 (1.01-1.17) 0.024
SXS terciles 1.29 (1.11-1.51) 0.001
cAbG
Age 1.02 (1.01-1.04) 0.010
Congestive heart failure 1.85 (1.07-3.19) 0.028
Peripheral vascular disease 2.02 (1.36-2.99) <0.001 1.82 (1.21-2.74) 0.004
Low ejection fraction (<35%) 2.19 (1.03-4.67) 0.042
Logistic EuroSCORE 1.05 (1.03-1.08) <0.001
Parsonnet score 1.04 (1.02-1.06) <0.001 1.03 (1.01-1.05) 0.006
CABG = coronary artery bypass grafting; CI = confidence interval; HR = hazard ratio; PCI = percutaneous coronary 
intervention
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The impact of incomplete revascularization on adverse events after CABG has been stud-
ied extensively since the early 1980s.11-13 These studies uniformly concluded that survival 
and symptom relief after complete revascularization is favourable compared with incom-
plete revascularization. After the introduction of stents, many studies have also focused on 
the impact of completeness of revascularization in PCI patients. Several studies found that 
incomplete revascularization was associated with higher risk of long-term mortality or repeat 
revascularization.14 There are, however, only a handful of studies that compared the influ-
ence of complete revascularization on MACCE in CABG and PCI patients simultaneously 
and there is only one report from a randomized study.6, 15, 16 The evaluation of incomplete 
revascularization in non-randomized CABG and PCI cohorts is therefore limited because of 
differences in patient characteristics. Studies can also not be compared due to differences in 
definitions of complete revascularization.
Rates of complete revascularization vary significantly between studies. The ARTS trial 
showed an 82.1 and 70.5% rate of complete revascularization after CABG and PCI for mul-
tivessel disease.17These rates are much higher compared to this study, which rates were 63.2 
and 56.7%, respectively. The rate of revascularization in the ARTS trial was probably higher 
due to less complex coronary lesions, but also due to the fact that the significant coronary 
lesions that needed treatment were not defined by the heart team prior to randomization. 
The surgical procedure was scored as complete revascularization if the diseased segments 
had been treated according to the surgical report. The ARTS trial showed a significant higher 
MACCE rate after PCI in the incomplete revascularization group compared with complete 
revascularized patients (30.6 versus 23.4% respectively, P < 0.05), which was driven by a 
higher rate of repeat CABG (10.0 versus 2.0%, P < 0.05).6 Similar as in ARTS (12.2 versus 
10.1%), however, we found no differences between incomplete and complete revascular-
ization groups within CABG patients.6, 16
The 43% incompletely revascularized rate with PCI in SYNTAX is lower than 69% that 
was reported from 39 centres in a study with 11 294 PCI patients.18 ARTS-II performed PCI 
with a drug-eluting stent and had a 49% incomplete revascularization rate, quite similar to 
other studies that reported rates above 50%.15, 16
In other studies, the rate of incomplete revascularization in CABG patients is ~10–19%, 
which is much lower than in the SYNTAX trial,5, 6, 19, 20 although Kim et al.,15 who also 
used the SYNTAX score to classify lesions, found a rate of 33% which is close to the 37% 
in SYNTAX. The reason for such a high incomplete revascularization rate in the SYNTAX 
CABG cohort is due to the used definition. Previous studies have often based incomplete 
revascularization on the surgeons report without a pre-operative statement which vessels 
contained a significant lesion that needed treatment. In the SYNTAX trial, the heart team 
was obliged to state before the randomization process took place which vessels needed 
revascularization. Linking this statement to the actual revascularization concludes whether 
revascularization was complete.
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The number of lesions and total occlusion were predictive of incomplete revascularization 
in the multivariate model, while the SYNTAX score terciles were significant in the univariate 
analysis. Therefore, incomplete revascularization with PCI is more likely in patients with 
extensive coronary disease and technically more challenging lesions. In CABG patients, 
incomplete revascularization was higher in patients with diffusely diseased or narrowed (<2 
mm) segments distal to the lesion.
study limitations
We are aware that this subgroup analysis has limited power due to the methodological 
limitations of such analyses. The complete and incomplete revascularization subgroups 
were not predefined in the study protocol. We have performed and reported 10 subgroup 
analyses and this will produce one significant result by chance only. These results should be 
interpreted with caution and be considered hypothesis generating.
conclusIons
At 3 years, incomplete versus complete revascularization with PCI is associated with 
increased rates of MACCE and repeat revascularization. In patients treated with CABG, 
adverse events are similar in incomplete and complete revascularization groups.
Part 3 Stenting versus bypass surgery312
reFerences
1.  Hannan EL, Racz M, Holmes DR, King SB, 3rd, Walford G, Ambrose JA, Sharma S, Katz S, Clark 
LT, Jones RH. Impact of completeness of percutaneous coronary intervention revascularization on 
long-term outcomes in the stent era. Circulation 2006;113:2406-2412.
2.  Synnergren MJ, Ekroth R, Oden A, Rexius H, Wiklund L. Incomplete revascularization reduces 
survival benefit of coronary artery bypass grafting: role of off-pump surgery. J Thorac Cardiovasc 
Surg 2008;136:29-36.
3.  Bell MR, Gersh BJ, Schaff HV, Holmes DR, Jr., Fisher LD, Alderman EL, Myers WO, Parsons LS, 
Reeder GS. Effect of completeness of revascularization on long-term outcome of patients with 
three-vessel disease undergoing coronary artery bypass surgery. A report from the Coronary Artery 
Surgery Study (CASS) Registry. Circulation 1992;86:446-457.
4.  Martuscelli E, Clementi F, Gallagher MM, D’Eliseo A, Chiricolo G, Nigri A, Marino B, Romeo 
F, trialists C. Revascularization strategy in patients with multivessel disease and a major vessel 
chronically occluded; data from the CABRI trial. Eur J Cardiothorac Surg 2008;33:4-8.
5.  Osswald BR, Blackstone EH, Tochtermann U, Schweiger P, Thomas G, Vahl CF, Hagl S. Does the 
completeness of revascularization affect early survival after coronary artery bypass grafting in 
elderly patients? Eur J Cardiothorac Surg 2001;20:120-125, discussion 125-126.
6.  van den Brand MJ, Rensing BJ, Morel MA, Foley DP, de Valk V, Breeman A, Suryapranata H, 
Haalebos MM, Wijns W, Wellens F, Balcon R, Magee P, Ribeiro E, Buffolo E, Unger F, Serruys PW. 
The effect of completeness of revascularization on event-free survival at one year in the ARTS trial. 
J Am Coll Cardiol 2002;39:559-564.
7.  Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, Stahle E, Feldman TE, 
van den Brand M, Bass EJ, Van Dyck N, Leadley K, Dawkins KD, Mohr FW, SYNTAX Investigators. 
Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary 
artery disease. N Engl J Med 2009;360:961-972.
8.  Ong AT, Serruys PW, Mohr FW, Morice MC, Kappetein AP, Holmes DR, Jr., Mack MJ, van den 
Brand M, Morel MA, van Es GA, Kleijne J, Koglin J, Russell ME. The SYNergy between percutane-
ous coronary intervention with TAXus and cardiac surgery (SYNTAX) study: design, rationale, and 
run-in phase. Am Heart J 2006;151:1194-1204.
9.  Head SJ, Bogers AJJC, Serruys PW, Takkenberg JJM, Kappetein AP. A crucial factor in shared deci-
sion making: the team approach. Lancet 2011;377:1836.
10.  Kappetein AP, Feldman TE, Mack MJ, Morice MC, Holmes DR, Stahle E, Dawkins KD, Mohr FW, 
Serruys PW, Colombo A. Comparison of coronary bypass surgery with drug-eluting stenting for the 
treatment of left main and/or three-vessel disease: 3-year follow-up of the SYNTAX trial. Eur Heart 
J 2011;32:2125-2134.
11.  Cukingnan RA, Carey JS, Wittig JH, Brown BG. Influence of complete coronary revascularization 
on relief of angina. J Thorac Cardiovasc Surg 1980;79:188-193.
12.  Jones EL, Craver JM, Guyton RA, Bone DK, Hatcher CR, Jr., Riechwald N. Importance of complete 
revascularization in performance of the coronary bypass operation. Am J Cardiol 1983;51:7-12.
13.  Buda AJ, Macdonald IL, Anderson MJ, Strauss HD, David TE, Berman ND. Long-term results fol-
lowing coronary bypass operation. Importance of preoperative actors and complete revasculariza-
tion. J Thorac Cardiovasc Surg 1981;82:383-390.
14.  Samson M, Meester HJ, De Feyter PJ, Strauss B, Serruys PW. Successful multiple segment coronary 
angioplasty: effect of completeness of revascularization in single-vessel multilesions and multives-
sels. Am Heart J 1990;120:1-12.
Incomplete revascularization with PCI and CABG 313
C
ha
pt
er
 1
9
15.  Kim YH, Park DW, Lee JY, Kim WJ, Yun SC, Ahn JM, Song HG, Oh JH, Park JS, Kang SJ, Lee SW, 
Lee CW, Park SW, Park SJ. Impact of angiographic complete revascularization after drug-eluting 
stent implantation or coronary artery bypass graft surgery for multivessel coronary artery disease. 
Circulation 2011;123:2372-2381.
16.  Sarno G, Garg S, Onuma Y, Gutierrez-Chico JL, van den Brand MJ, Rensing BJ, Morel MA, Serruys 
PW, Investigators A-I. Impact of completeness of revascularization on the five-year outcome in 
percutaneous coronary intervention and coronary artery bypass graft patients (from the ARTS-II 
study). Am J Cardiol 2010;106:1369-1375.
17.  Serruys P, Unger F, Sousa J, Jatene A, Bonnier H, Schönberger J, Buller N, Bonser R, van den 
Brand MJ, van Herwerden LA, Morel MA, van Hout B, Arterial Revascularization Therapies Study 
Group. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel 
disease. NEngl J Med 2001;344:1117-1124.
18.  Hannan EL, Wu C, Walford G, Holmes DR, Jones RH, Sharma S, King SB, 3rd. Incomplete revas-
cularization in the era of drug-eluting stents: impact on adverse outcomes. JACC Cardiovasc Interv 
2009;2:17-25.
19.  Kleisli T, Cheng W, Jacobs MJ, Mirocha J, Derobertis MA, Kass RM, Blanche C, Fontana GP, Raissi 
SS, Magliato KE, Trento A. In the current era, complete revascularization improves survival after 
coronary artery bypass surgery. J Thorac Cardiovasc Surg 2005;129:1283-1291.
20.  Moon MR, Sundt TM, 3rd, Pasque MK, Barner HB, Gay WA, Jr., Damiano RJ, Jr. Influence of 
internal mammary artery grafting and completeness of revascularization on long-term outcome in 
octogenarians. Ann Thorac Surg 2001;72:2003-2007.
Dallas
Chapter 20
Analysis of stroke occurring in the SYNTAX trial 
comparing coronary artery bypass surgery and 
percutaneous coronary intervention in the treatment 
of complex coronary disease
Mack MJ, Head SJ, Holmes DR Jr, Ståhle E, Feldman TE, 
Colombo A, Morice MC, Unger F, Erglis A, Stoler R, Dawkins KD, 
Serruys PW, Mohr FW, Kappetein AP
JACC Cardiovasc Interv 2013;6:344-354
Part 3 Stenting versus bypass surgery316
AbstrAct
Objectives
To analyze stroke rates in the SYNTAX randomized and registry cohorts of patients being 
treated with coronary artery bypass graft surgery (CABG) or percutaneous coronary interven-
tion (PCI) for treatment of complex coronary artery disease.
Background
The SYNTAX trial (NCT00114972) compared PCI to CABG in patients with de novo three-
vessel and/or left main coronary disease.
Methods
The SYNTAX randomized trial was conducted at 85 US and European sites (n=1,800). All 
strokes (up to 4 years) were independently adjudicated by a Clinical Events Committee that 
included a neurologist. An additional 644 and 192 patients were included in the CABG and 
PCI registries, respectively.
Results
In the randomized cohort, a total of 31 CABG and 19 PCI patients experienced 33 and 20 
strokes post-randomization at 4-year follow-up, respectively (p=0.06). Three strokes occurred 
preprocedurally but following randomization in CABG-treated patients. After CABG, a large 
proportion of strokes occurred acutely (0-30 days: 9/33) while in the PCI arm most strokes 
occurred >30 days after the procedure (18/20). Stroke resulted in death in 3 patients in both 
the PCI and CABG group. Of the patients who developed stroke, 68% (21/31) in the CABG 
group had residual deficits at discharge; in the PCI group, 47% (9/19) had residual deficits. In 
a multivariate analysis, treatment with CABG was not significantly associated with increased 
stroke rates (OR=1.67, 95% CI 0.93-3.01, p=0.089). The incidence and outcomes of stroke 
were similar in the randomized trial and registries.
Conclusions
There is a higher risk of periprocedural stroke in patients undergoing CABG compared with 
PCI; however, the risk converges over the first 4 years of follow-up.
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IntroductIon
In the past few decades, differences in the rates of adverse cardiac events including death 
and myocardial infarction after percutaneous coronary intervention (PCI) have converged 
with coronary artery bypass grafting (CABG), predominantly because PCI techniques and 
technology as well as adjuvant medical therapy have improved.1-5 Though CABG is the 
established method of revascularization in patients with left main (LM) and three-vessel 
disease (3VD), PCI has become an increasingly utilized alternative in this group of high-risk 
patients. 
Stroke, especially early postoperative stroke, is considered a serious risk for patients 
undergoing CABG but not as much for patients receiving PCI.4-7 The causes of stroke follow-
ing CABG are multifactorial and the impact of newer surgical revascularization techniques 
– no touch off-pump CABG – on the incidence of stroke is uncertain. With the improved 
outcomes for PCI using drug-eluting stents, the increase in the risk of stroke with CABG 
needs to be weighed against the increased likelihood of repeated revascularization.
Few randomized studies comparing CABG and PCI have focused on stroke, and espe-
cially stroke during follow-up has been an underrepresented analysis.8 The objective of this 
post hoc analysis was to assess stroke in the large, complex patient population enrolled in 
both the SYNTAX randomized trial and nested registries, and to define the risk factors and 
outcomes of patients who experienced a stroke within the first 4 years of follow-up.
Methods
study design and treatment description
SYNTAX is a prospective, multinational, randomized clinical trial (RCT; N=1800, CABG 
N=897, PCI N=903) with parallel nested registries (CABG N=1077, N=644 followed for 5 
years; PCI registry N=192) designed to assess clinical outcomes after PCI with TAXUS Express 
stents compared with CABG for the treatment of de novo LM and/or 3VD. By consensus of 
the Heart Team, consisting of at least one interventional cardiologist and cardiac surgeon, 
CABG-ineligible patients were enrolled in a PCI registry and PCI-ineligible patients were 
enrolled in a CABG registry.9-10 Trial design and detailed methods of this study have been 
previously published.5, 11 Analysis of the subset of patients in the randomized controlled 
trial with stroke was not prespecified. Additionally, as the primary endpoint of the overall 
SYNTAX study was not met,5 the results of these subgroup analyses are intended to be 
observational and hypothesis-generating and should, therefore, be interpreted with caution.
The Institutional Review Board at each participating site approved the study and all 
subjects provided written informed consent before enrollment. The protocol and consent 
forms were consistent with the International Conference on Harmonisation Guidance for 
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Industry E6 Good Clinical Practice, the Declaration of Helsinki, and all local regulations, as 
appropriate. The study is registered as identifier NCT00114972 on the National Institute of 
Heath website (www.clinicaltrials.gov).
definitions
A cerebrovascular event, or stroke, was characterized by a focal neurological deficit lasting 
>72 hours resulting in irreversible brain damage or permanent impairment. Confirmation of 
neurological injury by head CT scan or MRI was recommended. Strokes were also classified 
as ischemic or hemorrhagic. In the randomized controlled cohort of SYNTAX, all strokes 
and TIAs were confirmed by a local neurologist and adjudicated by an independent Clinical 
Events Committee (CEC) that included a neurologist. In the CABG and PCI registries, strokes 
were site-reported but not adjudicated by a CEC. Atrial fibrillation (AF) and/or atrial flutter 
was reported by the investigative sites as a serious adverse event and was not adjudicated 
by the CEC. Stroke was assumed to be directly correlated with AF whenever the timing 
of events was interlinked and/or when this association was confirmed in the patient chart 
narratives.
statistical methods
Analysis was based on the intent-to-treat principle and was conducted using SAS System 
Software, Version 8.0 or higher (SAS Institute, Cary, North Carolina, USA). Data are sum-
marized using descriptive statistics, presented as percent, count/sample size or mean ± 
standard deviation. The Student t-test was used to compare continuous variables; differ-
ences in discrete variables were assessed by means of the chi-square or Fisher exact test, as 
appropriate. 
The cumulative incidence of stroke was analyzed using the Kaplan-Meier method. The 
rate of stroke was analyzed in pre-specified subgroups by lesion subsets (3VD and LM), gen-
der, age (≤70 and >70), and the presence of diabetes. Post hoc analyses according to prior 
stroke/TIA, peripheral vascular disease, carotid artery disease, and SYNTAX score tertiles 
were furthermore performed (low ≤22, intermediate 23-32, high ≥33).5 In-hospital outcome 
comparisons between treatments and stroke rates within these subgroups does not seem 
appropriate because of the low stroke rate at this 30-day time-point. Landmark analyses after 
one-year follow-up were performed.
Univariate analysis including a combination of preoperative and intraoperative variables; 
in the overall model: age per 10 years increase, gender, previous MI, prior TIA or stroke, 
medically treated diabetes, angina class, cigarette use, hypertension, hyperlipidemia, carotid 
artery disease, 3VD/LM, moderate or poor LVEF, renal failure (creatinine ≥200), peripheral 
vascular disease, overall SYNTAX score, number of vessels treated, treatment group. In 
addition for the PCI model the variable anti-platelet medication compliance was included, 
and off-pump surgery was specifically included in the CABG model. These variables were 
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believed to be clinically relevant to identify potential predictors of 4-year post-allocation 
stroke. Subsequently, multivariate predictors were identified using step-wise selection with 
a significance level of <0.10 for entry and exit in a logistic regression model in the overall, 
CABG, and PCI cohorts separately; medically treated diabetes and left main/three-vessel 
disease were forced into the model based on previous findings. Predictors are expressed as 
odds ratio (OR) ± 95% confidence interval.
results
randomized arms
Incidence of stroke
The 30-day stroke rate was 1.0% (9/897) after CABG and 0.2% (2/903) after PCI (p=0.037).
At 4 years of follow-up, 3.7% of CABG-randomized patients experienced stroke (n=31 
patients, n=33 strokes) compared with 2.3% of PCI-randomized patients (n=19 patients, 
n=20 strokes; p=0.06) (Figure 1). The majority of strokes were ischemic (CABG 29/33 and 
PCI 13/20).
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Figure 1 unadjusted cumulative stroke rate to 4 years post-allocation
Kaplan-Meier estimates (± 1.5 x SE) for stroke in randomized patients treated with CABG (light line) or PCI (dark 
line) (A), CABG registry patients (B) or PCI registry patients (C). P value in (A) from log-rank test.
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Three patients in the CABG arm of the RCT suffered a stroke before the index procedure 
(Figure 2); 47 days before treatment in 1 patient and on the day of randomization (3 days before 
surgery) in a second patient.One patient had a stroke the day before the index procedure, 7 
days after allocation; this patient ultimately received medical therapy and not CABG but was 
counted in the CABG group by intention-to-treat. No pre-procedural strokes occurred in the 
PCI arm. In those patients who experienced stroke, the length of time between randomization 
and index procedure was similar between treatment arms (CABG: 12.6 ± 22.4 days [median 
and IQR: 6, 2-11 days] vs. PCI 17.5 ± 38.8 days [median and IQR: 2, 1-6 days]).
Baseline and procedural characteristics
Baseline characteristics of the randomized cohort of SYNTAX are presented in Table 1. 
Patients who experienced stroke were older and had more severe cardiovascular disease 
as defined by increased incidences of prior cerebrovascular events, peripheral vascular 
disease, hypertension, and a higher mean logistic EuroSCORE.
The rate of off-pump bypass surgery was 15.0% (128/853) in the randomized CABG 
patient population, with a similar cumulative 4-year stroke rate of 3.6% in the off-pump 
group compared to 3.5% in patients that underwent on-pump surgery (p=0.98 by log rank).
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Figure 2
timing of stroke relative to treatment group allocation and index procedure in the 
randomized controlled trial
The date of allocation (x), index procedure (+), first stroke (●) and second stroke (if applicable, ▲) in each patient 
are represented on a single line. The dotted grey lines indicate yearly follow-up intervals and the * indicates those 
strokes which occurred before the index procedure. CABG = coronary artery bypass grafting; PCI = percutaneous 
coronary intervention
Stroke during long-term follow-up after PCI and CABG 321
C
ha
pt
er
 2
0
Atrial fibrillation/flutter during follow-up was reported in 3.4% (31/903) after PCI and 
in 7.9% (71/897) after CABG. The rate of stroke in patients with versus without arrhythmia 
was 9.7% (3/31) versus 1.8% (16/872) after PCI, and 5.6% (4/71) versus 3.3% (27/826) after 
CABG. 
In general, patients in the PCI cohort received dual antiplatelet therapy at greater rates 
before, during and after the index procedure compared with CABG patients up to 3 years 
post randomization (4-year data not available).12
Outcomes after stroke
Of the RCT patients who had strokes, 3 in each treatment arm died as a result of the event 
(PCI vs. CABG, p=0.66) (Figure 3). The median length of stay in the hospital – whether this 
was the index hospitalization or readmission – in patients experiencing stroke was 8 days in 
the CABG arm (IQR 7-14 days) and 7 days (IQR 2-21 days) in the PCI arm. Overall, stroke 
patients were discharged equally to home or to a rehabilitation facility.
There were 7 patients (23%) in the CABG group and 7 patients (37%) in the PCI group 
that were alive with no long-term residual deficits after stroke (p=0.28) (Figure 3). The 
table 1 baseline characteristics of rct stroke patients
Parameter All Patients
(n=1800)
cAbG PcI
stroke
Patients
(n=31)
non-stroke
Patients
(n=866)
stroke
Patients
(n=19)
non-stroke
Patients
(n=884)
Age, yr 65.1±9.7 (1800) 67.7±9.2 (31) 64.9±9.8 (866) 71.5±8.0 (19) 65.1±9.7 (884)
Female gender 22.3% 
(402/1800)
29.0% (9/31) 20.8% 
(180/866)
26.3% (5/19) 23.5% 
(208/884)
Prior stroke 4.4% (78/1789) 0% (0/30) 5.0% (43/860) 10.5% (2/19) 3.8% (33/880)
Prior TIA 4.7% (84/1789) 10.0% (3/30) 4.9% (42/858) 10.5% (2/19) 4.2% (37/882)
Carotid artery disease 8.2% (148/1800) 16.1% (5/31) 8.1% (70/866) 0% (0/19) 8.3% (73/884)
Peripheral artery 
disease
9.8% (177/1800) 22.6% (7/31) 10.2% 
(88/866)
15.8% (3/19) 8.9% (79/884)
History of smoking 64.7% 
(1160/1793)
74.2% 
(23/31)
68.9% 
(592/859)
63.2% 
(12/19)
60.3% 
(533/884)
Current smoker 20.2% 
(363/1793)
29.0% (9/31) 21.8% 
(187/859)
15.8% (3/19) 18.6% 
(164/884)
Medically treated 
diabetes
25.1% 
(452/1800)
29.0% (9/31) 24.5% 
(212/866)
26.3% (5/19) 25.6% 
(226/884)
Hypertension 75.5% 
(1349/1787)
93.5% 
(29/31)
76.4% 
(657/860)
89.5% 
(17/19)
73.7% 
(646/877)
Logistic EuroSCORE 3.8±4.5 (1800) 4.6±3.3 (31) 3.9±4.4 (866) 6.1±5.9 (19) 3.7±4.5 (884)
Mean SYNTAX score 28.7±11.4 (1789) 29.1±11.2 
(31)
29.1±11.4 
(859)
31.8±10.4 
(19)
28.3±11.5 
(880)
Numbers are % (n), or as mean ± standard deviation (n). CABG = coronary artery bypass grafting; PCI = 
percutaneous coronary intervention; TIA = transient ischemic attack
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remaining 21 (68%) and 9 (47%) alive CABG and PCI patients, respectively, had residual 
deficits including (but were not limited to): hypoesthesia/numbness, motor deficits, language 
deficits, visual deficits, muscle weakness, muscle spasms, paresis/paralysis, and dysphasia. 
The most common residual symptoms were language deficit and paresis/paralysis.
Subgroups
In the subgroup of RCT patients with LM disease, stroke was significantly increased in CABG-
treated patients (CABG 4.3% [n=14] vs. PCI 1.5% [n=5], p=0.03); whereas, in patients 
with 3VD no significant difference was found (3.4% [n=17] vs. 2.8% [n=14], p=0.53). No 
significant differences in stroke were found between pre-specified subgroups of gender, age, 
or the presence of diabetes, nor in post hoc analyses according to prior stroke/TIA, or the 
presence of carotid artery disease (Figure 4).
Although no statistical comparisons were made because of the low number of events, 
it was noted that the stroke rate in the CABG and PCI arms of the RCT was differentially 
affected by complexity of coronary artery disease as measured by the SYNTAX score. In 
CABG-randomized patients, the stroke rate was similar in each SYNTAX score tertile (low 
SYNTAX score 4.0% [n=10], intermediate 3.6% [n=10], and high 3.7% [n=11]). A step-wise 
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Figure 3 outcomes after stroke
Nearly all patients who experienced a stroke were either discharged to home or to a rehabilitation centre. 
Almost half of CABG stroke patients and a third of PCI stroke patients had long-term residual deficits. CABG = 
coronary artery bypass grafting; PCI = percutaneous coronary intervention; RCT = randomized clinical trial; other 
abbreviations as previous.
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increase in the risk of stroke was found within SYNTAX score tertiles in PCI-treated patients 
(low 1.4% [n=4], intermediate 2.0% [n=6] and high 3.5% [n=9]).
Predictors of stroke
By multivariate analysis, the predictors with the greatest impact on likelihood of stroke 
within 4 years in all randomized patients were age per 10 years, hypertension, moderate or 
poor LVEF, and angina class CSS 3/4 (Table 2). Treatment with CABG was not significantly 
associated with increased stroke rates (OR=1.67, 95% CI 0.93-3.01, p=0.089).
In the PCI arm, several markers of the severity of cardiovascular disease (e.g. previous MI, 
peripheral vascular disease, moderate or poor LVEF, and angina class CSS 3/4) were found 
to be predictors of stroke within 4 years. In the CABG arm, patients had an increased risk of 
stroke if they were older and had previously experienced a TIA or stroke. 
nested registries
The CABG registry (N=644 followed for 5 years) predominantly included patients in whom 
PCI was not considered technically feasible by the Heart Team, and the PCI registry (n=192) 
included patients in whom it was felt that the outcome of CABG would be unfavorable.10 
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Figure 4 rate of stroke at 4 years in predefined and post hoc subgroups
The percentage of patients experiencing a stroke within the first through fourth years of follow-up (CABG blue; 
PCI orange/yellow) in the overall patient population, patients with LM or 3VD (without LM disease), patients with 
or without medically-treated diabetes, males and females, patients younger or older than 70 years of age, patients 
with or without carotid artery disease, and patients with or without prior TIA/stroke. Numbers are from the Kaplan-
Meier estimate (%) for the cumulative event rates (cumulative number of patients with events in the specified time 
window). 3VD = three-vessel disease; CABG = coronary artery bypass grafting; CAD = carotid artery disease; LM 
= left main; PCI = percutaneous coronary intervention; TIA = transient ischemic event
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As a result, patients in the CABG registry are comparable to the randomized trial except 
on SYNTAX score (37.8±13.3 versus 29.1±11.4 in the trial). In contrast, patients in the 
PCI registry had similar lesion complexity but higher Logistic EuroSCORE (7.7±9.0 versus 
3.8±4.5 in the trial).
The rate of stroke in the CABG registry was 4.2% (n=26 patients, n=29 strokes) at 4 years 
of follow-up; there were 3 patients that had 2 strokes. The rate was 3.1% (n=5 patients, 
n=5 strokes) in the PCI registry (Figure 1B and 1C). Baseline characteristics of the PCI and 
CABG registries are presented in Table 3. Similar as to the randomized cohorts, patients 
who experienced stroke more often had prior cerebrovascular events, peripheral vascular 
disease, or hypertension.
Off-pump CABG was performed in 120 patients, of which 6 patients had a stroke. Twenty 
patients suffered a stroke after on-pump CABG. The cumulative rate of stroke was 5.3% and 
4.0% in patients that underwent off-pump and on-pump surgery, respectively (p=0.57 by 
log rank).
table 2 univariate and multivariate predictors of stroke
  univariate or (95% cI) P-value Multivariate or (95% cI) P-value
overall cohort (n=1800)
Age per 10 years 1.65 (1.21-2.25) 0.001 1.56 (1.14-2.14) 0.006
Hypertension 4.02 (1.44-11.24) 0.008 3.47 (1.23-9.80) 0.019
Peripheral vascular disease 2.37 (1.16-4.84) 0.017 1.96 (0.94-4.10) 0.071
Moderate or poor LVEF 2.02 (1.10-3.71) 0.023 2.06 (1.08-3.95) 0.029
Angina class CSS 3/4 1.79 (0.99-3.22) 0.052 1.84 (1.01-3.35) 0.048
CABG treatment group 1.78 (1.00-3.18) 0.051 1.67 (0.93-3.01) 0.089
Medically treated diabetes* … … 0.91 (0.47-1.77) 0.790
Left main disease* … … 0.83 (0.46-1.53) 0.559
PcI cohort (n=903)
Previous MI 0.29 (0.10-0.84) 0.023 0.18 (0.05-0.62) 0.007
Hypertension 4.67 (1.10-19.76) 0.036 4.10 (0.95-17.62) 0.058
Peripheral vascular disease 2.58 (1.08-6.18) 0.033 2.73 (1.09-6.83) 0.031
Moderate or poor LVEF 1.99 (0.92-4.32) 0.081 2.62 (1.12-6.14) 0.027
Angina class CCS 3/4 2.27 (1.09-4.73) 0.028 2.54 (1.18-5.46) 0.017
Medically treated diabetes* … … 0.88 (0.37-2.06) 0.762
Left main disease* … … 1.04 (0.49-2.23) 0.915
cAbG cohort (n=897)
Age per 10 years 2.41 (1.38-4.20) 0.002 2.57 (1.43-4.63) 0.002
Prior TIA or stroke 3.43 (1.11-10.66) 0.033 3.58 (1.13-11.38) 0.031
Medically treated diabetes* … … 1.03 (0.36-2.94) 0.956
 Left main disease* … … 0.49 (0.17-1.40) 0.186
*Forced into the model. CABG = coronary artery bypass grafting; CCS = Canadian Cardiovascular Society; 
LVEF = left ventricular ejection fraction; MI = myocardial infarction; PCI = percutaneous coronary intervention; 
TIA = transient ischemic attack
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In the CABG registry, 3 patients suffered strokes that led to death. There were 26 dis-
charges of which 14 were to home, 8 were to a rehabilitation centre, and 4 to another facil-
ity. Seven (27%) CABG registry patients recovered from the stroke without residual deficits. 
The median hospital stay post-stroke was 11 days (range 6-21 days). In the PCI registry, one 
patient died as the result of a stroke. Three patients were discharged with residual deficits; 
one was discharged home and 2 to another facility. One patient recovered from the stroke 
without residual deficits. The median hospital stay after the stroke in PCI registry patients 
was 12 days (range 7-14 days).
dIscussIon
The overall incidence of stroke was low at 4 years in the SYNTAX trial and was not sig-
nificantly different between PCI and CABG. In the short-term after treatment, patients that 
table 3 baseline characteristics of registry stroke patients
cAbG registry PcI registry
Parameter overall
(n=644)
stroke 
Patients
(n=26)
non-stroke 
patients (n=618)
overall 
(n=192)
stroke 
Patients
(n=5)
non-stroke 
Patients
(n=187)
Age, yr 65.7±9.4 
(644)
67.0±9.7 
(26)
65.6±9.3 (618) 71.2±10.4 
(192)
74.4±7.2 
(5)
71.1±10.5 
(187)
Female gender 19% 
(124/644)
35% (9/26) 18.6% (115/618) 30% 
(57/192)
40% (2/5) 29.4% 
(55/187)
Prior stroke 6% (35/639) 12% (3/25) 5.2% (32/614) 8% (15/192) 40% (2/5) 7.0% (13/187)
Prior TIA 6% (36/638) 19% (5/26) 5.1% (31/612) 8% (15/191) 20% (1/5) 7.5% (14/186)
Carotid artery 
disease
12% 
(79/644)
19% (5/26) 12.0% (74/618) 10% 
(20/192)
0% (0/5) 10.7% 
(20/187)
Peripheral artery 
disease
14% 
(89/644)
19% (5/26) 13.6% (84/618) 16% 
(31/192)
60% (3/5) 15.0% 
(28/187)
History of 
smoking
64% 
(411/639)
65% 
(17/26)
64.3% (394/613) 57% 
(108/188)
40% (2/5) 57.9% 
(106/183)
Current smoker 22% 
(140/639)
19% (5/26) 22.0% (135/613) 11% 
(21/188)
0% (0/5) 11.5% 
(21/183)
Medically 
treated diabetes
26% 
(170/644)
35% (9/26) 26.1% (161/618) 30% 
(58/192)
80% (4/5) 28.9% 
(54/187)
Hypertension 74% 
(465/633)
88% 
(23/26)
72.8% (442/607) 76% 
(145/191)
80% (4/5) 75.8% 
(141/186)
Logistic 
EuroSCORE
4.0±4.4 
(644)
5.2±5.2 
(26)
4.0±4.4 (618) 7.7±9.0 
(192)
10.3±12.4 
(5)
7.7±8.9 (187)
SYNTAX score 37.8±13.3 
(632)
35.8±12.8 
(25)
37.9±13.3 (607) 31.6±12.3 
(189)
36.0±11.2 
(5)
31.5±12.4 
(184)
Numbers are % (n), or as mean ± standard deviation (n). CABG = coronary artery bypass grafting; PCI = 
percutaneous coronary intervention; TIA = transient ischemic attack
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underwent CABG were more likely to experience a stroke compared with PCI-treated 
patients. After this procedure-related risk, a similar stroke hazard was found in PCI and 
CABG patients during follow-up.
While large registries and randomized trials comparing PCI and CABG have mainly 
focused on survival, MI, and repeat revascularization, stroke is particularly underrepresented 
from such studies.13-15 Especially assessments of stroke over long-term follow-up have been 
limited. Yet, in-depth analysis of stroke is crucial to determine the true risk/benefit ratio of 
PCI and CABG, weighting the risk of stroke versus the risk of repeat revascularization.16 In 
our report the hazard of stroke during follow-up was low and there was a similar incidence 
of stroke after PCI and CABG, providing reassuring information especially for the surgical 
perspective. Nevertheless, the outcome of patients in this cohort was poor; stroke led to 
death in 6 patients (CABG n=3, PCI n=3) and a significant amount of surviving patients 
experience residual impairment after the stroke (CABG 68% and PCI 47%).
Procedure-related stroke remains a serious complication after isolated CABG occurring 
in as many as 1-4% of patients.5, 8, 17, 18 Previous nonrandomized studies of CABG versus 
PCI in LM or multivessel disease (MVD) patient populations have found either an increase 
in stroke in CABG-treated patients 6, 7 or no difference in stroke rate.19-21 However, data 
from randomized trials is limited and, like SYNTAX, not powered to detect a significant dif-
ference in stroke rate. A meta-analysis of 7 randomized trials comparing PCI (with balloon 
angioplasty of bare-metal stents) with CABG for multivessel disease showed that the 90-day 
stroke rate after randomization to PCI was significantly lower (0.5% vs. 1.1%, p=0.02).8 
Moreover, Daemen and colleagues reported in a meta-analysis of 5 randomized trials using 
bare metal stents that rates appear to be comparable at 5-year follow-up; 3.6% versus 3.1% 
for CABG and PCI, respectively.22 After adjustment for several clinical characteristics, there 
was little evidence of a benefit for either treatment, with an adjusted hazard ratio of 1.16 
(95% CI 0.73-1.83). Considering these data, the results presented here of the SYNTAX trial 
are comparable to other trials comparing PCI with CABG. However, the recent results from 
the FREEDOM trial showed a significant increase in stroke at 5-year follow-up after CABG 
as compared to PCI in 1,900 randomized diabetic patients.23 
Attempts in improving outcomes after surgical coronary revascularization should be 
directed towards reducing the rate of stroke. Indeed, some studies have shown a stroke 
benefit with off-pump surgery due to avoidance of cardiopulmonary bypass and indirect 
by reducing the rate of AF.24 In SYNTAX, 15% of randomized and 18.6% of registry CABG 
patients underwent off-pump surgery. No differences in rates of stroke in the trial (3.1% 
vs. 3.7% with on-pump) nor in the registry (5.0% vs. 3.8% with on-pump) were found, 
suggesting no benefit of off-pump CABG in reducing the rate of stroke. However, no data 
was available on manipulation of the ascending aorta or the use of epiaortic scanning so 
whether off-pump surgery would truly be beneficial cannot be evaluated. Furthermore, the 
numbers treated with the off-pump technique were small and no firm conclusions should 
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be based on these data. It should not be expected that off-pump surgery is useful in all 
patients undergoing isolated CABG, but it could be more beneficial to consider it merely 
for subgroups of patients with, for example, severe aortic calcification.25, 26 Further efforts 
should be directed in screening the aorta and the use of ‘no touch’ off-pump CABG if severe 
calcification is found. 
New-onset atrial fibrillation occurs in up to 40% of patients shortly after cardiac surgery 
and has clearly been associated with an increase in the incidence of stroke.27 Very limited 
data is available on AF during follow-up after revascularization. One study reported AF 
during follow-up in 11.4% of patients after CABG, but did not find show that this was 
related to stroke.28 In the SYNTAX trial, we found a low rate of atrial fibrillation/flutter during 
follow-up (PCI: 3.4% and CABG: 7.9%). The low incidence of AF and the smaller fraction 
of AF patients who experienced stroke make it difficult to draw any meaningful conclusions 
regarding the relationship between AF and stroke, especially when considering that the 
arrhythmia event was not adjudicated by the CEC. In this regard, the correlation between 
AF and stroke was only base on chart narratives, while the rate of stroke was clearly higher 
in patients with late arrhythmia. Unfortunately, AF could not be added to the univariate and 
multivariate analyses because it was considered an adverse event by itself, occurring late 
during follow-up.
Despite technical improvements, the cause of stroke after revascularization is multifacto-
rial and depends on many more factors, which are also relevant for patients treated with 
PCI. The presence of multivessel disease has been shown to independently predict stroke 
after both PCI and CABG.29, 30 In SYNTAX, the incidence of stroke in the PCI arm, but not 
the CABG arm, increased with SYNTAX score tertile, suggesting that stroke occurs more 
frequently in complex disease. Looking more specifically to LM or 3VD subgroups, LM 
disease has been shown to be a correlate of carotid artery disease, which may increase 
stroke in LM CABG patients.30-32 Additionally, aortic manipulation may be more prevalent in 
the LM compared with the 3VD subgroup, suggesting that the likelihood of stroke is higher 
in the LM subgroup. Nevertheless, LM/3VD was not significantly associated with stroke in 
the overall, PCI, or CABG multivariate model.
There is significant variation in the incidence of stroke among different subgroups of 
patients. Diabetes, female gender, prior TIA or stroke, and advanced age may influence the 
risk of stroke potentially because of widespread cerebrovascular disease, impaired cerebral 
blood flow and/or increased susceptibility to atheroembolism or thromboembolism.29, 30, 
33-37 Examining these subgroups in the SYNTAX patient population, there is a non-significant 
difference in the timing of stroke events in these subgroups that could impact potential 
preventative or treatment strategies. The timing of strokes in the PCI arm of these subgroups 
occurs throughout follow-up, whereas in CABG treated patients the majority of strokes 
occur in the first year. In the multivariate analysis we found that advanced age emerged as a 
significant independent predictor of stroke in the overall patient population as well as in the 
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CABG-treated cohort. Furthermore, several factors (e.g., hypertension, moderate or poor left 
ventricular ejection fraction) that have been shown to predict stroke 38 indeed emerged as 
independent predictors in our analysis. Patients in the randomized trial and nested registries 
that suffered a stroke more often had prior cerebrovascular events. Clearly this factor is 
related to an increased risk of stroke after revascularization, although we were only able to 
confirm this through multivariate analyses in the CABG cohort. Furthermore, female gender 
and diabetes did not emerge as significant predictors of stroke, but these results may be the 
consequence of the low number of events. 
The length of time between randomization and treatment was similar in those CABG 
and PCI patients who suffered a stroke suggesting the numeric increase in preprocedural 
stroke in the CABG arm was not related to a delay in surgical therapy. Nevertheless, patients 
randomized to CABG would have been less likely to receive antiplatelet therapy while 
awaiting their index revascularization. This may have influenced the preprocedure stroke 
rate as dual antiplatelet therapy has been shown to reduce the risk of a major vascular event 
compared with aspirin alone (though it is less effective than oral anticoagulant therapy).39, 
40 There were three preprocedure strokes in the CABG arm; one stroke may have been the 
result of preoperatively discontinuing antiplatelet medications, since the stroke occurred on 
the day before the procedure when the platelet count would have been relatively high. The 
other 2 strokes were unlikely to be related to discontinued medications due to the timing 
of the stroke.
As dual antiplatelet therapy is not the accepted standard of care for post-CABG patients, 
the overall increase in stroke could have been influenced by the reduced use of aspirin or 
other antiplatelet agents in the CABG arm. However, the cause of stroke in PCI and CABG 
cohorts could be different, and even if medication use was comparable this may therefore 
only have a limited affect on stroke rates. Still, establishing clinical directives for aggressive 
medical therapy in CABG patients might result in a decrease in stroke risk and is worthy of 
further study.
study limitations
Although this analysis provides contemporary insights into the incidence of stroke in a com-
plex PCI and CABG-treated patient population, it is underpowered to detect a difference 
in stroke rate. Furthermore, more patients withdrew consent (or were lost to follow-up) in 
the CABG treatment arm, which may have affected our findings, although this is unlikely.12
Data on preoperative atrial fibrillation or new atrial fibrillation during index revascular-
ization admission was not recorded in the SYNTAX trial and therefore such analyses could 
not be included. Follow-up data on atrial fibrillation or flutter were reported by investigator 
sites as adverse events and were not adjudicated by an independent Clinical Events Commit-
tee, and therefore the conclusions derived from these data are limited. Furthermore, patient 
level details concerning the level of aortic manipulation and the presence of asymptomatic 
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carotid stenosis and mild neuropsychological disturbance pre- and post-revascularization 
were not captured.
Finally, a rule of thumb regarding multivariate analyses is to include one covariate per 
approximately 10 events. We have limited the inclusion of covariates strictly to those deemed 
clinically relevant, but still have over-fitted the model to include more covariates. These data 
from the multivariate analyses should therefore be interpreted with caution. However, the 
limited number of stroke comparisons from randomized PCI versus CABG trials was an 
incentive to over-fit the model as this may provide novel hypothesis-generating data as to 
the multifactorial cause of stroke after myocardial revascularization.
conclusIons
The overall incidence of stroke was low at 4 years in the SYNTAX trial in both CABG and 
PCI-treated patients. Though more strokes occurred in the CABG arm versus the PCI arm 
early in the study, no significant differences were found at 4 years and the outcome of stroke 
after PCI and CABG was similar.
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AbstrAct
Objective
This prespecified subgroup analysis examined the effect of diabetes on left main coronary 
disease (LM) and/or three-vessel disease (3VD) in patients treated with percutaneous coro-
nary intervention (PCI) or coronary artery bypass surgery (CABG) in the SYNTAX trial.
Methods
Patients (N=1800) with LM and/or 3VD were randomized to receive either PCI with TAXUS 
Express paclitaxel-eluting stents or CABG. Five-year outcomes in subgroups with (N=452) 
or without (N=1348) diabetes were examined: major adverse cardiac or cerebrovascular 
events (MACCE), the composite safety endpoint of all-cause death/stroke/myocardial infarc-
tion (MI), and individual MACCE components death, stroke, MI, and repeat revasculariza-
tion. Event rates were estimated with Kaplan-Meier analyses.
Results
In diabetic patients, 5-year rates were significantly higher for PCI versus CABG for MACCE 
(PCI: 46.5% versus CABG: 29.0%; p<0.001) and repeat revascularization (PCI: 35.3% ver-
sus CABG: 14.6%; p<0.001). There was no difference in the composite of all-cause death/
stroke/MI (PCI: 23.9% versus CABG: 19.1%; p=0.26), or individual components all-cause 
death, stroke, or MI. In non-diabetic patients, rates with PCI were also higher for MACCE 
(PCI: 34.1% versus CABG: 26.3%; p=0.002) and repeat revascularization (PCI: 22.8% versus 
CABG: 13.4%; p<0.001), but not for the composite endpoint of all-cause death/stroke/MI 
(PCI: 19.8% versus CABG: 15.9%; p=0.069). There were no differences in all-cause death or 
stroke, but rates of MI (PCI: 9.9% versus CABG: 3.4%; p<0.001) were significantly increased 
in the PCI arm in non-diabetic patients.
Conclusions
In both diabetic and non-diabetic patients, PCI resulted in higher rates of MACCE and repeat 
revascularization at 5 years. Although PCI is a potential treatment option in patients with 
less complex lesions, CABG should be the revascularization option of choice for patients 
with more complex anatomic disease, especially with concurrent diabetes.
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IntroductIon
The global prevalence of diabetes mellitus has continuously increased over the last decades, 
currently affecting more than 347 million people.1, 2 Diabetes is a common co-morbidity in 
patients with coronary artery disease that are evaluated for revascularization, and is shown 
to be a predictor of adverse events during ollow-up after coronary artery bypass grafting 
(CABG) and percutaneous coronary intervention (PCI).3, 5 However, long-term data from 
randomized trials are limited, particularly for the comparison between CABG and PCI with 
drug-eluting stents.
The Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Sur-
gery (SYNTAX) trial compared PCI with paclitaxel-eluting stents (PES) and CABG for patients 
with de novo three-vessel and/or left main disease.6, 7 Prespecified subgroup analyses of 
diabetic versus non-diabetic patients have been reported at one- and three-year follow-
up.8, 9 This study examined the impact of diabetes on 5-year outcomes after PCI and CABG.
Methods
study design
The design and methods of the SYNTAX trial have been reported previously.10 It was a 
prospective multinational randomized (1:1) trial in which 1800 patients with de novo 
three-vessel and/or left main coronary artery disease were randomly assigned to undergo 
PCI with TAXUS Express paclitaxel-eluting stents (Boston Scientific, Natick, MA, USA) or 
CABG. Based on the clinical judgment and consensus of a multidisciplinary Heart Team 
consisting of an cardiovascular surgeon and interventional cardiologist,11 patients with 
anticipated clinical revascularization equipoise through PCI and CABG were randomized 
(CABG n=897, PCI n=903). Those with expected unfavourable outcomes for PCI or CABG 
were included in the CABG-ineligible PCI registry (n=198) or PCI-ineligible CABG registry 
(n=1077), respectively.12 Five-year clinical follow-up was completed by a clinic visit or tele-
phone call in 86.5% of CABG patients and 94.5% of PCI patients. Follow-up was complete 
(clinical follow-up or death) in 88.0% and 95.2%, respectively.
Randomization was stratified according to the status of diabetes and left main disease. 
The subgroup analysis according to diabetes status was prespecified in the trial protocol, 
although no formal statistical hypothesis was defined a priori.
The institutional review board of each of the 85 participating cites approved the protocol. 
All patients provided written informed consent before enrolment. The trial is registered on 
the National Institute of Health website with identifier NCT00114972.
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definitions
Medically treated diabetes was defined as treatment with oral hypoglycemic agents or 
insulin at the time of enrollment. The composite endpoint of major adverse cardiac or 
cerebrovascular events (MACCE) included all-cause death, cerebrovascular accident (CVA), 
myocardial infarction (MI), or repeat revascularization (subsequent PCI or CABG). Cerebro-
vascular events, or stroke, were defined as focal neurological deficits of central origin lasting 
>72 h, resulting in permanent brain damage or body impairment. Myocardial infarction was 
defined in relation to intervention status as follows: (i) after allocation but before treatment: 
Q-wave [new pathological Q-waves in ≥2 leads lasting ≥0.04 s with creatine kinase-MB 
(CK-MB) levels elevated above normal] and non-Q-wave MI [elevation of CK levels >2× 
the upper limit of normal (ULN) with positive CK-MB or elevation of CK levels to >2× ULN 
without new Q-waves if no baseline CK-MB was available]; (ii) <7 days after intervention: 
new Q-waves and either peak CK-MB/total CK >10% or plasma level of CK-MB 5× ULN; 
and (iii) ≥7 days after intervention: new Q-waves or peak CK-MB/total CK >10% or plasma 
level of CK-MB 5× ULN or plasma level of CK 5× ULN. The CK/CK-MB enzyme levels were 
obtained and measured by a core laboratory for all randomized patients. An independent 
Clinical Event Committee adjudicated the events.
statistical analysis
All analyses were according to the intention-to-treat principle, and performed using SAS 
software version 8.0 or higher (SAS Institute, Cary, NC, USA). Data are summarized using 
descriptive statistics, presented as proportions (%, count/sample size) or mean ± standard 
deviation. Continuous variables were compared using the Student t test; differences in dis-
crete variables were assessed with the χ2 test or Fisher’s exact test, where appropriate. Time-
to-event Kaplan-Meier estimates with log rank testing were used to compare PCI and CABG 
in diabetic and nondiabetic patients, and to compare diabetics versus nondiabetics in PCI 
and CABG groups. P values for interaction were generated by logistic regression χ2 test. Post 
hoc subgroup analyses according to SYNTAX Score tertiles (low 0-22, intermediate 23-32, 
high ≥33) were performed using time-to-event Kaplan-Meier estimates.13 Univariate analysis 
including a combination of preoperative and intraoperative variables was used to identify 
potential predictors of 5-year outcomes. Subsequently, multivariate predictors of MACCE, 
the composite safety endpoint of all-cause death/stroke/MI, and repeat revascularization 
after PCI and CABG were identified using step-wise selection with a significance level of 
<0.10 for entry and exit in a logistic regression model. A p value <0.05 was considered to 
be statistically significant.
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results
baseline characteristics
In the SYNTAX trial 1800 patients were randomly assigned to PCI (n=903) and CABG 
(n=897), producing two well-matched treatment groups.6 Compared to non-diabetic patients 
(n=1348), patients with diabetes (n=452) had a significantly higher risk profile, which was 
reflected in a higher EuroSCORE of 4.0 ± 2.7 versus 3.7 ± 2.6, respectively (p=0.027) (Table 
1). Diabetics also had more coronary lesions (4.6 ± 1.8 versus 4.3 ± 1.8, p=0.003) and a 
trend towards more diffuse disease or small vessels (13% versus 10%, p=0.061), although 
the mean SYNTAX Score was comparable to non-diabetics (29.0 ± 11.2 versus 28.6 ± 11.5, 
p=0.52).
diabetes status subgroups
Table 2 lists the clinical outcomes according to diabetes status and treatment arm. The rate of 
MACCE was significantly different between CABG and PCI among both nondiabetic patients 
and diabetic patients (Figure 1). There were no differences in the composite safety endpoint 
of all-cause death/stroke/MI in nondiabetic or diabetic patients. Rates of all-cause death 
were similar among nondiabetic CABG and PCI patients (HR=1.12 [95% CI 0.81-1.55], 
p=0.48), and diabetic patients (HR=1.57 [95% CI 0.97-2.55], p=0.065). Cardiac death was 
significantly more frequent in patients treated with PCI than those who underwent CABG, 
in nondiabetics (HR=1.62 [95% CI 1.03-2.55]; p=0.035) and diabetics (HR=2.01 [95% CI 
1.04-3.88]; p=0.034). Increased repeat revascularization after PCI as compared to CABG 
was present in nondiabetic (HR=1.82 [95% CI 1.39-2.38]; p<0.001) and diabetic (HR=2.75 
[95% CI 1.78-4.24]; p<0.001) patients. There was a significantly higher rate of myocardial 
infarction after PCI than after CABG in nondiabetic patients (HR=2.90 [95% CI 1.79-4.70]; 
p<0.001), but this was not significant in diabetic patients (HR=1.62 [95% CI 0.77-3.41]; 
p=0.20). There were no differences in stroke or graft occlusion/stent thrombosis between 
groups.
Although patients with diabetes who underwent CABG had numerically higher rates of 
clinical adverse events than nondiabetic CABG patients, there were no statistically signifi-
cant differences at 5-year follow-up. However, diabetic patients who underwent PCI had 
significantly higher rates of MACCE (p<0.001), death (p=0.003), and repeat revasculariza-
tion (p<0.001) than nondiabetic patients. There were no significant interactions between 
diabetes status and treatment. 
diabetes control subgroups
Subgroup analyses according to diabetes treatment (oral hypoglycemic agents or insulin) 
(Table 3) showed that the MACCE rate was significantly increased after PCI in the group on 
oral hypoglycemic agents (PCI: 40.4% versus CABG: 26.4%; p=0.022) and insulin (PCI: 
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table 1 baseline characteristics
nondiabetic (n=1348) diabetic (n=452) p Value
Age, years 65.0 ± 9.9 (1348) 65.4 ± 9.2 0.049
Male gender 79.9 (1077/1348) 71.0 (321/452) <0.001
Comorbid risk factors
Body mass index, kg/m2 27.5 ± 4.4 29.5 ± 5.2 <0.001
Metabolic syndrome 37% (398/1064) 70% (258/369) <0.001
Waist >40 inch male, >35 inch female 42% (502/1194) 61% (238/393) <0.001
Triglycerides ≥150 mg/dL 33% (409/1230) 42% (170/408) 0.002
HDL <40 mg/dL male, <50 mg/dL female 45% (544/1199) 61% (238/389) <0.001
Blood pressure ≥130/85 mm Hg 65% (80/1348) 70% (316/452) 0.071
Fasting glucose ≥110 mg/dL 28% (260/934) 82% (286/348) <0.001
Hemoglobin A1c ≥7.0% 3% (31/1179) 57% (215/378) <0.001
Hyperlipidemia 77% (1029/1341) 82% (362/444) 0.035
Medically treated diabetes 0% (0/1348) 100% (452/452) <0.001
Insulin-requiring diabetes 0% (0/1348) 40% (182/452) <0.001
Cardiovascular history
Current smoker 22% (292/1343) 16% (71/450) 0.006
Prior myocardial infarction 33% (442/1333) 32% (143/447) 0.65
Congestive heart failure 4% (50/1334) 7% (33/444) 0.001
Carotid artery disease 7% (99/1348) 11% (49/452) 0.019
Prior cerebrovascular accident 4% (51/1341) 6% (27/448) 0.046
Prior transient ischemic attack 4% (58/1341) 6% (26/448) 0.20
Peripheral vascular disease 8% (111/1348) 15% (66/452) <0.001
Creatinine >200 μmol/L 1% (13/1348) 3% (13/452) 0.003
Unstable angina 28% (378/1348) 30% (134/452) 0.51
LVEF <30% 2% (21/1348) 3% (13/452) 0.075
Parsonnet score 7.5 ± 6.8 11.3 ± 6.4 <0.001
Additive EuroSCORE 3.7 ± 2.6 4.0 ± 2.7 0.027
Lesion complexity
Diffuse disease or small vessels 10% (136/1338) 13% (60/449) 0.061
SYNTAX score 28.6 ± 11.5 29.0 ± 11.2 0.52
Lesion Characteristics
Number of lesions 4.3 ± 1.8 4.6 ± 1.8 0.003
Left main, any 36% (480/1338) 29% (130/449) 0.007
Left main only 4% (52/1338) 2% (10/449) 0.096
Left main + 1 vessel 6% (75/1338) 4% (18/449) 0.19
Left main + 2 vessel 12% (160/1338) 11% (50/449) 0.64
Left main + 3 vessel 14% (193/1338) 12% (52/449) 0.13
Three-vessel disease only 64% (858/1338) 71% (319/449) 0.007
HDL = high-density lipoprotein; LVEF = left ventricular ejection fraction
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56.2% versus CABG: 32.6%; p=0.002). Rates of repeat revascularization were also higher 
in both the insulin dependent and oral hypoglycemic groups (PCI: 29.9% versus CABG: 
12.0%; p<0.001 and PCI: 44.3% versus CABG: 18.1%; p=0.001, respectively). However, 
the composite safety endpoint of all-cause death/stroke/MI was comparable between PCI 
and CABG in the group on oral hypoglycemic agents (PCI: 18.8% versus CABG: 17.7%; 
p=0.92), although there was a significantly higher rate of cardiac death (PCI: 18.8% versus 
CABG: 7.1%; p=0.023) in patients that underwent PCI. There were no differences in stroke 
or myocardial infarction in either the groups of patients on oral hypoglycemic agents or 
insulin.
A
B
C
D
E
F
Figure 1
Five-year outcomes of percutaneous coronary intervention versus coronary artery bypass 
grafting in diabetic patients and nondiabetic patients
Kaplan-Meier estimates of major adverse cardiac or cerebrovascular events (MACCE) (A and D), the composite 
endpoint of all-cause death/stroke/myocardial infarction (B and E), repeat revascularization (C and F) in diabetic 
patients (A-C) and nondiabetic patients (D-F). CABG = coronary artery bypass grafting (solid lines); PCI = 
percutaneous coronary intervention (dotted lines)
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The rate of graft occlusion or stent thrombosis was not significantly different in the oral 
hypoglycemic agents group (PCI: 3.2% versus CABG: 5.7%; p=0.35) or the patients that 
were on insulin (PCI: 8.6% versus CABG: 2.5%; p=0.081). However, the interaction term 
was statistically significant (p=0.046), suggesting a different impact of diabetes treatment 
effect on outcomes after PCI and CABG. None of the interaction terms for the other out-
comes were significant.
sYntAX score subgroups
Subgroup analyses according to the complexity of coronary artery disease demonstrated 
that there was a consistent increase in adverse events after PCI with increasing SYNTAX 
Scores, while this was not the case for CABG patients (Figure 2). Event rates of MACCE 
and the composite safety endpoint therefore showed a stepwise increase in the difference 
between PCI and CABG with increasing SYNTAX Scores, irrespective of the diabetes status. 
Among nondiabetic patients the rates of repeat revascularization showed a similar trend 
table 2 Five-year clinical outcomes according to diabetes status
nondiabetic (n=1348) diabetic (n=452) nondiabetic 
versus diabetic
clinical 
outcome
cAbG 
(n=676)
PcI 
(n=672)
p 
Value
cAbG 
(n=221)
PcI 
(n=231)
p 
Value
p Value 
(cAbG)
p Value 
(PcI)
Interaction 
p Valuea
MACCE 26.3% 
(167)
34.1% 
(226)
0.002 29.0% 
(59)
46.5% 
(105)
<0.001 0.37 <0.001 0.17
All-cause 
death/Stroke/
myocardial 
infarction
15.9% 
(101)
19.8% 
(131)
0.069 19.1% 
(39)
23.9% 
(54)
0.26 0.25 0.18 0.76
All-cause death 10.9% 
(68)
12.0% 
(79)
0.48 12.9% 
(26)
19.5% 
(44)
0.065 0.34 0.003 0.43
Cardiac death 4.9% 
(30)
7.7% 
(50)
0.035 6.5% 
(13)
12.7% 
(28)
0.034 0.31 0.018
Stroke 3.5% 
(22)
2.2% 
(14)
0.15 4.7% 
(9)
3.0% 
(6)
0.34 0.49 0.55 0.97
Myocardial 
infarction
3.4% 
(22)
9.9% 
(64)
<0.001 5.4% 
(11)
9.0% 
(19)
0.20 0.22 0.66 0.18
Repeat 
revascularization
13.4% 
(82)
22.8% 
(145)
<0.001 14.6% 
(28)
35.3% 
(75)
<0.001 0.60 <0.001 0.081
PCI 12.9% 
(78)
19.3% 
(123)
0.001 12.9% 
(24)
28.5% 
(60)
<0.001 0.95 0.004
CABG 1.1% 
(7)
5.8% 
(36)
<0.001 1.9% 
(4)
8.7% 
(18)
0.004 0.35 0.12
Graft occlusion/
stent thrombosis
3.9% 
(24)
5.6% 
(36)
0.14 4.3% 
(8)
5.3% 
(11)
0.61 0.84 0.84 0.73
aBinary logistic regression interaction term for diabetes status by treatment arm. CABG = coronary artery bypass 
grafting; MACCE = major adverse cardiac or cerebrovascular events; PCI = percutaneous coronary intervention
PCI versus CABG in diabetic patients 343
C
ha
pt
er
 2
1
ta
bl
e 
3
Fi
ve
-y
ea
r 
cl
in
ic
al
 o
ut
co
m
es
 a
cc
or
di
ng
 t
o 
di
ab
et
es
 t
re
at
m
en
t
o
ra
l h
yp
og
ly
ce
m
ic
 A
ge
nt
s 
(n
=
27
0)
In
su
lin
 (
n=
45
2)
o
ra
l v
er
su
s 
In
su
lin
 
tr
ea
tm
en
t
c
lin
ic
al
 o
ut
co
m
e
c
A
b
G
 (
n=
12
8)
Pc
I 
(n
=
14
2)
p 
V
al
ue
c
A
b
G
 (
n=
93
)
Pc
I 
(n
=
89
)
p 
V
al
ue
p 
V
al
ue
 
(c
A
b
G
)
p 
V
al
ue
 
(P
c
I)
In
te
ra
ct
io
n 
p 
V
al
ue
a
M
A
C
C
Eb
26
.4
%
 (3
1)
40
.4
%
 (5
6)
0.
02
2
32
.6
%
 (2
8)
56
.2
%
 (4
9)
0.
00
2
0.
37
0.
02
3
0.
34
A
ll-
ca
us
e 
de
at
h/
St
ro
ke
/m
yo
ca
rd
ia
l 
in
fa
rc
tio
n
17
.7
%
 (2
1)
18
.8
%
 (2
6)
0.
92
21
.0
%
 (1
8)
32
.1
%
 (2
8)
0.
09
1
0.
65
0.
01
8
0.
25
A
ll-
ca
us
e 
de
at
h
12
.0
%
 (1
4)
16
.6
%
 (2
3)
0.
32
14
.0
%
 (1
2)
24
.1
%
 (2
1)
0.
08
2
0.
70
0.
15
0.
53
C
ar
di
ac
 d
ea
th
6.
0%
 (7
)
8.
9%
 (1
2)
0.
42
7.
1%
 (6
)
18
.8
%
 (1
6)
0.
02
3
0.
79
0.
03
0
St
ro
ke
5.
2%
 (6
)
1.
6%
 (2
)
0.
09
4
4.
0%
 (3
)
5.
2%
 (4
)
0.
65
0.
56
0.
13
0.
17
M
yo
ca
rd
ia
l i
nf
ar
ct
io
n
5.
1%
 (6
)
7.
5%
 (1
0)
0.
49
5.
7%
 (5
)
11
.6
%
 (9
)
0.
23
0.
83
0.
34
0.
76
R
ep
ea
t r
ev
as
cu
la
ri
za
tio
n
12
.0
%
 (1
3)
29
.9
%
 (4
0)
<
0.
00
1
18
.1
%
 (1
5)
44
.3
%
 (3
5)
0.
00
1
0.
19
0.
06
3
>
0.
99
PC
I
12
.9
%
 (7
8)
24
.8
%
 (3
3)
0.
00
4
15
.0
%
 (1
2)
34
.6
%
 (2
7)
0.
00
5
0.
41
0.
21
C
A
B
G
1.
1%
 (7
)
7.
0%
 (9
)
0.
02
0
3.
3%
 (3
)
11
.6
%
 (9
)
0.
06
4
0.
19
0.
23
G
ra
ft 
oc
cl
us
io
n/
st
en
t t
hr
om
bo
si
s
5.
7%
 (6
)
3.
2%
 (4
)
0.
35
2.
5%
 (2
)
8.
6%
 (7
)
0.
08
1
0.
30
0.
07
2
0.
04
6
D
at
a 
ar
e 
K
ap
la
n-
M
ei
er
 ti
m
e-
to
-e
ve
nt
 e
st
im
at
es
 e
xp
re
ss
ed
 a
s 
%
 (n
); 
lo
g 
ra
nk
 p
 v
al
ue
. a
B
in
ar
y 
lo
gi
st
ic
 r
eg
re
ss
io
n 
in
te
ra
ct
io
n 
te
rm
 fo
r 
di
ab
et
es
 s
ta
tu
s 
by
 tr
ea
tm
en
t a
rm
. b
M
A
C
C
E 
co
ns
is
ts
 
of
 a
ll-
ca
us
e 
de
at
h,
 s
tr
ok
e,
 m
yo
ca
rd
ia
l i
nf
ar
ct
io
n,
 o
r 
re
pe
at
 r
ev
as
cu
la
ri
za
tio
n 
(C
A
B
G
 o
r 
PC
I) 
in
 a
ny
 v
es
se
l. 
C
A
B
G
 =
 c
or
on
ar
y 
ar
te
ry
 b
yp
as
s 
gr
af
tin
g;
 M
A
C
C
E 
=
 m
aj
or
 a
dv
er
se
 c
ar
di
ac
 o
r 
ce
re
br
ov
as
cu
la
r 
ev
en
ts
; P
C
I =
 p
er
cu
ta
ne
ou
s 
co
ro
na
ry
 in
te
rv
en
tio
n
Part 3 Stenting versus bypass surgery344
as for MACCE and the composite safety endpoint. However, in diabetic patients even in 
the low SYNTAX Score tertile was there a significantly higher event rate after PCI than after 
CABG (PCI: 39.4% versus CABG: 17.2%; p=0.006).
Figure 2
Five-year outcomes for diabetic patients and nondiabetic patients according to anatomic 
lesion complexity, as measured by the sYntAX score
Binary event rates of major adverse cardiac or cerebrovascular events (MACCE) (A and D), the composite 
endpoint of all-cause death/stroke/myocardial infarction(B and E), repeat revascularization (C and F) in diabetic 
patients (A-C) and nondiabetic patients (D-F). Rates are separated according to SYNTAX Score tertiles, indicating 
low (0-22), intermediate (23-32), and high (≥33) anatomic lesion complexity. CABG = coronary artery bypass 
grafting (open bars); PCI = percutaneous coronary intervention (solid bars)
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Multivariate analysis
The final multivariate model did not identify medically treated diabetes as an independent 
predictor in the CABG cohort. However, for patients that underwent PCI, medically treated 
diabetes was an independent predictor of MACCE (OR=1.71 [95% CI 1.22-2.39]; p=0.002) 
and repeat revascularization (OR=1.73 [95% CI 1.27-2.36]; p<0.001), but not for the com-
posite safety endpoint of all-cause death/stroke/MI.
dIscussIon
This study examined the impact of diabetes on clinical outcomes after PCI and CABG in 
the SYNTAX trial. The rates of MACCE were significantly higher after PCI as compared with 
CABG in both the diabetic and nondiabetic patient subgroups, and this difference is mainly 
driven by an increase in repeat revascularization. However, the difference between PCI and 
CABG is larger for patients with diabetes than for those without. In contrast to the previous 
one- and three-year follow-up reports, patients that underwent PCI also had significantly 
higher rates of cardiac death at five years.
Randomized comparisons between PCI and CABG for the treatment of coronary artery 
disease in diabetic patients have mainly been limited by subgroup analyses of large trials. 
These trials found no significant difference in long-term survival between the two treat-
ment strategies for diabetic patients, but were underpowered and limited by being post hoc 
exploratory subgroup analyses. The only analysis that found a significant benefit of CABG 
over PCI from the BARI trial included 353 patients and reported 10-year survival rates of 
57.9% and 45.5% (p=0.025), respectively.14 These data of 10 randomized trials (of which 
only four used bare-metal stents) were summarized in a meta-analysis of 7794 patients, 
demonstrating that CABG is superior over PCI in diabetic patients.3 A pooled analysis of 
trials exclusively using stents showed no difference in outcomes between PCI and CABG, 
irrespective of diabetes status.15 The debate between PCI and CABG remained ongoing but 
the introduction of drug-eluting stents was promising since it showed a reduction in the rate 
of restenosis in diabetic patients.16, 17 This drove new analyses of CABG versus PCI with 
drug-eluting stents. Although results were indeed better with drug-eluting stents, PCI failed 
to reach non-inferiority to CABG in the first randomized trial dedicated to patients with dia-
betes (CARDia).18 Recently the results from the randomized FREEDOM trial (n=1900) even 
showed that CABG was superior to drug-eluting stents for the composite primary endpoint 
of death, stroke, and MI (p=0.005).19
This substudy of the SYNTAX trial was also from a hypothesis-generating subgroup 
analysis and, although predefined, should be interpreted with caution. Nevertheless, the 
results are similar to that from the CARDia and FREEDOM trials.18, 19 There was a significant 
difference between PCI and CABG in clinical outcomes, which was more pronounced in 
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diabetic than nondiabetic patients. This suggests that diabetes may be more relevant in 
PCI patients than in CABG patients. Clinical outcomes in CABG patients were similar for 
diabetic and nondiabetic patients, while outcomes after PCI were significantly worse for 
diabetic patients as compared with nondiabetic patients. A reason for this might be that a 
patent distal graft functions as protection for future more proximal lesions caused by pro-
gressing diffuse disease. After PCI, progression of diffuse disease in diabetic patients forms 
new lesions that may cause ischemia and/or symptoms. This may also explain why diabetes 
was not an independent predictor of MACCE after CABG in the SYNTAX trial.20, 21
Analyses according to diabetes control show that especially insulin-dependent diabetic 
patients are at higher risk of adverse events during follow-up. Diabetic patients on insulin that 
underwent PCI had significantly higher rates of MACCE, the composite safety endpoint of 
all-cause death/stroke/MI, and cardiac death than patients on oral hypoglycemic agents who 
underwent PCI. Apart from MACCE and repeat revascularization, there were no significant 
differences between PCI and CABG for patients on oral hypoglycemic agents. In contrast, 
compared with insulin-dependent patients that underwent CABG, those who underwent PCI 
had significantly more cardiac deaths (p=0.023). Therefore, the Heart Team may particularly 
advocate for CABG to treat insulin-dependent patients, while it should be carefully assessed 
whether PCI should be preferred over medical therapy for insulin-dependent patients unsuit-
able for CABG. The SYNTAX trial did not include a medical therapy treatment arm, but it will 
be interested to see what new developments in improved antiplatelet therapy (e.g. prasugrel, 
ticagrelor) will contribute to the debate regarding PCI versus medical therapy for diabetics 
with complex coronary disease.
The complexity of coronary artery disease is crucial when considering different revas-
cularization options. In contrast to the results from the FREEDOM trial where there was no 
treatment-by-SYNTAX Score interaction,19previous studies found that the SYNTAX Score was 
a predictor of adverse events after PCI but not after CABG. In the current study, differences 
in outcomes increased incrementally with lesion complexity, even more so in diabetics than 
nondiabetics. However, recent evidence suggests that a Logistic Clinical SYNTAX Score 
-- consisting of the SYNTAX Score, age, creatinine clearance, and left ventricular ejection 
fraction -- is a better predictor of 1-year all-cause death than the SYNTAX Score itself.22 The 
addition of diabetes added little improvement of model performance of the Logistic Clini-
cal SYNTAX Score. Nevertheless, in our study the presence of diabetes seems to reinforce 
the superiority of CABG over PCI and current SYNTAX Score thresholds may need to be 
adjusted accordingly for patients with diabetes.
According to the SYNTAX study CABG should remain the gold standard for patients 
complex coronary artery disease, especially those with diabetes. However, new stents 
may have the potential of reducing rates of adverse events after PCI. In the SYNTAX trial 
paclitaxel-eluting stents were exclusively used, a stent that is less frequently used in current 
practice due to superiority of other sirolimus- and everolimus-eluting stents. It is still unclear 
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which stent should be preferred for patients with diabetes, since improved outcomes with 
sirolimus- or everolimus-eluting stents over paclitaxel-eluting stents for diabetics has been 
debated.23, 24 In the FREEDOM trial both paclitaxel- and sirolimus-eluting stents were used, 
but the absolute difference in the primary endpoint between stenting and CABG did not 
differ: ∆6.5% and ∆6.7%, respectively.19
study limitations
Subgroup analyses have been criticized by methodologists and should be interpreted with 
caution. The diabetes subgroup was predefined and stratified randomization was performed 
to ensure equal distribution of diabetic patients over the PCI and CABG treatment arms. 
Nevertheless, the current analyses were not adequately powered and the results should be 
viewed as hypothesis-generating only. 
The SYNTAX trial enrolled patients with complex left main and/or three-vessel disease 
and the results should therefore not be extrapolated to the overall cohort of patients with 
symptomatic coronary artery disease evaluated for coronary revascularization. 
conclusIons
In both diabetic and non-diabetic patients, PCI resulted in higher rates of MACCE, cardiac 
death, and repeat revascularization at 5 years. Although PCI is a potential treatment option 
in patients with less complex lesions, CABG should be the revascularization option of choice 
for patients with more complex anatomic disease, especially with concurrent diabetes. 
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AbstrAct
Percutaneous coronary intervention (PCI) with bare-metal stents (BMS) has been performed 
increasingly ever since its introduction in the late 1970s. BMS have been replaced by drug-
eluting stents (DES), and many interventional cardiologists consider this as a breakthrough 
therapy that might compete with coronary artery bypass grafting (CABG) as the standard 
treatment for coronary artery disease. Several DES are currently used and elute different 
agents. This review described what these agents are and provides an overview regarding the 
outcomes and associated adverse events. More importantly, this review compares outcomes 
of PCI with DES to CABG for patients with left anterior descending coronary artery involve-
ment, left main involvement, or multivessel disease.
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IntroductIon
Coronary artery disease (CAD) effects a large population, approximately 5000 per million 
US adults undergo revascularization treatment, accumulating to over 1 million procedures 
annually.1 Coronary artery bypass surgery (CABG) has been the golden standard for revas-
cularization of CAD since the early 1980s. However, the introduction of percutaneous 
coronary interventions (PCI) has decreased the annual rate of CABG to only ~20% of all 
coronary revascularizations in 2008, and it continues to decline.1 Of all revascularization 
procedures with PCI approximately 68% are performed with drug-eluting stents (DES), 
around 28% are performed with bare-metal stents (BMS), and still around 3.5% of patients 
receive balloon angioplasty. In patients with complex multivessel disease and/or left main 
involvement CABG is the golden standard as it offers the best long-term outcome. However, 
owing to its invasiveness, CABG is not always offered to the patient. The heart team, a 
team of interventional cardiologists and surgeons,2 should decide whether PCI or CABG is 
the preferred treatment according to the coronary characteristics and co-morbidities of the 
patient. The multidisciplinary approach unfortunately only exists in a minority of centers. 
This may result in unnecessary revascularization procedures, mainly PCI. A recent study 
showed that 11.6% of PCIs for nonacute indications were performed inappropriate as it 
was unlikely to improve patient’s health status or survival. Another 38.0% were classified 
as ‘uncertain’ appropriateness since the correctness of indication could not be based on the 
available patient information and/or diagnostics.3
Despite the fact that the introduction of DES has converged outcomes after PCI and 
CABG, it is crucial to remain reticent towards the capacity of DES in reducing adverse 
events in coronary patients, especially since CABG shows excellent results.4 In this review 
we discuss the current DES with their eluting agents and the negative events associated 
with DES. More importantly, we review the available literature of studies comparing DES to 
CABG and discuss which treatment is preferred in specific left anterior descending (LAD), 
MVD, or LM patient cohorts.
des Versus bMs - FIrst GenerAtIon stents
sirolimus-eluting stent (ses)
Sirolimus, originally developed as antifungal agent, is an immunosuppressant and has been 
linked with a reduction of neointimal proliferation by inhibition of cytokine-mediated and 
growth-factor-mediated proliferation of lymphocytes and smooth muscle cells.5 The first 
DES ever implanted was the sirolimus coated Cypher stent (Cordis, Warren, New Jersey, 
USA) in 1999, after which studies succeeded rapidly.
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A randomized comparison between SES and BMS was published in 2002.6 Results were 
very promising, with lower late luminal loss and restenosis at 6 months, and significantly 
less major cardiac events. Many following studies confirmed these results, and SESs were 
the first DES to be approved for treatment of CAD. Meta-analyses of SES versus BMS have 
shown similar rates of death and MI, but have seen a tremendous improvement regarding 
repeat revascularization.7-9 The largest analysis by Stettler et al. reported a hazard ratio as 
low as 0.30 (0.24–0.37) in reducing subsequent interventions.8
Paclitaxel-eluting stent (Pes)
Simultaneously with the SES, the TAXUS Express PES (Boston Scientific, Natick, Massachu-
setts, USA) was developed. This is a stent coated with paclitaxel, an anticancer agent, which 
reduces smooth cell proliferation and migration.10 The initial study compared PES to BMS 
and showed favorable results for PES, similar to what SES had shown.10 No restenosis at 6 
months, and lower rates of late lumen loss. Randomized trials that followed all confirmed 
these findings.11 Meta-analyses of individual patient data showed again similar rates of death 
and MI after PES implantation compared to BMS and a reduction of repeat revascularization 
(HR = 0.42, 95% CI 0.33–0.53).8, 9
The TAXUS Liberté PES was introduced soon after Food and Drug Administration (FDA) 
approval of the EXPRESS stent. The new stent was designed to improve deliverability, con-
formability, and homogeneous drug distribution.12It showed to be non-inferior to the old 
Express stent in revascularization rates after 9 months, with similar rates of death and MI.
The SES and PES competed to be the golden standard replacing bare-metal stenting, and 
several trials have thus compared both stents in a randomized fashion.11 A meta-analysis 
showed that SES performed slightly better, with events of MI (HR = 0.83, 95% CI 0.71–1.00) 
and target lesion revascularization (TLR) (HR = 0.70, 95% CI 0.56–0.84) significantly lower 
than after PES. Other outcomes of overall death, cardiac death, and stent thrombosis were 
comparable.8 It is debated whether SES should be preferred over PES in diabetic patients, 
since sirolimus may be less effective in the inhibition of smooth muscle cell migration than 
paclitaxel. A recent meta-analysis, however, showed that also in diabetic patients SES was 
associated with lower rates of TLR and restenosis.
des Versus bMs - second GenerAtIon stents
Zotarolimus-eluting stents (Zes)
Zotarolimus is an immunosuppressant drug that has been shown to induce complete and 
uniform neointimal coverage of the stent, with better strut coverage then other DES and 
lower rates of late-acquired incomplete stent apposition.13 Naked uncovered struts are 
associated with increased risk of thrombotic events.14 In addition, stent polymer coatings of 
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first generation DES have been linked with allergic reactions and inflammation, which also 
contribute to stent thrombosis.15 Second generation polymers better mimic the endothelial 
lining, preventing thrombosis.16 Thus, the Endeavor ZES (Medtronic, Minneapolis, Minne-
sota, USA) would, on paper, have a lower adverse event rate.
The first randomized trial showed similar safety and improved efficacy of the ZES over 
BMS,17 and was important for gaining FDA approval in early 2008. Compared to first gen-
eration stents, however, ZES could not prove to be better. In a study that compared ZES 
to SES, the new stent did reduce rates of MI, but also had significantly higher late lumen 
loss, rates of in-stent restenosis, and TLR. Increased rates of TLR were later confirmed by 
other studies,18, 19 which furthermore questioned the safety profile of the ZES as it showed 
increased rates of death and MI.19 Compared to the PES, the ZES also showed significantly 
higher late lumen loss and rates of TLR, while at longer follow-up (3 years), MI was lower in 
the ZES group.20 These results were contradicting of an earlier publication, which reported 
similar rates of death and MI, but higher rates or TLR with PES at 12 months.18
everolimus-eluting stents (ees)
Everolimus was originally developed as an immunosuppressant for organ transplant rejec-
tion and is a derivative of sirolimus. Two EES are currently available, the Xience V EES 
(Abbott Vascular, Santa Clara, California, USA) and the Promus (Boston Scientific, Natick, 
Massachusetts, USA).
The initial study with EES compared the stent to BMS in only 56 patients total, but 
already showed improvement in late lumen loss, in-stent restenosis, and TLR rates [21]. 
Comparisons of the EES with PES followed, and not only demonstrated improvements in 
late lumen loss, in-stent restenosis, in-stent thrombosis, and TLR, but also in death, MI, and 
MACE rates.11, 22-25 In a large propensity matched analysis of EES versus SES with results up 
to 3 years, EES showed reduced rates of MI (3.3% versus 5.0%, p = 0.017), target vessel 
revascularization (7.0% versus 9.6%, p = 0.039), and definite stent thrombosis (0.5% versus 
1.6%, p = 0.01).26
Two recent trials compared EES to ZES and found no differences in death, MI, or repeat 
revascularization between the two stents.16, 27 Thus the results of EES are very promising, but 
are limited because no trials have yet compared outcomes of EES to SES. The EXCELLENT 
study is expected to report such results sometime in 2012.28
coMPlIcAtIons oF des
Despite the obvious advantages of DES over balloon angioplasty and BMS therapies, there 
are still some complications associated with DES. The possibility of stent fracture raises 
concerns, as the true incidence is uncertain. It has, however, been found in 29% of cases 
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in a recent pathologic study.29Another complication which incidence is largely unknown 
is coronary aneurysms. An angiographic follow-up study found aneurysms in 1.3% of the 
patients treated with DES,30 but others consider this an underreporting.31 Both these phe-
nomenons are associated with restenosis, ST elevation, and embolization.11
Stent implantation warrants long-term antiplatelet therapy. However, which agent should 
be used, whether dual or triple antiplatelet therapy is superior, and the length of therapy is 
debated, since studies report controversial findings. Nevertheless, patients needing CABG 
after PCI for an acute coronary syndrome are at high risk of increased blood-loss and reop-
eration for bleeding.32 Novel agents might be able to reduce these negative aspects, but data 
remain limited.33, 34
des Versus cAbG
Several meta-analyses and large registries have shown favorable outcomes after CABG 
compared to PCI.35-37 However, the Heart Team has agreed that certain patient groups can 
be treated with a DES as standard therapy.38, 39 Especially patients with single-vessel or 
two-vessel disease benefit from DES by replacing the need to undergo intensive surgery 
and rehabilitation. Contraindications for DES are a previously stented vessel which can-
not receive anymore new stents, or whenever previous stenting has lead more than once 
to in-stent thrombosis. There are more contraindications, but many of these are physician 
dependent and vary between hospitals. The preference for CABG over PCI is most often 
lesion specific, which is discussed below.
Proximal lAd
The current guidelines on myocardial revascularization indicate that CABG should be 
preferred over PCI in patients with proximal LAD lesions.38 This advice is supported by 
historical data from studies that compared PCI with BMS to CABG. A meta-analysis which 
included 8 studies that compared PCI with BMS to CABG demonstrated that CABG is associ-
ated with significantly lower rates of recurrent angina (OR = 2.62, 95% CI 1.32–5.21), 
repeat revascularization (OR = 4.55, 95% CI 2.47–8.37), and major adverse cardiac or 
cerebrovascular events (MACCE) (OR = 2.86, 95% CI 1.62–5.08).40 A later meta-analysis 
reported similar findings.41
Since the rates of recurrent angina and repeat revascularization have been significantly 
reduced with DES compared to BMS, several studies again attempted to show similar results 
between PCI and CABG in patients with LAD lesions (Table 1).42-47 A recent analysis of 5 
year ARTS I and II data showed that SES and CABG had similar rates of death, stroke, and MI, 
but DES still had significantly increased rates of repeat revascularization (HR = 0.37, 95% 
CI 0.21–0.65, p < 0.001). The authors rightfully concluded comparable safety of DES and 
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CABG, but stated that CABG has superior efficacy.42 Therefore, CABG should indeed remain 
the standard therapy for patients with proximal LAD involvement.
Multi-vessel disease
PCI versus CABG in MVD has been a topic of discussion for decades. Outcomes after 
PCI improved after the introduction of BMS compared to balloon dilatation, but CABG 
remained the standard of care. This was supported by numerous randomized trials in the 
mid 1990s, but also by later trials performed after improvement of antiplatelet therapy and 
peri-procedural care. A meta-analysis of trials that compared BMS to CABG showed that PCI 
had similar rates of death, and death or MI, but repeat revascularization was significantly 
higher.36 A more comprehensive meta-analysis that furthermore included trials comparing 
PCI to off-pump or minimally invasive CABG did also show increased rates of angina and 
repeat revascularization with PCI.48 Next to outcomes within delineated patient groups in 
randomized trials, ‘real-world’ studies found similar results and furthermore concluded 
superior outcomes with CABG for MVD.49
With the introduction of DES, interventional cardiologist became more optimistic in 
expecting results of PCI and CABG to converge even more, and many patients were treated 
with PCI even though randomized trials had not yet proven similar results.50 The random-
ized ‘all comers’ SYNTAX trial 39 confirmed that CABG remains the standard of care for 
treatment of MVD.51, 52 Rates of MACCE were significantly higher in the PCI cohort (28.0% 
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Randomized cohort:
High SYNTAX score
Intermediate SYNTAX score
Low SYNTAX score
PCI           CABG       P value
Low SYNTAX score (0-22)                         22.7%         22.5%         0.98
Intermediate SYNTAX score (23-32)          27.4%        18.9%          0.02
 
High SYNTAX score (≥33)                          34.1%        19.5%        <0.001
         PCI          CABG       P value
Low SYNTAX score (0-22)                         25.8%         22.2%          0.45
Intermediate SYNTAX score (23-32)          29.4%        16.8%         0.003    
 
High SYNTAX score (≥33)                          31.4%        17.9%         0.004
         PCI          CABG       P value
Low SYNTAX score (0-22)                         23.0%         18.0%          0.33
Intermediate SYNTAX score (23-32)          23.4%        23.4%          0.90
 
High SYNTAX score (≥33)                          37.3%        21.2%         0.003
Figure 1 distribution and outcomes of patients enrolled in the sYntAX trial
The Heart Team concluded that 6% and 35% of patients were best treated with respectively PCI and CABG. 
Within the randomized cohort of 1,800 patients, patients were divided into three terciles based on their SYNTAX 
Score: low SYNTAX Score (green), intermediate SYNTAX Score (orange), and high SYNTAX Score (red). Outcomes 
within subgroups showed that PCI could be an alternative to CABG in patients with a low coronary lesion 
complexity, while CABG is preferred for patients with complex lesions.
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versus 20.2%), driven by an increase in repeat revascularization (19.7% versus 10.7% after 
CABG). With the SYNTAX study the SYNTAX score was introduced which characterizes the 
complexity of the coronary disease. A hypothesis-generating subgroup analyses showed 
similar results with PCI compared to CABG in patients with low SYNTAX scores (<23, with 
less complex lesions),53 thus showing promising results that patients with lower lesion com-
plexity can undergo PCI with satisfactory results, which might broaden the indication of PCI 
to those patients with less complex 3VD (Figure 1).
Patients that suffer from diabetes have historically been a subgroup of patients that show 
better results after CABG than after PCI.36 The introduction of DES and improved antiplatelet 
therapy has provided better outcomes after PCI than before, but the SYNTAX trial continued 
to demonstrate significantly better outcomes with CABG.54, 55These results are in line with 
the CARDia randomized comparison of PCI versus CABG in diabetics.56 This should there-
fore remain the current standard of therapy in diabetic patients, independent of the coronary 
complexity.
Nevertheless, despite these conclusions, decisions should be made within a heart team. 
A large registry demonstrated that specialists should be praised for their clinical judgment. 
From similar unadjusted rates of death and MI in PCI and CABG cohorts it seems that the 
current decision-making process to determine PCI or CABG treatment seems appropriate for 
certain indications.35, 57
left main disease
Even more so than for MVD, a debate is ongoing about the optimal treatment for patients 
with LM disease.4 Despite efforts to demonstrate non-inferiority of PCI with DES to CABG, 
the current guidelines on myocardial revascularization still recommend CABG as the most 
appropriate revascularization strategy.38 Recent meta-analyses report satisfactory outcomes 
with stenting, but uniformly agree that CABG provides significantly better rates of less repeat 
revascularization.58, 59
The SYNTAX trial reported a pre-defined hypothesis-generating subgroup analysis in left 
main patients.39, 60 In 705 randomized LM patients, rates of repeat revascularization were 
significantly lower after CABG, but higher rates of stroke complicated surgery. Especially in 
patients with a SYNTAX score <33 PCI showed comparable results. This was recently con-
firmed in a ‘real-world’ registry.61The number of patients in the left main group in SYNTAX 
was however too small to draw firm conclusions and the ongoing EXCEL study will address 
the issue in an adequately powered trial.62
The recently published PRECOMBAT trial reported data of exclusively LM patients. It 
concluded that PCI with DES is non-inferior to CABG with results up to 2 years. The primary 
end-point of death, MI, stroke, or ischemia-driven TVR was 12.2% and 8.1% respectively in 
the PCI and CABG cohorts.63 Nevertheless, the trial was subject to extensive methodological 
flaws, with (1) an event rate much lower than projected, (2) a large number of cross-overs 
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from CABG to PCI, and (3) a very generous non-inferiority margin. The authors therefore 
rightfully stated that these results should not be clinically directive.
Thus, data remain limited, and it should be stressed again that both SYNTAX and PRE-
COMBAT data have low statistical power. Results from the ongoing EXCEL trial should be 
awaited before any definitive conclusions can be drawn.
conclusIons
PCI with stenting has shown major improvements gained over the past decades, resulting in 
significant converged outcomes after PCI and CABG. Patients with low complexity coronary 
lesions show good results after PCI with DES. However, both currently available observa-
tional and trial data suggest that CABG should, for the time being, remain the preferred 
treatment for patients with LAD or LM involvement and complex MVD.
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AbstrAct
Since first introduced in the mid-1960s, coronary artery bypass grafting (CABG) has become 
the standard of care for patients with coronary artery disease. Surprisingly, the fundamental 
surgical technique itself did not change much over time. Nevertheless, outcomes after 
CABG have dramatically improved over the first 50 years. Randomised trials comparing 
percutaneous coronary intervention (PCI) to CABG have shown converging outcomes for 
select patient populations, providing more evidence for wider use of PCI. It is increasingly 
important to focus on the optimization of the short- and long-term outcomes of CABG and 
to reduce the level of invasiveness of this procedure. This review provides an overview on 
how new techniques and widespread consideration of evolving strategies have the potential 
to optimize outcomes after CABG. Such developments include off-pump CABG, clampless/
anaortic CABG, minimally invasive CABG with or without extending to hybrid procedures, 
arterial revascularisation, endoscopic vein harvesting, intraprocedural epiaortic scanning, 
graft flow assessment and improved secondary prevention measures. In addition, this review 
represents a framework for future studies by summarizing the areas that need more rigorous 
clinical (randomised) evaluation.
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IntroductIon
Coronary artery bypass grafting (CABG) was first introduced in the mid-1960s and evolved 
rapidly as the standard of care for patients with extensive coronary artery disease.1 However, 
the introduction of percutaneous coronary intervention (PCI) led to a reconsideration of 
therapeutic strategies.2 Improvements in stent design, adjuvant medical therapy and techni-
cal skills quickly turned PCI into a very attractive alternative treatment option for patients 
with acute coronary syndromes and less complex coronary disease.3-7 The broader use of 
PCI is reflected by declining CABG rates over the last decades,8 even though recent long-
term results from the SYNTAX,9 ASCERT 10 and FREEDOM 11 trials showed significantly bet-
ter survival rates after CABG than after PCI. Despite converging outcomes between the two 
treatments in select patient populations, coronary surgery currently remains the standard of 
care for most elective patients, including those with diabetes and/or complex left main or 
three-vessel disease.9, 12
Although short-term outcomes have dramatically improved over the first 50 years, sur-
prisingly, technical aspects of the CABG procedure did not change significantly. Particularly 
in an era of increasing and sometimes overuse of PCI, several aspects of CABG should 
be improved to further optimize short- and long-term outcomes, while at the same time 
improving the appeal of CABG which is regarded as an overly invasive attractive treatment 
option by some. A number of advancements have been proposed, but adoption rates for 
these techniques are low.
This review provides a summary of how CABG outcomes can be optimized by adop-
tion of new developments. These developments include off-pump, clampless/anaortic, 
and minimally invasive CABG with or without extending to hybrid procedures, arterial 
revascularisation, endoscopic vein harvesting, intraprocedural epiaortic scanning and graft 
flow assessment and improved secondary prevention measures. Furthermore, this review 
represents a framework for future studies by summarizing the areas that need more rigorous 
clinical evaluation.
oPerAtIVe technIques
off-pump cAbG
In 2001, approximately 25% of CABG procedures were performed off-pump.13 In the West-
ern world, the contemporary rate of off-pump CABG procedures is about 20%, while in Asia 
the majority of procedures are performed off-pump.14Theoretically off-pump CABG could 
reduce morbidity --particularly stroke-- and even mortality by avoiding cardiopulmonary 
bypass that is associated with formation of microemboli, an increased blood-brain barrier 
permeability and aortic manipulation during cross-clamping and cannulation.15
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Numerous risk-adjusted studies have found that the off-pump technique appears favour-
able in terms of both hard and surrogate endpoints.16, 17 A meta-analysis of propensity score 
adjusted studies that included more than 120,000 patients demonstrated the superiority of 
the off-pump technique with respect to 11 selected short-term outcomes, particularly for 
mortality as the most important one (OR=0.69; 95% CI 0.60-0.75; p<0.0001) and for stroke 
(OR=0.42; 95% CI 0.33-0.54; p<0.0001).18In addition, the most recent meta-analysis of 59 
randomised trials on a total of 8,961 patients comparing on-pump with off-pump CABG 
demonstrated a 30% [95% CI 1-51%] relative risk reduction for stroke.13 However, some 
studies have shown increased rates of mortality and repeat revascularisation during follow-
up;19, 20 probably caused by reduced graft patency after off-pump vs. on-pump CABG.21, 22 
Although single-centre prospective angiographic studies have shown similar excellent graft 
patency rates with off-pump and on-pump CABG 23, the one-year results from the ROOBY 
trial showed a 27% higher risk of graft occlusion in the off-pump group (95% CI 9-48%); 
graft patency was 87.8% in the on-pump and 82.6% in the off-pump patients (p<0.001).24 
These results were criticized for the lack of sufficient experience that contributing surgeons 
had with off-pump procedures..25 However, several other trials involving highly experienced 
surgeons and a meta-analysis pointed in a similar direction as the findings from the ROOBY 
trial.25-27 Off-pump CABG has also been associated with increased rates of incomplete 
revascularisation, and could result in reduced long-term survival.28
The CORONARY trial showed no benefit of off-pump CABG over on-pump CABG at 30 
days or 1 year in 4,752 randomised patients.29, 30 Although there appears to be a significant 
benefit of off-pump over on-pump CABG in patients at high operative risk 31 and in patients 
with atherosclerotic aortas,32 the hypothesis that off-pump CABG is beneficial for ‘all-
comers’ may be too optimistic.33 Despite the encouragement to a general use of off-pump 
techniques, it has been recommended specifically for high-risk patients.34 However, even 
this recommendation was recently challenged by the results of the GOPCABE trial, which 
did include elderly higher-risk patients (n=2,539) but was still unable to confirm superiority 
of the off-pump over the on-pump approach in this subset of patients.35 Patient selection is 
critical, since the majority of patients can safely and efficiently undergo on-pump CABG 
without the risk of increased 30-day repeat revascularisation rates associated with off-pump 
procedures in the latest trials. 29, 30, 35It may therefore be cumbersome for trainees to gain 
experience in a procedure with a steep learning curve that is infrequently performed only 
in selected patients.
It is worth noting that although evidence for a survival benefit of off-pump CABG is 
inconsistent across the peer-reviewed literature, a preponderance of evidence suggests that 
off-pump CABG is associated with significant reductions in transfusion requirements, pro-
longed ventilation, ICU and hospital length of stay, new renal failure, stroke/neurocognitive 
decline and other clinical endpoints.36
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clampless / Anaortic off-pump cAbG
If off-pump CABG is performed, the degree of aortic manipulation should be reduced to a 
minimum. The benefit of off-pump CABG may be limited unless partial clamping of the aorta 
is avoided. Aortic clamping produces a significantly higher number of solid microemboli on 
transcranial Doppler than clampless surgery and can therefore lead to procedural stroke.37 It 
is to note that in most trials, including the major randomised trials, off-pump CABG was not 
performed using an anaortic technique, the major driver for reducing stroke.
The number of studies that compared clampless CABG to ‘regular’ CABG with clamping 
is limited (Table 1). In the absence of a large randomised comparison, Börgermann and col-
leagues used propensity matching to compare mortality and stroke rates between patients 
who underwent clampless off-pump or conventional CABG.38 In the propensity-matched 
cohort of 395 pairs, clampless off-pump CABG reduced rates of death (OR=0.25, 95% CI 
0.05-1.18; p=0.080) and stroke (OR=0.36, 95% CI 0.13-0.99; p=0.048). More specifically, 
one of the largest studies to date found significantly lower stroke rates after off-pump than 
on-pump CABG, if an all-arterial “no touch” technique was applied or when the proximal 
vein graft anastomoses were performed clampless using the HeartString device (Guidant, 
Indianapolis, USA).39 This evidence is complemented by a meta-analysis including 11,398 
patients that showed that the absence of aortic manipulation was associated with a signifi-
cant reduction of neurologic complications (OR=0.46, 95% CI 0.29-0.72; p=0.0008).40
Minimally invasive cAbG / hybrid revascularization
One of the drawbacks of CABG remains its invasiveness, even without the use of cardiopul-
monary bypass. Quality of life scores at 30 days and patient treatment satisfaction surveys 
throughout the first 6 months are significantly higher after PCI than after CABG.41 Moreover, 
CABG is sometimes referred to as a procedure where “the chest is cracked open”, which from 
a patient’s perspective presents a frightening prospect of postoperative pain and extended 
rehabilitation. As a result, patients often prefer PCI to CABG because of “temporal discount-
ing”, i.e. disproportionally emphasize short-term results even though CABG has been shown 
to be superior to PCI with respect to long-term survival and angina relief.10, 41-44 Less invasive 
surgical techniques may present an attractive alternative; minimally invasive direct coronary 
artery bypass (MIDCAB) does not require sternotomy and is therefore more acceptable to 
patients than conventional CABG.45 The left minithoracotomy incision is smaller, the risk 
of scarring is less, and risks of deep sternal wound infection and problems with sternum 
healing are omitted. Although MIDCAB may be associated with slightly increased pain 
postoperatively due to spreading of the ribs, the length of stay is markedly reduced and there 
is an early postoperative quality of life benefit over conventional CABG.46-48 MIDCAB was 
shown to be as safe and efficient as off-pump CABG, while reducing the recovery time.49 
Holzhey and colleagues recently reported long-term results from their single-centre experi-
ence on 1,768 patients.50 Five and 10 year survival was 88.3% and 76.6%, respectively. 
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The rates of freedom from major adverse cardiac or cerebrovascular events and angina were 
85.3% and 70.9%, respectively.
Exposure during MIDCAB is largely limited to the left anterior descending (LAD) artery 
and eventually diagonal branches, and therefore almost exclusively performed in patients 
with isolated LAD stenosis or occlusion. An open left internal mammary artery (IMA) graft to 
the LAD is without doubt the single most important conduit that offers a prognostic benefit 
based on its proven long-term patency and improved survival. Patients with multivessel 
disease - especially at younger age - also derive a survival benefit from total arterial grafting 
with bilateral IMA grafts.51 The added benefit of a second arterial graft in older patients is 
less well documented;52 however, the rate of early vein graft failure, especially to distal 
targets and severely diseased small vessels, is high and ranges from 10 to 26% between 
12 and 18 months after surgery.53, 54 In some patients, a hybrid procedure can combine 
the benefits of a MIDCAB --providing a left IMA (LIMA) graft to the LAD-- and stenting of 
the circumflex and/or the right coronary artery. This type of management may yield results 
similar to those of a full CABG procedure,55 but randomised trials are still lacking (Table 
2). The hospitalization costs of hybrid revascularisation are similar to the costs of off-pump 
CABG, but the time to return to work is shorter and patient satisfaction higher.56 Halkos 
and colleagues showed that survival after hybrid revascularisation at 5-year follow-up was 
comparable with off-pump CABG in patients with left main disease (88.6% versus 83.4%, 
respectively; p=0.55) and in patients with multivessel disease (86.8% versus 84.3%, respec-
tively; p=0.61) (Figure 1).57, 58
Complete revascularisation in patients with multivessel disease by minimally invasive 
CABG can also be achieved via a totally endoscopic coronary artery bypass (TECAB) proce-
dure,59 by combining an endoscopic with an open approach,60 or by a hybrid endoscopic 
and percutaneous procedure.61 Such procedures are only performed in selected patients at 
specialized centres and require extensive operating times. Earlier series reported unsatisfac-
tory patency results, but with the evolution of better endoscopic stabilizers the results from 
table 2 reasoning supporting hybrid revascularisation
Patients with double vessel disease and chronic total occlusion of the LAD
Patients with multivessel disease and an indication for CABG requiring complete revascularisation in whom 
a full sternotomy is contraindicated or not desired
Patients with multivessel disease with a dominant LAD or complex proximal LAD lesion morphology and 
poor surgical targets in the distal CX or RCA territory amenable for PCI
Patients with multivessel disease with an indication for PCI (SYNTAX score <22) or CABG in clinical trials 
comparing hybrid revascularisation with PCI or CABG (SYNTAX score >23)
Patients with multivessel disease undergoing emergent PCI of a culprit lesion of a CX or RCA lesion (in the 
setting of STEMI, Non-STEMI or ACS) with a staged surgical revascularisation of the LAD
ACS = acute coronary syndrome; CABG = coronary artery bypass grafting; Cx = Circumflex; LAD = left anterior 
descending artery; PCI = percutaneous coronary intervention; RCA = right coronary artery; STEMI = ST-elevation 
myocardial infarction; Non-STEMI = Non-ST-elevation myocardial infarction
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these highly experienced centres are similar to conventional CABG with a reported mortality 
rate of 1-2% 59-62 and a five-year survival in the range of 85-95%.61-63
Adoption of minimally invasive CABG procedures has been slow. For MIDCAB, this may 
be explained in part by the low incidence of isolated proximal LAD stenosis 64 and also 
by the high technical demands of this procedure. Hybrid revascularisation for multivessel 
disease, theoretically, has a much larger target population. However, a systematic search 
of the literature shows that the accumulated evidence is based on small non-randomised 
studies comprising just over 1,000 patients in total (Table 3). 
Between October 2003 and April 2010, only 174 patients underwent hybrid revasculari-
sation in the United States.57, 58 Apart from technical issues, the low adoption rate is partly 
due to logistic reasons; the staging of two procedures in a (hybrid) operating room and/or 
catheterisation laboratory, and the administration or discontinuation of antiplatelet therapy. 
A survey performed in 2002 indicated that 80% of US surgeons perform <5 MIDCAB pro-
cedures annually.65 When asked about hybrid procedures, only 10% of surgeons were in 
favour. In contrast, 50% of 180 cardiologists were in favour of hybrid revascularisation. 
Yet, only two cardiologists (1.1%) had referred patients for MIDCAB (with or without PCI). 
Stronger evidence to support a recommendation for hybrid revascularisation is expected 
from a number of currently on-going registries, the largest of which is the Hybrid Revas-
cularisation Observational Study (NCT01121263) that includes patients throughout the US 
and is sponsored by the National Heart, Lung, and Blood Institute (NHLBI). 
Figure 1
long-term survival of hybrid revascularisation in comparison with off-pump coronary 
artery bypass grafting
A comparison between treatment strategies shows no differences in 5-year survival in patients with multivessel 
disease (A), nor in patients with left main disease (B). Adapted with permission from Halkos and colleagues.57, 58
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Arterial grafting
The use of one IMA graft, most often the left IMA anastomosed to the LAD combined 
with venous conduits represents the standard therapy for patients undergoing CABG.66, 67 
However, venous bypass grafts tend to fail: a recent study by Kim and colleagues found 
that 11.8% of saphenous vein grafts failed within 7 days,68 which is similar to the failure 
rate reported by FitzGibbon in 1978.69 Therefore, bilateral IMA (BIMA) grafting should be 
strongly considered in patients with multivessel coronary disease, because BIMA grafting is 
associated with reduced mortality during the first year post-surgery and during long-term 
follow-up.70 A meta-analysis of 7 pooled studies with 11,269 single and 4,693 bilateral IMA 
grafts demonstrated that BIMA was associated with a reduced risk for death: HR=0.81 [95% 
CI 0.70-0.94].51
In the Arterial Revascularization Trial (ART), the only randomised trial to date comparing 
BIMA and single IMA (SIMA), 3,102 patients were randomised in 28 centres in 7 coun-
tries.71 Mortality rates at 30 days were 1.2% in both groups, and 2.3% versus 2.5% at 
one-year for SIMA and BIMA groups, respectively. There were also no differences in the 
incidence of stroke, MI and repeat revascularization. While the use of a second IMA graft 
added 23 minutes to the operative procedure which in itself took 3-4 hours, the trial clearly 
demonstrated that BIMA grafting was as safe as SIMA grafting, even though the risk of a 
need for later sternal reconstruction was increased: relative risk 3.24 [95% CI 1.54-6.83]. 
An extended follow-up (for up to 10 years) is expected for this study and will hopefully 
determine whether survival with BIMA grafts is indeed superior. The trial, however, also 
highlighted the difficulties with BIMA grafting; 16.4% of patients randomised to BIMA did 
not receive the allocated treatment compared with 3.3% patients not receiving SIMA graft-
ing.72
The proportion of procedures that are performed with IMA grafts is increasing, but a large 
inter-hospital variance remains. The use of at least one IMA can be as low as 45-65% in some 
centres, failing to provide optimal care to patients.73 It is disconcerting that in the United 
States the use of BIMA grafts was only 4.0% among 541,368 patients.73 The respective 
figures are 12% in Europe and 30% in Japan.74 Among 1,541 procedures performed in the 
SYNTAX trial and registry, 97.1% included a single arterial conduit while 22.7% received a 
second IMA graft. Due to the technically more challenging and time-consuming nature of 
BIMA grafting, the fear of higher morbidity (i.e. sternal wound complications) and mortality, 
and the absence of clear randomised data showing a survival benefit, some surgeons may 
be reluctant to use BIMA grafts. Nevertheless, in order to improve CABG outcomes, the use 
of both IMA grafts should be considered more frequently. 
When unilateral IMA grafting is performed, the saphenous vein is the most frequently 
chosen conduit for additional graft(s). Because of high failure rates of venous grafts, the 
radial artery has been investigated as an alternative. The long-term results from the RSVP 
trial (n=142) suggested favourable radial artery graft patency rates.75 More recent 5-year 
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results from the larger randomised RAPS trial (n=510) showed that, compared with the 
saphenous vein grafts, the radial artery had lower rates of functional graft occlusion (12.0% 
versus 19.7%, respectively; p=0.03) and complete occlusion (8.9% versus 18.6%, respec-
tively; p=0.002), although the string sign was observed more frequently in radial artery 
grafts (3.4% versus 0%, p=0.01).76 Several large observational studies have confirmed excel-
lent graft patency and have even reported superior long-term survival rates,77, 78 also after 
applying propensity matching.79-81 However, widespread utilisation of the radial artery has 
been hampered by concerns regarding vessel spasm, graft atherosclerosis and unfavourable 
results from a number of studies. The largest trial (n=733) to date found no differences in 
graft patency at 1-year follow-up;82 similar results have been reported from a number of 
observational studies.80, 83 At least one study has shown radial artery graft patency to be 
significantly worse than right IMA graft patency.84 To ensure good graft patency, the radial 
artery should be used preferably in high-grade lesions.85 Data from the STS database suggest 
that only 9% of CABG procedures are performed with the radial artery.86
A higher rate of disease progression to total occlusion in native coronaries has been 
reported after CABG than after PCI.87 Patent arterial grafts, by virtue of their nitric oxide 
secreting properties, may protect against future atherosclerotic lesions. Therefore, arterial 
grafting can be viewed as a preventive measure that goes beyond pure treatment.88, 89
endoscopic vein harvesting
Traditional open saphenous vein graft harvesting requires a large incision, resulting in a 
large scar and a risk of postoperative wound complications. Endoscopic vein harvesting was 
introduced in the mid-1990s as an alternative.90This method has the advantages of reduced 
scarring, less pain, decreased postoperative complications, and shorter length of stay.91
Several randomised studies and meta-analyses have shown that endoscopic harvesting 
significantly reduces rates of wound infection, wound dehiscence, and overall complica-
tions.92 However, subgroup analyses from the PREVENT IV and ROOBY randomised 
trials suggested that endoscopic vein harvesting resulted in reduced graft patency during 
follow-up.93, 94 In PREVENT IV, there even were significantly higher rates of death. Although 
this is of potential concern, long-term follow-up analyses from large observational studies 
have not been able to confirm that clinical outcomes are worse in patients that underwent 
endoscopic vein harvesting.95, 96 A recent study that included 235,394 patients with 3-year 
follow-up showed no increased risk of mortality (adjusted HR=1.00 [95% CI 0.97-1.04]; 
p<0.99) or the composite of mortality, myocardial infarction, and repeat revascularisation 
(adjusted HR=1.00 [95% CI 0.98-1.05]; p=0.34).96
Current data indicate a paradigm shift towards endoscopic harvesting as opposed to open 
vein graft harvesting. Between 2003 and 2008, 52% of grafts were harvested endoscopically 
at 989 sites in the United Stated; in 2008, the rate was already 70%.96 Trainees in the United 
States now almost exclusively learn how to perform endoscopic harvesting.91 It is important 
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to start using this technique at an early stage, especially because inexperienced surgeons 
are known to cause significantly more vein injury.97 The International Society of Minimally 
Invasive Cardiothoracic Surgery (ISMICS) Consensus statement has given a Class IB recom-
mendation for endoscopic vein harvesting.98 Still, endoscopic harvesting is performed in 
only a minority of cases in Europe. A recent single-centre study showed that only 12.4% of 
veins were harvested endoscopically between 2008 and 2010.99 Unfortunately, large-scale 
real-world data from European centres are scarce.
IntrAoPerAtIVe AssessMents
epiaortic scanning
Atherosclerosis of the ascending aorta is present in >50% of patients undergoing CABG.100 
Aortic atherosclerosis was found to be a significant predictor of postoperative neurologic 
events and renal failure, both caused by atheroembolism.101, 102 Palpation of the aorta is 
frequently employed prior to cannulation and/or aortic manipulation, but the sensitivity of 
this technique is very limited.103 Therefore, imaging is advocated to detect atherosclerosis 
if an anaortic technique cannot be applied. Depending on the findings, the operative tech-
nique can be modified as needed.104Both transesophageal echocardiography and epiaortic 
ultrasonography were introduced as methods for detecting severe atherosclerosis. While 
transesophageal echocardiography severely underestimates the degree of atherosclerosis, 
epiaortic scanning is an easy, safe and efficient procedure and is preferred.105
Epiaortic scanning is not routinely used probably because of the cost of the machine 
(>€100,000) and the fact that there have been no direct randomised comparisons between 
CABG with and without epiaortic scanning that demonstrate a benefit. Such a study would be 
problematic because of the large sample size required. However, although one small study 
indicated no reduction in transcranial Doppler-detected cerebral emboli,106 several studies 
have suggested that early postoperative stroke is significantly reduced when the operative 
technique is modified in accordance with results of epiaortic scanning.107-110 Wareing and 
colleagues reported that in 14% of elderly patients undergoing cardiac procedures (CABG 
in 89%), the site of aortic cannulation and/or clamping, the sites for attaching vein grafts, 
and/or the sites for instillation of cardioplegic solution were altered.111 The precise rates of 
such modifications provided in the literature vary, between 4% and 31%.100 A recent study 
by Daniel and colleagues showed that epiaortic scanning was increasingly performed from 
2002 to 2009 (45% and 90%, respectively) and coincided with less frequent aortic clamping 
(98% and 73%, respectively).112
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Graft flow measurement
Data from the PREVENT IV trial showed a suboptimal rate of saphenous vein graft failure after 
on- and off-pump CABG at one year;113 a meta-analysis reported a failure rate of approxi-
mately 5% and 25% at 3 and 12 months, respectively.114 Several mechanisms of graft failure 
have been described. Early graft failure can occur as a result of anastomotic problems, 
limited outflow, graft kinking upon chest closure and thrombosis, while thrombosis and 
processes of intimal hyperplasia and atherosclerosis are causes of late failure. Intraoperative 
graft assessment has been introduced to evaluate grafts and identify anastomotic problems 
and limited outflow. Disturbingly, Balacumaraswami and colleagues demonstrated that 
intraoperative graft assessment identified 9% of grafts with inadequate flow in 25% of CABG 
patients, which led to revision in 3% of grafts and 8% of patients.115 Multiple techniques for 
intraoperative graft assessment have been proposed: coronary angiography, transit time flow 
measurement (TTFM), high-frequency epicardial echocardiography, thermal coronary angi-
ography, and intraoperative fluorescence imaging (IFI).116 Although angiography is thought 
to be the best and most reliable method for assessing flow,117 the infrastructure required for 
coronary angiography is rarely available in standard operating rooms. Wider implementa-
tion of hybrid operating rooms could potentially facilitate the use of coronary angiography. 
Currently, intraoperative graft assessment is most frequently performed by TTFM or IFI.
Both TTFM and IFI have strengths and weaknesses and have been criticized for their 
inability to identify grafts with minor abnormalities that present a risk for failure. Further-
more, inconsistent and variable measurements may lead to unnecessary graft revisions.115 
Two parameters, graft function and anatomy, are required for complete assessment of bypass 
grafts. TTFM assesses function and can very accurately detect truly poor and truly good 
grafts (true positives, true negatives), but there is an issue with respect to detecting poor 
grafts with a low pulsatility index (PI) (false negatives). False positives (good graft, high PI) 
rarely occur. IFI evaluates anatomy but is associated with more inter-observer error than 
standard angiography. Comparisons between TTFM and IFI suggest that IFI is more sensi-
tive.114, 115, 118 TTFM combined with epicardial ultrasonic scanning is a recently introduced 
approach that may provide both a functional as well as anatomic assessment.
Despite issues, the clinical value of TTFM has been demonstrated in studies that found 
that TTFM predicted graft failure at 3, 6 and/or 12 months post-CABG.119-121 Inadequate 
graft flow as defined by PI >5 on TTFM was found to be an independent predictor of major 
adverse cardiac events, operative death in particular.122 No studies have yet explored the 
impact of IFI measurements on clinical outcomes during follow-up. In general, randomized 
comparisons between CABG with and without graft flow measurement remain absent. Such 
studies would be required to evaluate the true benefit their routine intraoperative use would 
have on early and late rates of reintervention, myocardial infarction, and death. One issue 
that remains, however, is that long-term graft failure would still occur as caused by other 
mechanisms that those controlled by intraoperative graft assessment. This could be one of 
Part 3 Stenting versus bypass surgery384
the reasons why surgeons doubt its clinical impact and consequently why routine use has 
been limited.
secondArY PreVentIon
Apart from technical and procedural considerations, further optimization of long-term 
outcomes after CABG can be achieved through a strict medical regimen. Progression of 
atherosclerosis in the native coronary arteries continues after CABG and is associated with 
deterioration of left ventricular function. However, this can be prevented by administration 
of antiplatelet agents,123 β-blockers,124 angiotensin-converting enzyme inhibitors (ACE-I),125 
statins126, 127 and fatty acids,128 all of which have been identified as independent predictors 
of survival after CABG. The PREVENT IV trial found that secondary prevention medica-
tions were associated with significantly reduced rates of death or myocardial infarction 
after CABG.129 Moreover, data suggests that graft patency may be better in patients taking 
statins,130 fatty acids,131 aspirin 66 and possibly dual antiplatelet therapy.132 Administration 
Aspirin               ACE-I             β-blocker             Lipid-             Smoking
            lowering          cessation
                drugs                advice
CABG
PCI
p<0.001 for all comparisons
100%
  90%
  80%
  70%
  60%
  50%
  40%
  30%
  20%
  10%
     0%
Figure 2
difference in secondary prevention measures after percutaneous coronary intervention 
and coronary artery bypass grafting
Data from Hiratzka and colleagues.158 ACE-I = Angiotensin-converting-enzyme inhibitor CABG = coronary artery 
bypass grafting; PCI = percutaneous coronary intervention
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of secondary prevention medications has increased remarkably 133, 134 and differences 
between PCI and CABG have shown to converge (Table 4).Nevertheless, some data have 
shown that differences between PCI and CABG still remain and again stressed the need for 
further progress (Figure 2).135-137
Furthermore, the effect of lifestyle interventions on outcomes may be underestimated. A 
plethora of data exists on the impact of lifestyle intervention on outcomes after CABG. Van 
Domburg and colleagues, for example, reported that patients who quit smoking had signifi-
cantly improved 30-year survival as compared with persistent smokers after CABG (HR=0.60 
[95% CI 0.48-0.72]).138 Education and counselling on eliminating risk factors, healthy food 
choices, stress relief, and exercise provide substantial benefit for patients.139 A meta-analysis 
that combined 63 randomised clinical trials with follow-up data on 21,295 patients found that 
implementation of secondary prevention programs significantly reduced all-cause mortality 
(risk ratio (RR)=0.85 [95% CI 0.77-0.94]) and myocardial infarction (RR=0.83 [95% CI 0.74-
0.94]).140 Notably, specific patient subgroups may benefit most from rigorous behavioural 
modifications: young (age <60 years) or old (age ≥75 years) patients, patients with a sedentary 
lifestyle and/or a smoking habit, patients with a low Mediterranean diet score and those who 
live alone.141 However, data from 3 EUROASPIRE surveys showed that there was a clear 
need for more effective lifestyle management among patients with previous coronary revas-
cularisation.142 The authors rightfully stated that treatment of coronary artery disease “without 
addressing the underlying causes of the disease is futile; we need to invest in prevention”. 
table 4
trends in the use of secondary preventive medication and the difference between 
coronary artery bypass grafting and percutaneous coronary intervention
euroAsPIre I
1995-1996
n=9 countries
euroAsPIre II
1999-2000
n=15 countries
euroAsPIre III
2006-2007
n=22 countries
Antiplatelets CABG 87,9% 86,8% 92,9%
PCI 89,4% 90,0% 94,9%
Δ -1,5% -3,2% -2,0%
Beta-Blockers CABG 56,5% 68,0% 90,7%
PCI 61,7% 73,6% 84,4%
Δ -5,2% -5,6% +6,3%
Blood-pressure-lowering drugs CABG 86,2% 90,1% 98,7%
PCI 87,4% 91,3% 95,9%
Δ -1,2% -1,2% +2,8%
Lipid-lowering drugs CABG 36,7% 67,6% 90,5%
PCI 42,2% 69,9% 89,4%
Δ -5,5% -2,3% +1,1%
Data from Kotseva and colleagues.134 CABG = coronary artery bypass grafting; PCI = percutaneous coronary 
intervention
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Initiatives should be undertaken to increase the rate of prescribing appropriate discharge 
medications and to emphasize the need for long-term medication compliance and lifestyle 
changes. In particular home-based programs may be efficient and more acceptable to 
patients -- with the additional benefit of lower costs.143Such quality improvement programs 
can be easily instated and could potentially improve patient care significantly.
decIsIon-MAkInG
Despite the potential for further optimization of CABG outcomes, PCI will remain an 
excellent alternative in specific patients. Evidence suggests that there is overuse, underuse 
and inappropriate selection of revascularisation strategies.144 Inappropriateuse  and unde-
ruse may partly explain the preferences expressed by patients,145 who prefer less invasive 
techniques with minimized pain over the long-term prospect of improved survival. In that 
respect, MIDCAB or hybrid procedures may present an alternative, but often patients are not 
*Preoperative renail failure,
Porcelain or serverily atherosclerotic aorta
High EuroSCORE
Neurological dysfunction
Figure 3 Proposal for a decision-tree for revascularisation
Some of these recommendations have not yet been validated and still require randomised evaluation. CABG, 
coronary artery bypass grafting; LAD, left anterior descending; LM, left main; MIDCAB, minimally invasive 
coronary artery bypass; PCI, percutaneous coronary intervention
CABG: optimizing outcomes and future prospects 387
C
ha
pt
er
 2
3
even informed about the survival advantage with CABG.146Naturally, if two treatments are 
considered to produce similar results, patients will opt for the least invasive.
Reflecting on the current revascularisation guidelines, recent trial results, and weighting 
risk-benefit ratios of (new) developments, Figure 3 provides a proposal for a decision-tree 
for revascularisation. The myriad of treatment options emphasize the need for targeted 
patient selection, and the mix of surgical and interventional therapies provides rationale 
for multidisciplinary Heart Team decision-making to discuss al potential treatment options 
and obtain informed consent. Clinical cardiologists, interventional cardiologists, and car-
diovascular surgeons should convene on a regular basis to recommend the most appropriate 
treatment strategy for individual patients.144, 147 The importance of a Heart Team was once 
more stressed in the SYNTAX trial 148 and was subsequently included in the European and 
American guidelines.3, 149 Practice may be different across centres and countries, and a local 
protocol should be established to define patient populations that are candidates for certain 
therapies. The various pros and cons of surgical revascularisation strategies should then be 
considered by the Heart Team(Table 5).
table 5 Pros and cons of different surgical revascularisation techniques
conventional 
cAbG
off-pump 
cAbG
MIdcAb tecAb hybrid 
revascularisation
Lesions Multivessel 
disease (+)
Multivessel 
disease (+)
Isolated LAD 
stenosis (+/-)
Multivessel 
disease (+)
Multivessel 
disease (+)
Technical difficulty None (+) Moderate (+/-) Moderate (+/-) Difficult (-) Moderate (+/-)
Incision Sternotomy (-) Sternotomy (-) J-incision (+/-) Endoscopic (+) J-incision (+/-)
Cardiopulmonary 
bypass
Yes (-) No (+) No (+) No (+) No (+)
Procedure time Short (+) Prolonged (+/-) Long (-) Long (-) Long (-)
Blood products Many (-) Less (+/-) Few (+) Few (+) Few (+)
Completeness of 
revascularisation
Complete (+) Complete (+) 
or incomplete 
(+/-)
Complete (+) 
or incomplete 
(+/-)
Complete (+) 
or incomplete 
(+/-)
Complete (+)
Postoperative length 
of stay
Long (-) Prolonged (+/-) Short (+) Short (+) Short (+)
Postoperative pain Yes (-) Yes (-) Yes (-) Less (+/-) Yes (-)
Recovery time Long (-) Long (-) Short (+) Short (+) Short (+)
Rate of stroke High (-) Less (+/-) Less (+/-) Less (+/-) Less (+/-)
Rate of repeat 
revascularisation
Good (+) Moderate (+/-) Good (+) Moderate (+/-) Moderate (+/-)
The various features are scored as following: in favour of the technique (+), reasonable in favour (+/-), detrimental 
for the technique (-). CABG = coronary artery bypass grafting; LAD = left anterior descending; MIDCAB = 
minimally invasive coronary artery bypass
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Future studIes
Rigorous evaluation of potential advancements remains crucial before they are introduced 
on a wide scale. Even an extensive body of evidence supporting some interventions is not 
necessarily sufficient to provide evidence-based recommendations. This is exemplified by 
the more than 60 randomised trials comparing off-pump with on-pump surgery:13, 30, 35 
a benefit of off-pump CABG has been suggested in many studies that included different 
patient populations. Nevertheless, the two latest and largest randomized trials that included 
low- and high-risk patients found no difference between the two treatment options.30, 35
In contrast, data on some new therapeutic strategies remain scarce, but the existing 
data may demonstrate excellent safety and efficacy. Such results often represent outcomes 
from highly selected patients treated by experienced surgeons in high-volume centres. This 
introduces a bias; the generalizability of such results is limited and caution is advised. An 
example of this is the evaluation of TECAB procedures.
PcI versus cAbG studies
Continuous evaluation of PCI versus CABG calls for a specific focus on new develop-
ments in both interventions. For PCI patients, new stents will become available and the 
use of fractional flow reserve to assess the need and completeness of revascularisation 
Figure 4 Functional and anatomical imaging using Pet computed tomography
Case: 70-year old male with three-vessel coronary artery disease for which he underwent stenting of the RCA 
in 2012, had atypical symptoms. Scan is positive for inferolateral wall ischaemia (purple). LAD = left anterior 
descending artery; LCX = left circumflex artery; RCA = right coronary artery
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is emphasized.150, 151 Equivalent data on FFR-guided CABG are scarce.152 Future studies 
should explore the use and differences of FFR-guided revascularisation between PCI and 
CABG.153 The impact of the degree of ischemia and viability on the outcomes of both 
CABG and PCI in patients with stable angina is still under debate. Whether image guided 
revascularization that is based on a combination of functional and anatomical imaging -- for 
example PET computed tomography (Figure 4) -- can improve the outcomes as compared to 
the traditional occulostenotic approach warrants further trials. 
Traditionally, trials are limited to their internal validity, i.e. the results are only applicable 
to the included patient cohort; large ‘real-world’ registries are required to demonstrate 
whether trial results are also applicable to the general population.10 Alternatively, an ‘all-
comers’ trial design with none to limited patient exclusion criteria increases external valida-
tion, and presents a more balanced trade-off between internal and external validation.154 
Furthermore, reporting the experience of centres and operators will also contribute to the 
internal and external validity of trial results: superior outcomes in experienced centres as 
opposed to inexperienced centres unveils limited external validity and should restrict one 
from over-extrapolating trial results to real-world clinical settings.
In the SYNTAX trial a new angiographic score was validated --the SYNTAX score-- for 
grading the complexity of coronary artery disease.155 This score appears to be a very promis-
ing tool for deciding if PCI or CABG would be preferable. Use of the score is therefore 
recommended for decision-making. Recently the SYNTAX II score was introduced and 
showed an improvement in guiding decision-making.156 Yet, further validation of these 
hypothesis-generating data are needed and future studies should provide a larger body of 
evidence about the SYNTAX (II) score.
Pharmacologic management of patients after PCI and CABG differs significantly and has 
an impact on long-term results. It would be interesting to see the results of PCI and CABG 
if the pharmacological management and treatment adherence after PCI and CABG would 
be identical. 
dIscussIon
Broadening indications for and increasing use of PCI calls for more focus on the optimiza-
tion of short- and long-term outcomes after CABG. Expanding the use of lesser invasive 
techniques may persuade patients to accept surgery as the preferable treatment option. 
Particularly studies comparing PCI with CABG require the most optimal surgical revascu-
larisation strategy to show superiority over PCI. Arterial revascularisation with minimized 
aortic manipulation and intraoperative graft flow measurement is a relatively easy way to 
improve outcomes.
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Adoption rates of new techniques have been low, despite all advances. This may be due 
to: (i) the familiarity that surgeons have with existing techniques, a reluctance to change and 
the willingness to go through the learning curve typical for a new technique, (ii) the more 
demanding nature of some technical advances, (iii) complications related to the use of a 
new technique and/or device, (iv) time-consuming steps that may have to be carried out 
during the procedure, and (v) logistic reasons with regard to the need for additional equip-
ment, planning and sterility. Particularly when the presumed benefits with new techniques 
are not yet clearly proven, these factors play a major role in maintaining existing protocols. 
However, the benefit of advancements will often become evident when overcoming the 
learning curve. On the other hand, some techniques will always be time-consuming and 
reserved for highly specialized centres.
Guidelines
One explanation for the underuse of new techniques and secondary prevention measures 
may be the lack of data supporting their benefit. This calls for large registries and randomised 
trials to provide additional rigorous evaluation of, in particular, MIDCAB, hybrid revascu-
larisation, epiaortic scanning and graft flow measurement. Another reason for lack of wide-
spread implementation and geographic variations may be the differing recommendations of 
the American and European guidelines concerning their use (Table 6). This is illustrated by 
recommendations for epiaortic scanning and graft flow assessment. The current European 
ESC/EACTS revascularisation guidelines include a class 1C recommendation for intra-oper-
ative graft flow assessment 3 and the American guidelines state that “epiaortic ultrasound is 
reasonable to evaluate…”, which translates to a class IIa B recommendation.149 However, 
the American guidelines do not include a recommendation for graft flow assessment, while 
the European guidelines lack a recommendation for epiaortic scanning. 
Patient, cost, and market considerations
Adoption of minimally invasive techniques that result in lower postoperative complications 
and reduced length of stay will significantly improve patient satisfaction, and raise patients’ 
willingness to undergo CABG as opposed to PCI. On the background of the issue of rising 
health care expenditures, these improvements may also help reduce overall costs.
Continued optimization of short- and long-term outcomes of CABG will reduce costs for 
health insurance providers who may therefore favour adoption of new techniques associated 
with shorter initial in-hospital stays, reduced complication rates and fewer repeat revascu-
larisations. In addition, pay for performance is increasingly instated.157This system provides 
additional incentives to innovate and improve outcomes. 
Containing costs to both health insurance providers and societies may in some health 
care systems require a reduction of the number of centres performing CABG. Innovation 
and integrating technological advances into everyday clinical practice may be rewarded 
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table 6 American and european guideline recommendations
Guidelines
American european
Off-pump 
CABG
“In patients with preoperative renal dys-
function (creatinine clearance <60 mL/
min), off-pump CABG may be reason-
able to reduce the risk of acute kidney 
injury” IIb b
“It is reasonable to consider off-pump 
CABG to reduce perioperative bleeding 
and allogeneic blood transfusion” IIa A
“Off-pump CABG may be considered, rather 
than on-pump CABG for patients with mild to 
moderate chronic kidney disease” IIb b
MIDCAB No recommendation No recommendation
Hybrid revas-
cularisation
“Hybrid coronary revascularisation is 
reasonable in patients with 1 or more 
of the following: limitations to tradi-
tional CABG, such as heavily calcified 
proximal aorta or poor target vessels 
for CABG (but amenable to PCI); lack 
of suitable graft conduits; unfavourable 
LAD artery for PCI (i.e., excessive vessel 
tortuosity or chronic total occlusion)” 
IIa b
“Hybrid coronary revascularisation 
may be reasonable as an alternative to 
multivessel PCI or CABG in an attempt 
to improve the overall risk-benefit ratio 
of the procedures” IIb c
“Hybrid procedure, defined as consecutive or 
combined surgical and interventional revascu-
larisation may be considered in specific patient 
subsets at experienced centres” IIb b
Clampless / 
‘no touch’
Patients with extensive disease of the 
ascending aorta pose a
special challenge for on-pump CABG; 
for these patients,
cannulation or cross-clamping of the 
aorta may create an
unacceptably high risk of stroke. In such 
individuals, offpump
CABG in conjunction with avoidance of 
manipulation
of the ascending aorta (including place-
ment of proximal
anastomoses) may be beneficial. (no 
formal recommendation, no level of 
evidence)
No recommendation
Endoscopic 
vein harvest-
ing
No recommendation Endoscopic vein-graft harvesting cannot be 
recommended at present as it has been associ-
ated with vein-graft failure and adverse clinical 
outcomes. (no formal recommendation, no 
level of evidence)
Epiaortic scan-
ning
“Routine epiaortic ultrasound scanning 
is reasonable to evaluate the presence, 
location, and severity of plaque in the 
ascending aorta to reduce the incidence 
of atheroembolic complications” IIa b
No recommendation
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table 6 Continued
Guidelines
American european
Graft flow 
assessment
No recommendation “Graft evaluation is recommended before leav-
ing the operating theatre” Ic
Arterial revas-
cularisation/
Complete 
revascularisa-
tion
“If possible, the LIMA should be used to 
bypass the LAD artery when bypass of 
the LAD artery is indicated” Ib
“When anatomically and clinically suit-
able, use of a second IMA to graft the 
left circumflex or right coronary artery 
(when critically stenosed and perus-
ing LV myocardium) is reasonable to 
improve the likelihood of survival and to 
decrease reintervention” IIa b
“Complete arterial revascularisation may 
be reasonable in patients ≤60 years of 
age with few or no comorbidities” IIb c
“Arterial grafting to the LAD system is indi-
cated” IA
“Complete revascularisation with arterial graft-
ing to non-LAD coronary systems is indicated 
in patients with reasonable life expectancy” IA
Secondary 
prevention
“All smokers should receive in-hospital 
educational counselling and be offered 
smoking cessation therapy during CABG 
hospitalisation” IA
“[Aspirin] should be initiated within 
6 hours postoperatively and then 
continued indefinitely to reduce the 
occurrence of SVG closure and adverse 
cardiovascular events” IA
“All patients undergoing CABG should 
receive statin therapy, unless contrain-
dicated” IA
“β-blockers should be prescribed to all 
CABG patients without contraindica-
tions at the time of hospital discharge” 
Ic
“ACE inhibitors and ARBs should be 
initiated postoperatively and continued 
indefinitely in CABG patients who 
were not receiving them preoperatively, 
who are stable, and who have an LVEF 
≤40%, hypertension, diabetes mellitus, 
or CKD, unless contraindicated” IA
In general, an ‘ABCDE’ approach is proposed: 
‘A’ for antiplatelet therapy (Table 36), anticoag-
ulation, ACE inhibition, or angiotensin receptor 
blockade; ‘B’ for b-blockade and blood pres-
sure control; ‘C’ for cholesterol treatment and 
cigarette smoking cessation; ‘D’ for diabetes 
management and diet; and ‘E’ for exercise.”
Several recommendations are provided with 
regard to lifestyle and risk factor management 
(e.g., counselling on physical activity and 
exercise training, IA; diet and weight control 
management, Ib; smoking cessation, Ib).
“Secondary prevention demands lifelong anti-
platelet therapy with 75-325 mg acetylsalicylic 
acid daily”
“ACE inhibitors should be started and contin-
ued indefinitely in all patients with LVEF ≤40% 
and for those with hypertension, diabetes, or 
CKD, unless contraindicated” IA
“It is indicated to start and continue β-blocker 
therapy in all patients after MI or ACS or left 
ventricular dysfunction, unless contraindi-
cated” IA
“High-dose lipid lowering drugs are indicated 
in all patients regardless of lipid levels, unless 
contraindicated” IA
“Fibrates and omega-3 fatty acids (1 g/day) 
should be considered in combination with 
statins and in patients intolerant of statins” IIb 
b
The level of evidence is shown in bold. ACE = angiotensin-converting enzyme; ACS = acute coronary syndrome; 
CABG = coronary artery bypass grafting; CKD = chronic kidney disease; LAD = left anterior descending; 
LVEF = left ventricular ejection fraction; (L)IMA = (left) internal mammary artery; MI = myocardial infarction; 
PCI = percutaneous coronary intervention
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by certification as a centre of excellence, by continued issuance of a practice licence and 
by more patient referrals. Implementation of the Heart Team decision-making process may 
furthermore strengthen the position of a centre. This approach highlights the centre’s col-
laborative environment between specialties, which is appreciated by patients.144 There may 
also be major cost implications by eradicating suboptimal treatment: health care costs will 
be contained as rates of adverse events requiring rehospitalisation and additional procedures 
are reduced.
conclusIons
Outcomes after surgical revascularisation have the potential to improve beyond the level 
achieved during recent decades (Figure 5). However, to facilitate these improvements, 
surgeons need to be willing to adopt new techniques that increase procedural safety, patient 
satisfaction, and long-term survival. To achieve these goals, guidelines should be conclusive 
about recommending certain techniques and provide guidance for their use. Future trials 
will need to provide sufficient evidence for such recommendations by focussing on specific 
areas where optimal therapy has yet to be substantiated.
Less invasine:
MIDCAB/Hybrid
TECAB
EVH
Increase durability:
BIMA
Complete arterial
Measure graft flow Prevention:
Medications
Dietary intake
Stress relief
Excercise
Future
CABG
Low complications:
Off-pump
Clampless
Epiaortic scanning
EBM:
Guidelines
Heart Team
Figure 5
summary of developments to optimize short- and long-term results after coronary artery 
bypass grafting
BIMA = bilateral internal mammary artery; CABG = coronary artery bypass grafting; EBM = evidence-based 
medicine; EVH = endoscopic vein harvesting; MIDCAB = minimally invasive coronary artery bypass; TECAB = 
totally endoscopic coronary artery bypass
Part 3 Stenting versus bypass surgery394
reFerences
1.  Head SJ, Kieser TM, Valk F, Huysmans HA, Kappetein AP. Coronary artery bypass grafting: Part 1 
-- The evolution over the first 50 years. Eur Heart J 2013; in press.
2.  Gruntzig A. Transluminal dilatation of coronary-artery stenosis. Lancet 1978;1:263.
3.  Kolh P, Wijns W, Danchin N, Di Mario C, Falk V, Folliguet T, Garg S, Huber K, James S, Knuuti 
J, Lopez-Sendon J, Marco J, Menicanti L, Ostojic M, Piepoli MF, Pirlet C, Pomar JL, Reifart N, 
Ribichini FL, Schalij MJ, Sergeant P, Serruys PW, Silber S, Sousa Uva M, Taggart D. Guidelines on 
myocardial revascularization. Eur J Cardiothorac Surg 2010;38 Suppl:S1-S52.
4.  Stefanini GG, Kalesan B, Serruys PW, Heg D, Buszman P, Linke A, Ischinger T, Klauss V, Eberli 
F, Wijns W, Morice MC, Di Mario C, Corti R, Antoni D, Sohn HY, Eerdmans P, van Es GA, Meier 
B, Windecker S, Juni P. Long-term clinical outcomes of biodegradable polymer biolimus-eluting 
stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease 
(LEADERS): 4 year follow-up of a randomised non-inferiority trial. Lancet 2011;378:1940-1948.
5.  Palmerini T, Biondi-Zoccai G, Della Riva D, Stettler C, Sangiorgi D, D’Ascenzo F, Kimura T, 
Briguori C, Sabate M, Kim HS, De Waha A, Kedhi E, Smits PC, Kaiser C, Sardella G, Marullo 
A, Kirtane AJ, Leon MB, Stone GW. Stent thrombosis with drug-eluting and bare-metal stents: 
evidence from a comprehensive network meta-analysis. Lancet 2012;379:1393-1402.
6.  Onuma Y, Serruys PW, Ormiston JA, Regar E, Webster M, Thuesen L, Dudek D, Veldhof S, Rapoza 
R. Three-year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in 
patients with de novo coronary artery disease: the ABSORB trial. EuroIntervention 2010;6:447-
453.
7.  Serruys PW, Garcia-Garcia HM, Onuma Y. From metallic cages to transient bioresorbable scaf-
folds: change in paradigm of coronary revascularization in the upcoming decade? Eur Heart J 
2012;33:16-25b.
8.  Epstein AJ, Polsky D, Yang F, Yang L, Groeneveld PW. Coronary revascularization trends in the 
United States, 2001-2008. JAMA 2011;305:1769-1776.
9.  Mohr FW, Morice MC, Kappetein AP, Feldman TE, Stahle E, Colombo A, Mack MJ, Holmes DR, 
Jr., Morel MA, Van Dyck N, Houle VM, Dawkins KD, Serruys PW. Coronary artery bypass graft 
surgery versus percutaneous coronary intervention in patients with three-vessel disease and 
left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet 
2013;381:629-638.
10.  Weintraub WS, Grau-Sepulveda MV, Weiss JM, O’Brien SM, Peterson ED, Kolm P, Zhang Z, Klein 
LW, Shaw RE, McKay C, Ritzenthaler LL, Popma JJ, Messenger JC, Shahian DM, Grover FL, Mayer 
JE, Shewan CM, Garratt KN, Moussa ID, Dangas GD, Edwards FH. Comparative effectiveness of 
revascularization strategies. N Engl J Med 2012;366:1467-1476.
11.  Farkouh ME, Domanski M, Sleeper LA, Siami FS, Dangas G, Mack M, Yang M, Cohen DJ, Rosen-
berg Y, Solomon SD, Desai AS, Gersh BJ, Magnuson EA, Lansky A, Boineau R, Weinberger J, 
Ramanathan K, Sousa JE, Rankin J, Bhargava B, Buse J, Hueb W, Smith CR, Muratov V, Bansilal 
S, King S, 3rd, Bertrand M, Fuster V. Strategies for multivessel revascularization in patients with 
diabetes. N Engl J Med 2012;367:2375-2384.
12.  Kappetein AP, Head SJ, Morice MC, Banning AP, Serruys PW, Mohr FW, Dawkins KD, Mack MJ, 
SYNTAX Investigators. Treatment of complex coronary artery disease in patients with diabetes: 
5-year results comparing outcomes of bypass surgery and percutaneous coronary intervention in 
the SYNTAX trial. Eur J Cardiothorac Surg 2013;45;1006-1013.
CABG: optimizing outcomes and future prospects 395
C
ha
pt
er
 2
3
13.  Afilalo J, Rasti M, Ohayon SM, Shimony A, Eisenberg MJ. Off-pump vs. on-pump coronary artery 
bypass surgery: an updated meta-analysis and meta-regression of randomized trials. Eur Heart J 
2012;33:1257-1267.
14.  Abu-Omar Y, Taggart DP. The present status of off-pump coronary artery bypass grafting. Eur J 
Cardiothorac Surg 2009;36:312-321.
15.  Van Dijk D, Jansen EW, Hijman R, Nierich AP, Diephuis JC, Moons KG, Lahpor JR, Borst C, 
Keizer AM, Nathoe HM, Grobbee DE, De Jaegere PP, Kalkman CJ, Octopus Study G. Cognitive 
outcome after off-pump and on-pump coronary artery bypass graft surgery: a randomized trial. 
JAMA 2002;287(11):1405-1412.
16.  Mack MJ, Pfister A, Bachand D, Emery R, Magee MJ, Connolly M, Subramanian V. Comparison of 
coronary bypass surgery with and without cardiopulmonary bypass in patients with multivessel 
disease. J Thorac Cardiovasc Surg 2004;127:167-173.
17.  Racz MJ, Hannan EL, Isom OW, Subramanian VA, Jones RH, Gold JP, Ryan TJ, Hartman A, Cul-
liford AT, Bennett E, Lancey RA, Rose EA. A comparison of short- and long-term outcomes after 
off-pump and on-pump coronary artery bypass graft surgery with sternotomy. J Am Coll Cardiol 
2004;43:557-564.
18.  Kuss O, von Salviati B, Börgermann J. Off-pump versus on-pump coronary artery bypass grafting: 
a systematic review and meta-analysis of propensity score analyses. J Thorac Cardiovasc Surg 
2010;140:829-835.
19.  Williams ML, Muhlbaier LH, Schroder JN, Hata JA, Peterson ED, Smith PK, Landolfo KP, Messier 
RH, Davis RD, Milano CA. Risk-adjusted short- and long-term outcomes for on-pump versus 
off-pump coronary artery bypass surgery. Circulation 2005;112:I366-I370.
20.  Filardo G, Grayburn PA, Hamilton C, Hebeler RF, Jr., Cooksey WB, Hamman B. Comparing 
long-term survival between patients undergoing off-pump and on-pump coronary artery bypass 
graft operations. Ann Thorac Surg 2011;92:571-577; discussion 577-578.
21.  Hattler B, Messenger JC, Shroyer AL, Collins JF, Haugen SJ, Garcia JA, Baltz JH, Cleveland JC, Jr., 
Novitzky D, Grover FL. Off-Pump coronary artery bypass surgery is associated with worse arterial 
and saphenous vein graft patency and less effective revascularization: Results from the Veterans 
Affairs Randomized On/Off Bypass (ROOBY) trial. Circulation 2012;125:2827-2835.
22.  Widimsky P, Straka Z, Stros P, Jirasek K, Dvorak J, Votava J, Lisa L, Budesinsky T, Kolesar M, Vanek T, 
Brucek P. One-year coronary bypass graft patency: a randomized comparison between off-pump 
and on-pump surgery angiographic results of the PRAGUE-4 trial. Circulation 2004;110:3418-
3423.
23.  Puskas JD, Williams WH, Mahoney EM, Huber PR, Block PC, Duke PG, Staples JR, Glas KE, 
Marshall JJ, Leimbach ME, McCall SA, Petersen RJ, Bailey DE, Weintraub WS, Guyton RA. Off-
pump vs conventional coronary artery bypass grafting: early and 1-year graft patency, cost, and 
quality-of-life outcomes: a randomized trial. JAMA 2004;291:1841-1849.
24.  Shroyer AL, Grover FL, Hattler B, Collins JF, McDonald GO, Kozora E, Lucke JC, Baltz JH, 
Novitzky D, Veterans Affairs Randomized On/Off Bypass Study Group. On-pump versus off-
pump coronary-artery bypass surgery. N Engl J Med 2009;361:1827-1837.
25.  Puskas JD, Mack MJ, Smith CR. On-pump versus off-pump CABG. N Engl J Med 2010;362:851; 
author reply 853-854.
26.  Sousa Uva M, Cavaco S, Oliveira AG, Matias F, Silva C, Mesquita A, Aguiar P, Bau J, Pedro 
A, Magalhaes MP. Early graft patency after off-pump and on-pump coronary bypass surgery: a 
prospective randomized study. Eur Heart J 2010;31:2492-2499.
Part 3 Stenting versus bypass surgery396
27.  Takagi H, Matsui M, Umemoto T. Lower graft patency after off-pump than on-pump coronary 
artery bypass grafting: an updated meta-analysis of randomized trials. J Thorac Cardiovasc Surg 
2010;140:e45-e47.
28.  Synnergren MJ, Ekroth R, Oden A, Rexius H, Wiklund L. Incomplete revascularization reduces 
survival benefit of coronary artery bypass grafting: role of off-pump surgery. J Thorac Cardiovasc 
Surg 2008;136:29-36.
29.  Lamy A, Devereaux PJ, Prabhakaran D, Taggart DP, Hu S, Paolasso E, Straka Z, Piegas LS, Akar 
AR, Jain AR, Noiseux N, Padmanabhan C, Bahamondes JC, Novick RJ, Vaijyanath P, Reddy S, Tao 
L, Olavegogeascoechea PA, Airan B, Sulling TA, Whitlock RP, Ou Y, Ng J, Chrolavicius S, Yusuf S, 
CORONARY Investigators. Off-pump or on-pump coronary-artery bypass grafting at 30 days. N 
Engl J Med 2012;366:1489-1497.
30.  Lamy A, Devereaux PJ, Dorairaj P, Taggart DP, Hu S, Paolasso E, Straka Z, Piegas LS, Akar AR, 
Jain AR, Noiseux N, Padmanabhan C, Bahamondes JC, Novick RJ, Vaijyanath P, Reddy SK, Tao L, 
Olavegogeascoechea PA, Airan B, Sulling TA, Whitlock RP, Ou Y, Pogue J, Chrolavicius S, Yusuf 
S, CORONARY Investigators. Effects of off-pump and on-pump coronary-artery bypass grafting at 
1 year. N Engl J Med 2013;368:1179-1188.
31.  Puskas JD, Thourani VH, Kilgo P, Cooper W, Vassiliades T, Vega JD, Morris C, Chen E, Schmotzer 
BJ, Guyton RA, Lattouf OM. Off-pump coronary artery bypass disproportionately benefits high-
risk patients. Ann Thorac Surg 2009;88:1142-1147.
32.  Sharony R, Bizekis CS, Kanchuger M, Galloway AC, Saunders PC, Applebaum R, Schwartz CF, 
Ribakove GH, Culliford AT, Baumann FG, Kronzon I, Colvin SB, Grossi EA. Off-pump coronary 
artery bypass grafting reduces mortality and stroke in patients with atheromatous aortas: a case 
control study. Circulation 2003;108 Suppl 1:II15-II20.
33.  Head SJ, Kappetein AP. Off-pump or on-pump coronary-artery bypass grafting. N Engl J Med 
2012;367:577-578.
34.  Magee MJ, Coombs LP, Peterson ED, Mack MJ. Patient selection and current practice strategy for 
off-pump coronary artery bypass surgery. Circulation 2003;108 Suppl 1:II9-II14.
35.  Diegeler A, Borgermann J, Kappert U, Breuer M, Boning A, Ursulescu A, Rastan A, Holzhey D, 
Treede H, Riess FC, Veeckmann P, Asfoor A, Reents W, Zacher M, Hilker M, The GOPCABE Study 
Group. Off-pump versus on-pump coronary-artery bypass grafting in elderly patients. N Engl J 
Med 2013;368:1189-1198.
36.  Puskas JD, Edwards FH, Pappas PA, O’Brien S, Peterson ED, Kilgo P, Ferguson TB, Jr. Off-pump 
techniques benefit men and women and narrow the disparity in mortality after coronary bypass 
grafting. Ann Thorac Surg 2007;84:1447-1454; discussion 1454-1456.
37.  Guerrieri Wolf L, Abu-Omar Y, Choudhary BP, Pigott D, Taggart DP. Gaseous and solid cere-
bral microembolization during proximal aortic anastomoses in off-pump coronary surgery: 
the effect of an aortic side-biting clamp and two clampless devices. J Thorac Cardiovasc Surg 
2007;133:485-493.
38.  Börgermann J, Hakim K, Renner A, Parsa A, Aboud A, Becker T, Masshoff M, Zittermann A, 
Gummert JF, Kuss O. Clampless off-pump versus conventional coronary artery revascularization: 
a propensity score analysis of 788 patients. Circulation 2012;126:S176-S182.
39.  Emmert MY, Seifert B, Wilhelm M, Grunenfelder J, Falk V, Salzberg SP. Aortic no-touch technique 
makes the difference in off-pump coronary artery bypass grafting. J Thorac Cardiovasc Surg 
2011;142:1499-1506.
CABG: optimizing outcomes and future prospects 397
C
ha
pt
er
 2
3
40.  Misfeld M, Brereton RJ, Sweetman EA, Doig GS. Neurologic complications after off-pump coro-
nary artery bypass grafting with and without aortic manipulation: meta-analysis of 11,398 cases 
from 8 studies. J Thorac Cardiovasc Surg 2011;142:e11-e17.
41.  Cohen DJ, Van Hout B, Serruys PW, Mohr FW, Macaya C, den Heijer P, Vrakking MM, Wang 
K, Mahoney EM, Audi S, Leadley K, Dawkins KD, Kappetein AP, SYNTAX Investigators. Qual-
ity of life after PCI with drug-eluting stents or coronary-artery bypass surgery. N Engl J Med 
2011;364:1016-1026.
42.  Serruys P, Morice M, Kappetein A, Colombo A, Holmes DR, Mack MJ, Ståhle E, Feldman TE, van 
den Brand MJ, Bass E, van Dyck N, Leadley K, Dawkins KD, Mohr FW, SYNTAX Investigators. 
Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary 
artery disease. N Engl J Med 2009;360:961-972.
43.  Hlatky MA, Boothroyd DB, Bravata DM, Boersma E, Booth J, Brooks MM, Carrie D, Clayton 
TC, Danchin N, Flather M, Hamm CW, Hueb WA, Kahler J, Kelsey SF, King SB, Kosinski AS, 
Lopes N, McDonald KM, Rodriguez A, Serruys P, Sigwart U, Stables RH, Owens DK, Pocock SJ. 
Coronary artery bypass surgery compared with percutaneous coronary interventions for multives-
sel disease: a collaborative analysis of individual patient data from ten randomised trials. Lancet 
2009;373:1190-1197.
44.  Hannan EL, Wu C, Walford G, Culliford AT, Gold JP, Smith CR, Higgins RS, Carlson RE, Jones RH. 
Drug-eluting stents vs. coronary-artery bypass grafting in multivessel coronary disease. N Engl J 
Med 2008;358:331-341.
45.  Acuff TE, Landreneau RJ, Griffith BP, Mack MJ. Minimally invasive coronary artery bypass graft-
ing. Ann Thorac Surg 1996;61:135-137.
46.  Groh MA, Sutherland SE, Burton HG, 3rd, Johnson AM, Ely SW. Port-access coronary artery 
bypass grafting: technique and comparative results. Ann Thorac Surg 1999;68:1506-1508.
47.  Diegeler A, Walther T, Metz S, Falk V, Krakor R, Autschbach R, Mohr FW. Comparison of MID-
CAP versus conventional CABG surgery regarding pain and quality of life. Heart Surg Forum 
1999;2:290-295; discussion 295-296.
48.  Martens TP, Argenziano M, Oz MC. New technology for surgical coronary revascularization. 
Circulation 2006;114:606-614.
49.  Lapierre H, Chan V, Sohmer B, Mesana TG, Ruel M. Minimally invasive coronary artery bypass 
grafting via a small thoracotomy versus off-pump: a case-matched study. Eur J Cardiothorac Surg 
2011;40:804-810.
50.  Holzhey DM, Cornely JP, Rastan AJ, Davierwala P, Mohr FW. Review of a 13-year single-center 
experience with minimally invasive direct coronary artery bypass as the primary surgical treat-
ment of coronary artery disease. Heart Surg Forum 2012;15:E61-E68.
51.  Taggart DP, D’Amico R, Altman DG. Effect of arterial revascularisation on survival: a systematic 
review of studies comparing bilateral and single internal mammary arteries. Lancet 2001;358:870-
875.
52.  Kieser TM, Lewin AM, Graham MM, Martin BJ, Galbraith PD, Rabi DM, Norris CM, Faris PD, 
Knudtson ML, Ghali WA, Approach Investigators. Outcomes associated with bilateral internal 
thoracic artery grafting: the importance of age. Ann Thorac Surg 2011;92:1269-1275; discussion 
1275-1276.
53.  Hattler B, Messenger JC, Shroyer AL, Collins JF, Haugen SJ, Garcia JA, Baltz JH, Cleveland JC, 
Jr., Novitzky D, Grover FL, Veterans Affairs Randomized On/Off Bypass Study Group. Off-Pump 
coronary artery bypass surgery is associated with worse arterial and saphenous vein graft patency 
Part 3 Stenting versus bypass surgery398
and less effective revascularization: Results from the Veterans Affairs Randomized On/Off Bypass 
(ROOBY) trial. Circulation 2012;125:2827-2835.
54.  Alexander JH, Hafley G, Harrington RA, Peterson ED, Ferguson TB, Jr., Lorenz TJ, Goyal A, 
Gibson M, Mack MJ, Gennevois D, Califf RM, Kouchoukos NT, Prevent IV Investigators. Efficacy 
and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure 
following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. JAMA 
2005;294:2446-2454.
55.  Friedrich GJ, Bonatti J, Dapunt OE. Preliminary experience with minimally invasive coronary-
artery bypass surgery combined with coronary angioplasty. N Engl J Med 1997;336:1454-1455.
56.  Kon ZN, Brown EN, Tran R, Joshi A, Reicher B, Grant MC, Kallam S, Burris N, Connerney I, 
Zimrin D, Poston RS. Simultaneous hybrid coronary revascularization reduces postoperative 
morbidity compared with results from conventional off-pump coronary artery bypass. J Thorac 
Cardiovasc Surg 2008;135:367-375.
57.  Halkos ME, Rab ST, Vassiliades TA, Morris DC, Douglas JS, Kilgo PD, Liberman HA, Guyton 
RA, Thourani VH, Puskas JD. Hybrid coronary revascularization versus off-pump coronary artery 
bypass for the treatment of left main coronary stenosis. Ann Thorac Surg 2011;92:2155-2160.
58.  Halkos ME, Vassiliades TA, Douglas JS, Morris DC, Rab ST, Liberman HA, Samady H, Kilgo PD, 
Guyton RA, Puskas JD. Hybrid coronary revascularization versus off-pump coronary artery bypass 
grafting for the treatment of multivessel coronary artery disease. Ann Thorac Surg 2011;92:1695-
1701; discussion 1701-1702.
59.  Bonaros N, Schachner T, Lehr E, Kofler M, Wiedemann D, Hong P, Wehman B, Zimrin D, Vesely 
MK, Friedrich G, Bonatti J. Five hundred cases of robotic totally endoscopic coronary artery 
bypass grafting: predictors of success and safety. Ann Thorac Surg 2013;95:803-812.
60.  McGinn JT, Jr., Usman S, Lapierre H, Pothula VR, Mesana TG, Ruel M. Minimally invasive 
coronary artery bypass grafting: dual-center experience in 450 consecutive patients. Circulation 
2009;120:S78-S84.
61.  Bonatti JO, Zimrin D, Lehr EJ, Vesely M, Kon ZN, Wehman B, de Biasi AR, Hofauer B, Weidinger 
F, Schachner T, Bonaros N, Friedrich G. Hybrid coronary revascularization using robotic totally 
endoscopic surgery: perioperative outcomes and 5-year results. Ann Thorac Surg 2012;94:1920-
1926; discussion 1926.
62.  Holzhey DM, Jacobs S, Mochalski M, Merk D, Walther T, Mohr FW, Falk V. Minimally invasive 
hybrid coronary artery revascularization. Ann Thorac Surg 2008;86:1856-1860.
63.  Bonatti J, Schachner T, Bonaros N, Lehr EJ, Zimrin D, Griffith B. Robotically assisted totally 
endoscopic coronary bypass surgery. Circulation 2011;124:236-244.
64.  Thiele H, Neumann-Schniedewind P, Jacobs S, Boudriot E, Walther T, Mohr FW, Schuler G, Falk 
V. Randomized comparison of minimally invasive direct coronary artery bypass surgery versus 
sirolimus-eluting stenting in isolated proximal left anterior descending coronary artery stenosis. J 
Am Coll Cardiol 2009;53:2324-2331.
65.  D’Ancona G, Vassiliades TA, Boyd WD, Donias HW, Stahl KD, Karamanoukian H. Is hybrid 
coronary revascularization favored by cardiologists or cardiac surgeons? Heart Surg Forum 
2002;5:393-395.
66.  Goldman S, Zadina K, Moritz T, Ovitt T, Sethi G, Copeland JG, Thottapurathu L, Krasnicka B, Ellis 
N, Anderson RJ, Henderson W, V. A. Cooperative Study Group. Long-term patency of saphenous 
vein and left internal mammary artery grafts after coronary artery bypass surgery: results from a 
Department of Veterans Affairs Cooperative Study. J Am Coll Cardiol 2004;44:2149-2156.
CABG: optimizing outcomes and future prospects 399
C
ha
pt
er
 2
3
67.  Hayward PA, Buxton BF. Contemporary coronary graft patency: 5-year observational data from a 
randomized trial of conduits. Ann Thorac Surg 2007;84:795-799.
68.  Kim KB, Kim JS, Kang HJ, Koo BK, Kim HS, Oh BH, Park YB. Ten-year experience with off-pump 
coronary artery bypass grafting: lessons learned from early postoperative angiography. J Thorac 
Cardiovasc Surg 2010;139:256-262.
69.  FitzGibbon GM, Burton JR, Leach AJ. Coronary bypass graft fate: angiographic grading of 1400 
consecutive grafts early after operation and of 1132 after one year. Circulation 1978;57:1070-
1074.
70.  Lytle BW, Blackstone EH, Loop FD, Houghtaling PL, Arnold JH, Akhrass R, McCarthy PM, Cos-
grove DM. Two internal thoracic artery grafts are better than one. J Thorac Cardiovasc Surg 
1999;117:855-872.
71.  Taggart DP, Altman DG, Gray AM, Lees B, Nugara F, Yu LM, Campbell H, Flather M, ART 
Investigators. Randomized trial to compare bilateral vs. single internal mammary coronary 
artery bypass grafting: 1-year results of the Arterial Revascularisation Trial (ART). Eur Heart J 
2010;31:2470-2481.
72.  Kappetein AP. Bilateral mammary artery vs. single mammary artery grafting: promising early 
results: but will the match finish with enough players? Eur Heart J 2010;31:2444-2446.
73.  Tabata M, Grab JD, Khalpey Z, Edwards FH, O’Brien SM, Cohn LH, Bolman RM, 3rd. Prevalence 
and variability of internal mammary artery graft use in contemporary multivessel coronary artery 
bypass graft surgery: analysis of the Society of Thoracic Surgeons National Cardiac Database. 
Circulation 2009;120:935-940.
74.  Kinoshita T, Asai T. Bilateral internal thoracic artery grafting: current state of the art. Innovations 
(Phila) 2011;6:77-83.
75.  Collins P, Webb CM, Chong CF, Moat NE, Radial Artery Versus Saphenous Vein Patency Trial 
Investigators. Radial artery versus saphenous vein patency randomized trial: five-year angio-
graphic follow-up. Circulation 2008;117:2859-2864.
76.  Deb S, Cohen EA, Singh SK, Une D, Laupacis A, Fremes SE, RAPS Investigators. Radial artery 
and saphenous vein patency more than 5 years after coronary artery bypass surgery: results from 
RAPS (Radial Artery Patency Study). J Am Coll Cardiol 2012;60:28-35.
77.  Tranbaugh RF, Dimitrova KR, Friedmann P, Geller CM, Harris LJ, Stelzer P, Cohen BM, Ko W, 
DeCastro H, Lucido D, Hoffman DM. Coronary artery bypass grafting using the radial artery: 
clinical outcomes, patency, and need for reintervention. Circulation 2012;126:S170-S175.
78.  Achouh P, Isselmou KO, Boutekadjirt R, D’Alessandro C, Pagny JY, Fouquet R, Fabiani JN, Acar 
C. Reappraisal of a 20-year experience with the radial artery as a conduit for coronary bypass 
grafting. Eur J Cardiothorac Surg 2012;41:87-92.
79.  Schwann TA, Al-Shaar L, Engoren M, Habib RH. Late effects of radial artery vs saphenous vein 
grafting for multivessel coronary bypass surgery in diabetics: a propensity-matched analysis. Eur 
J Cardiothorac Surg 2013;doi: 10.1093/ejcts/ezt061.
80.  Zacharias A, Habib RH, Schwann TA, Riordan CJ, Durham SJ, Shah A. Improved survival with 
radial artery versus vein conduits in coronary bypass surgery with left internal thoracic artery to 
left anterior descending artery grafting. Circulation 2004;109:1489-1496.
81.  Locker C, Schaff HV, Dearani JA, Joyce LD, Park SJ, Burkhart HM, Suri RM, Greason KL, Stulak 
JM, Li Z, Daly RC. Multiple arterial grafts improve late survival of patients undergoing coro-
nary artery bypass graft surgery: analysis of 8622 patients with multivessel disease. Circulation 
2012;126:1023-1030.
Part 3 Stenting versus bypass surgery400
82.  Goldman S, Sethi GK, Holman W, Thai H, McFalls E, Ward HB, Kelly RF, Rhenman B, Tobler GH, 
Bakaeen FG, Huh J, Soltero E, Moursi M, Haime M, Crittenden M, Kasirajan V, Ratliff M, Pett S, 
Irimpen A, Gunnar W, Thomas D, Fremes S, Moritz T, Reda D, Harrison L, Wagner TH, Wang Y, 
Planting L, Miller M, Rodriguez Y, Juneman E, Morrison D, Pierce MK, Kreamer S, Shih MC, Lee 
K. Radial artery grafts vs saphenous vein grafts in coronary artery bypass surgery: a randomized 
trial. JAMA 2011;305:167-174.
83.  Khot UN, Friedman DT, Pettersson G, Smedira NG, Li J, Ellis SG. Radial artery bypass grafts have 
an increased occurrence of angiographically severe stenosis and occlusion compared with left 
internal mammary arteries and saphenous vein grafts. Circulation 2004;109:2086-2091.
84.  Ruttmann E, Fischler N, Sakic A, Chevtchik O, Alber H, Schistek R, Ulmer H, Grimm M. Second 
internal thoracic artery versus radial artery in coronary artery bypass grafting: a long-term, pro-
pensity score-matched follow-up study. Circulation 2011;124:1321-1329.
85.  Desai ND, Cohen EA, Naylor CD, Fremes SE, Radial Artery Patency Study Investigators. A ran-
domized comparison of radial-artery and saphenous-vein coronary bypass grafts. N Engl J Med 
2004;351:2302-2309.
86.  Tranbaugh RF, Dimitrova KR, Friedmann P, Geller CM, Harris LJ, Stelzer P, Cohen B, Hoffman 
DM. Radial artery conduits improve long-term survival after coronary artery bypass grafting. Ann 
Thorac Surg 2010;90:1165-1172.
87.  Rupprecht HJ, Hamm C, Ischinger T, Dietz U, Reimers J, Meyer J. Angiographic follow-up results 
of a randomized study on angioplasty versus bypass surgery (GABI trial). GABI Study Group. Eur 
Heart J 1996;17:1192-1198.
88.  Alfieri O, Maisano F, Benussi S, Toracca L, Castiglioni A. Drug-eluting stents or drug-eluting 
conduits for multivessel disease? J Cardiovasc Med (Hagerstown) 2007;8:359-361.
89.  Dimitrova KR, Hoffman DM, Geller CM, Dincheva G, Ko W, Tranbaugh RF. Arterial grafts 
protect the native coronary vessels from atherosclerotic disease progression. Ann Thorac Surg 
2012;94:475-481.
90.  Lumsden AB, Eaves FF, 3rd, Ofenloch JC, Jordan WD. Subcutaneous, video-assisted saphenous 
vein harvest: report of the first 30 cases. Cardiovasc Surg 1996;4:771-776.
91.  Dacey LJ. Endoscopic vein-graft harvest is safe for CABG surgery. JAMA 2012;308:512-513.
92.  Cadwallader RA, Walsh SR, Cooper DG, Tang TY, Sadat U, Boyle JR. Great saphenous vein 
harvesting: a systematic review and meta-analysis of open versus endoscopic techniques. Vasc 
Endovascular Surg 2009;43:561-566.
93.  Lopes RD, Hafley GE, Allen KB, Ferguson TB, Peterson ED, Harrington RA, Mehta RH, Gibson 
CM, Mack MJ, Kouchoukos NT, Califf RM, Alexander JH. Endoscopic versus open vein-graft 
harvesting in coronary-artery bypass surgery. N Engl J Med 2009;361:235-244.
94.  Zenati MA, Shroyer AL, Collins JF, Hattler B, Ota T, Almassi GH, Amidi M, Novitzky D, Grover FL, 
Sonel AF. Impact of endoscopic versus open saphenous vein harvest technique on late coronary 
artery bypass grafting patient outcomes in the ROOBY (Randomized On/Off Bypass) Trial. J 
Thorac Cardiovasc Surg 2011;141:338-344.
95.  Dacey LJ, Braxton JH, Jr., Kramer RS, Schmoker JD, Charlesworth DC, Helm RE, Frumiento C, 
Sardella GL, Clough RA, Jones SR, Malenka DJ, Olmstead EM, Ross CS, O’Connor GT, Likosky 
DS, Northern New England Cardiovascular Disease Study Group. Long-term outcomes of endo-
scopic vein harvesting after coronary artery bypass grafting. Circulation 2011;123:147-153.
96.  Williams JB, Peterson ED, Brennan JM, Sedrakyan A, Tavris D, Alexander JH, Lopes RD, Dok-
holyan RS, Zhao Y, O’Brien SM, Michler RE, Thourani VH, Edwards FH, Duggirala H, Gross 
T, Marinac-Dabic D, Smith PK. Association between endoscopic vs open vein-graft harvesting 
CABG: optimizing outcomes and future prospects 401
C
ha
pt
er
 2
3
and mortality, wound complications, and cardiovascular events in patients undergoing CABG 
surgery. JAMA 2012;308:475-484.
97.  Desai P, Kiani S, Thiruvanthan N, Henkin S, Kurian D, Ziu P, Brown A, Patel N, Poston R. Impact 
of the learning curve for endoscopic vein harvest on conduit quality and early graft patency. Ann 
Thorac Surg 2011;91:1385-1391; discussion 1391-1392.
98.  Allen K, Cheng D, Cohn W, Connolly M, Edgerton J, Falk V, Martin J, Ohtsuka T, Vitali R. Endo-
scopic vascular harvest in coronary artery bypass grafting surgery: A consensus statement of the 
International Society of Minimally Invasive Cardiothoracic Surgery (ISMICS) 2005. Innovations 
(Phila) 2005;1:51-60.
99.  Grant SW, Grayson AD, Zacharias J, Dalrymple-Hay MJ, Waterworth PD, Bridgewater B. What is 
the impact of endoscopic vein harvesting on clinical outcomes following coronary artery bypass 
graft surgery? Heart 2012;98:60-64.
100. Whitley WS, Glas KE. An argument for routine ultrasound screening of the thoracic aorta in the 
cardiac surgery population. Semin Cardiothorac Vasc Anesth 2008;12:290-297.
101. Davila-Roman VG, Barzilai B, Wareing TH, Murphy SF, Schechtman KB, Kouchoukos NT. 
Atherosclerosis of the ascending aorta. Prevalence and role as an independent predictor of 
cerebrovascular events in cardiac patients. Stroke 1994;25:2010-2016.
102. Davila-Roman VG, Kouchoukos NT, Schechtman KB, Barzilai B. Atherosclerosis of the ascend-
ing aorta is a predictor of renal dysfunction after cardiac operations. J Thorac Cardiovasc Surg 
1999;117:111-116.
103. Van Zaane B, Zuithoff NP, Reitsma JB, Bax L, Nierich AP, Moons KG. Meta-analysis of the diag-
nostic accuracy of transesophageal echocardiography for assessment of atherosclerosis in the 
ascending aorta in patients undergoing cardiac surgery. Acta Anaesthesiol Scand 2008;52:1179-
1187.
104. Davila-Roman VG, Barzilai B, Wareing TH, Murphy SF, Kouchoukos NT. Intraoperative ultra-
sonographic evaluation of the ascending aorta in 100 consecutive patients undergoing cardiac 
surgery. Circulation 1991;84:III47-III53.
105. Royse C, Royse A, Blake D, Grigg L. Screening the thoracic aorta for atheroma: a comparison of 
manual palpation, transesophageal and epiaortic ultrasonography. Ann Thorac Cardiovasc Surg 
1998;4:347-350.
106. Djaiani G, Ali M, Borger MA, Woo A, Carroll J, Feindel C, Fedorko L, Karski J, Rakowski H. Epi-
aortic scanning modifies planned intraoperative surgical management but not cerebral embolic 
load during coronary artery bypass surgery. Anesth Analg 2008;106:1611-1618.
107. Lyons JM, Thourani VH, Puskas JD, Kilgo PD, Baio KT, Guyton RA, Lattouf OM. Intraoperative 
epiaortic ultrasound scanning guides operative strategies and identifies patients at high risk dur-
ing coronary artery bypass grafting. Innovations (Phila) 2009;4:99-105.
108. Zingone B, Rauber E, Gatti G, Pappalardo A, Benussi B, Dreas L, Lattuada L. The impact of 
epiaortic ultrasonographic scanning on the risk of perioperative stroke. Eur J Cardiothorac Surg 
2006;29:720-728.
109. Rosenberger P, Shernan SK, Loffler M, Shekar PS, Fox JA, Tuli JK, Nowak M, Eltzschig HK. The 
influence of epiaortic ultrasonography on intraoperative surgical management in 6051 cardiac 
surgical patients. Ann Thorac Surg 2008;85:548-553.
110. Hangler HB, Nagele G, Danzmayr M, Mueller L, Ruttmann E, Laufer G, Bonatti J. Modification of 
surgical technique for ascending aortic atherosclerosis: impact on stroke reduction in coronary 
artery bypass grafting. J Thorac Cardiovasc Surg 2003;126:391-400.
Part 3 Stenting versus bypass surgery402
111. Wareing TH, Davila-Roman VG, Barzilai B, Murphy SF, Kouchoukos NT. Management of the 
severely atherosclerotic ascending aorta during cardiac operations. A strategy for detection and 
treatment. J Thorac Cardiovasc Surg 1992;103:453-462.
112. Daniel WT, 3rd, Kilgo P, Puskas JD, Thourani VH, Lattouf OM, Guyton RA, Halkos ME. Trends in 
aortic clamp use during coronary artery bypass surgery: Effect of aortic clamping strategies on 
neurologic outcomes. J Thorac Cardiovasc Surg 2013;doi: 10.1016/j.jtcvs.2013.02.021.
113. Magee MJ, Alexander JH, Hafley G, Ferguson TB, Jr., Gibson CM, Harrington RA, Peterson ED, 
Califf RM, Kouchoukos NT, Herbert MA, Mack MJ, Prevent IV Investigators. Coronary artery 
bypass graft failure after on-pump and off-pump coronary artery bypass: findings from PREVENT 
IV. Ann Thorac Surg 2008;85:494-499; discussion 499-500.
114. Balacumaraswami L, Taggart DP. Intraoperative imaging techniques to assess coronary artery 
bypass graft patency. Ann Thorac Surg 2007;83:2251-2257.
115. Balacumaraswami L, Abu-Omar Y, Choudhary B, Pigott D, Taggart DP. A comparison of transit-
time flowmetry and intraoperative fluorescence imaging for assessing coronary artery bypass 
graft patency. J Thorac Cardiovasc Surg 2005;130:315-320.
116. Mack MJ. Intraoperative coronary graft assessment. Curr Opin Cardiol 2008;23:568-572.
117. Desai ND, Miwa S, Kodama D, Koyama T, Cohen G, Pelletier MP, Cohen EA, Christakis GT, Gold-
man BS, Fremes SE. A randomized comparison of intraoperative indocyanine green angiography 
and transit-time flow measurement to detect technical errors in coronary bypass grafts. J Thorac 
Cardiovasc Surg 2006;132:585-594.
118. Waseda K, Ako J, Hasegawa T, Shimada Y, Ikeno F, Ishikawa T, Demura Y, Hatada K, Yock PG, 
Honda Y, Fitzgerald PJ, Takahashi M. Intraoperative fluorescence imaging system for on-site 
assessment of off-pump coronary artery bypass graft. JACC Cardiovasc Imaging 2009;2:604-612.
119. Jokinen JJ, Werkkala K, Vainikka T, Perakyla T, Simpanen J, Ihlberg L. Clinical value of intra-
operative transit-time flow measurement for coronary artery bypass grafting: a prospective 
angiography-controlled study. Eur J Cardiothorac Surg 2011;39:918-923.
120. Di Giammarco G, Pano M, Cirmeni S, Pelini P, Vitolla G, Di Mauro M. Predictive value of 
intraoperative transit-time flow measurement for short-term graft patency in coronary surgery. J 
Thorac Cardiovasc Surg 2006;132:468-474.
121. Tokuda Y, Song MH, Ueda Y, Usui A, Akita T. Predicting early coronary artery bypass graft failure 
by intraoperative transit time flow measurement. Ann Thorac Surg 2007;84:1928-1933.
122. Kieser TM, Rose S, Kowalewski R, Belenkie I. Transit-time flow predicts outcomes in coronary 
artery bypass graft patients: a series of 1000 consecutive arterial grafts. Eur J Cardiothorac Surg 
2010;38:155-162.
123. Mangano DT, Multicenter Study of Perioperative Ischemia Research Group. Aspirin and mortality 
from coronary bypass surgery. N Engl J Med 2002;347:1309-1317.
124. Chan AY, McAlister FA, Norris CM, Johnstone D, Bakal JA, Ross DB, Alberta Provincial Program 
for Outcome Assessment in Coronary Heart Disease Investigators. Effect of beta-blocker use on 
outcomes after discharge in patients who underwent cardiac surgery. J Thorac Cardiovasc Surg 
2010;140:182-187.
125. Kjoller-Hansen L, Steffensen R, Grande P. The Angiotensin-converting Enzyme Inhibition Post 
Revascularization Study (APRES). J Am Coll Cardiol 2000;35:881-888.
126. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose 
anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. The Post 
Coronary Artery Bypass Graft Trial Investigators. N Engl J Med 1997;336:153-162.
CABG: optimizing outcomes and future prospects 403
C
ha
pt
er
 2
3
127. Shah SJ, Waters DD, Barter P, Kastelein JJ, Shepherd J, Wenger NK, DeMicco DA, Breazna A, 
LaRosa JC. Intensive lipid-lowering with atorvastatin for secondary prevention in patients after 
coronary artery bypass surgery. J Am Coll Cardiol 2008;51:1938-1943.
128. Benedetto U, Melina G, di Bartolomeo R, Angeloni E, Sansone D, Falaschi G, Capuano F, Comito 
C, Roscitano A, Sinatra R. n-3 polyunsaturated fatty acids after coronary artery bypass grafting. 
Ann Thorac Surg 2011;91:1169-1175.
129. Goyal A, Alexander JH, Hafley GE, Graham SH, Mehta RH, Mack MJ, Wolf RK, Cohn LH, 
Kouchoukos NT, Harrington RA, Gennevois D, Gibson CM, Califf RM, Ferguson TB, Jr., Peterson 
ED, Prevent IV Investigators. Outcomes associated with the use of secondary prevention medica-
tions after coronary artery bypass graft surgery. Ann Thorac Surg 2007;83:993-1001.
130. Kulik A, Voisine P, Mathieu P, Masters RG, Mesana TG, Le May MR, Ruel M. Statin therapy and 
saphenous vein graft disease after coronary bypass surgery: analysis from the CASCADE random-
ized trial. Ann Thorac Surg 2011;92:1284-1290; discussion 1290-1291.
131. Eritsland J, Arnesen H, Gronseth K, Fjeld NB, Abdelnoor M. Effect of dietary supplementation 
with n-3 fatty acids on coronary artery bypass graft patency. Am J Cardiol 1996;77:31-36.
132. de Leon N, Jackevicius CA. Use of aspirin and clopidogrel after coronary artery bypass graft 
surgery. Ann Pharmacother 2012;46:678-687.
133. Martin TN, Irving RJ, Sutherland M, Sutherland K, Bloomfield P. Improving secondary prevention 
in coronary bypass patients: closing the audit loop. Heart 2005;91:456-459.
134. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyorala K, Keil U, Group ES. Cardiovascular 
prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in 
eight European countries. Lancet 2009;373:929-940.
135. Hiratzka LF, Eagle KA, Liang L, Fonarow GC, LaBresh KA, Peterson ED, Get With the Guidelines 
Steering Committee. Atherosclerosis secondary prevention performance measures after coronary 
bypass graft surgery compared with percutaneous catheter intervention and nonintervention 
patients in the Get With the Guidelines database. Circulation 2007;116:I207-I212.
136. Kappetein AP, Feldman TE, Mack MJ, Morice MC, Holmes DR, Stahle E, Dawkins KD, Mohr FW, 
Serruys PW, Colombo A. Comparison of coronary bypass surgery with drug-eluting stenting for 
the treatment of left main and/or three-vessel disease: 3-year follow-up of the SYNTAX trial. Eur 
Heart J 2011;32:2125-2134.
137. Turley AJ, Roberts AP, Morley R, Thornley AR, Owens WA, de Belder MA. Secondary prevention 
following coronary artery bypass grafting has improved but remains sub-optimal: the need for 
targeted follow-up. Interact Cardiovasc Thorac Surg 2008;7:231-234.
138. van Domburg RT, op Reimer WS, Hoeks SE, Kappetein AP, Bogers AJ. Three life-years gained from 
smoking cessation after coronary artery bypass surgery: a 30-year follow-up study. Am Heart J 
2008;156:473-476.
139. Opie LH, Commerford PJ, Gersh BJ. Controversies in stable coronary artery disease. Lancet 
2006;367:69-78.
140. Clark AM, Hartling L, Vandermeer B, McAlister FA. Meta-analysis: secondary prevention pro-
grams for patients with coronary artery disease. Ann Intern Med 2005;143:659-672.
141. Griffo R, Ambrosetti M, Tramarin R, Fattirolli F, Temporelli PL, Vestri AR, De Feo S, Tavazzi L, 
ICAROS Investigators. Effective secondary prevention through cardiac rehabilitation after coro-
nary revascularization and predictors of poor adherence to lifestyle modification and medication. 
Results of the ICAROS Survey. Int J Cardiol 2012; doi.org/10.1016/j.ijcard.2012.04.069.
Part 3 Stenting versus bypass surgery404
142. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyorala K, Keil U, EUROASPIRE Study Group. 
Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and 
III surveys in eight European countries. Lancet 2009;373:929-940.
143. Clark AM, Haykowsky M, Kryworuchko J, MacClure T, Scott J, DesMeules M, Luo W, Liang Y, 
McAlister FA. A meta-analysis of randomized control trials of home-based secondary prevention 
programs for coronary artery disease. Eur J Cardiovasc Prev Rehabil 2010;17:261-270.
144. Head SJ, Kaul S, Mack MJ, Serruys PW, Taggart DP, Holmes Jr DR, Leon MB, Marco J, Bogers AJ, 
Kappetein AP. The rationale for Heart Team decision-making for patients with stable, complex 
coronary artery disease. Eur Heart J 2013; doi: 10.1093/eurheartj/eht059.
145. Marso SP, Teirstein PS, Kereiakes DJ, Moses J, Lasala J, Grantham JA. Percutaneous coronary 
intervention use in the United States: defining measures of appropriateness. JACC Cardiovasc 
Interv 2012;5:229-235.
146. Chandrasekharan DP, Taggart DP. Informed consent for interventions in stable coronary artery 
disease: problems, etiologies, and solutions. Eur J Cardiothorac Surg 2011;39:912-917.
147. Head SJ, Bogers AJ, Serruys PW, Takkenberg JJ, Kappetein AP. A crucial factor in shared decision 
making: the team approach. Lancet 2011;377:1836.
148. Head SJ, Holmes Jr DR, Mack MJ, Serruys PW, Mohr FW, Morice M, Colombo A, Kappetein AP. 
Risk profile and 3-year outcomes from the SYNTAX percutaneous coronary intervention and 
coronary artery bypass grafting nested registries. JACC Cardiovasc Interv 2012;5:618-625.
149. Hillis LD, Smith PK, Anderson JL, Bittl JA, Bridges CR, Byrne JG, Cigarroa JE, Disesa VJ, Hiratzka 
LF, Hutter AM, Jr., Jessen ME, Keeley EC, Lahey SJ, Lange RA, London MJ, Mack MJ, Patel MR, 
Puskas JD, Sabik JF, Selnes O, Shahian DM, Trost JC, Winniford MD, American College of Car-
diology Foundation, American Heart Association Task Force on Practice Guidelines, American 
Association for Thoracic Surgery, Society of Cardiovascular Anesthesiologists, Society of Thoracic 
Surgeons. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery. A report of the 
American College of Cardiology Foundation/American Heart Association Task Force on Practice 
Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, 
Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons. J Am Coll Cardiol 
2011;58:e123-e210.
150. Tonino PA, De Bruyne B, Pijls NH, Siebert U, Ikeno F, van’ t Veer M, Klauss V, Manoharan G, 
Engstrom T, Oldroyd KG, Ver Lee PN, MacCarthy PA, Fearon WF. Fractional flow reserve versus 
angiography for guiding percutaneous coronary intervention. N Engl J Med 2009;360:213-224.
151. De Bruyne B, Pijls NH, Kalesan B, Barbato E, Tonino PA, Piroth Z, Jagic N, Mobius-Winckler S, 
Rioufol G, Witt N, Kala P, MacCarthy P, Engstrom T, Oldroyd KG, Mavromatis K, Manoharan G, 
Verlee P, Frobert O, Curzen N, Johnson JB, Juni P, Fearon WF. Fractional flow reserve-guided PCI 
versus medical therapy in stable coronary disease. N Engl J Med 2012;367:991-1001.
152. Botman CJ, Schonberger J, Koolen S, Penn O, Botman H, Dib N, Eeckhout E, Pijls N. Does 
stenosis severity of native vessels influence bypass graft patency? A prospective fractional flow 
reserve-guided study. Ann Thorac Surg 2007;83:2093-2097.
153. Kim YH, Ahn JM, Park DW, Song HG, Lee JY, Kim WJ, Yun SC, Kang SJ, Lee SW, Lee CW, Moon 
DH, Chung CH, Lee JW, Park SW, Park SJ. Impact of ischemia-guided revascularization with 
myocardial perfusion imaging for patients with multivessel coronary disease. J Am Coll Cardiol 
2012;60:181-190.
154. de Boer SP, Lenzen MJ, Oemrawsingh RM, Simsek C, Duckers HJ, van der Giessen WJ, Serruys 
PW, Boersma E. Evaluating the ‘all-comers’ design: a comparison of participants in two ‘all-
comers’ PCI trials with non-participants. Eur Heart J 2011;32:2161-2167.
CABG: optimizing outcomes and future prospects 405
C
ha
pt
er
 2
3
155. Head SJ, Farooq V, Serruys PW, Kappetein AP. The SYNTAX Score and its clinical implications. 
Heart 2013; doi:10.1136/heartjnl-2012-302482.
156. Farooq V, van Klaveren D, Steyerberg EW, Meliga E, Vergouwe Y, Chieffo A, Kappetein AP, 
Colombo A, Holmes DR, Jr., Mack M, Feldman T, Morice MC, Stahle E, Onuma Y, Morel MA, 
Garcia-Garcia HM, van Es GA, Dawkins KD, Mohr FW, Serruys PW. Anatomical and clinical 
characteristics to guide decision making between coronary artery bypass surgery and percutane-
ous coronary intervention for individual patients: development and validation of SYNTAX score 
II. Lancet 2013;381:639-650.
157. Sutton M, Nikolova S, Boaden R, Lester H, McDonald R, Roland M. Reduced mortality with 
hospital pay for performance in England. N Engl J Med 2012;367:1821-1828.
158. Hiratzka LF, Eagle KA, Liang L, Fonarow GC, LaBresh KA, Peterson ED, Get With the Guidelines 
Steering C. Atherosclerosis secondary prevention performance measures after coronary bypass 
graft surgery compared with percutaneous catheter intervention and nonintervention patients in 
the Get With the Guidelines database. Circulation 2007;116:I207-I212.

Part 4
Interpretation of cardiovascular clinical research
Borneo
Chapter 24
Non-inferiority study design: lessons to be learned 
from cardiovascular trials
Head SJ, Kaul S, Bogers AJ, Kappetein AP
Eur Heart J 2012;33:1318-1324
Part 4 Interpretation of cardiovascular clinical research410
AbstrAct
The non-inferiority trial design has gained popularity within the last decades to compare a 
new treatment to the standard active control. In contrast to superiority trials, this design is 
complex and is based on assumptions that cannot be validated directly. Many readers and 
even investigators, therefore, have difficulty grasping the full methodological nature of non-
inferiority trials. Non-inferiority margins are often arbitrarily chosen such that a favourable 
margin can bias a trial towards declaring non-inferiority. Pitfalls of non-inferiority trials are 
not fully appreciated, and without having identified these shortcomings, objective conclu-
sions from non-inferiority trials cannot be made. This methodological review elaborates 
on what is a non-inferiority trial, why such a trial is performed, what the hazards are, and 
how conclusions from non-inferiority trials are derived, by providing examples of recent 
cardiovascular trials.
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IntroductIon
Unlike superiority trials that are designed to show that one treatment is better than another, 
a non-inferiority trial is designed to show that a new treatment is ‘not unacceptably worse’ 
than the current standard therapy. Since the introduction of non-inferiority trials in the 
mid-1990s it has been debated whether such trials should be performed.1, 2 The design 
of a non-inferiority trial is complicated and is founded on assumptions that are difficult 
to verify.3–6 Readers often fail to fully understand the concept, statistical approaches, and 
conclusions; even some trialists may have difficulties with grasping the sense of a non-
inferiority study. Non-inferiority studies often have ‘substantial methodological flaws’ with 
the risk of incorrectly claiming non-inferiority.3 This could potentially expose patients to 
the possibility of receiving a treatment that is inferior to the ‘gold standard’. In addition, the 
reporting of analyses and conclusions has been shown to be misleading in a review of 116 
non-inferiority trials.3, 7
In the last few years, several cardiovascular trials have been published that compared 
surgical to catheter-based therapies for the treatment of heart diseases, with a great impact 
on clinical practice.8–10 More trials are currently underway and it is crucial that these and 
future trials are adequately designed, well performed, rigorously analysed, and prudently 
interpreted.11
In this review, we discuss the aspects of non-inferiority trials; when to perform such a 
study, how to design a non-inferiority trial, and how to derive conclusions from such a trial. 
To elaborate on these topics, examples of recent cardiovascular trials are provided.
superIorIty, equIvAlence, non-InferIorIty
A superiority trial is designed to show that a new treatment is better than an active control 
or placebo. The null hypothesis states that no difference between treatments exists. The 
trial is determined to reject this hypothesis and show a statistically significant difference in 
favour of the new treatment. In equivalence trials, which are rarely performed, the difference 
between two treatments is pre-defined as Δ, and the goal of the trial is to demonstrate that 
treatment with either therapy is equally good and the confidence intervals (CIs) do not 
exceed a difference of −Δ and +Δ.
A non-inferiority trial is different as it is designed not to show that treatments are equal, or 
‘not different’, but that the new treatment is not unacceptably worse than, or ‘non-inferior’ 
to, an active control. Statistically, such a study differs from an equivalence trial because the 
Δ is only one-sided towards −Δ. Non-inferiority is claimed if the lower bound of the CI of the 
treatment effect difference does not exceed −Δ, thus meaning that the risk of it being inferior 
is within acceptable boundaries (Figure 1).
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Why A non-InferIorIty trIAl?
Non-inferiority trials have become more popular in the last decades, especially in cancer 
and cardiovascular studies. A common misunderstanding is that this is caused by safety 
and efficacy regulations, which would suggest that a new therapy first needs to show non-
inferiority before it can be tested in a superiority trial. However, non-inferiority trials were 
originally designed for studies in which it is unethical to include a placebo arm. For cancer 
and cardiovascular conditions where a ‘gold standard’ therapy already exists, it would be 
unethical to perform a placebo-controlled trial with a newly introduced treatment. For 
example, elderly patients with symptomatic severe aortic stenosis are generally treated by 
means of surgical aortic valve replacement (SAVR). Whenever patients are considered to be 
at too high a risk for surgery, they are managed medically. Transcatheter aortic valve replace-
ment (TAVR) is a new less invasive therapy suited for these extreme high-risk patients, with 
initially good results from the PARTNER trial.12, 13 However, in lower risk patients TAVR has 
to compete with the gold standard SAVR, which shows excellent long-term results in these 
patients. A TAVR vs. medical management trial would therefore be unethical in lower risk 
patients due to the superiority of SAVR over medical management in patients who are good 
-∆                  0
Standard therapy
is better
Difference
New therapy
is better
Superior
Non-inferior
Non-inferior 
Inconclusive
Non-inferior and
Inferior
Inferior
figure 1 possible conclusions from non-inferiority trials
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candidates for surgery. Patients randomized to medical management would then not receive 
established effective therapy.
Even if a new treatment is shown to be non-inferior to the ‘gold standard’ therapy with 
regard to an efficacy endpoint, it would still need to demonstrate an ancillary benefit, 
i.e. lower procedural risks (safety), favourable costs, or improved convenience for it to be 
considered the preferred treatment. In the previous example, if TAVR shows non-inferior 
efficacy (and safety), its preference over SAVR might be potentially justified due to the lower 
invasiveness (avoidance of sternotomy and cardiopulmonary bypass) and reduced length 
of stay. An example where a non-inferiority trial would be adequate in a pharmacologic 
trial is the comparison between warfarin and new anticoagulant drugs. Warfarin has been 
the standard anticoagulant therapy for over 60 years but has some disadvantages including 
the requirement for routine monitoring of the international normalized ratio (INR). Several 
new drugs that are more convenient with regard to drug administration have been shown to 
demonstrate non-inferiority compared with warfarin.14, 15
Not only are there clinical indications to perform a non-inferiority trial, but also the costs 
of a randomized trial are very high, and the stakes for companies are crucial. In a non-
inferiority trial investigators can choose unreasonably wide margins and high active control 
event rates that yield lower sample sizes, and thus improve the trial efficiency, i.e. achieve 
a positive trial result at a minimized cost. For example, the Stroke Prevention Using Oral 
Thrombin Inhibitor in Atrial Fibrillation (SPORTIF) V trial used an unreasonably generous 
non-inferiority margin of a 2% absolute risk difference (ARD) and an expected warfarin 
event rate of 3.1% per year [equivalent to a relative risk margin of (3.1 + 2)/3.1 = 1.65]; 
with 90% power this produced a sample size of 3156 patients.16 Using the more accurate 
expected warfarin event rate of 1.9% per year derived from pooled historical data, the study 
would have needed 4875 patients for a similar 90% power and a relative risk margin of 
1.65 (equivalent to an ARD margin of 1.23%). The sample size would even be 8190 patients 
if the observed warfarin event rate of 1.2% per year had been used for the sample size 
calculation.11 Thus only 39% (3156/8190) of the actually needed sample was included, 
thereby drastically reducing costs. Although the cost of a trial is merely one of the factors 
influencing trial design, it should not be the main contributor.
Methodology of non-InferIorIy trIAls
One major issue with a non-inferiority trial is that, unlike a superiority trial, it is biased 
towards non-inferiority if the trial is poorly designed and sloppily conducted.17 Part of 
the basis of a randomized trial is the expected event rate with the corresponding sample 
size calculation. A non-inferiority trial has the same principle, but an additional non-
inferiority margin is included. This margin quantifies when the new therapy is considered 
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to be non-inferior to the standard therapy. Several factors need to be considered during the 
trial design before a reasonable margin can be adopted. If these factors are not taken into 
account, it could lead to a phenomenon called ‘biocreep’ or ‘technology creep’; an inferior 
therapy is granted non-inferiority and becomes the control group in future trials, ultimately 
leading to an active therapy being no better than a placebo.4
choise of margin: absolute vs. relative risk difference
A non-inferiority margin can be chosen as an ARD or risk ratio (RR). It is recommended 
to use a relative difference to account for changes in event rates; fixed RRs provide more 
conservative margins in trials in which the event rate is unpredictable or the observed rate 
is lower than expected.11
In the previously used example of the SPORTIF V trial, non-inferiority was met using 
an ARD of 2%, even with the observed event rate of 1.2% instead of the expected 3.1%/
year. This lower event rate caused inflation of the RR from 1.65 to 2.67 (Table 1). Had 
the investigators fixed the RR at 1.65 (and correspondingly used a more conservative ARD 
margin of 0.78% [(1.65 × 1.2) − 1.2], non-inferiority would not have been met. However, it 
is evident that conservative margins result in larger sample sizes.
Margins based on ARD can potentially introduce a bias towards non-inferiority, since it 
can result in an underpowered trial due to lower than expected event rates.9,11 For example, 
in the recent PRECOMBAT trial that compared percutaneous coronary intervention (PCI) 
with coronary artery bypass grafting (CABG) for left main disease, the expected event rate in 
the CABG arm was 13%, and the pre-specified margin was an ARD of 7%.9 In an analysis 
with a one-sided alpha of 0.025, the upper bound of the difference was 6.3%. Because this 
was below the predefined margin of 7%, the investigators declared non-inferiority. Had they 
fixed the margin as an RR [(13 + 7)/13 = 1.54], the upper bound of the RR would be 2.12 
(1.30, 95% CI: 0.81–2.12), thereby not allowing a claim of non-inferiority. In trials that use 
an ARD, a judgement of non-inferiority would be more convincing if analyses on the basis 
of absolute and relative difference were concordant.3, 11
table 1 Inflation of the relative risk in the sportIf v trial
expected pooled historical observed
Standard Rx event rate 3.1%/year 1.9%/year 1.2%/year
New Rx event rate acceptable 5.1%/year 3.9%/year 3.2%/year
RR 1.65 2.05 2.67
RR  = Relative risk difference
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Active control event rate
It is crucial that the active control event rate be chosen properly, since an overestimation can 
result in an underpowered trial. Frequently the event rate is unsubstantiated. For example, 
the PRECOMBAT trial used a 1-year event rate of 13% based on a previously published 
meta-analysis, while the actual observed event rate was only 6.7%.9, 18 The investigators 
could, however, have foreseen differences in the event rate. The meta-analysis was not 
representative of the current clinical practice as it included four trials that enrolled patients 
between 1995 and 2000 treated with bare-metal stents, while PRECOMBAT enrolled 
patients between 2004 and 2009 that were treated with drug-eluting stents. Furthermore, 
their own clinical practice demonstrated low rates similar to PRECOMBAT, but these data 
were not taken into account when performing the sample size calculation.19 An interim 
analysis during the trial would have demonstrated lower than expected event rates and 
a sample size adjustment would have been appropriate given the contemporary data.19 
Although the trial extended the primary endpoint to 2 years, this still did not result in an 
adequate number of events.20
In some instances, there are no previous trials to reliably estimate the expected active 
control event rate. In such cases, investigators have no other option but to extrapolate from 
their own experiences or use pooled feasibility data for a propensity-matched analysis. An 
advantage of this technique is that it can provide a ratio of the new treatment vs. the active 
control. This is, however, often cumbersome due to diverse ‘all-comer’ patients treated with 
the control and the highly selected patients treated with the new intervention.
nature of events
One must be aware of the fact that the margin should be based on the number and nature 
of the events that are included in a composite endpoint. The use of composite endpoints 
that are driven by ‘softer’ events poses a dilemma in the estimation of the margin. On 
the one hand, one is willing to accept a greater degree of inferiority (given the ancillary 
benefits), thereby resulting in a wider margin. On the other hand, ‘softer’ events occur 
more frequently and inflate the event rate, which would require more stringent margins. 
Whether composite endpoints should include both safety and efficacy outcomes remains 
debatable. For example, in the SYNTAX trial the composite of death, stroke, myocardial 
infarction, and repeat revascularization was used as the primary endpoint. Some argue that 
repeat revascularization should not have been included in the endpoint, since this was a 
‘softer’ efficacy event. The primary endpoint of non-inferiority was not met in the analysis 
that included revascularization, while PCI would have been non-inferior to CABG in the 
composite analysis without repeat revascularization. However, this composite of death, 
myocardial infarction, and stroke was not a predefined endpoint. Had it been chosen as the 
primary endpoint of the trial, sample size adjustments due to a lower event rate would have 
been required, resulting in a prohibitively large sample size.21
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The recently published EVEREST II trial randomized patients to percutaneous mitral valve 
repair or mitral valve surgery.8 For the primary endpoint, the investigators chose a combi-
nation of clinical (death and surgery for mitral valve dysfunction) and echocardiographic 
endpoints (grade ≥3 + mitral regurgitation), which is unusual for a device vs. surgery trial. 
Ideally, the regurgitation endpoint should not have been included in the primary endpoint, 
but this ‘softer’ and more frequent endpoint drove the event rate. A composite endpoint of 
death or need for surgery (hard, but less frequent, endpoints) would have required a pro-
hibitively large sample size. In contrast, the PARTNER trial had a clinical primary endpoint, 
while valve function was considered a secondary endpoint.12
clinical relevance
A crucial step in determining a margin is to contemplate what difference between therapies 
is clinically acceptable. An overly conservative margin might result in a high risk of not 
being able to claim non-inferiority when it actually is non-inferior. Conversely, overly liberal 
margins could result in a high risk of claiming non-inferiority when it actually is not non-
inferior. A reasonable margin would be best derived from a combination of factors: the 
expected event rate, the duration of follow-up, and the number and nature of the events. 
However, arbitrary clinical judgment and the sponsor budget are of a great influence, result-
ing in a somewhat subjective non-inferiority margin.
A formal approach for choosing the margin is based upon a combination of statistical 
reasoning and clinical judgment.4, 5, 11 The first step is to reliably estimate the efficacy of 
the active control compared with placebo, often derived from a meta-analysis of historical 
placebo-controlled superiority trials. The lower 95% CI of this effect is the largest accept-
able non-inferiority margin, M1, to provide assurance that the new treatment is at least 
better than placebo.4, 5, 22 The second step in selecting the margin is choosing a reasonable 
fraction of the control effect (M1) that needs to be preserved, typically set at 50% of M1. 
This new non-inferiority margin is called M2, and is typically based upon clinical judgment. 
An example of a trial using this method is the RE-LY trial (Table 2).14 The investigators used 
a meta-analysis of trials of vitamin K antagonist compared with control therapy in patients 
with atrial fibrillation. The hazard ratio of 1.46 was used as the margin in RE-LY, which was 
defined by using half the upper bound of the 95% CI derived from the estimated effect of 
control therapy over warfarin.
follow-up
The duration of follow-up for the primary endpoint is important as well. The shorter the 
follow-up, the more conservative a margin should be. While after 1 year a certain difference 
in events might be acceptable, the same difference at 30 days could raise serious concerns 
regarding the safety of the treatment. This becomes more important whenever a trial is 
designed with an ARD (Δ) as the non-inferiority margin, as opposed to a trial with a hazard 
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ratio.23 As shown in Figure 2, data from the SYNTAX trial show that the hazard ratio remains 
constant over time, while the absolute difference may increase.
statistical power
The minimal acceptable standard for statistical power in superiority trials generally is 80% 
with a two-sided alpha of 0.05. Both superiority and non-inferiority trials should ideally be 
designed with a ≥90% statistical power. In non-inferiority trials this is more crucial, since 
lower power biases the results towards non-inferiority. In addition, although practice varies, 
a one-sided alpha of 2.5% is considered to be more robust for non-inferiority assessment; 
the CI is wider and therefore more likely to cross the non-inferiority margin.
Assumptions
An adequately powered superiority trial allows one to conclude that a new treatment is 
superior to placebo. Conclusions from non-inferiority trials, however, are based on assump-
tions that cannot be verified directly.11 In contrast to superiority trials, a major issue in non-
inferiority trials is that although a new treatment can be non-inferior to the active control, it 
does not necessarily imply that the active control is more effective, and to what extent, than 
a placebo. This is referred to as the ‘constancy’ and ‘assay sensitivity’ principle. The effect 
of the active control in relation to the placebo could be different from historical data.4, 5, 24, 
25 For example, in a trial comparing PCI with CABG, if the non-inferiority margin exceeds 
the treatment difference between CABG and medical treatment, non-inferiority of PCI does 
not mean it would be superior to medical treatment. To overcome these problems, one can 
HR=1.41 (1.16-1.71)
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figure 2 the influence of the length of follow-up on the non-inferiority margin
Data from the SYNTAX trial demonstrate that the duration of follow-up is of different influence on an absolute risk 
difference or risk ratio. CABG = coronary artery bypass grafting; PCI = percutaneous coronary intervention
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include a third (placebo) arm in a trial, so that a check of the superiority of the active control 
over the placebo (‘assay sensitivity’) is available. In case of the example, the PCI vs. CABG 
trial should include a medical treatment arm, to show that CABG is indeed superior to the 
placebo. If a third arm is not included, investigators can perform a separate analysis in which 
the new treatment is compared with historical placebo data, but this relies on the assump-
tion that the observed outcomes are constant over trials (‘constancy’). This is frequently not 
the case as treatment effects can be heterogeneous due to differences in patient populations, 
outcome definitions, treatment allocation, or other study factors.
reportIng of non-InferIorIty trIAls
Analysis
Conclusions from non-inferiority trials are highly sensitive to the method of analysis. The 
intention-to-treat analysis, typically preferred as the more robust analytical framework in 
a superiority trial, can be biased towards non-inferiority. For example, if a large number 
of patients ‘cross-over’—patients randomized to treatment A receive treatment B or vice 
versa—groups will be ‘blended’ and it is likely that outcomes will be similar in an intention-
to-treat analysis. In a superiority trial this strengthens the final effect of a difference, because 
the analysis makes the results of two arms more similar and thus harder to detect a signifi-
cant difference. Loss to follow-up will also increase the similarity between groups, because 
of the assumption that none of these patients met the primary endpoint. Other protocol 
deviations such as non-adherence to the assigned therapy can bias the results towards non-
inferiority.26 Therefore, a non-inferiority trial should always report both the intention-to-treat 
and per-protocol (or as-treated) analyses, since either analysis has strengths and limitations. 
However, the intention-to-treat analysis should be the primary analysis as it preserves the 
advantages of randomization, while the per-protocol analysis can be used as the supporting 
sensitivity analysis for non-inferiority assessment.
Patients who cross over or drop out need close examination. If a specific reason for a 
cross-over or drop-out is found in one treatment group, this shows that the two treatments 
are not similar by concept, thereby providing evidence of lack of non-inferiority.26
trial conclusions
Non-inferiority can be concluded when the CI does not exceed −Δ (the non-inferiority 
margin). It is, however, often misinterpreted as equivalence. Non-inferiority means that the 
new treatment is not significantly worse (inferior) than the active control, while equivalence 
means that the new treatment is not significantly worse (inferior) or better (superior) (Figure 
1). If non-inferior, the new treatment can be preferred because of an associated ancillary 
benefit in terms of invasiveness, cost, or convenience.
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If the non-inferiority endpoint is not met, the interpretation becomes more difficult. 
Frequently one concludes that the new treatment is inferior to the active control. It could 
also mean, however, that the trial result is ‘inconclusive’. To conclude which is the case, 
it depends on the side of the CI being considered (Figure 1). An inconclusive result is the 
case when the mean difference is larger than −Δ and the lower bound of the CI exceeds 
−Δ. Inferiority is concluded if the mean difference is smaller than −Δ and the upper bound 
of the CI does not exceed the −Δ. From a statistical point of view, a trial can show both 
non-inferiority and inferiority at the same time (Figure 1). This can potentially occur in two 
ways: (i) if the trial is too large, so that an extremely narrow CI can exclude both 0 and 
a reasonably conservative margin, or (ii) when the choice of the margin is too generous, 
providing the opportunity for the CI to fit in between −Δ and 0. Although rare, it is often the 
result of a poor trial design and should be avoided. From a clinical standpoint, a treatment 
can be inferior and non-inferior when non-inferiority is met but the margin might have been 
chosen too generously. The EVEREST II trial is an example of this, where the MitraClip was 
non-inferior to surgery but this conclusion was difficult to accept due to unduly wide ARD 
margins of 31 and 25% for the per-protocol and ‘comparison of strategy’ analyses, respec-
tively.8 Even the claim of superior safety of the device was driven by blood transfusions that 
were more frequent with surgery. Excluding these transfusions, the rate of major adverse 
events in the MitraClip group was not significantly lower (5 vs. 10% after surgery, P = 0.23). 
Thus, one can reasonably argue that MitraClip is less effective than surgery while not dem-
onstrating a clinically relevant safety advantage. In the EVEREST trial the investigators chose 
a 65% preservation of the active control (surgery) effect over the placebo. This treatment 
effect being 90%, the investigators were willing to accept an unreasonably large decline 
in efficacy. In contrast, the ARISTOTLE trial comparing apixaban with warfarin for atrial 
fibrillation was designed to maintain at least 50% of the 62% relative reduction in warfarin 
over the placebo.27 In general, large standard treatment effects require greater preservation 
(and correspondingly narrow margins) for non-inferiority assessment.
Even in a non-inferiority trial, a new treatment can show superiority over the active con-
trol, a sort of ‘bonus’ in the trial. This is the case if the lower bound CI exceeds 0 in which 
there is only a 5% chance (alpha) that the active control is better (Figure 1). Sequential test-
ing for superiority is only justified after non-inferiority has been successfully demonstrated. 
Although somewhat obvious, post hoc non-inferiority testing in a negative superiority trial is 
not appropriate, as the margins are not pre-specified and the trial not adequately powered 
for non-inferiority.
Table 1 provides an overview of recent non-inferiority trials. It demonstrates the differ-
ences in trial design, conduct, and analysis based on the expected event rate, power, sample 
size, non-inferiority margin, and preservation of the effect of standard therapy.
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conclusIons
The design and interpretation of non-inferiority trials is more complex than for superiority 
trials. Therefore, many readers and investigators have difficulties understanding the full con-
cept of these trials. When starting a non-inferiority trial, investigators need to make several 
assumptions and should be aware of not choosing inaccurate or unreasonably generous 
active control event rates or non-inferiority margins. For readers, to objectively interpret 
non-inferiority trial results, one must be conscious of several pitfalls of the methodology. 
Assay sensitivity and trial inconsistency impede conclusions from non-inferiority trials.
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to the edItor:
In a recent issue of the Journal, Park et al. presented long-term follow-up results from the 
Asan-Multivessel Registry in which patients are followed after percutaneous coronary 
intervention (PCI) with drug-eluting stents (DES) or coronary artery bypass grafting (CABG) 
for the treatment of multivessel coronary artery disease.1 After 5 years, similar rates of 
death or the composite endpoint of death, myocardial infarction, or stroke were found in 
the DES and CABG groups. This is the first paper to compare these groups after such long 
follow-up, but it should be highlighted that this is a nonrandomized study. To date, only the 
SYNTAX (Synergy Between PCI With TAXUS and Cardiac Surgery) trial compared patients 
randomized to DES or CABG and after 1 year already showed that DES failed to reach 
noninferiority to CABG.2 A possible explanation for the contradicting results of Park et al. 1 is 
that apart from baseline characteristics (age, sex, body mass index) and comorbid conditions 
(hypertension, hyperlipidemia, diabetes requiring insulin, heart failure, prior myo-cardial 
infarction), the severity of multivessel disease is less worse than in the SYNTAX trial (Table 
1), with an overall SYNTAX coronary score that is much lower in the DES group (SYNTAX 
trial 28.4% vs. 17.4% in the present study). The SYNTAX trial also included more than twice 
as many patients with a left main lesion; these patients have been identified as having the 
worst prognosis.3 Furthermore, CABG has always shown a better prognosis in patients with 
table 1 baseline characteristics comparison
syntAX (n=1,800) Asan registry (n=3,042)
des cAbg des cAbg
Age (years)* 65.2 65.0 62.0 61.8
Male (%)* 76.4 78.9 69.4 73.2
Mean body mass index (kg/cm2)* 28.1 27.9 25.1 24.8
Current smoker (%)† 18.5 22.0 29.5 33.6
Hypertension (%)* 68.9 64.0 57.1 47.9
Hyperlipidemia (%)* 78.7 77.2 24.1 31.7
Medically treated diabetes
          Any (%)† 25.6 24.6 31.6 26.9
          Requiring insulin(%)* 9.9 10.4 5.6 5.1
Ejection fraction <30% (%) 1.3 2.5 0.9 3.3
Congestive heart failure (%)* 4.0 5.3 1.4 4.5
Prior myocardial infarction (%)* 31.9 33.8 10.1 19.7
Left main lesion (%)* 39.5 38.8 11.5 24.9
Total occlusion (%) 24.2 22.2 7.1 43.9
SYNTAX score (%)* 28.4 29.1 17.4 29.9
* Higher risk profile patients in SYNTAX. †Higher risk profile patients in Asan-Multivessel Registry. DES = drug-
eluting stent; CABG = coronary artery bypass grafting
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more extensive coronary artery disease. Outcomes in the study by Parks et al.,1 therefore, 
represent results from a patient cohort in whom it is unlikely that an advantage of surgery 
could be demonstrated.
To conclude, the recently published results show interesting data on patients treated with 
DES in perspective to CABG in a real-world design, but this should not lead to treatment 
preferences for patients with multivessel coronary artery disease. SYNTAX remains the only 
randomized trial addressing this issue, and although we anticipate the stronger long-term 
results from this trial, conclusions from the Asan-Multivessel Registry can only be drawn 
with caution.
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coMMent:
Randomized trials provide crucial information about “competing” treatment options, but the 
implementation of the results are often limited because of highly selective patient groups. 
Observational data is needed to examine treatment differences within the ”real world.” 
However, differences in patient characteristics between groups frequently prevent one from 
drawing robust conclusions. Propensity analysis is a method that includes patients who have 
been evaluated according to clinical judgment instead of randomization, and it provides the 
option of examining the true effect of competing treatments.
The study presented by Velazquez and colleagues 1 is important because it attempts to 
mimic the randomized STICH (Surgical Treatment for Ischemic Heart Failure) trial.2 Inclu-
sion and exclusion criteria of the trial were applied and the propensity score was used to 
determine whether patients, based on their baseline characteristics, were more likely to be 
treated medically or with coronary artery bypass grafting (CABG). To represent a similar 
population as in the STICH trial, they excluded patients with a high propensity score for 
CABG according to the hypothesis that these patients would not be eligible for randomiza-
tion in the trial. This might be considered controversial because patients are now excluded 
based on their score and not on clinical profile; thus whether patients would really be 
ineligible is unclear. Furthermore, baseline characteristics were not really comparable; 1:1 
or 2:1 propensity matching to CABG instead of the current propensity score analysis would 
perhaps have been a better option in obtaining comparable cohorts.3
Nevertheless it is remarkable that the current method using a ”real world” cohort with 
different baseline characteristics shows outcomes similar to those of the STICH trial. The 
authors rightfully concluded that ”carefully collected prospective observational data can 
complement the results of randomized trials,” with obvious benefits of observational stud-
ies over randomized trials (eg, costs, patient inclusion, data management, study approval). 
However there are also limitations to the current article. The STICH trial showed comparable 
outcomes between patients treated with CABG and medically treated patients according to 
the intention-to-treat analysis. Only in the as-treated analysis was CABG associated with 
better survival when compared with medical management. The article concerning the 
STICH trial did not specify why patients crossed over to CABG; were there specific clinical 
characteristics that altered the treatment to CABG? The current study, being an observational 
study, also reports results from an as-treated analysis, but it remains unclear as to which 
characteristics patients were selected to undergo CABG. Therefore identification of patients 
who benefit from CABG is still lacking. Without clear identification, the heart team consist-
ing of cardiologists, surgeons, and heart failure specialists can best weigh the different pros 
and cons of medical and surgical treatment.4
Part 4 Interpretation of cardiovascular clinical research436
To conclude, this study provides a useful perspective of the STICH trial in daily clini-
cal practice. Currently it remains challenging to select patients in ischemic heart failure 
for CABG. Future studies, however, should compare medical management and CABG in 
specific patient cohorts of single- or multivessel disease, low- or high-risk patients, coronary 
lesion complexity,5 or other characteristic stratification.
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to the edItor:
In a recent issue of the Journal, Flather et al. 1 reported a subgroup analysis of individual 
patient data from 10 randomized trials comparing percutaneous coronary intervention (PCI) 
and coronary artery bypass grafting (CABG) for multivessel coronary disease. Their analy-
sis showed that there was a significant treatment-by-age interaction for 10-year mortality 
(p<0.001). Strikingly enough, in the youngest age group of patients ≤56.2 years old there 
was no difference in mortality (hazard ratio for PCI = 1.23; 95% CI 0.95-1.59), while the 
hazard ratio shifted towards a significant benefit of CABG over PCI in older patients ≥65.2 
years old (hazard ratio = 0.79; 95% CI 0.67-0.94).
Although the data from these trials are compelling, they were not performed according 
to the ‘all-comers’ design and it is therefore likely that there was a severe selection bias in 
the inclusion of patients. Young patients were probably those with low lesion complexity 
and it is known that in these patients CABG does not offer a survival benefit.2 In contrast, 
even though the results of this study suggest superiority of CABG over PCI in elderly patients, 
this is counterintuitive and these results may not be generalizable to the majority of patients 
requiring coronary revascularization. Those patients with a higher risk profile were excluded 
from randomization because of procedural risks associated with CABG.3 The advantage of 
PCI in the elderly patients could therefore not be identified in this pooled analysis.
Furthermore, long-term survival of young patients with more complex coronary artery 
disease is best realized through surgical revascularization with a left internal mammary 
artery to the left anterior descending artery. This will optimize long-term survival due to 
excellent graft patency,4 which is critical especially in young patients with a relatively long 
life expectancy. Young patients that undergo PCI will have a high risk of multiple repeat 
revascularizations and are susceptive to the associated procedural risks. 
The ancillary benefit of PCI to be preferred over CABG is its lesser invasiveness and 
shorter initial hospitalization.5 However, the short-term deterrence of CABG in younger, 
fitter patients is less due to lower complication rates and shorter length-of-stay and time 
needed to resume normal activities of daily living. The benefit of PCI over CABG in younger 
patients may therefore be small, while long-term efficacy is clearly superior in the majority 
of young patients. The treatment of choice in young patients should therefore preferable be 
CABG.
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to the edItor:
In the article by Lamy et al. (April 19 issue)1 regarding the CABG Off or On Pump Revas-
cularization Study (CORONARY), coronary-artery bypass grafting with a beating-heart 
technique (off-pump CABG) showed no benefit over cardiopulmonary bypass (on-pump 
CABG) in reducing adverse events among 4752 patients at 30 days. The trial was designed 
to show that off-pump CABG could reduce the expected on-pump event rate of 8.86% 
by a relative 28%. This hypothesis might have been appropriate for high-risk subgroups,2,3 
but we believe it is unrealistic and too optimistic in a population that includes low-risk 
patients. (In the study, 82.3% of patients had a grade of 5 or less on the European System for 
Cardiac Operative Risk Evaluation [EuroSCORE] at baseline). Since data from recent trials 
have already suggested that the benefit of off-pump CABG is limited,4 Lamy et al. could 
have used an adaptive study design and modified their sample size accordingly.5 With a less 
liberal estimate of a relative risk reduction of about 15%, a prohibitively large sample size of 
15,000 to 20,000 patients would have been required. As a result, it is unlikely that the 5-year 
CORONARY results will be able to show a benefit for off-pump CABG.
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IntroductIon
Recently, transcatheter aortic valve replacement (TAVR) has been shown to result in similar 
12-month survival as surgical aortic valve replacement (SAVR) for high-risk patients with 
severe aortic stenosis.1 For patients deemed inoperable TAVR showed a 20% survival benefit 
at one year compared to medical treatment.2
the pArtner trIAl
During the focused late-breaking clinical trial session at TCT in San Francisco new data on 
TAVR were presented. Good news came from the PARTNER B trial which tested TAVR with 
the SAPIEN device (Edwards Lifesciences, Irvine, CA, USA) in inoperable patients against 
best medical care. Data showed that survival curves are continuing to diverge. By two years, 
67.6% of patients in the medical group had died, compared with 43.3% in the TAVR group, 
a difference of 24.3%. The number needed to treat to save one life therefore dropped to four 
patients, which was five patients at one year.
The potential cost-effectiveness of TAVR versus SAVR in the PARTNER trial was examined 
and the results were presented by Matthew Reynolds. Health-state utilities were estimated 
using the EuroQOL (EQ-5D) at baseline, one, six and 12 months. Medical resource utilisa-
tion data were collected on all study patients, and hospital billing data were collected for 
both index and follow-up hospitalisations for any cause. The costs of the SAPIEN valve were 
projected at $30.000. The objectives of the study were to combine cost data with survival 
and quality of life (QoL) data in order to estimate the 12-month cost-effectiveness of TAVR 
compared with AVR. The secondary objective was to explore potential differences in costs 
and cost-effectiveness of TAVR vs. SAVR for the transfemoral and transapical populations.
The PARTNER A cohort randomised patients with severe, symptomatic aortic stenosis 
and high surgical risk to either TAVR (N=348) or SAVR (N=351), and followed them for 
a minimum of 12 months. The PARTNER A study was designed to test the SAPIEN valve 
against surgery in high-risk patients. Patients randomised to TAVR had a transfemoral-first 
approach; only when the patient was unsuitable for transfemoral valve delivery did they 
undergo a transapical procedure. This type of study design is biased towards finding more 
favourable results with transfemoral TAVR.
Quality of life data of the PARTNER A trial was presented by David Cohen. He showed 
that there was a quality of life benefit of transfemoral TAVR compared to surgery at one 
month, but similar benefits at later time points. For the small group of transapical patients 
(n=104) the quality of life measurements tended to be slightly better with surgical AVR at six 
months only. From a clinical standpoint this is difficult to explain.
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Transfemoral TAVR provided small but significant advantages in 12-month quality 
adjusted life expectancy. TAVR was associated with higher procedural costs, but slightly 
lower index hospitalisation and costs at one year. The study also indicated that for the trans-
apical approach there was no difference in quality of life compared to SAVR at one year and 
the costs were somewhat higher compared to surgery (about $10,000/patient) due to the 
same length of hospital stay as with surgery. Transcatheter aortic valve replacement therefore 
seems an economically attractive intervention especially for the transfemoral approach.
stAccAto
In the STACCATO trial patients were randomised to transapical TAVR or surgical AVR. The 
design of the trial can be criticised. The only inclusion criterion was that patients had to be 
older than 70 years of age. As a result, the enrolled patients had a mean STS score of only 3.1 
and 3.4 in the TAVR and SAVR groups, respectively. So far TAVR has only been investigated 
in high-risk or inoperable patients, while this trial looked at patients at low risk for SAVR.
The primary endpoint of the trial was a composite of all-cause death, stroke, and renal 
failure requiring haemodialysis. The sample-size calculation of the trial was based on data 
that did not correspond to current outcomes. A surgical event rate of 13.5% was anticipated, 
which, based on data from the STS database, is far too high. The STS score of 3.1-3.4% cor-
responds to similar mortality rates, and is the same as reported by O’Brien et al.3 This mortal-
ity risk coincides with only a 1.5% stroke rate (total event rate would be ±5%). Although the 
addition of renal failure requiring haemodialysis would increase the event rates somewhat, 
this will never be 13.5%.
In the TAVR arm, only a 3% event rate was expected, which is much lower than in most 
European registries or the PARTNER trial. Two Danish centres participated after more than 
40 TAVR procedures had been performed. Whether these were transfemoral or transapical 
cases was not presented.
The trial was first stopped after inclusion of 11 of the 200 planned patients due to three 
adverse events in the TAVR group. The inclusion and exclusion criteria were modified and 
after enrolling 70 patients the study was stopped again due to an excess of events in the 
transapical patients. The events that occurred, however, are more related to TAVR in general 
than to the transapical route. Primary endpoints included one patient who died on the 
waiting list, two major strokes (day 16 and 27), one left coronary blockage and one patient 
that needed dialysis. Other events were TIA (n=1), left main occlusion during balloon val-
vuloplasty (n=1), aortic rupture (n=1), severe paravalvular leakage (n=2), valve embolisation 
(n=1), abnormally positioned heart (n=1) and bleeding complication (n=1). It is clear that 
only the bleeding event might possibly be attributed to the transapical route.
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Multislice computed tomography (MSCT) was not used in the pre-operative assessment 
for valve sizing, and this could have led to valve under-sizing and the high rate of paraval-
vular leakage.4 MSCT could also have been used to assess the annulus to left main distance 
and potentially avoid coronary ostia blockage.
The conclusion that “transapical aortic valve replacement is inferior to surgical valve 
repair” seems not to be justified. Transapical AVR has the advantage of being an antegrade 
approach as opposed to all the other techniques; the transaortic, subclavian artery and 
transfemoral being retrograde. This may have potential advantages like reduction of peripro-
cedural strokes due to a minimum of manipulations in the aortic arch.
It is important to note that the STACCATO trial was designed three years ago and the 
PARTNER trial enrolled patients up until two years ago – techniques have changed since 
then. In the PARTNER trial, the first generation of the SAPIEN device was used, while in 
Europe new generation devices and improved techniques are currently employed. Thus the 
results from these studies cannot be translated to other devices or newer generations of 
these devices, and new studies with these devices are necessary in order to define the role 
of transapical valve replacement. Sizing of the valve has improved by the use of MSCT, 
incisions for transapical replacement have become smaller and the spreading of the ribs 
reduced, leading to less postoperative pain. The centres in the PARTNER trial did not have 
any previous experience with TAVR and still achieved remarkably good results. These will 
improve even further with experience. Procedural times for transapical TAVR were 224 min 
in the PARTNER US trial much longer than the 132 min in the PARTNER EU trial. The 
transapical group in the PARTNER trial was rather small; only 104 patients were enrolled at 
a large number of sites with, therefore, little experience for a technically more demanding 
procedure than transfemoral replacement. The transfemoral and transapical groups were not 
powered to look at the quality of life or cost-effectiveness endpoints separately, and it is very 
likely that in an inexperienced centre the costs will be higher.
The costs of the procedure depend very much on the cost of the device and it is to be 
expected that in the coming years, with more competition, the costs of the device will come 
down and transapical TAVR will mimic the cost of surgical AVR.
conclusIons
From the data presented at TCT it is clear that TAVR will play an important role in the 
future. To which extent the valve will be replaced transfemorally or transapically cannot be 
concluded from the data, but will need additional research.
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AbstrAct
Objectives
The objective of this study was to describe and evaluate the use of subgroup analyses in a 
continuum of publications that arise from randomized trials comparing percutaneous coro-
nary intervention (PCI) to coronary artery bypass grafting (CABG) for coronary artery disease.
Methods
PubMed was systematically searched through January 1, 2012. Primary endpoint papers 
were extracted. Subsequently follow-up and separate publications that focus on specific 
subgroups of patients were identified by a combined search of author and trial names. Two 
researchers collected data on subgroup pre-specification, analyzed outcomes, emphasis of 
results, and whether authors advised caution with interpreting subgroup result.
Results
From 17 trials we included 17 primary, 19 follow-up, and 28 subgroup papers. Thirteen 
(76%) trials reported subgroup analyses. In 5 primary, 13 follow-up, and 28 subgroup papers 
the number of reported subgroup analyses was 70, at least 372, and 952, respectively. Sub-
groups were pre-specified in only 7 (54%) trials, and 9 (69%) trials also performed post hoc 
exploratory analyses on subgroups that were not pre-specified. Analyses were performed 
on secondary endpoints 71%. Subgroup differences were claimed in all primary papers, 
33% of follow-up papers, and 68% of subgroup papers. Appropriate interaction tests were 
reported in only 43%. Subgroup results were emphasized in the conclusion or abstract in 
40%, 68% and 100% of primary, follow-up, and subgroup papers, respectively. In 78% of 
papers the authors failed to advise appropriate caution with subgroup analysis interpreta-
tion. From primary papers to follow-up papers to subgroup papers, the quality of reporting 
is increasingly flawed.
Conclusions
An excessive number of subgroup analyses (n >1,394) have been reported in PCI versus 
CABG trials. The method of reporting subgroup analyses is suboptimal and frequently 
methodologically invalid due to an inadequate statistical basis for validity, which has led to 
unsubstantiated treatment recommendations.
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IntroductIon
Reports of randomized trials according to the rules from the CONSORT statement are con-
sidered to be the highest standard of original research.1-3 Data originating from randomized 
trials are often used to determine whether a treatment effect varies across patient subgroups. 
It is important to identify potential treatment heterogeneity; after all, personalized medicine 
emphasizes treatment differences between individuals. An example is the impact of diabetes 
on outcomes after percutaneous coronary intervention (PCI) or coronary artery bypass graft-
ing (CABG), where it was suggested that long-term survival after CABG is superior over PCI 
particularly in diabetics.4-6
However, methodologists have warned against the validity of such subgroup results.7-13 
Although the statistical methodology of subgroup analyses requires additional consider-
ation, literature reviews of subgroup analyses in primary endpoint papers of randomized 
trials found low credibility of subgroup results due to methodological issues.7, 11, 13, 14
In addition to the primary report, authors often publish separately secondary results 
for longer follow-up or focusing on specific subgroups of patients (e.g. diabetics). These 
follow-up or subgroup papers are frequently of a lower standard than primary reports, and 
subgroup claims derived from these papers are even more methodologically flawed. How-
ever, no studies have systematically examined the frequency and methodological accuracy 
of subgroup analyses across subsequent papers. Our aim was therefore to i) describe and 
critically evaluate the use of subgroup analyses in the primary report, and follow-up or 
subgroup papers, ii) assess the difference in quality among a continuum of publications, 
and iii) point out the corresponding hazardsof over-emphasizing subgroup conclusions in 
a clinical-trial context of randomized studies comparing PCI with CABG. Furthermore, the 
CONSORT statement provides little guidance on how subgroup analyses should be reported 
and lacks any specific guidance in drafting follow-up or subgroup papers.1-3 We therefore 
provide recommendations to improve analysis and interpretation of subgroup data in order 
to prevent many, if not all, spurious observations and minimize treatment errors.7, 15, 16
Methods
search strategy and study inclusion
The PubMed database was searched from its inception through January 1st 2011 to identify 
published English-language parallel-group randomized trials comparing PCI with CABG for 
complex coronary artery disease. We searched the title and abstract using the following 
keywords: (“randomized” OR “randomised” OR “randomly”) AND (“bypass” OR “CABG”) 
AND (“angioplasty” OR “PCI” OR “PTCA”). Trials focusing exclusively on off-pump or 
minimally invasive CABG were excluded. Reference lists from meta-analyses, systematic 
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reviews, and other relevant publications were audited to ensure no potentially valid trials 
were missed.
We identified papers that reported the primary (clinical) endpoint of the trial (later 
referred to as “mainpaper”). By combining author and trial names, the PubMed database 
was searched through January 1st 2012 to identify subsequent publications that reported fol-
low-up analyses (“follow-up paper”) or results on specific subgroups of patients (“subgroup 
paper”). The timing of the search is different than for primary papers because we allowed 
sufficient time (≥1 year) to publish subsequent papers. Follow-up papers were defined as 
manuscripts that focused specifically on long-term follow-up of at least the primary end-
point. Subgroup papers were defined as manuscripts that focused on a subpopulation of 
the original cohort or focused exclusively on the effect of a single baseline variable (e.g. 
diabetes) on outcomes, or determined to find a difference in primary or secondary endpoints 
between subgroups with(in) PCI and CABG. We excluded subgroup papers that performed 
analyses with combined randomized and registry patients.
Identification of papers and data extraction were independently performed by multiple 
researchers (S.J.H., E.L.S.), and checked (A.P.K.). In case of disagreement consensus was 
reached by discussion.
criteria of subgroup analyses and strength of a subgroup claim
Pre-specification. Pre-specification is recommended to avoid excessive post-hoc exploratory 
analyses (e.g. data mining), to limit the risk of false-positive findings.
Endpoints. In the context of randomized trials, primary endpoints are frequently compos-
ite endpoints. Subgroup analyses have limited power to detect differences in the primary 
endpoint because of a smaller patient cohort. However, power may be even lower for 
individual secondary or tertiary endpoints because event rates are lower.
Interaction test. To detect a difference in outcomes between subgroups, a subgroup-by-
treatment interaction should be performed.17, 18 Such a test is necessary to assess whether a 
treatment effect is different across subgroups.
Emphasis. Interaction tests have low statistical power and thus subgroup analyses should 
always be interpreted with caution despite significant interaction. Emphasis of subgroup 
analyses in the conclusion section or abstract can distract readers from the overall conclu-
sion of the trial.
Advised caution. Caution with interpretation of subgroup results should be specified 
explicitly, and it needs to be clarified that results are hypothesis-generating. Policy or guide-
line recommendations of clinical practice based on results of subgroup analyses should 
therefore be avoided.
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Assessment of analyses
The total of subgroup analyses was calculated as the product of the number of factors (e.g. 
diabetes) and the number of outcomes (e.g. death) the subgroup was tested for, except for 
trials with varying baseline factors for different outcomes.7 We extracted information from 
the included papers using a standardized extraction spreadsheet. Information on whether 
subgroups were pre-specified in the trial protocol was collected per trial. Furthermore, we 
assessed: i) whether subgroup analyses were reported for primary or secondary endpoints, 
ii) if an interaction test was reported for none, part, or all analyses, iii) whether subgroup 
analyses were emphasized in the manuscript conclusion or abstract, iv) if caution was 
advised with interpretation of subgroup results, and v) whether analyses were reported as 
hypothesis-generating.
Analysis 
Results were reported as proportions, mean ± standard deviation, or median. All results 
were reported as observational and no statistical comparisons were performed.
results
Seventeen randomized trials comparing PCI to CABG were identified. We included 17 main 
(19-34), 19 follow-up (eReferences 1), and 28 subgroup papers (eReferences 2) in the final 
analyses.
There were 13 trials (76%) that reported subgroup analyses in the main paper (n=5), 
and/or in follow-up papers (n=8), and /or in specific subgroup papers (n=9) (Table 1). Pre-
specification of subgroups was present in 4 (31%) trials, 3 trials also performed exploratory 
post-hoc analyses in addition to these pre-specified groups, and 6 (46%) trials only had 
post-hoc defined subgroups.
table 1 reported subgroup analyses in pcI versus cAbg randomized trials
reporting of subgroup 
analyses
number of trials (n=17) trials
In the main paper 5 (29%) CABRI, BARI, ERACI-II, SYNTAX, CARDia
In subsequent follow-up 
papers
9 (53%) RITA, EAST, BARI, ERACI-II, ARTS, GABI, SoS, 
MASS-II, SYNTAX 
In subgroup papers 9 (53%) MASS, CABRI, BARI, AWESOME, ERACI-II, ARTS, 
SoS, MASS-II, SYNTAX
No subgroup analyses 
reported
4 (24%) ERACI, Lausanne, FMS, SIMA
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Main papers
A total of 70 subgroup analyses were reported in main papers (Table 2). Four of the 5 trials 
that reported subgroup analyses performed the analyses on the primary endpoint, of which 
2 also reported analyses on secondary endpoints. One trial, ERACI-II, reported subgroup 
analysis only for secondary endpoints. In total, 53 (76%) subgroup analyses were performed 
for the primary endpoint and 17 for a secondary endpoint. 
An interaction test was reported in only 3 of the 5 trials, with one trial (SYNTAX) reporting 
an interaction term for some of the analyses. All trials claimed that there was a subgroup 
difference, while this was not always confirmed by a significant interaction term. Three 
trials reported subgroup results with a major emphasis on the result by reporting them 
in the manuscript conclusion or in the abstract. Only the SYNTAX trial labeled results as 
hypothesis-generating, although the BARI and CARDia trials did advise some caution with 
interpretation of the subgroup results. 
follow-up papers
Of 19 follow-up papers, 6 papers did not report any subgroup analyses. Thirteen papers 
from 9 trials reported a total of at least 372 subgroup analyses (Table 3). Of 3 papers, the 
exact number of subgroup analyses could not be extracted from the text. Five trials reported 
pre-specified subgroups, but in addition the BARI, ARTS, and SYNTAX trials reported a large 
number of subgroups that were not pre-specified. In all but one paper, analyses of secondary 
outcomes were reported. Of all subgroup analyses, 52% were performed on secondary 
endpoints.
An interaction test was frequently not reported, but this did not withhold authors from 
claiming subgroup differences. In only 2 (17%) papers the authors advised caution with 
interpretation of subgroup analyses. Only the 3-year follow-up paper of the SYNTAX trial 
reported subgroup analyses as hypothesis-generating.35
subgroup papers
Nine trials reported 28 subgroup papers (CABRI (n=2), MASS (n=1), BARI (n=5), ERACI II 
(n=1), ARTS (n=7), AWESOME (n=4), SoS (n=3), MASS II (n=1), and SYNTAX (n=4); eRefer-
ences 2). These papers reported a total of 952 subgroup analyses; a mean of 34 ± 5.8 
(median = 26) analyses per paper (Table 4). Both the CABRI and AWESOME study reported 
the least number (n=3) of subgroup analyses in a single paper, the SYNTAX trial the most 
(n=136).
In 93% of the papers at least one subgroup analysis was performed for the primary end-
point and only in two papers (7%) the authors reported results exclusively of the primary 
endpoint (Table 4); of the 952 analyses in total, 82% were performed on secondary endpoints 
(versus 18% on the primary endpoint). An interaction test was reported in 9 papers (32%). 
A difference in treatment effects among subgroups was claimed in 19 (68%) of the papers. 
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Since subgroups were the main topic of the publication, an emphasis on these results was 
always present. However, in only 12 of 26 papers (43%) the authors advised caution with 
the interpretation of the results. In even fewer papers (n=7, 25%) the results were specifically 
reported as hypothesis-generating.
cumulative results
At least 1,394 subgroup analyses in 17 trials comparing PCI with CABG were reported. In 
papers that reported subgroup analyses, subgroup differences were claimed in all primary 
papers, in 33% of follow-up papers, and 68% of subgroup papers. However, appropriate 
interaction tests were performed in only 43% of papers and not even for all analyses. Still, 
subgroup results were emphasized in the conclusion or abstract in 40%, 68%, and 100% 
of primary, follow-up, and subgroup papers, respectively. In 78% of the papers, the authors 
failed to advise appropriate caution with subgroup analysis interpretation by reporting them 
as hypothesis-generating.
table 4 reported subgroup analyses in subgroup papers
number of papers (n=28)
number of subgroup analyses reported
1-10 7 (25%)
11-20 5 (18%)
21-30 4 (14%)
≥31 12 (43%)
outcomes analyzed in subgroup analyses was
Primary endpoint 2 (8%)
Secondary endpoint 2 (8%)
Both primary and secondary endpoints 24 (86%)
reported test for interaction
Yes 9 (32%)
No 19 (68%)
subgroup difference claimed in abstract or conclusion
Yes 19 (68%)
No 9 (32%)
Indicate caution with interpretation of subgroup results 
Yes 12 (43%)
No 16 (57%)
reported results as hypothesis-generating
Yes 7 (25%)
No 21 (75%)
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table 5 summary of studies systematically assessing the quality of subgroup analyses
Author, year specialty 
area
design study 
inclusion
Main findings conclusion
This study PCI versus 
CABG for 
coronary 
disease
Systematic 
electronic 
database 
search
17 main, 
18 follow-
up, and 26 
subgroup 
papers of 
RCTs
29%, 47%, and 53% of 
trials reported subgroup 
analyses in main, follow-
up, and subgroup papers; 
76% of trials reported 
subgroup analyses.
Analyses most frequently 
on secondary endpoints.
Lack of interaction 
testing. 
Lack of indicating 
that results should be 
hypothesis-generating.
In 17 RCTs comparing PCI 
versus CABG, more than 
1,394 subgroup analyses 
were reported.
Quality of analysis and 
reporting of subgroup 
analysis in main papers of 
trials is poor, but the qual-
ity decreases even more in 
subsequent follow-up and 
subgroup papers.
Sun, 2011 None in 
particular
Systematic 
electronic 
database 
search
469 main 
papers of 
RCTs
Subgroup analyses in 
42% of trials.
Several factors influence 
the reporting of subgroup 
analyses: sample size, 
journal impact factor, 
type of trial (surgical), 
and industry funding.
Industry funding is also 
associated with lower 
methodological quality.
Industry funding influences 
reporting and the quality of 
subgroup analyses. These 
results should be viewed 
with caution.
Wang, 2007 None in 
particular
Hand-
search 
NEJM
97 main 
papers of 
RCTs
Subgroup analyses in 
61% of trials.
Unclear whether 
subgroup analyses are 
predefined or post hoc.
Lack of interaction 
testing.
Reporting of subgroup 
analyses is neither uniform 
nor complete.
Encourage to report sub-
group analyses more clear 
and complete.
Hernández, 
2006
Cardiovas-
cular clinical 
trials
Hand-
search 
4 major 
impact 
journals
63 main 
papers of 
RCTs
Subgroup analyses in 
62% of trials.
No trial was powered to 
detect subgroup effects.
Low rate of prespecifica-
tion of subgroups.
Lack of interaction 
testing.
Significant inappropriate 
emphasis on subgroup 
results.
Several shortcomings in re-
porting subgroup analyses.
Reporting of subgroup 
analyses needs to be im-
proved substantially.
Bhandari, 
2006
Orthopaedic 
surgical RCTs
Hand-
search 4 
journals
72 main 
papers of 
RCTs
Subgroup analyses in 
38% of trials.
Inappropriate emphasis 
on subgroup analyses 
occurred frequently.
Analyses most often post 
hoc (91%).
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dIscussIon
In the results of clinical trials comparing PCI to CABG, more than 1,394 subgroup analyses 
were reported in the main, follow-up, and subgroup papers. We have identified many short-
comings in these subgroup analyses, with a step-wise increase in the number of subgroup 
analyses and the methodological issues from main papers to follow-up papers to subgroup 
papers. Although previous systematic reviews have identified significant methodological 
flaws of subgroup analyses in main papers of randomized clinical trials (Table 5), we found 
that to assessinterpretations and conclusions that arise from trials one must consider not 
only the main article, but also the follow-up papers and the separate publications that 
focus on specific subgroups of patients. This is of concern because many subsequent papers 
are published and used to guide treatment recommendations, while the conclusions are 
frequently not substantiated and are not sufficiently robust to change treatment policy in 
certain types of patients. 
Follow-up and subgroup papers are often encouraged by study sponsors and investigators 
to produce multiple publications. However, subgroup analyses should only be performed 
when a proper rationale is given and groups have been pre-specified in the study protocol. 
Post hoc analyses in “interesting” groups are, nevertheless, frequently conducted. These 
analyses are of lower credibility and raise concerns because of confounding 36 and because 
there are no limitations to how many analyses are performed. These large number of analy-
ses (k) cause inflated error rates 18 and should be corrected either through adjusted P-values 
(adjusted P = unadjusted P-[1-unadjusted P]k) or adjusted α (Bonferroni: adjusted α = 0.05/k, 
table 5 Continued
Author, year specialty 
area
design study 
inclusion
Main findings conclusion
Hernández, 
2005
Traumatic 
brain injury
Systematic 
electronic 
database 
search
18 main 
papers of 
RCTs
Subgroup analyses in 
61% of trials.
Significant inappropriate 
emphasis on subgroup 
results.
Subgroup analyses were 
insufficiently described 
and clearly different as 
planned in the protocol.
Methodological shortcom-
ings in subgroup analyses 
reporting.
Improvement of appropri-
ate performance and 
reporting is needed.
Assmann, 
2000
None in 
particular
Hand-
search 
4 major 
impact 
journals
50 main 
papers of 
RCTs
Subgroup analyses in 
70% of trials.
Interaction testing was 
used in <50%.
Difficult to determine 
whether analyses were 
predefined or post hoc. 
Low statistical power.
A predefined statistical 
plan is needed.
Caution is advised when 
drawing conclusions from 
subgroup findings.
CABG = coronary artery bypass grafting; PCI = percutaneous coronary intervention; RCT = randomized clinical trial; 
NEJM = New England Journal of Medicine
Part 4 Interpretation of cardiovascular clinical research476
or Sidák: adjusted α = 1-(1- α)1/k).11, 37 In this study, we found 70 subgroup analyses in the 
main, at least 372 in follow-up, and 952 in subgroup papers, while only 5 trials planned 
subgroup analyses. These analyses were not corrected for multiplicity.
The total number of analyses we found may even be an underestimate. It is likely that a 
larger number of subgroups were tested for a greater number of endpoints. Figure 1 provides 
an example from the SYNTAX trial where multiple subgroup analyses were reported for the 
left main cohort, while fewer analyses were reported for other subgroups.33 It is possible 
many subgroup analyses were performed but may not have been reported, suggesting a pos-
sible publication bias; non-significant results are less likely to be reported.15, 38, 39 Therefore, 
even pre-specified subgroups may not always be reported. For example, the CABRI trial 
stated in the methods section that mortality and angina would be analyzed by gender, but 
analyses were only performed for the angina endpoint.24
An interaction test is mandatory to analyze a difference in treatment effect between 
subgroups of patients. Frequently this statistical approach is violated and subgroup differ-
ences are claimed by a comparison of p-values within subgroups.40 For example, from a 
subgroup analysis of the SoS trial the authors concluded in the abstract that PCI and CABG 
resulted in similar 1-year health status in older patients (P>0.05), while younger patients 
had more health status benefits from CABG as compared with PCI (P<0.05).41 However, the 
interaction test was not significant (P>0.05) and thus a true difference of treatment effects 
cannot be claimed.
LM + 1VD (PCI vs CABG)
LM + 2VD (PCI vs CABG)
LM + 3VD (PCI vs CABG)
LM (PCI vs CABG)
Reported outcomes
Repeat revascularization
Cardiac death
MI
MACCE
CVA
All-cause death
Composite death/CVA/MI
figure 1 reported outcomes
Different outcomes reported from the SYNTAX trial for subgroups of patients with left main disease and left main 
disease with additional vessel involvement. Outcomes indicated by the asterisk are likely to have been performed, 
but are not reported. LM = left main; PCI = percutaneous coronary intervention; CABG = coronary artery bypass 
surgery; MI = myocardial infarction; MACCE = major adverse cardiac and cerebrovascular events; CVA = 
cerebrovascular event; VD = vessel disease
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Some subgroup papers are designed such that they exclude the possibility of performing 
an interaction test. These reports warrant extra caution, since the conclusions are inher-
ently methodologically incorrect. For example, the main analysis of the AWESOME trial 
showed similar survival for PCI and CABG while the authors concluded that PCI should 
be preferred over surgery in the subgroup of post-CABG patients.29, 42 This paper, however, 
focused exclusively on post-CABG patients and not the de novo coronary artery disease 
cases. Whether the results in post-CABG patients were really different from de novo cases 
could therefore not be assessed with an interaction term.
Even with an interaction test there is a high chance of false-positive findings.17 For 
example, an illustrative subgroup analysis from the ISIS-2 study demonstrated an adverse 
effect of aspirin on mortality (9% increase) for patients with Gemini or Libra as astrological 
birth signs, while patients with other signs had a 28% reduction.43 
It is also important to assess whether an interaction is quantitative in which the treatment 
effect is in similar direction but varies in magnitude, or qualitative, in which the direction 
of the effect is different (Figure 2A).44, 45 Quantitative interactions are more credible and 
very likely to be present, while qualitative interactions are seldom replicated and should 
not be emphasized.12, 44 In addition, when continuous variables are divided into (arbitrary) 
Males
Females
Age ≤60
Age 61-70
Age >70
                    Favours A         Favours  B                    Favours A          Favours  B
figure 2 features of interactions between treatment effects
The type of interaction (A) and smoothness (B) give necessary insights into the credibility of interactions. 
Quantitative and smooth interactions are more likely to be genuine.
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subgroups, the ‘smoothness’ of treatment differences may be an indication of whether the 
interaction is genuine, where smooth interactions are more likely to reflect a true difference 
in treatment effect (Figure 2B).
Still, when subgroup interactions appear genuine, they must not be overemphasized. 
Authors should highlight the limited applicability of subgroup results by emphasizing that 
subgroup results warrant caution in that they are hypothesis-generating only, and that no 
clinically directive recommendations should be derived from subgroup results. In reality, 
however, these statements are frequently ignored and the community may still overempha-
size subgroup results. For example, the result of the SYNTAX trial left main subgroup analy-
sis were clearly reported as hypothesis-generating,46, 47 yet some physicians may already 
consider left main stenting as a good alternative to CABG,48 resulting in wider adoption 
of PCI for this indication. In addition, the current revascularization guidelines have based 
many of their recommendations on these and other (e.g. SYNTAX score) subgroup analyses 
from the SYNTAX trial.49, 50 Only until the results from the ongoing EXCEL trial are available 
can a substantiated conclusion be derived.51 
In a negative trial, as were several of the PCI versus CABG trials, there is an additional 
incentive to perform subgroup analyses to find specific subgroups of patients in whom 
certain treatment does appear beneficial. However, if the overall trial result is negative, 
subgroup differences are even less substantiated because of data mining in search of a 
subgroup in which PCI is indeed equivalent to CABG. Hierarchical testing --where subgroup 
analyses are performed only if the overall trial result is positive-- could be a solution to 
protect against fishing for false-positive results. 
As shown by the example of the SYNTAX trial, subgroup analyses can be meaningfulto 
identify treatment heterogeneity among patient subgroups and thereby generate hypotheses 
for new trials. However, it is necessary to perform adequately powered trials to validate these 
hypotheses. Additional underpowered subgroup analyses from other trials are no solution. 
For example, the BARI trial reported better survival in diabetic patients randomly assigned 
to CABG as opposed to PCI patients.26 After BARI, several post hoc subgroup analyses of 
diabetic patients were reported from randomized trials. None of these 9 analyses showed a 
difference in survival,52, 53 likely due to the low statistical power. Even though there might 
be concordance of subgroup findings in different trials, this does not validate the assump-
tion that the result is accurate. In this case, the recently published FREEDOM trial indeed 
showed a significantly significant benefit of CABG over PCI in diabetics, thereby validating 
the hypothesis first generated from the post hoc observations in BARI.6
Pooling individual patient data could provide more power for subgroup analyses and 
could demonstrate the true treatment effect difference amongst subgroups. Establishing 
large research collaborations for subgroup analyses may be difficult and costly and therefore 
are unlikely to be done in many areas. Subgroup papers of individual randomized trials may 
then be particularly helpful, as it will allow systematic reviews and meta-analyses. However, 
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in this study we found evidence of methodological deficiencies in subgroup papers which 
may complicate accurate meta-analyses. Therefore, to prevent spurious subgroup findings, 
some experts have suggested to limit exploration of subgroups to those analyses with an 
a priori power of at least 40-50% which corresponds to subgroup sizes of 30-40% of the 
original study size.54 With low power the risk of claiming equivalent outcomes between 
treatments is inflated, when actually one treatment may be superior. Because the CONSORT 
statement provides little guidance on how subgroup analyses should be reported and lacks 
any specific guidance in drafting follow-up or subgroup papers,1-3 several recommendations 
for reporting subgroup analyses are provided (Table 6). 
conclusIons 
The method of reporting subgroup analyses from PCI versus CABG trials is suboptimal and 
methodologically invalid in most studies due to an inadequate statistical basis for validity, 
which can lead to false or exaggerated subgroup claims. From primary papers to follow-up 
papers to subgroup papers, the quality of reporting is increasingly flawed. We recommend 
that subgroup analyses be performed only when pre-specified in the original study, when an 
table 6 recommendations for reporting subgroup analyses
In general:
Avoid subgroup analyses on outcomes that are not primary endpoints.
Subgroup analyses should be performed on pre-specified patient subgroups only.
Restrict subgroup analyses ideally to those that represent approximately 35-40% of the original study size. 
To prevent spurious findings, exploration of subgroups should be limited to analyses with an a priori 
power of at least about 45-50%.
Do not overemphasize subgroup analyses by reporting specific findings in the abstract or conclusion.
A systematic review and meta-analyses can be used to put subgroup results in perspective and deal with 
inconsistency among subgroup analyses from different trials. 
In the Methods section: 
Report whether subgroups were pre-specified and powered.
In the results section: 
Perform a test for interaction and report heterogeneity of subgroup analyses.
Correct for multiple subgroup testing.
Report both significant and non-significant subgroup results.
In the discussion section: 
Indicate the total number of subgroup analyses in the present and previous papers from the trial.
Indicate the potential effect of multiple subgroup analyses on type I errors (false positives) across the 
present and previous papers from the trial.
Address multiplicity to inform readers of the power of subgroup results.
Use the general term hypothesis-generating to advise caution with interpretation of subgroup results.
Address if the subgroup effect is in the direction that was expected, and whether the treatment effect is 
clinically plausible.
Discuss whether other trials have performed similar subgroup analyses and compare findings.
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appropriate interaction test has been performed and if adequately powered to support the 
analysis. Although our study focused on a specific area of interest, the problem of errone-
ous and misleading subgroup analyses is likely common to other scenarios as well. The 
next version of the CONSORT statement should provide additional guidance in reporting 
subgroup papers of randomized controlled trials. Adherence to these principles will help 
avoid erroneous conclusions and unsubstantiated treatment recommendations based on 
invalid evidence.
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AbstrAct
Objectives
The aim of the current Valve Academic Research Consortium (VARC)-2 initiative was to 
revisit the selection and definitions of transcatheter aortic valve implantation (TAVI) clinical 
endpoints to make them more suitable to the present and future needs of clinical trials. In 
addition, this document is intended to expand the understanding of patient risk stratification 
and case selection.
Background
A recent study confirmed that VARC definitions have already been incorporated into clinical 
and research practice and represent a new standard for consistency in reporting clinical 
outcomes of patients with symptomatic severe aortic stenosis (AS) undergoing TAVI. How-
ever, as the clinical experience with this technology has matured and expanded, certain 
definitions have become unsuitable or ambiguous.
Methods and Results
Two in-person meetings (held in September 2011 in Washington, DC, USA, and in February 
2012 in Rotterdam, the Netherlands) involving VARC study group members, independent 
experts (including surgeons, interventional and non-interventional cardiologists, imaging 
specialists, neurologists, geriatric specialists, and clinical trialists), the US Food and Drug 
Administration (FDA), and industry representatives, provided much of the substantive 
discussion from which this VARC-2 consensus manuscript was derived. This document 
provides an overview of risk assessment and patient stratification that need to be considered 
for accurate patient inclusion in studies. Working groups were assigned to define the fol-
lowing clinical endpoints: mortality, stroke, myocardial infarction, bleeding complications, 
acute kidney injury, vascular complications, conduction disturbances and arrhythmias, and 
a miscellaneous category including relevant complications not previously categorized. Fur-
thermore, comprehensive echocardiography recommendations are provided for the evalua-
tion of prosthetic valve (dys)function. Definitions for the quality of life assessments are also 
reported. These endpoints formed the basis for several recommended composite endpoints.
Conclusions
This VARC-2 document has provided further standardization of endpoint definitions for 
studies evaluating the use of TAVI, which will lead to improved comparability and inter-
pretability of the study results, supplying an increasingly growing body of evidence with 
respect to TAVI and/or surgical aortic valve replacement. This initiative and document can 
furthermore be used as a model during current endeavors of applying definitions to other 
transcatheter valve therapies (for example, mitral valve repair).
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IntroductIon
The first Valve Academic Research Consortium (VARC) consensus manuscript was published 
in January 2011 with the goal of achieving consensus for (i) selecting appropriate clinical 
endpoints reflecting device, procedure and patient-related effectiveness and safety, and 
(ii) standardizing definitions for single and composite clinical endpoints, for transcatheter 
aortic valve implantation (TAVI) clinical trials.1, 2 A recent pooled analysis, which included 
3,519 patients from 16 unique studies, confirms that VARC definitions have already been 
incorporated into clinical and research practice and represent a new standard for consis-
tency in reporting clinical outcomes of patients with symptomatic severe aortic stenosis (AS) 
undergoing TAVI.3 However, as the clinical experience with this technology has matured 
and expanded, certain definitions have become unsuitable or ambiguous.3-7 The aim of the 
current VARC was therefore to revisit the selection and definitions of TAVI-related clinical 
endpoints to make them more suitable to the present and future needs of clinical trials. In 
addition, this document is intended to expand the understanding of patient risk stratification 
and case selection.
Similar to the VARC-1 process, two in-person meetings (held in September 2011 in 
Washington, DC, USA, and in February 2012 in Rotterdam, the Netherlands) involving 
VARC study group members, independent experts (including surgeons, interventional and 
non- interventional cardiologists, imaging specialists, neurologists, geriatric specialists, and 
clinical trialists), the US Food and Drug Administration (FDA), and industry representatives, 
provided much of the substantive discussion from which this VARC-2 consensus manuscript 
was derived.
rIsK scores And coMorbIdItIes
Risk stratification of patients is crucial to identifying appropriate candidates for specific car-
diac procedures. The EuroSCORE and Society of Thoracic Surgeons (STS) score are the most 
widely used risk scores to predict operative mortality in cardiac surgery. These models were 
developed and validated in a standard surgical risk population. The predictive power of 
both models is therefore suboptimal in high-risk patients with valvular disease, although the 
STS score has shown to outperform the Logistic EuroSCORE.8 These models are even more 
limited in application to patients who are considered at prohibitive risk for cardiac surgery, 
a cohort that could particularly benefit from TAVI. Current models could be improved by the 
addition of specific clinical and anatomical variables that affect mortality.9 As an example, 
the presence of a porcelain aorta and frailty are important factors not included in either risk 
model but are routinely considered during patient evaluation (Figure 1, Table 1).
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figure 1 porcelain aorta or severely atherosclerotic aorta
table 1 risk factors not captured by traditional risk scores
co-morbidities definition/criteria diagnostic modalities
Porcelain aorta 
or severely 
atherosclerotic aorta
Heavy circumferential calcification or severe 
atheromatous plaques of the entire ascending 
aorta extending to the arch such that aortic 
cross-clamping is not feasible
Non-contrast axial CT at levels:
Sinotubular junction
Tubular ascending aorta 
between sinotubular junction 
and innominate
Innominate artery
Entire transverse arch
Frailty Slowness, weakness, exhaustion, wasting and 
malnutrition, poor endurance and inactivity, 
loss of independence 
Criteria:
5 meter walking time*
Grip strength*
BMI <20 kg/m2 and/or weight loss 5 kg/yr
Serum albumin <3.5 g/dL
Cognitive impairment or dementia
Medical history
Physical examination
Physical performance measures
Cognitive assessments
Laboratory tests
Severe liver disease/
cirrhosis
Any of the following:
Child-Pugh class C 
MELD score ≥10
Portal-caval, spleno-renal, or transjugular 
intrahepatic portal shunt, 
Biopsy proven cirrhosis with portal 
hypertension or hepatocellular dysfunction
Medical history
Physical examination
Laboratory tests
Child-Pugh classification
MELD score
Liver biopsy
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Perhaps the most important patient characteristic not included in current risk models is 
frailty.10 Frailty is frequently assessed subjectively based upon an informal ‘eyeball test’. 
However, physical performance assessments such as gait speed and grip strength are more 
objective performance measures that may capture an individual’s overall functional status.11 
These continuous measures are reproducible and can be re-assessed at various time points. 
In addition, they require no language translation. Assessments of cognition, weight (loss), 
activity level, and independence in the activities of daily living provide additional informa-
tion on the overall health state of the individual.11 These limitations are more often found in 
patients with a high comorbidity burden and may co-exist with certain laboratory findings 
table 1 Continued
co-morbidities definition/criteria diagnostic modalities
Hostile chest Any of the following or other reasons that 
make redo operation through sternotomy 
or right anterior thoracotomy prohibitively 
hazardous:
Abnormal chest wall anatomy due to 
severe kyphoscoliosis or other skeletal 
abnormalities (including thoracoplasty, 
Potts’ disease)
Complications from prior surgery
Evidence of severe radiation damage (e.g. 
skin burns, bone destruction, muscle 
loss, lung fibrosis or esophageal stricture)
History of multiple recurrent pleural 
effusions causing internal adhesions
Medical history
Physical examination
Chest X-Ray
CT scan
IMA or other critical 
conduit(s) crossing 
midline and/or 
adherent to posterior 
table of sternum
A patent IMA graft that is adherent to 
the sternum such that injuring it during 
re-operation is likely. A patient may be 
considered extreme risk if any of the following 
are present: 
The conduit(s) are radiographically 
indistinguishable from the posterior table 
of the sternum.
The conduit(s) are radiographically 
distinguishable from the posterior table of 
the sternum but lie within 2-3 mm of the 
posterior table.
Axial CT scan images illustrating 
graft crossing the midline so 
the distance from sternum to 
graft can be measured.
Angiogram from the lateral and 
PA projections and/or a CPR 
or VR (Volume rendering) 
3-D reconstructed CT scan 
image showing relationships 
between graft and sternum 
Severe pulmonary 
hypertension
Severe right 
ventricular 
dysfunction
Primary or secondary pulmonary hypertension 
with PA systolic pressures greater than 2/3 of 
systemic pressure
Criteria as defined by the guidelines (e.g. 
TAPSE <15mm, RV end-systolic area >20cm2, 
etc)†
Echocardiography, right-and 
left heart-catheterization 
documenting PA and systemic 
pressures
Documentation of secondary 
causes of pulmonary 
hypertension
*Variable with respect to age and gender without validated scientific thresholds. †Rudski et al.72 CT = computed 
tomography; MELD = Model for End-Stage Liver Disease; INR = international normalized ratio; IMA = internal 
mammary artery; PA = pulmonary artery
Part 5 Improving clinical research in the future494
(e.g. low serum albumin, elevated inflammatory markers, anemia) that further reflect the 
health state and physiological reserve of the frail patient.
Baseline evaluation of the presence of cognitive dysfunction (mild cognitive impair-
ment or dementia) has also emerged as an essential part of the initial risk stratification, 
especially in older populations, where the risk, benefit, and cost-effectiveness of invasive 
procedures must be weighed judiciously. Pre-procedural cognitive assessment may also 
help avoid attributing post-procedural mental status changes to stroke categories. Among 
the several clinically established rating scales [e.g. Mini-Mental State Examination, modified 
Telephone Interview of Cognitive Status (TICS-M), Clinical Dementia Rating Scale],12 there 
is no particular standard for TAVI. Nevertheless, some systematic cognitive assessment by 
neuropsychological experts should be a part of the initial heart team evaluation.Table 1 
provides an overview of these and other risk factors (Figure 1, Figure 2 and Figure 3) and 
VARC-2 recommendations on how each should be assessed. In clinical trials, it will be 
important to capture variables that predict extreme operative risk and to standardize the 
evaluation criteria and process. This will help to determine which subsets of patients are 
likely to benefit from TAVI treatment.
patient stratification: the heart team approach
Valve Academic Research Consortium-2 recommends the use of a heart team for patient 
evaluation. The heart team should consist of at least (interventional) cardiologists, cardio-
vascular surgeons, and imaging specialists, but its composition is dynamic and can also 
include anesthesiologists, geriatricians, neurologists, etc. This multi-disciplinary team 
should convene as a group on a regular basis to review and interpret clinical data to arrive 
at a consensus on the optimal treatment strategy for each patient. The heart team approach 
 
figure 2 hostile chest
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also allows for the adjustment of the decision-making process according to local experience 
and circumstances.
The heart team should agree on an estimated 30-day mortality risk for each patient based 
upon integrating a careful clinical assessment and utilizing appropriate risk prediction scor-
ing systems, preferably the STS score. Surgical mortality risk strata are difficult to precisely 
assign, but an estimated 30-day mortality of <4% is considered low risk, 4–10% is interme-
diate risk, >10% is high risk, and >15% is very high risk. A patient is considered at extreme 
risk if at least two cardiovascular surgeons from a tertiary centre of excellence deny surgery 
because of prohibitive operative risks, estimated to be a combined >50% risk of irreversible 
morbidity or mortality.13 In addition to the specific risk factors that can prohibit patients 
from undergoing TAVI or surgical aortic valve replacement (SAVR) (Table 1), the operative 
risk assessment is also important to identify patients who are likely not to benefit from either 
TAVI or SAVR (the so-called ‘futility’ category of high-risk patients). An expected improve-
ment in the quality of life (QOL) may further be necessary to identify treatment responders 
vs. non- responders. Individualized life expectancy assumptions should be incorporated by 
the heart team in the clinical decision-making process as a central factor in weighing the 
risk-benefit ratio. Prognostic indices of life expectancy may play a central role in moving 
beyond arbitrary age-based cut-offs.14
The most important role of the heart team is to provide customized management deci-
sions for common and unusual clinical scenarios in terms of patient selection, procedural 
performance, and complication management. An example is the frequent situation of severe 
AS and concomitant coronary artery disease (CAD). The complexity of CAD and appro-
priate revascularization strategies in the setting of AS should be determined by consensus 
from interventional cardiologists and cardiovascular surgeons.15, 16 In new TAVI clinical 
trials, angiographic risk scores (e.g. SYNTAX score) may be utilized to help determine the 
 
figure 3 patient IMA graft crossing midline and/or adherent to the posterior table of the sternum
Part 5 Improving clinical research in the future496
complexity of CAD, as a basis for the inclusion in the trial. Thresholds for coronary revas-
cularization and the choice for a staged or concomitant PCI with TAVI should be guided 
by the complexity of the CAD and other factors as determined by the heart team.17, 18 In 
general, the plan to deal with other co-existing conditions [such as atrial fibrillation (AF), 
other valvular lesions, and other congenital lesions] should be pre-specified and all com-
plications encountered in the treatment of associated conditions (including treatment after 
the TAVI procedure) should be captured. Such thorough pre-procedural assessment is also 
valuable in discriminating new post-procedural complications from simple exacerbations of 
pre-existing conditions.
clInIcAl endpoInts
Mortality
In addition to the original VARC definitions, VARC-2 recommends the collection of imme-
diate procedural mortality to capture intra-procedural events that result in immediate or 
consequent death <72 h post-procedure. Taking into account the surgical literature, pro-
cedural mortality consists of all-cause mortality within 30 days or during index procedure 
hospitalization—if the postoperative length of stay is longer than 30 days.
The cause of death should be captured, based on a careful review of narrative summaries 
and source material. All-cause, cardiovascular, and non-cardiovascular mortality should be 
reported after 30 days during the follow-up (Table 2). In determining the cause of death, 
the adjudication committee should consider the clinical context at the time of the index 
procedure and during the time interval leading up to death. All efforts (including the use of 
table 2 Mortality
All-cause mortality
cardiovascular mortality
Any of the following criteria: 
Death due to proximate cardiac cause (e.g. myocardial infarction, cardiac tamponade, worsening heart 
failure)
Death caused by non-coronary vascular conditions such as neurological events, pulmonary embolism, 
ruptured aortic aneurysm, dissecting aneurysm, or other vascular disease
All procedure-related deaths, including those related to a complication of the procedure or treatment for 
a complication of the procedure
All valve-related deaths including structural or nonstructural valve dysfunction or other valve-related 
adverse events
Sudden or unwitnessed death
Death of unknown cause
non-cardiovascular mortality
Any death in which the primary cause of death is clearly related to another condition (e.g. trauma, 
cancer, suicide)
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national death registries) should be made to identify, precisely characterize, and appropri-
ately classify any death.
Myocardial infarction
Myocardial injury as determined by a significant rise in cardiac biomarkers occurs frequently 
following TAVI, and a significant magnitude of myocardial injury has been associated with 
worse outcomes.19 Valve Academic Research Consortium-2 recommends the systematic 
collection of biomarkers of myocardial injury prior to the procedure, within 12–24 h after 
the procedure, at 24 h thereafter, at 72 h or at discharge, and, if still elevated, daily until 
values show a decline. Similar to the previous VARC recommendations, the definition of 
peri-procedural (<72 h following TAVI) MI will be based on a combination of clinical criteria 
and cardiac biomarkers. However, the threshold values have been adjusted (Table 3). Acute 
ischemic events occurring after 72 h should be considered spontaneous myocardial infarc-
tions and defined in accordance with the universal MI guidelines.20
table 3 Myocardial infarction
peri-procedural MI (≤72 h after the index procedure)
New ischaemic symptoms (e.g. chest pain or shortness of breath), or new ischaemic signs (e.g. 
ventricular arrhythmias, new or worsening heart failure, new ST-segment changes, haemodynamic 
instability, new pathological Q waves in at least two contiguous leads, imaging evidence of new loss 
of viable myocardium or new wall motion abnormality) AND
Elevated cardiac biomarkers (preferable CK-MB) within 72 h after the index procedure, consisting of at 
least one sample post-procedure with a peak value exceeding 15x upper reference limit (troponin) or 
5x for CK-MB.* If cardiac biomarkers are increased at baseline (>99th percentile), a further increase of 
at least 50% post-procedure is required AND the peak value must exceed the previously stated limit.
spontaneous MI (>72 h after the index procedure)
Any one of the following criteria:
Detection of rise and/or fall of cardiac biomarkers (preferably troponin) with at least one value above 
the 99th percentile URL, together with evidence of myocardial ischaemia with at least one of the 
following:
Symptoms of ischaemia
ECG changes indicative of new ischaemia [new ST-T changes or new left bundle branch block 
(LBBB)]
New pathological Q waves in at least two contiguous leads
Imaging evidence of new loss of viable myocardium or new wall motion abnormality
Sudden, unexpected cardiac death, involving cardiac arrest, often with symptoms suggestive of 
myocardial ischaemia, and accompanied by presumably new ST elevation, or new LBBB, and/or 
evidence of fresh thrombus by coronary angiography and/or at autopsy, but death occurring before 
blood samples could be obtained, or at a time before the appearance of cardiac biomarkers in the 
blood.
Pathological findings of an acute myocardial infarction.
*Previously in the original VARC it was 10x and 5x for troponin and CK-MB, respectively.
Part 5 Improving clinical research in the future498
stroke
With increasing attention to stroke as an important peri-procedural complication of TAVI,21 
the FDA has emphasized the need for an accurate assessment of stroke and has participated 
actively in recommending specific details of the VARC-2 definitions. In an attempt to further 
align with the fundamental definitions now endorsed by the FDA,22 consensus was reached 
at VARC-2 to further refine the definition of stroke and recommend the use of these defini-
tions in future TAVI clinical trials (Table 4). The definitions endorsed by the FDA are intended 
to apply to a wide range of clinical trials and to enable those trials to assess the clinically 
relevant consequences of vascular brain injury for determining the safety or effectiveness of 
an intervention.
table 4 stroke and tIA
diagnostic criteria
Acute episode of a focal or global neurological deficit with at least one of the following: change in 
level of consciousness, hemiplegia, hemiparesis, numbness or sensory loss affecting one side of the 
body, dysphasia or aphasia, hemianopia, amaurosis fugax, or other neurological signs or symptoms 
consistent with stroke
Stroke – Duration of a focal or global neurological deficit ≥24 h; OR <24 h if available neuroimaging 
documents a new hemorrhage or infarct; OR the neurological deficit results in death
TIA – Duration of a focal or global neurological deficit <24 h, any variable neuroimaging does not 
demonstrate a new hemorrhage or infarct
No other readily identifiable non-stroke cause for the clinical presentation (e.g. brain tumor, trauma, 
infection, hypoglycemia, peripheral lesion, pharmacological influences), to be determined by or in 
conjunction with designated neurologist*
Confirmation of the diagnosis by at least one of the following: 
Neurologist or neurosurgical specialist 
Neuroimaging procedure (CT scan or brain MRI), but stroke may be diagnosed on clinical grounds 
alone
stroke classification
Ischemic – An acute episode of focal cerebral, spinal, or retinal dysfunction caused by infarction of 
central nervous 
system tissue
Hemorrhagic – An acute episode of focal or global cerebral or spinal dysfunction caused by 
intraparenchymal,
intraventricular, or subarachnoid hemorrhage
A stroke may be classified as undetermined if there is insufficient information to allow categorization as 
ischemic or hemorrhagic
stroke definitions†
Disabling stroke –  a mRS score of 2 or more at 90 days and an increase of at least one mRS category 
from an individual’s pre-stroke baseline
Non-disabling stroke – a mRS score of less than 2 at 90 days or one that does not result in an increase of 
at least one mRS category from an individual’s pre-stroke baseline
*Patients with non-focal global encephalopathy will not be reported as a stroke without unequivocal evidence of 
cerebral infarction based upon neuroimaging studies (CT scan or Brain MRI). †Modified Rankin Scale assessments 
should be made by qualified individuals according to a certification process.23-25 mRS = modified Rankin Scale
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Stroke is defined as an acute episode of focal or global neurological dysfunction caused 
by the brain, spinal cord, or retinal vascular injury as a result of hemorrhage or infarction. 
Stroke may be classified as ischemic or hemorrhagic with appropriate subdefinitions. Isch-
emic stroke is defined as an acute episode of focal cerebral, spinal, or retinal dysfunction 
caused by infarction of central nervous system tissue. Hemorrhagic stroke is defined as an 
acute episode of focal or global cerebral or spinal dysfunction caused by intraparenchymal, 
intraventricular, or subarachnoid hemorrhage. A stroke may be classified as ‘undetermined’ 
if there is insufficient information to allow the categorization as ischemic or hemorrhagic.
An entity closely related to an ischemic stroke that should be assessed is a transient 
ischemic attack (TIA). Transient ischemic attack is defined as a transient episode of focal 
neurological dysfunction caused by the brain, spinal cord, or retinal ischemia, without acute 
infarction. The difference between TIA and ischemic stroke is the presence of tissue damage 
on neuro-imaging studies or new sensory-motor deficit persisting >24 h. By definition, a TIA 
does not produce a lasting disability.
Valve Academic Research Consortium-2 recognizes that an assessment of stroke is 
incomplete without an appropriate measurement of the disability resulting from the stroke. 
Valve Academic Research Consortium-2 recommends the use of the modified Rankin Scale 
(mRS) to assess this clinical disability.23-25 The assessment of the mRS should occur at all 
scheduled visits in a trial and at 90 days after the onset of any stroke. This approach will 
maximize the detection of new or recurrent strokes, assist in the ongoing evaluation of 
events previously determined as TIAs, and provide an accepted and reliable indicator of the 
long-term impact of a given stroke.
Previously, VARC recommended categorizing strokes as ‘major’ and‘minor’ based upon 
mRS scores. To enhance the accuracy in the description of a given stroke and to provide 
accurate categorization of strokes within a given trial, VARC-2 now recommends the use 
of the terms ‘disabling’ and ‘non-disabling’. A disabling stroke is one that results (at 90 
days after stroke onset) in an mRS score of >2 and an increase in >1 mRS category from an 
individual’s pre-stroke baseline. A non-disabling stroke is one that results (at 90 days after 
stroke onset) in an mRS score of <2 or that does not result in an increase in >1 mRS category 
from an individual’s pre-stroke baseline. In addition to this categorization of disabling and 
non-disabling strokes, the endpoint of all strokes should be reported.
Although brain imaging (typically, MRI for acute and chronic ischemia and hemorrhage, 
and CT for acute and chronic hemorrhage and chronic ischemia) is often used to supplement 
the clinical diagnosis of stroke,26 a diagnosis of stroke may be made on clinical grounds 
alone. Valve Academic Research Consortium-2 recognizes that stroke symptoms are protean 
and not well suited to a pre-specified itemized listing. Accordingly, VARC-2 recommends 
that a vascular neurologist experienced in clinical trials involving stroke be included in all 
phases of trial planning, execution, and monitoring, including involvement in the Clinical 
Events Committee and the Data and Safety Monitoring Board.
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New insights into the timing of events show delayed or late occurrence of strokes, beyond 
the early post-implantation phase.27 This may suggest that the cause of stroke is additionally 
related to other factors or patient susceptibilities and should necessitate active investigation 
of devices and adjunctive pharmacotherapy to reduce the frequency and severity of strokes 
after TAVI, including precise documentation of the use and dosage of antithrombotic and 
antiplatelet medication. Patient baseline characteristics (e.g. carotid stenosis) and postop-
erative complications (e.g. AF) need to be carefully documented to be able to identify the 
contributing causes of stroke.
Invasive stroke management (catheter-based intracranial intervention) is gaining an 
increasingly important role and may impact morbidity and mortality. Valve Academic 
Research Consortium-2 therefore recommends the ascertainment of any acute stroke man-
agement strategy (e.g. aspiration, thrombolysis, or conservative management).
bleeding complications
Valve Academic Research Consortium-2 acknowledges the fact that the Bleeding Academic 
Research Consortium (BARC) recently convened and established standardized bleeding 
define-tions for patients receiving antithrombotic therapy and undergoing coronary revas-
cularization (PCI or CABG).28, 29 However, because the current definitions have been well 
adopted and shown to be accurate in predicting adverse events,30 VARC-2 has chosen to 
maintain the original VARC definitions with BARC classifications (Table 5), recognizing that 
table 5 bleeding
life-threatening or disabling bleeding
Fatal bleeding (BARC type 5) OR
Bleeding in a critical organ, such as intracranial, intraspinal, intraocular, or pericardial necessitating 
pericardiocentesis, or intramuscular with compartment syndrome (BARC type 3b and 3c) OR
Bleeding causing hypovolemic shock or severe hypotension requiring vasopressors or surgery (BARC 
type 3b) OR
Overt source of bleeding with drop in haemoglobin of ≥5 g/dL or whole blood or packed red blood cells 
(RBCs) transfusion ≥4 units* (BARC type 3b)
Major bleeding (BARC type 3a)
Overt bleeding either associated with a drop in the haemoglobin level of at least 3.0 g/dL or requiring 
transfusion of 2 or 3 units of whole blood/RBC, or causing hospitalization or permanent injury, or 
requiring surgery AND
Does not meet criteria of life-threatening or disabling bleeding
Minor bleeding (BARC type 2 or 3a, depending on the severity)
Any bleeding worthy of clinical mention (e.g. access site haematoma) that does not qualify as life-
threatening, disabling, or major
*Given one unit of packed RBC typically will raise haemoglobin concentration by 1 g/dL, an estimated decrease in 
haemoglobin will be calculated. BARC = Bleeding Academic Research Consortium 29; RBC = red blood cell
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future validation of BARC criteria in this population may warrant revision of the current 
recommendations. 
With respect to blood transfusions, it is critical to acknowledge that a bleeding com-
plication has to be the result of overt bleeding and cannot be adjudicated based on blood 
transfusions alone.
Acute kidney injury
The original VARC definitions recom-mended the use of a modified version of the RIFLE 
classification. However, we now recommend using the AKIN system (Table 6), which is a 
modified version of RIFLE that has been adopted by many in the nephrology community, 
including the KDIGO initiative.21, 31 As a result, acute kidney injury (AKI) can also be diag-
nosed according to urine output measures (Table 6).
In comparison with the original VARC, the timing for the diagnosis of AKI is extended 
from 72 h to 7 days. Patients who experience AKI should have follow-up renal function 
assessments after 7 days until stabilization.
vascular complications
Table 7 lists VARC-2 definitions for major and minor vascular complications. Further 
clarifications of these definitions to supplement the original VARC document are as fol-
lows. Pre-planned surgical access or a planned endovascular approach to vascular closure 
(e.g. ‘pre- closure’) 33, 34 should be considered as part of the TAVI procedure and not as 
a complication, unless untoward clinical consequences are documented (e.g. bleeding 
complications, limb ischemia, distal embolization, or neurological impairment). Unplanned 
endovascular stenting or surgical repair for any vascular complications during the index 
table 6 Acute kindey injury (AKIn classification*).
stage 1 
Increase in serum creatinine to 150–199% (1.5–1.99 × increase compared with baseline) OR increase of 
≥0.3 mg/dL (≥26.4 mmol/L) OR
Urine output <0.5 ml/kg per hour for >6 but <12 hours
stage 2 
Increase in serum creatinine to 200–299% (2.0–2.99 × increase compared with baseline) OR
Urine output <0.5 ml/kg per hour for >12 but <24 hours
stage 3†
 Increase in serum creatinine to ≥300% (>3 × increase compared with baseline) OR serum creatinine of 
≥4.0 mg/dL (≥354 mmol/L) with an acute increase of at least 0.5 mg/dL (44 mmol/L) OR
Urine output <0.3 ml/kg per hour for ≥24 hours OR
Anuria for ≥12 hours
The increase in creatinine must occur within 48 hours. *Mehta et al.31 †Patients receiving renal replacement therapy 
are considered to meet Stage 3 criteria irrespective of other criteria.
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procedure without other clinical sequelae should be considered a minor vascular complica-
tion, except if associated with qualifying consequences (Table 7). Complications related to 
alternative access sites, including the left-ventricular apex, subclavian artery, or aorta should 
be systematically recorded. To ensure accurate capture of these elements, VARC-2 strongly 
recommends that detailed information regarding the access site and pre-planned vascular 
closure technique be recorded as well as the use of any additional unplanned access or 
closure techniques (surgical repair, endovascular stenting, or endovascular balloon therapy). 
Since many vascular complications will also result in a bleeding complication, events that 
meet VARC-2 definitions for both categories should be reported in both categories. Finally, 
VARC-2 recommends that all vascular complications be recorded as either access (e.g. iliac 
rupture) or non-access site-related (e.g. ascending aorta dissection or rupture unless aortic 
access is used and the event originates from the cannulation site).
conduction disturbances and arrhythmias
Valve Academic Research Consortium-2 proposes the systematic collection of data on 
the frequency of implant-related new and/or worsened conduction disturbances and the 
table 7 vascular access site and access-related complications
Major vascular complications
Any aortic dissection, aortic rupture, annulus rupture, left ventricle perforation, or new apical aneurysm/
pseudo-aneurysm OR
Access site or access-related vascular injury (dissection, stenosis, perforation, rupture, arterio-venous 
fistula, pseudoaneurysm, hematoma, irreversible nerve injury, compartment syndrome, percutaneous 
closure device failure) leading to death, life-threatening or major bleeding*, visceral ischaemia or 
neurological impairment OR
Distal embolization (non-cerebral) from a vascular source requiring surgery or resulting in amputation or 
irreversible end-organ damage OR
The use of unplanned endovascular or surgical intervention associated with death, major bleeding, 
visceral ischaemia or neurological impairment OR
Any new ipsilateral lower extremity ischemia documented by patient symptoms, physical exam, and/or 
decreased or absent blood flow on lower extremity angiogram OR
Surgery for access site-related nerve injury OR
Permanent access site-related nerve injury OR
Minor vascular complications
Access site or access-related vascular injury (dissection, stenosis, perforation, rupture, arterio-venous 
fistula, pseudoaneuysms, hematomas, percutaneous closure device failure) not leading to death, life-
threatening or major bleeding*, visceral ischaemia or neurological impairment OR
Distal embolization treated with embolectomy and/or thrombectomy and not resulting in amputation or 
irreversible end-organ damage OR
Any unplanned endovascular stenting or unplanned surgical intervention not meeting the criteria for a 
major vascular complication OR
Vascular repair or the need for vascular repair (via surgery, ultrasound-guided compression, transcatheter 
embolization, or stent-graft) OR
percutaneous closure device failure
Failure of a closure device to achieve hemostasis at the arteriotomy site leading to alternative treatment 
(other than manual compression or adjunctive endovascular ballooning)
*Refers to VARC bleeding definitions 
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incidence and indication for permanent pacemaker implantation (Table 8). In addition, the 
frequency of specific arrhythmias following TAVI should be recorded as they may result 
in prolonged hospitalization and impaired clinical outcomes. New-onset AF (or flutter) is 
diagnosed as any arrhythmia within hospitalization that has the ECG characteristics of AF 
and lasts sufficiently long to be recorded on a 12-lead ECG, or for at least 30 s on a rhythm 
strip.35 The therapeutic approach to new-onset AF (spontaneous conversion, electrical or 
medical cardioversion, 
initiation of oral anticoagulation, and rate or rhythm control medications) and any clini-
cal consequences should be thoroughly documented in the case report form.
other tAvI-related complications
The original VARC document recommended the collection of a number of TAVI-related 
complications, but did not provide specific endpoint definitions for several endpoints. Valve 
Academic Research Consortium-2 recommends reporting any other complications related 
to the TAVI procedure, even those occurring less frequently, and provides formal VARC-2 
definitions (Table 9).36-38
Additional considerations
For studies or trials where the occurrence, prevention, or treatment of cerebral infarction is a 
fundamental feature (e.g. embolic protection devices) additional appropriate imaging in all 
or a subset of patients may be necessary to allow determination of effectiveness.
table 8 conduction sisturbances and arrhythmias
Up to 72 h, continuous rhythm monitoring is recommended in order to maximize detection of arrhythmias
Data elements to be collected should include:
Baseline conduction abnormalities, paroxysmal or permanent atrial fibrillation (or flutter), and presence 
of permanent pacemaker* 
Implant-related new or worsened cardiac conduction disturbance (new or worsened first degree 
atrioventricular (AV) block, second degree AV block (Mobitz I or Mobitz II), third degree AV block, 
incomplete right bundle branch block, right bundle branch block, intraventricular conduction delay, 
left bundle branch block, left anterior fascicular block, or left posterior fascicular block, including 
block requiring permanent pacemaker implant
Persistent or transient high degree AV block. High grade AV block is persistent if  it is present every time 
the underlying rhythm is checked
New permanent pacemaker implantation, with precision of the indication and number of days post-
implant of placement of new permanent pacemaker
New-onset atrial fibrillation (or flutter)† 
Any new arrhythmia resulting in hemodynamic instability or requiring therapy‡ 
‡ Therapy includes electrical/medical cardioversion or initiation of a new medication (oral anticoagulation, rhythm 
or rate controlling therapy). * Type of permanent pacemaker should be recorded (e.g. defibrillator, single versus 
dual chamber, biventricular) † New-onset atrial fibrillation (or flutter)* is diagnosed as any arrhythmia within 
hospitalization that has the ECG characteristics of atrial fibrillation (or flutter) and lasts sufficiently long to be 
recorded on a 12-lead ECG, or at least 30 seconds on a rhythm strip.
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table 9 other tAvI-related complications
conversion to open surgery
Conversion to open sternotomy during the TAVI procedure secondary to any procedure-related 
complications
unplanned use of cardiopulmonary bypass (cpb)
Unplanned use of CPB for hemodynamic support at any time during the TAVI procedure
coronary obstruction
Angiographic or echocardiographic evidence of a new, partial or complete, obstruction of a coronary 
ostium, either by the valve prosthesis itself, the native leaflets, calcifications, or dissection, occurring 
during or after the TAVI procedure
ventricular septal perforation
Angiographic or echocardiographic evidence of a new septal perforation during or after the TAVI 
procedure
Mitral valve apparatus damage or dysfunction
Angiographic or echocardiographic evidence of new damage (chordae papillary muscle, or to the 
leaflet) to the mitral valve apparatus or dysfunction (e.g. restrictions due to the THV) of the mitral valve 
during or after the TAVI procedure
cardiac tamponade
Evidence of a new pericardial effusion associated with hemodynamic instability and clearly related to 
the TAVI procedure 
endocarditis
Any one of the following:
Fulfillment of the Duke endocarditis criteria*
Evidence of abscess, paravalvular leak, pus, or vegetation confirmed as secondary to infection by 
histological or bacteriological studies during a re-operation
Findings of abscess, pus, or vegetation involving a repaired or replaced valve during an autopsy
valve thrombosis
Any thrombus attached to or near an implanted valve that occludes part of the blood flow path, 
interferes with valve function, or is sufficiently large to warrant treatment. Note that valve-associated 
thrombus identified at autopsy in a patient whose cause of death was not valve-related should not be 
reported as valve thrombosis
valve malpositioning
valve migration
After initial correct positioning, the valve prosthesis moves upward or downward, within the aortic 
annulus from its initial position, with or without consequences
valve embolization
 The valve prosthesis moves during or after deployment such that it loses contact with the aortic 
annulus
ectopic valve deployment
 Permanent deployment of the valve prosthesis in a location other than the aortic root
tAv-in-tAv deployment
An additional valve prosthesis is implanted within a previously implanted prosthesis because of 
suboptimal device position and/or function, during or after the index procedure
* Durack et al.73 TAVI = transcatheter aortic valve implantation; THV = transcatheter heart valve
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vAlvulAr functIon
Valve Academic Research Consortium-2 maintains the original recommendations to use 
echocardiography as the primary imaging modality for the assessment of prosthetic valve 
function.39 This should include the valve position, morphology, function, and evaluation of 
the left ventricle (LV) and right ventricle (RV) size and function. The suggested time points for 
routine follow-up transthoracic echocardiography (TTE) following valve implantation are: 
immediately (before discharge) following the implantation for transarterial approaches or 
within 30 days for transapical or transaortic approaches, 6 months following implantation, 1 
table 10 prosthetic valve dysfunction
prosthetic aortic valve stenosis*
normal Mild stenosis Moderate/severe stenosis
quantitative parameters (flow-dependent)†
Peak velocity <3 m/s 3-4 m/s >4 m/s
Mean gradient <20 mmHg 20-40 mmHg >40 mmHg
quantitative parameters (flow-independent) 
Doppler velocity index‡ >0.35 0.35-0.25 <0.25
Effective orifice area¶ >1.1 cm2 1.1-0.8 cm2 <0.8 cm2
Effective orifice area§ >0.9 cm2 0.9-0.6 cm2 <0.6 cm2
prosthesis-patient mismatch (ppM)
Insignificant Moderate severe
Indexed effective orifice area** >0.85 cm2/m2 0.85-0.65 cm2/m2 <0.65 cm2/m2
Indexed effective orifice area†† >0.70 cm2/m2 0.90-0.60 cm2/m2 <0.60 cm2/m2
prosthetic aortic valve regurgitation
Mild Moderate severe
semi-quantitative parameters
Diastolic flow reversal in the 
descending aorta—PW 
Absent or brief 
early diastolic
Intermediate Prominent, holodiastolic
Circumferential extent of 
prosthetic valve paravalvular 
regurgitation (%)¶¶
<10% 10-29% ≥30%
Quantitative Parameters‡
Regurgitant volume (ml/beat) <30 ml 30-59 ml ≥60 ml
Regurgitant fraction (%) <30% 30-49% ≥50%
EROA (cm2) 0.10 cm2 0.10-0.29 cm2 ≥0.30 cm2
*In conditions of normal or near normal stroke volume (50–70 mL). †These parameters are more 
affected by flow, including concomitant aortic regurgitation. ‡For LVOT >2.5 cm, significant stenosis 
criteria is <0.20. ¶Use in setting of BSA ≥1.6 cm2 (note: dependent on the size of the valve and the 
size of the native annulus). §Use in setting of BSA <1.6 cm2. **Use in setting of BMI <30 kg/cm2. 
††Use in setting of BMI ≥30 kg/cm2. ¶¶Not well-validated and may overestimate severity compared 
to quantitative Doppler.
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year following implantation, and yearly thereafter. At these endpoints, prosthetic aortic valve 
stenosis and regurgitation should be reported.
transcatheter valve stenosis
The assessment of prosthetic valve stenosis should be an integrative process utilizing multiple 
parameters of valve function. Table 10 outlines the primary parameters used for assessing 
prosthetic valve function based on published guidelines.40 Divergence from the guidelines 
is based on a number of studies,41, 42 as well as methods used in large randomized control 
trials of TAVI.43, 44 In addition, VARC-2 does not recommend using acceleration time, which 
is dependent on ventricular function and heart rate.42 The limitation of flow-dependent 
parameters such as peak jet velocity or mean transprosthetic gradient is obvious, however, 
even flow-independent parameters such as the effective orifice area (EOA) and the Doppler 
velocity index (DVI) have limitations: (i) the absolute EOA does not account for the cardiac 
output requirements in relation to the patient’s body size; thus lower criteria should be used 
to define prosthetic valve stenosis in patients with BSA <1.6 m2 (Table 10), (ii) the indexed 
EOA may overestimate the valve-related hemodynamic burden in obesity; hence, lower 
criteria may be more appropriate in patients with a body mass index >30 kg/m2, (iii) DVI 
severity criteria are dependent on the left ventricular outflow tract (LVOT) size; thus a lower 
threshold may be more appropriate in patients with LVOT diameters of >25 mm. The EOA 
should generally be calculated with the use of the LVOT diameter and the velocity measured 
just underneath the apical margin of the valve stent.45, 46 In cases where the landing zone of 
the stent is low in the LVOT, the diameter and velocity may both be measured in the proxi-
mal portion of the stent. Unlike the surgically implanted valve, the transcatheter prosthetic 
valve EOA is defined not only by the size of the valve but also by the patient’s aortic valve/ 
annular anatomy and procedural variables. Thus, well-established normal transcatheter 
valve gradients and EOAs based on pre-implant aortic annular dimensions do not currently 
exist. Clinicians should be aware of this variability when assessing a patient for transcatheter 
valve function and VARC-2 strongly recommends that the patient’s own initial post-implant 
study be used as a reference for serial comparisons.
The assessment of transcatheter valve dysfunction includes the immediate post-TAVI 
hemodynamics and the follow-up evaluation. The immediate post-TAVI evaluation docu-
ments initial valve appearance (position and circularity of the stent, and leaflet morphology 
and motion) and a comprehensive hemodynamic evaluation. Valve Academic Research 
Consortium-2 advocates using the integrative approach outlined in the algorithm shown in 
Figure 4 as part of a comprehensive hemodynamic evaluation by initially using one flow 
dependent (e.g. mean gradient) and one flow independent criterion (e.g. EOA) for the initial 
hemodynamic evaluation. If there is discordance between these measurements, then the 
DVI should be calculated. An abnormal DVI indicates possible prosthetic valve dysfunction. 
A normal DVI indicates intrinsically normal prosthetic valve function, and the indexed EOA 
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can then be used to determine the reason for the initial measurement discordance. When 
the indexed EOA is low in the setting of a normal DVI, the patient probably has a prosthesis-
patient mismatch (PPM), an indicator of the intrinsic relationship of the implanted valve 
to the cardiac output requirements of the patient.47 Prosthesis-patient mismatch occurs in 
the setting of a morphologically normal valve and is considered to be hemodynamically 
insignificant if the indexed EOA is >0.85 cm2/m2, moderate if between 0.65 and 0.85 cm2/
m2, and severe if <0.65 cm2/m2. However, for obese patients (body mass index >30 kg/m2) 
lower criteria may be more appropriate (Table 10).
transcatheter valve regurgitation
There is growing evidence suggesting a significant association of post-procedural paraval-
vular aortic regurgitation (AR) with short- and long- term mortality.48, 49 As the duration of 
implanted transcatheter heart valves increases, valve durability and dysfunction become 
more crucial issues. Evaluating the presence and severity of regurgitation should include an 
assessment of both central and paravalvular components, with a combined measurement 
of ‘total’ aortic regurgitation (AR) reflecting the total volume load imposed on the LV (Table 
10). The quantitative and semi-quantitative hemodynamic assessment of AR severity should 
be performed with Doppler echocardiography according to the guidelines.39, 50, 51 Color 
figure 4 transcatheter heart valve hemodynamic evaluation algorithm
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Doppler evaluation should be performed just below the valve stent for paravalvular jets, 
and at the coaptation point of the leaflets for central regurgitation. Although all imaging 
windows should be used, the parasternal short-axis view is critical in assessing the number 
and severity of paravalvular jets. Whenever possible, the quantification of the prosthetic 
regurgitant volume, effective regurgitant orifice area, and regurgitant fraction (Table 10) 
should be performed.40, 51, 52 The regurgitant volume may be calculated as the difference 
between the stroke volume across any non-regurgitant orifice (RVOT or mitral valve) and the 
stroke volume across the LVOT.
It is important to realize that at this time the body of evidence supporting the numerical 
criteria used in Table 10 as well as Figure 4 may be limited. These criteria should be used 
as guidelines for clinical decision-making and require further validation as our experience 
continues to expand.
follow-up assessments
The follow-up assessment should also begin with valve imaging and documentation of 
changes in morphology. When determining whether a patient has developed hemody-
namically significant structural valve failure, the patient’s own baseline echocardiographic 
parameters should be used as a reference. An increase in the mean gradient >10 mm Hg, a 
decrease in the EOA >0.3–0.4 cm2, or a reduction in the DVI >0.1–0.13 probably indicates 
a change in valve function and should trigger a comprehensive hemodynamic evaluation. 
Whenever valve dysfunction is suspected, the careful evaluation of valve morphology should 
confirm a structurally abnormal valve. In addition, measurement error must be excluded; 
the use of a consistent LVOT diameter for more accurate follow-up study comparisons is 
recommended. Finally, changes in ventricular morphology would be expected in the setting 
of long-standing significant valvular dysfunction and this parameter may support the clinical 
assessment of severity.
Although the rate of moderate or severe regurgitation may appear to be less at the follow-
up, this may be the result of attrition of the sickest patients. To assess such time trends, it is 
recommended to report an individual patient’s progression of regurgitation, in a table that 
provides changes between short-term and long-term regurgitation, including mortality.48
quAlIty of lIfe
quality of life evaluation in aortic stenosis
New York Heart Association (NYHA) classification is limited by the discrete nature of the 
scale, which provides only modest resolution to detect clinically relevant changes. More-
over, since the NYHA class is assessed by an external body rather than the patient, it does 
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not reflect the patient’s perspective. Thus, the NYHA class is more properly considered a 
measure of the functional status than the QOL.
The Minnesota Living with Heart Failure Questionnaire (MLHF) 53 and the Kansas City 
Cardiomyopathy Questionnaire (KCCQ) 54, 55 have a number of desirable properties for the 
evaluation of health-related QOL (HRQOL) in the setting of AS. Both instruments produce 
outcomes on a continuous scale, which improves responsiveness and sensitivity. Although 
only the MLHF has been specifically validated in patients with aortic valve disease,56 pre-
liminary experience with the KCCQ in patients undergoing TAVI has also demonstrated a 
high degree of responsiveness and internal consistency.57
recommended endpoints and timing of assessment
Valve Academic Research Consortium-2 recommends that a comprehensive assessment 
of HRQOL for patients undergoing TAVI incorporate both a heart failure-specific measure 
(such as the KCCQ or MLHF) as well as one or more generic measures [such as the Medical 
Outcomes Study Short-Form 36 (SF-36), the Short-Form 12 (SF-12), or the EuroQOL (EQ-
5D)].58-60 The disease-specific measures offer improved sensitivity/responsiveness as well as 
clinical interpretability, whereas the inclusion of a generic health status measure is useful 
because it captures some additional domains. Furthermore, generic measures can enhance 
the comparability across different diseases and populations and can be used to compare 
patients with population-level benchmarks.
For the comparison of TAVI vs. SAVR (or for the comparison of alternative access sites for 
TAVI), we recommend that early QOL assessment be performed at 2 weeks, 1 month, and 
3 months using a combination of generic instruments and pain scales (e.g. visual analogue 
scale) to assess the early recovery process. The evaluation of the QOL at an intermediate 
time point (e.g. 6 months) could also be considered in order to confirm that QOL recovery 
is complete by this stage. At later time points (1–5 years), the use of heart failure-specific 
instruments to identify the consequences of long-term valve performance may be more use-
ful. Finally, the assessment of cognitive function at later time points (1–5 years) may be valu-
able for the comparison of surgical vs. catheter-based techniques, although these endpoints 
generally require highly specialized and demanding neuropsychiatric testing.61 In contrast, 
for the comparison of alternative TAVI systems (as may be expected in the near future), 
HRQOL assessment should focus mainly on heart failure-specific endpoints at intermediate 
and later time points (1–5 years), wherein between-device differences in the hemodynamic 
performance or structural valve deterioration may emerge. The inclusion of disease-specific 
QOL measures in these studies can also provide insight into the consequences of valve-
related complications such as the need for pacemaker insertion.
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Additional considerations
It is essential to ensure complete ascertainment of HRQOL at each time point, as missing 
data cannot be retrieved retrospectively and statistical adjustment techniques (e.g. multiple 
imputation) that assume that data are ‘missing at random’ may not be adequate. Differential 
mortality between two treatments may complicate the interpretation of QOL results since 
the QOL may appear to ‘improve’ over time even with an ineffective therapy simply because 
of attrition of the sickest patients. The use of categorical endpoints that characterize out-
comes as favorable (e.g. survival AND improvement of QOL endpoints) 44, 57 or endpoints 
that integrate survival and the QOL (e.g. quality-adjusted life expectancy) may provide more 
interpretable results. In such cases, reporting the outcomes in both ways (i.e. among the 
entire study cohort and separately among only the surviving patients) will provide the most 
complete description of the results.
coMposIte endpoInts
rationale and caveats
Comparisons of the success, safety, and effectiveness with achievable study cohort sample 
sizes may at times require the use of composite endpoints. However, it is important that 
composites contain components that have roughly similar impacts on the patient. A family 
of single endpoints tending in the same direction may, as a family of hypotheses, be statisti-
cally significant when individual endpoints are not.
Each post-procedural event has a different temporal risk profile (hazard function) 
modulated by different risk factors. Therefore, traditionally, the evaluation of the safety and 
efficacy of procedures has focused on in-hospital events (complications and morbidity), 
events within 30 days of the procedure, and ‘late’ events.
specific composite endpoints
The assessment of TAVI, SAVR, and their alternatives or new devices should include device, 
procedure, and patient-oriented endpoints. These endpoints have been devised to be appli-
cable to both TAVI and SAVR. Previous clinical trials have used the all-cause mortality at 
1 year as the primary clinical endpoint. Owing to the emergence of stroke as an important 
clinical event, future trials should also require the composite of all-cause mortality and 
disabling stroke as a primary or secondary endpoint.
The first VARC document proposed three composite endpoints: device success, early 
safety, and clinical efficacy. Valve Academic Research Consortium-2 goes beyond the early 
and intermediate experience of TAVI, drawing upon prior surgical AVR guidelines to include 
time-related safety endpoints.62 Therefore, VARC-2 recommends a new composite endpoint, 
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time-related valve safety, which combines valve dysfunction, endocarditis, and thrombotic 
complications of the prosthesis (Table 11).
table 11 composite endpoints
device success
Absence of procedural mortality AND
Correct positioning of a single prosthetic heart valve into the proper anatomical location AND
Intended performance of the prosthetic heart valve (no prosthesis-patient mismatch* and mean aortic 
valve gradient <20 mmHg or peak velocity <3 m/s, AND no moderate or severe prosthetic valve 
regurgitation*)
early safety (at 30 days)
All-cause mortality
All stroke (disabling and non-disabling)
Life-threatening bleeding
Acute kidney injury—Stage 2 or 3 (including renal replacement therapy) 
Coronary artery obstruction requiring intervention
Major vascular complication
Valve-related dysfunction requiring repeat procedure (BAV, TAVI, or SAVR)
clinical efficacy (after 30 days)
All-cause mortality
All stroke (disabling and non-disabling)
Requiring hospitalizations for valve-related symptoms or worsening congestive heart failure†
NYHA class III or IV
Valve-related dysfunction (mean aortic valve gradient ≥20 mmHg, EOA ≤0.9-1.1 cm2‡ and/or 
DVI<0. 35m/s, AND/OR moderate or severe prosthetic valve regurgitation*)
time-related valve safety
Structural valve deterioration:
Valve-related dysfunction (mean aortic valve gradient ≥20 mmHg, EOA ≤0.9-1.1 cm2‡ and/or 
DVI<0.35m/s, AND/OR moderate or severe prosthetic valve regurgitation*)
Requiring repeat procedure (TAVI or SAVR)
Prosthetic valve endocarditis
Prosthetic valve thrombosis
Thromboembolic events (e.g. stroke)
VARC bleeding, unless clearly unrelated to valve therapy (e.g. trauma)
*Refers to VARC definitions. †As basis for calculation of “days alive outside the hospital” endpoint. Supplementary 
appendix of Leon et al.74 Includes heart failure, angina or syncope due to aortic valve disease requiring intervention 
or intensified medical management; clinical symptoms of CHF with objective signs including pulmonary edema, 
hypoperfusion or documented volume overload AND administration of IV diuresis or inotropic therapy, performance 
of aortic valvuloplasty, institution of mechanical support (IABP or ventilation for pulmonary edema) or hemodialysis 
for volume overload; clear documentation of anginal symptoms AND no clinical evidence that angina was related 
to CAD or ACS; documented loss of consciousness not related to seizure or tachyarrhythmia. ‡Depending on body 
surface area. BAV = balloon aortic valvuloplasty; TAVI = transcatheter aortic valve implantation; SAVR = surgical 
aortic valve replacement
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dIscussIon
Although the original VARC standardized endpoint definitions were fundamentally useful 
and have been widely adopted, growing experience with TAVI studies has identified some 
definitions as ambiguous, of limited clinical utility, or in need of updating or extension.5, 6, 
63, 64 This need provided the rationale for a VARC-2 document with such improvements and 
additions. As was the case with the original VARC process, it should be emphasized that this 
consensus manuscript is not intended to be a guidelines document, but rather a practical 
tool to facilitate and inform clinical research in TAVI.
Current clinical trials are focusing more on intermediate risk patients, and more stud-
ies are comparing TAVI with surgical AVR. Therefore, it becomes increasingly important to 
identify those patients who benefit from either treatment. Specific risk categories have been 
defined to allow universal clinical study designs and outcome comparisons.
Changes and additions that have been applied to improve the interpretation of clinical 
endpoint definitions and provide further insights on TAVI-related outcomes are as follows: 
(i) risk stratification should be done by a dedicated ‘heart team’ and include other factors 
(e.g. frailty, porcelain aorta) beyond the traditional risk scores, and should take into account 
co-existing conditions; (ii) immediate procedural mortality has been added to capture intra-
procedural events that result in immediate or consequent death; (iii) stroke ascertainment 
requires the use of precise definitions, standardized assessments, close collaboration with 
neurology experts including the consideration of acute stroke management, and has been 
re-categorized asnon-disabling or disabling; (iv) detailed documentation of the etiology 
of strokes and concomitant therapies is needed to provide insights into the multi-factorial 
nature of acute, early, and late strokes; (v) closure device failure is now a separate category 
within vascular complications, and if unplanned percutaneous or surgical intervention 
does not lead to adverse outcomes, these are not considered as a major vascular compli-
cationper se; (vi) the time for AKI diagnosis has been extended from 72 h to 7 days; (vii) 
AKI is diagnosed according to AKIN guidelines, which include classification by the urine 
output to detect a wider range of etiologies; (viii) peri-procedural myocardial infarction is 
defined by troponin or CK-MB elevation and the troponin threshold has changed from 10× 
ULN to 15× ULN based on recent data;19 (ix) assessment of conduction disturbances and 
arrhythmias has been reinforced;65-68 (x) new definitions for several TAVI-related complica-
tions and valve malpositioning are reported; (xi) echocardiography parameters of prosthetic 
valve stenosis and regurgitation have been updated and now include the assessment of the 
prosthesis-patient mismatch; (xii) for the QOL assessment, VARC-2 recommends the use 
of both heart failure-specific and generic measures during the follow-up between 30 days 
and 5 years to fully assess the impact of the procedure and the durability of clinical benefit. 
These definitions can be used in studies comparing TAVI to surgical AVR, as well as in future 
trials comparing first generation to next generation TAVI devices.
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The composite endpoint of device success has specifically been criticized for being too 
strict with regard to valve performance; for example, an AVA >1.2 cm2 seems unachievable 
in patients with smaller body habitus.5 The current VARC-2 definition therefore corrects 
for the body surface area so that valve performance is now assessed through the indexed 
EOA. It is notable that valve-in-valve procedures for failing bioprostheses will frequently 
have a low device success, even with this modified definition.69 Considering that stroke has 
emerged as an important concern, the composite of all-cause mortality and disabling stroke 
should be considered as a primary or secondary endpoint in future trials. Two ongoing large 
randomized trials [PARTNER II (NCT01314313) and SURTAVI (NCT01586910)] are already 
incorporating these composite endpoints.
With longer follow-up duration, it becomes more critical to include time-related valve 
safety composite endpoints. This will eventually provide linearized rates of complications 
with transcatheter valves, known as ‘objective performance criteria’, as has been used to 
evaluate surgical valves.70
conclusIons 
With this VARC-2 document, we have provided further standardization of endpoint defini-
tions and hope that the adoption of these criteria will continue to increase, ultimately lead-
ing to improved comparability and interpretability of the study results.32
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Patient selection and decision-making
Risk stratification in cardiac surgery has significant limitations. Current research is devoted 
to increase the predictability of risk models and its usefulness in decision-making. The new 
EuroSCORE II failed to be superior over the earlier additive and logistic EuroSCORE models 
in an analysis that included high-risk patients (Chapter 3). This may be the result of the lack 
of relevant risk factors in current risk models. For this reason, the European Association for 
Cardiothoracic Surgery has initiated a quality improvement programme with the objective to 
produce a new risk model.1 The first step of this process was to perform a systematic review 
of the literature to identify all independent predictors of mortality, stroke, renal failure, and 
length of stay after adult cardiac surgery (chapter 6). We found a great number of variables 
that are usually not taken into consideration; these factors could be used as a framework for 
future risk model development.
One of the risk factors that showed to be a predictor of adverse events was the SYNTAX 
Score.2 The SYNTAX Score is an angiographic anatomical risk model specifically designed 
to quantify the complexity of coronary artery disease. Several studies have proven its predic-
tive power in patients undergoing percutaneous intervention, but it fails to be a predictor in 
patients undergoing bypass surgery (Chapter 7). It showed to be useful in decision-making, 
differentiating between percutaneous coronary intervention and coronary artery bypass 
grafting (Chapter 18). 
We reviewed the literature on coronary revascularization and found that a great number 
of patients receive inappropriate revascularization, or are treated medically when there is 
an indication for revascularization (Chapter 9). These factors were associated with increased 
mortality during follow-up, and higher rates of myocardial infarction and recurrent angina. 
Therefore, to improve decision-making, the most recent American and European revascular-
ization guidelines recommend multidisciplinary Heart Team decision-making with a class 
IC recommendation.3, 4 The rationale behind the Heart Team is that a team consisting of 
at least a clinical/non-invasive cardiologist, interventional cardiologist, and cardiovascular 
surgeon, can better analyze and interpret the available diagnostic evidence, put into context 
the clinical condition of the patient as well as consider individual preference and local 
expertise, and through shared decision-making with the patient can arrive at a most optimal 
joint treatment strategy recommendation for patients with stable complex coronary artery 
disease (Chapters 8-9).
surgical or transcatheter treatment for aortic stenosis
Surgical aortic valve replacement has been the standard of care for patients with symptom-
atic severe aortic stenosis. Since the introduction of transcatheter aortic valve implantation 
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(TAVI) in 2002,5 the Heart Team evaluates patients with aortic stenosis. Transcatheter heart 
valve therapy has been a rapidly evolving technology. When compared to Europe, adoption 
of TAVI in the United States has been slower. The need for more rigorous data from random-
ized studies has led to the PARTNER trials.6, 7 Transcatheter aortic valve implantation was not 
only superior over medical therapy in patients deemed at prohibitive operative risk, it was 
also non-inferior to surgical valve replacement in patients at high operative risk for surgery. 
Nevertheless, despite its established role, continuous evaluation remains critical 
(Chapters 12-15). There are several complications that occur with high regularity. In a meta-
analysis we performed with data from 16 unique studies that included a total of 3,519 
patients, the pooled rate of major stroke was 3.2%, acute kidney injury stage II/III was 7.8%, 
major vascular complications was 11.9%, and life-threatening bleeding occurred in 15.6% 
of patients (Chapter 12). The relatively high rate of stroke led to a debate, but other com-
plications such as paravalvular leakage and permanent pacemaker implantations still cause 
some skepticism around transcatheter therapy. Especially since these complications hardly 
occur after aortic valve replacement (Chapter 11). However, apart from being less invasive, 
an advantage of transcatheter heart valves is the improved hemodynamics as compared to 
surgical valves. Prosthesis-patient mismatch occurs less frequently after transcatheter aortic 
valve implantation than after aortic valve replacement, which may pose a benefit in long-
term survival (Chapter 10).
Where surgical heart valves have shown to last about 12-15 years, no such durability 
data is yet available with respect to transcatheter valves. Caution should thus be advised 
to implant these devices in younger patients, although current trials are already performing 
comparative effectiveness studies between transcatheter therapy and surgical aortic valve 
replacement in (younger) patients at intermediate operative risk (Chapters 14 and 16). An 
additional factor that could weigh in when evaluating transcatheter and surgical therapy 
in intermediate risk patients is the cost (Chapter 17). A propensity-matched analysis of 42 
pairs showed that in-hospital costs were significantly higher for patients that underwent 
transcatheter therapy as opposed to those who underwent surgical therapy (€40,802 versus 
€33,354, respectively; p = 0.010). At one year this difference was even more pronounced; 
€46,217 vs €35,511, respectively (p = 0.009). In an era of increasing health care expen-
ditures and an economical crisis, cost-effectiveness considerations become increasingly 
important. Transfemoral aortic valve implantation only showed a quality-adjusted life-year 
gain of 0.068 in patients at high operative risk.8 In intermediate-risk patients the results of 
surgical aortic valve replacement will improve as compared with high-risk patients; the 
benefit of the lower deterrence of transcatheter therapy will be less. It will be interesting to 
see whether the (even more minimal) expected quality-adjusted life-year gain can weigh up 
against the higher costs.
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stenting versus byPass surgery
The SYNTAX trial is the first randomized study to compare percutaneous coronary interven-
tion with drug-eluting stents with coronary artery bypass grafting. The main result of the trial 
was that percutaneous intervention did not show to be non-inferior to bypass surgery at one 
year.9 A secondary analysis of the SYNTAX trial was in patients with and without diabetes 
(Chapter 21). Although previous analyses had shown a significant benefit of bypass surgery 
over percutaneous intervention in patients with diabetes but not in those without,10 the 
results of the SYNTAX trial are a contradiction to that. Bypass surgery was better in both 
patient subgroups, however, diabetes did reinforce the difference between the two treatment 
strategies.
Novel in the design of the SYNTAX trial was the inclusion of nested registry where 
patients were included if either percutaneous or surgical treatment was preferred by the 
Heart Team (Chapter 18). According to the Heart Team, in 58.5% of the patients there was 
expected clinical equipoise between percutaneous and surgical treatment, while in 6.4% 
percutaneous treatment was preferred and in 35.0% surgical treatment. This distribution was 
largely influenced by the preoperative risk of patients, which in the majority of patients in 
percutaneous registry was deemed to be too high for surgical treatment. Patients in whom 
surgical treatment was preferred most often had too complex disease for percutaneous 
treatment. This complexity can probably be correlated to the expected incompleteness 
of revascularization (Chapter 19),11 where the risk of inappropriate incomplete revascu-
larization 12 would be too high in patients with complex lesions (a high SYNTAX Score). 
Incomplete revascularization in patients that are treated with percutaneous intervention is a 
significant predictor of adverse events and should therefore be avoided. These results present 
the contemporary distribution of patients with coronary artery disease as assessed by the 
Heart Team and can be used as a benchmark to compare percutaneous-to-surgical treatment 
ratios across centers and countries.
One of the emphasized results of the SYNTAX trial was the higher cumulative incidence 
of stroke at one year follow-up in patients who underwent bypass surgery (2.2% versus 0.6%; 
p=0.003). With 4-year follow-up, we performed an in-depth analysis of stroke (Chapter 20). 
Interestingly, the short-term difference deluded during follow-up and there was no longer 
a difference between percutaneous and surgical treatment (3.7% versus 2.3%; p=0.07). 
Stroke resulted in death in 3 patients in both the treatment groups. Of the patients who 
developed stroke, 68% (21/31) in the bypass group had residual deficits at discharge; in the 
percutaneous group, 47% (9/19) had residual deficits. This is similar to the recent results of 
the FREEDOM trial.13
However, the SYNTAX trial was performed with a first generation paclitaxel-eluting 
stent, while newer stents have shown significant benefits over these stents (Chapter 22). 
The SYNTAX trial has thus been criticized by being outdated, and it has been suggested 
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that percutaneous coronary intervention would have been non-inferior to bypass surgery 
if everolimus-eluting stents would have been used.14 Nonetheless, bypass surgery in the 
SYNTAX trial might not have been at its best either. The rate of bilateral internal mammary 
artery grafting was only 27.6% and off-pump surgery was performed in 15.0% of cases.15 
Percutaneous coronary intervention can only show to be non-inferior to coronary artery 
bypass grafting in a new trial and it will be up to the surgeons to continue improvements in 
outcomes of bypass surgery as well. 
There are several considerations for surgeons that can improve short- and long-term 
outcomes and/or provide a less invasive surgical option, such as the use of both mam-
mary arteries, minimally invasive bypass surgery, ‘aortic no touch’ surgery, endoscopic vein 
harvesting, but also secondary prevention measures (Chapter 23). Further adoption of these 
techniques and actions could ensure that bypass surgery regains some ground as an attrac-
tive therapy for patients with coronary artery disease, although thorough evaluation of some 
of these relatively new promising strategies should still take place.
interPretation of cardiovascular clinical research
Randomized trials have strict in- and exclusion criteria, while observational studies evalu-
ate therapies in real-world practice. Where randomized trials show treatment feasibility, 
effectiveness, and/or safety in a niche, observational studies include patients without any 
restrictions. Nevertheless, the results of randomized trials are frequently extrapolated out of 
its original validation (Chapter 25), resulting in ‘experimental’ treatment of patient popula-
tions in whom treatment evaluation has not (yet) taken place. Observational studies should 
therefore complement randomized trial data to assess comparative effectiveness in both 
a trial and real-world setting (Chapter 26). Hypothesis-generating observational data can 
furthermore be used to strengthen the results of randomized trials. For example, data sug-
gested that off-pump coronary artery bypass grafting disproportionally benefitted high-risk 
patients. However, a randomized trial of on- versus off-pump surgery did not take these 
data into consideration. The design overestimated the effect of off-pump surgery within a 
population that included a majority of low-risk patients in whom on-pump surgery provides 
excellent results (Chapter 28). 
Research in medicine often seeks a single therapy to treat all patients with a certain con-
dition. However, personalized medicine has emerged over the recent years as an approach 
to provide the best care on an individual patient level. To evolve into such a health care 
setting, one needs to evaluate different therapies in different subgroups of patients with 
specific characteristics or disease subtypes. Frequently data from randomized trials is used 
for these subgroup analyses, although there are considerable limitations to subgroup analy-
ses. They are often underpowered and have limited ability in showing genuine interactions 
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between patient baseline characteristics and treatment effects. In addition, they are often 
not performed correctly and have misleading conclusions. Nevertheless, these limitations 
are often not appreciated, leading to unsubstantiated treatment recommendations that could 
result in suboptimal patient outcomes (Chapter 30). For example, a subgroup analysis of the 
randomized PARTNER trial showed that transfemoral aortic valve implantation was cost-
effective when compared to surgical therapy, while this was not the case for transapical 
aortic valve implantation. These results have discredited transapical therapy even though 
this analysis included only 104 patients and was not powered (Chapter 29).
Another pitfall of randomized trials is the interpretation of a non-inferiority trial (Chapter 
24). As compared to superiority trials, non-inferiority trials are more complex and need 
additional methodological consideration. These trials are designed to show that a new 
therapy is not significantly worse than the standard therapy. However, one should always 
ask themselves“What do I consider to be not significantly worse?” Several aspects should be 
taken into account: the length of follow-up, the type of events, and the margin that quantifies 
the acceptable maximum loss of effectiveness. Even though a group of investigators has 
designed a trial, this does not necessarily corresponds with someone else’s appreciation of 
effectiveness, and the non-inferiority trial design should therefore always be subject to one’s 
own perception.
future research and ProsPects
It will need to be shown that Heart Team decision-making can influence the trade-off 
between surgical and catheter-based interventions, translating into more appropriate 
treatment recommendations and eventually improved clinical outcomes. There is some 
resistance to coronary Heart Teams and so there is a clear need to evaluate its potential. 
However, the true effect on clinical outcomes can be difficult to proof due to the complexity 
of a potential study design. 
Transcatheter aortic valve intervention is here to stay as a treatment option for patients 
at prohibitive or high risk for surgery. How it will serve as an alternative in patients at 
intermediate risk is being investigated in current randomized trials. Furthermore, the coming 
years it will become apparent whether the Valve Academic Research Consortium definitions 
can further increase uniformity among studies of aortic valve interventions (Chapter 31).
Although the SYNTAX trial failed to show non-inferiority of percutaneous coronary 
intervention with drug-eluting stents when compared with coronary artery bypass surgery, 
the more recent generations of drug-eluting stents might show improved comparability to 
bypass surgery. Especially the EXCEL trial will answer part of these questions in the setting 
of left main disease; and also whether the global use of the SYNTAX Score can further be 
enhanced through expanding indications of the score in revascularization guidelines.
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conclusions
This thesis evaluated developments in surgical and catheter-based therapy to treat aortic 
valve disease and coronary artery disease.  Rigorous assessment of randomized trials and 
observational studies are needed to ensure that treatment recommendations are based on 
appropriate results that are properly weighted, based on their design and methodology. 
Hopefully this will results in even more strict guidelines with regard to study designs, as 
well as appreciation of study limitations when interpreting evidence to produce clinical 
guidelines.
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Patient selection and decision-making
Patient selection and decision-making remain essential to ensure good results of therapies. 
Risk models can be helpful in this regard. In chapter 3 the most recent version of the 
EuroSCORE, the EuroSCORE II, is applied to a cohort of high-risk patients that underwent 
cardiac surgery to assess its predictive ability. EuroSCORE II fails to be superior to the original 
additive and logistic EuroSCOREs, and several potential causes are discussed in chapter 4.
On the one hand, risk models can be user-friendly by incorporating a limited number 
of variables, while on the other hand clinically important variables may then be excluded, 
resulting in only limited usefulness. chapter 5 provides an example of a pragmatic risk 
model that can be used to decide whether a patient can better be referred to surgical aortic 
valve replacement or transcatheter aortic valve implantation. In chapter 6 the results of 
a systematic review show that a great number of variables are frequently not considered 
during decision-making and patient selection.
For coronary artery disease, one of the recently emerged risk factors is the SYNTAX 
Score. The SYNTAX Score has proven its ability to predict adverse events after percutaneous 
coronary intervention but not coronary artery bypass grafting. Therefore, the score can be 
used to differentiate between surgical and interventional treatment feasibility, and provides 
a reliable estimate with regard to patient prognosis. chapter 7 provides an overview of the 
SYNTAX Score in the literature.
Treatment decisions can be noticeable influenced by physician-related factors. The 
concept of shared decision-making involving patients and physicians has therefore received 
emphasis over the recent years. Moreover, there is precedence in the field of medicine 
that a multidisciplinary approach to decision-making can furthermore optimize treatment 
recommendations and consequently outcomes. This is discussed in chapters 8 and 9. 
surgical or transcatheter treatment for aortic stenosis?
Surgical aortic valve replacement is the standard treatment for patients with aortic stenosis. 
The choice of valve type translates to postoperative valve function, and too small prostheses 
can cause prosthesis-patient mismatch and mimic aortic stenosis. While the evidence on 
the impact of mismatch on long-term survival has been contradictory, chapter 10 presents 
a meta-analysis that shows a significantly reduction in survival of patients with prosthesis-
patient mismatch.
One of the complications of aortic valve replacement is the need for a pacemaker early 
after surgery. chapter 11 describes the risk of permanent pacemaker implantation during 
follow-up.
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Contemporary detailed data on surgical aortic valve replacement has become even more 
crucial since the introduction of transcatheter aortic valve implantation. As shown in chap-
ter 12, the risk of postoperative complications after transcatheter therapy is considerable. 
This needs to be thoroughly evaluated and compared with surgical treatment. In this regard, 
especially the presence of paravalvular leakage after transcatheter therapy may pose an 
additional risk during follow-up, a factor that is not apparent after aortic valve replacement 
(chapter 13).
chapter 14 summarizes the extensive literature showing the feasibility and evaluation 
of transcatheter aortic valve implantation. It concludes that outcomes have significantly 
improved over the last decade and that transcatheter therapy is an alternative to surgical 
aortic valve implantation for patients at prohibitive or high risk for surgery.
To improve outcomes even further, efforts should be directed to reduce the rate of 
complications. Knowledge of complication rates and predictors are necessary to focus on 
specific aspects of treatment. This is discussed in chapter 15.
The positive results of randomized trials and the widespread enthusiasm around trans-
catheter aortic valve implantation have led to current randomized trials focusing on lower 
risk patients (chapter 16). However, as indications for transcatheter aortic valve implanta-
tion may be expanding, cost considerations become a more important decisive factor during 
decision-making. Particularly in an era of increasing health care expenditures and reduced 
funds due to the economical crisis. This is investigated in chapter 17. 
stenting versus byPass surgery
The introduction of drug-eluting stents has provided an incentive to compare stenting with 
bypass surgery. The SYNTAX trial was the first large-scale trial to do so for treatment of com-
plex coronary artery disease. Moreover, it reinforced the coronary Heart Team for evaluation 
of patients. In chapter 18 the results of Heart Team decision-making are reported, demon-
strating which factors are most decisive in the balance between percutaneous coronary 
intervention and bypass surgery. Further analyses of the SYNTAX trial are provided, focusing 
on the impact of incomplete revascularization in chapter 19, the incidence and outcomes 
of stroke in chapter 20, and diabetic patients in chapter 21.
The SYNTAX trial was performed with a first-generation drug-eluting stent, but several 
new stents have since been developed. In chapter 22 an overview of these new stents 
is provided. However, not only standards for percutaneous coronary intervention have 
evolved over the last decades. A number of surgical techniques have been introduced to 
reduce the invasiveness and complication rate of coronary artery bypass surgery. These and 
other considerations to improve  bypass surgery are discussed in chapter 23.
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interPretation of cardiovascular clinical research
It is crucial to have insights into the methodology and study design of randomized clinical 
trials to be able to correctly interpret the conclusions. Non-inferiority trials are increas-
ingly performed, but these designs are more complex; many readers and even investigators, 
therefore, have difficulty grasping the full nature of non-inferiority trials. chapter 24 is a 
statistical review of recent cardiovascular non-inferiority trials and discusses the aspects that 
need to be taken in consideration when interpreting such trials.
Generalizability and selection bias are issues frequently associated with both randomized 
trials and observational registries. chapters 25-28 provide a number of ‘letters to the editor’ 
in which these issues are discussed in the context of recent studies on revascularization for 
coronary artery disease. Such commentaries are needed to point to study limitations and 
provide awareness of unsubstantiated conclusions. 
chapter 29 asks the question whether treatment recommendations for transcatheter aortic 
valve implantation are based on reliable data. Is transfemoral aortic valve implantation truly 
better than transapical implantation? Or are we inappropriately looking at underpowered 
analyses?
chapter 30 focuses even more specifically on the power of analyses. It addresses sub-
group analyses of trials comparing percutaneous to surgical treatment for complex coronary 
artery disease. Specific attention is directed to these analyses because they are often meth-
odologically flawed. This needs to be emphasized to improve analysis and ensure correct 
interpretation of subgroup data.
imProving clinical research in the future
The comparability of studies can be improved by uniform trial design and endpoint 
definitions. The Academic Research Consortium is a group of clinical experts (including 
surgeons, interventional and non-interventional cardiologists, imaging specialists, neurolo-
gists, geriatricians, and clinical trialists), regulatory bodies, and industry representatives. It 
provides standardized endpoint definitions as a framework for future trials. In the early years 
of transcatheter aortic valve implantation, no harmonized definitions were available. As a 
result, fair comparisons between studies were challenging. chapter 31 is the latest version 
(VARC-2) of endpoint definitions for transcatheter aortic valve implantation.
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Patiënt selectie en besluitvorming
Strikte selectie van patiënten en adequate besluitvorming zijn essentieel voor goede resul-
taten van behandelingen. Risico modellen kunnen hierbij helpen. In hoofdstuk 3 wordt de 
meest recente versie van de EuroSCORE, de EuroSCORE II, toegepast op een groep van hoog 
risico patiënten om de bruikbaarheid van de score te evalueren. De nieuwe EuroSCORE II 
blijkt niet beter dan de eerdere additieve en logistische EuroSCORE, en een aantal oorzaken 
hiervoor worden besproken in hoofdstuk 4.
Enerzijds moeten risico modellen gebruiksvriendelijk zijn door slechts een aantal 
variabelen te includeren, terwijl anderzijds in een te simpel model belangrijke variabelen 
geëxcludeerd worden. Hierdoor kan een model minder goed een uitkomst voorspellen. 
hoofdstuk 5 geeft het voorbeeld van een pragmatisch model dat gebruikt kan worden voor 
de selectie van patiënten voor transcatheter of chirurgische aortaklep therapie. In hoofdstuk 
6 worden de resultaten van een uitgebreide systematische review gepresenteerd. Hieruit 
komt voort dat meerdere variabelen niet beschouwd worden tijdens patiënt selectie en het 
besluitvormingsproces.
Eén van de recent geïntroduceerde risico modellen voor invasieve behandeling van 
coronairlijden is de SYNTAX Score. Het risicomodel blijkt goed te kunnen stratificeren in 
laag, middel, en hoog risico bij patiënten die een percutane interventie ondergaan maar 
niet bij patiënten die chirurgie ondergaan. De score kan daarom goed gebruikt worden om 
te differentiëren tussen patiënten die percutaan of chirurgisch behandeld zouden moeten 
worden. hoofdstuk 7 geeft een overzicht van het gebruik van de SYNTAX Score.
Besluitvorming kan beïnvloed worden door arts-gerelateerde factoren. Het concept van 
gezamenlijke besluitvorming met patiënten en artsen heeft daarom meer nadruk gekregen 
gedurende de laatste jaren. In het bijzonder is er bewustwording dat een multidisciplinaire 
besluitvorming een beter resultaat kan opleveren. Dit zou aanbevelingen over de optimale 
behandeling voor patiënten verder kunnen optimaliseren en zo dus ook de uitkomsten van 
percutane en chirurgische therapie. Dit is de focus van hoofdstukken 8 en 9.
chirurgische of transcatheter theraPie voor aortakleP 
stenose?
Chirurgische aortaklep vervanging is de standaard therapie voor patiënten met aortaklep 
stenose. Welk type klep wordt gekozen resulteert in een bepaalde hemodynamische functie; 
een te kleine klep kan een mismatch veroorzaken tussen de grote van de klep en de grote 
van de patiënt. Dit kan resulteren in een te hoge klepgradiënt en een (nieuwe) aortaklep 
stenose betekenen. Het bewijs over de invloed van mismatch op lange-termijn overleving is 
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tegenstrijdig; hoofdstuk 10 is een meta-analyse van de huidige literatuur en concludeert dat 
er inderdaad een significante reductie in overleving is van patiënten met mismatch.
Eén van de complicaties van aortaklep vervangingen is de beschadiging van het 
geleidingsweefsel van het hart en de noodzaak van een pacemaker implantatie direct na 
chirurgie. In hoofdstuk 11 wordt het lange-termijn risico van een permanente pacemaker 
implantatie besproken.
Het resultaat van chirurgische aortaklep vervangingen wordt over de laatste jaren nog meer 
benadrukt omdat tegenwoordig transcatheter aortaklep implantatie een alternatieve behan-
deling vormt voor patiënten met een aortaklep stenose. Zoals bediscussieerd in hoofdstuk 
12 is het risico op complicaties na transcatheter aortaklep implantatie belangrijk. Deze 
zullen moeten worden vergeleken met complicaties na chirurgische aortaklep vervanging. 
Met name de aanwezigheid van paravalvulaire lekkage na transcatheter therapie kan tot een 
verhoogde sterfte leiden terwijl deze complicatie nauwelijks wordt gezien na chirurgische 
behandeling (hoofdstuk 13).
hoofdstuk 14 beschrijft de literatuur met betrekking tot de uitvoerbaarheid en evaluatie 
van transcatheter aortaklep implantatie. Er wordt geconcludeerd dat de uitkomsten gewel-
dig verbeterd zijn gedurende de laatste jaren en dat transcatheter aortaklep implantatie een 
alternatieve therapie is voor patiënten met een (te) hoog operatie risico. 
Om de uitkomsten nog verder te verbeteren is het noodzakelijk om de incidentie van 
complicaties te verlagen. Kennis over de voorspellende factoren van complicaties is dan 
ook belangrijk om een specifieke invloed op deze factoren uit te kunnen oefenen. Dit is de 
focus van hoofdstuk 15.
De positieve resultaten van gerandomiseerde onderzoeken en het enthousiasme rondom 
transcatheter aortaklep implantatie hebben ervoor gezorgd dat huidige onderzoeken zich 
richten op patiënten met een lager risico (hoofdstuk 16). Omdat de indicaties voor transca-
theter therapie zouden kunnen uitbreiden, is het noodzakelijk om in tijden van toenemende 
uitgaven voor gezondheidszorg en economische crisis ook naar de kostenimplicaties te 
kijken. In hoofdstuk 17 worden deze aspecten onderzocht.
dotteren in vergelijking tot byPass chirurgie
De introductie van drug-eluting stents heeft gezorgd voor nieuwe initiatieven om wederom 
een vergelijking tussen dotteren en coronaire bypass chirurgie uit te voeren. De SYNTAX 
trial was de eerste grootschalige studie die onderzocht heeft of drug-eluting stents even goed 
waren als chirurgie. Bovendien heeft de studie de bespreking in het coronaire Heart Team 
aangewakkerd om patiënten te evalueren. In hoofdstuk 18 worden de resultaten van deze 
Heart Team besluitvorming besproken en wordt aangetoond welke factoren doorslaggevend 
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waren voor behandeling met percutane interventie met drug-eluting stents of coronair 
chirurgie. Nadere analyses van de SYNTAX trial worden besproken: de invloed van onvol-
ledige revascularisatie (hoofdstuk 19), de incidentie en uitkomsten van cerebrovasculaire 
accidenten (hoofdstuk 20), en de resultaten bij patiënten met diabetes mellitus (hoofdstuk 
21).
De SYNTAX trial werd uitgevoerd met de eerste generatie drug-eluting stents, maar 
nieuwe stents zijn sindsdien op de markt gekomen. In hoofdstuk 22 worden deze stents 
besproken. Niet alleen de uitkomsten van percutane interventie zijn verbeterd over de jaren 
maar er zijn ook een aantal chirurgische technieken geïntroduceerd om complicaties en de 
invasiviteit van bypass chirurgie te verminderen. Deze worden bediscussieerd in hoofdstuk 
23.
interPretatie van klinisch onderzoek oP het gebied van hart-en 
vaatziekten
Kennis over methodologie en de studieopzet van gerandomiseerde onderzoeken is nood-
zakelijk om conclusies op juiste wijze te kunnen interpreteren. ‘Non-inferiority’ studies 
worden steeds vaker uitgevoerd, maar de opzet en interpretatie is lastiger. hoofdstuk 24 
geeft inzicht in recent uitgevoerde non-inferiority studies op het gebied van cardiovasculaire 
afwijkingen en geeft aan op welke punten gelet moet worden tijdens het beoordelen van 
zo een studie. 
Generaliseerbaarheid en selectie bias zijn tekortkomingen van gerandomiseerde en obser-
vationele onderzoeken. hoofdstukken 25-28 zijn commentaren die wijzen op beperkingen 
van studies ter bewustwording van niet voldoende onderbouwde conclusies. hoofdstuk 29 
beschouwt de aanbevelingen omtrent de behandeling met transcatheter aortakleppen, met 
name of deze gebaseerd zijn op voldoende gegevens. Is er genoeg informatie om te stellen 
dat een klep implantatie via de lies beter is dan via de apex van het hart?
hoofdstuk 30 gaat nog specifieker in op de kracht van analyses. Dit is een systematische 
uiteenzetting van onderzoeken die percutane interventie en coronair chirurgie hebben ver-
geleken voor de behandeling van complex coronairlijden. Deze analyses zijn vaak metho-
dologisch niet juist.  Het is nodig om de interpretatie van subgroep resultaten te verbeteren 
om zo onjuiste bevindingen en aanbevelingen te minimaliseren. 
verbeteringen voor toekomstig klinisch onderzoek
De vergelijkbaarheid van onderzoeken kan verbeterd worden door uniformiteit in studie-
opzet en definities. De ‘Academic Research Consortium’ is een groep klinische experts 
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(chirurgen, interventie en klinische cardiologen, beeldvorming specialisten, neurologen, 
geriaters, en onderzoekdeskundigen), regelgevende instanties, en industrie vertegenwoordi-
gers. Deze groep organiseert vergaderingen om zo standaarden voor eindpunten in klinisch 
onderzoek te bewerkstelligen. In de vroege jaren van transcatheter aortaklep interventies 
waren er geen geharmoniseerde definities. Hierdoor was het moeilijk om studies met elkaar 
te vergelijken. hoofdstuk 31 presenteert de laatste versie van gestandaardiseerde eindpun-
ten voor het evalueren van transcatheter aortaklep interventies.
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Phd Portfolio
Erasmus MC Department: Cardiothoracic Surgery
PhD period:   2010-2013
Promotors:   Prof.dr A.P. Kappetein
   Prof.dr A.J.J.C. Bogers 
Conferences (15.0) Year ECTS
Dallas-Leipzig International Valve (Dallas) 2010 0,9
EuroPCR (Paris) 2011 0,9
European Association of CardioThoracic Surgery (Lisbon) 2011 1,2
Transcatheter Cardiovascular Therapeutics (San Francisco) 2011 1,5
Society of Thoracic Surgeons (Fort Lauderdale) 2012 0,6
European Association of CardioThoracic Surgery Symposium (London) 2012 0,3
Asian Society for Cardiovascular and Thoracic Surgery (Bali) 2012 0,9
EuroPCR (Paris) 2012 1,2
Transcatheter Cardiovascular Therapeutics (Miami) 2012 1,2
European Association of CardioThoracic Surgery (Barcelona) 2012 1,2
Dallas-Leipzig International Valve (Dallas) 2012 0,9
Association of Thoracic and Cardiovascular Surgeons of Asia (Borneo) 2012 0,9
EuroPCR (Paris) 2013 0,9
European Association of CardioThoracic Surgery (Vienna) 2013 1,2
Dutch Association for Cardiothoracic Surgery (Utrecht) 2010-2013 1,2
Presentations (12.0)
Dallas-Leipzig International Valve (Dallas) 2010 0,6
European Association of CardioThoracic Surgery (Lisbon) 2011 0,6
Transcatheter Cardiovascular Therapeutics (San Francisco) 2011 0,6
European Association of CardioThoracic Surgery Symposium (London) 2012 0,6
Asian Society for Cardiovascular and Thoracic Surgery (Bali) 2012 0,6
Transcatheter Cardiovascular Therapeutics (Miami) 2012 1,2
European Association of CardioThoracic Surgery (Barcelona) 2012 2,4
Dutch Association for Cardiothoracic Surgery (Utrecht) 2012 0,6
Dallas-Leipzig International Valve (Dallas) 2012 0,6
Association of Thoracic and Cardiovascular Surgeons of Asia (Borneo) 2012 2,4
Symposium (Calgary) 2012 0,6
European Association of CardioThoracic Surgery (Vienna) 2013 1,2
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Teaching (7.2)
Supervising students 2011-2013 3,0
Clinical Research Associate training (Düsseldorf) 2012 0,6
Minor students lecture: how to perform a systematic review? 2012 0,6
Supervising clinical researchers 2012-2013 3,0
Courses and seminars (5.4)
COEUR PhD day 2011 0,4
COEUR Heart Valve Implantation 2012 0,4
Academic Research Consortium meetings 2011-2012 1,6
Local scientific meetings department of cardiothoracic surgery 2010-2013 3,0
Local scientific meetings department of cardiothoracic surgery 2010-2013 3,0
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